{"config":{"lang":["en"],"separator":"[\\s\\-]+","pipeline":["stopWordFilter"]},"docs":[{"location":"","title":"GO-CAM Reviews","text":"<p>Website for browsing reviews of GO-CAMs. </p> <p>This contains an initial pass of reviews of GO-CAMs with &gt;2 causal edges, performed by the aurelian agentic framework using claude 3.7.</p> <p>THIS IS A DEMO FIRST PASS AND NEEDS FURTHER TUNING</p>"},{"location":"reviews/56170d5200000012-kctd10_in_heart_development_PMID_24430697_/","title":"56170d5200000012 kctd10 in heart development PMID 24430697","text":"<p>Based on the information gathered, I'll now review the GO-CAM model with ID 56170d5200000012.</p>"},{"location":"reviews/56170d5200000012-kctd10_in_heart_development_PMID_24430697_/#review-of-go-cam-model-gomodel56170d5200000012","title":"Review of GO-CAM Model: gomodel:56170d5200000012","text":""},{"location":"reviews/56170d5200000012-kctd10_in_heart_development_PMID_24430697_/#model-overview","title":"Model Overview","text":"<p>Title: \"kctd10 in heart development PMID:24430697\" Taxon: Zebrafish (Danio rerio) - NCBITaxon:7955 Status: Production Model ID: gomodel:56170d5200000012</p>"},{"location":"reviews/56170d5200000012-kctd10_in_heart_development_PMID_24430697_/#model-components-and-structure","title":"Model Components and Structure","text":"<p>This model describes the role of kctd10 in heart development in zebrafish, focusing on its regulation of the transcription factor tbx5a and downstream effects on atrioventricular canal (AVC) development. The model contains the following major activities:</p> <ol> <li>tbx5a (ZFIN:ZDB-GENE-991124-7) with:</li> <li>DNA-binding transcription factor activity (GO:0003700)</li> <li>Occurs in nucleus (GO:0005634)</li> <li>Part of regionalization (GO:0003002)</li> <li> <p>Positively regulates has2 activity</p> </li> <li> <p>has2 (ZFIN:ZDB-GENE-020828-1) with:</p> </li> <li>Molecular function (GO:0003674)</li> <li> <p>Part of atrioventricular canal development (GO:0036302)</p> </li> <li> <p>kctd10 (ZFIN:ZDB-GENE-040426-2843) with:</p> </li> <li>Molecular function (GO:0003674)</li> <li>Occurs in nucleus (GO:0005634)</li> <li>Part of regionalization (GO:0003002)</li> <li> <p>Negatively regulates tbx5a activity</p> </li> <li> <p>kctd10 (ZFIN:ZDB-GENE-040426-2843) with:</p> </li> <li>Protein binding (GO:0005515)</li> <li>Part of molecular function (GO:0003674)</li> <li>Has part of relationship with kctd10's main activity</li> </ol>"},{"location":"reviews/56170d5200000012-kctd10_in_heart_development_PMID_24430697_/#assessment-against-go-cam-best-practices","title":"Assessment Against GO-CAM Best Practices","text":""},{"location":"reviews/56170d5200000012-kctd10_in_heart_development_PMID_24430697_/#1-biological-content-accuracy","title":"1. Biological Content Accuracy","text":"<p>The biological content of the model is well-supported by the literature (PMID:24430697). The paper describes that Kctd10 directly binds to Tbx5a to repress its transcriptional activity, which is crucial for regulating the expression of has2, a key gene in atrioventricular canal development. The paper demonstrates that:</p> <ul> <li>Kctd10 deficiency leads to heart malformations</li> <li>In kctd10 mutants, has2 expression expands beyond the AVC region</li> <li>Knockdown of tbx5a rescues the ectopic expression of has2 in kctd10 mutants</li> <li>Kctd10 physically binds to Tbx5a in the nucleus to moderate its activity</li> </ul> <p>The model accurately captures these key findings, showing kctd10 negatively regulates tbx5a, which positively regulates has2, which is involved in AVC development.</p>"},{"location":"reviews/56170d5200000012-kctd10_in_heart_development_PMID_24430697_/#2-representation-of-molecular-activities","title":"2. Representation of Molecular Activities","text":"<p>The model correctly represents:</p> <ul> <li>tbx5a as a DNA-binding transcription factor (GO:0003700), which is appropriate based on its UniProt annotation and the paper's findings</li> <li>kctd10 with protein binding activity (GO:0005515), correctly showing its interaction with tbx5a</li> <li>has2 is appropriately shown as being regulated by tbx5a and involved in AVC development</li> </ul>"},{"location":"reviews/56170d5200000012-kctd10_in_heart_development_PMID_24430697_/#3-causal-relationships","title":"3. Causal Relationships","text":"<p>The causal relationships are correctly represented:</p> <ul> <li>kctd10 \"directly negatively regulates\" (RO:0002630) tbx5a, which accurately captures the direct physical interaction and regulatory relationship described in the paper</li> <li>tbx5a \"directly positively regulates\" (RO:0002629) has2, which correctly captures that tbx5a acts as a transcriptional activator for has2</li> </ul> <p>These relationships follow the GO-CAM guidelines for representing regulation.</p>"},{"location":"reviews/56170d5200000012-kctd10_in_heart_development_PMID_24430697_/#4-location-information","title":"4. Location Information","text":"<p>The model appropriately specifies the nucleus (GO:0005634) as the location for both kctd10 and tbx5a activities, which is consistent with the paper's findings that Kctd10 colocalizes with Tbx5 in the nucleus.</p>"},{"location":"reviews/56170d5200000012-kctd10_in_heart_development_PMID_24430697_/#5-areas-for-improvement","title":"5. Areas for Improvement","text":"<p>While the model is generally well-constructed, I've identified a few areas that could be enhanced:</p> <ol> <li> <p>More Specific Molecular Function for kctd10: The main activity of kctd10 uses a general \"molecular function\" (GO:0003674) rather than a more specific term. Based on the paper and UniProt entry, a more appropriate term might be \"transcription corepressor activity\" (GO:0003714) since it directly represses Tbx5a's transcriptional activity.</p> </li> <li> <p>More Specific Molecular Function for has2: has2 is annotated with the generic molecular function term (GO:0003674). Based on its UniProt entry, a more specific term would be \"hyaluronan synthase activity\" (GO:0050501).</p> </li> <li> <p>Expansion of downstream effects: The model could be expanded to show how has2 overexpression leads to excessive hyaluronic acid production, which affects cardiac jelly formation and ultimately heart morphogenesis. The paper clearly describes this mechanism.</p> </li> <li> <p>Inclusion of heart looping: The paper emphasizes that heart looping failure is a key phenotype in kctd10 mutants. The model could be expanded to show has2's involvement in heart looping (GO:0001947), which is mentioned in the paper.</p> </li> <li> <p>Regulatory mechanism details: The model could include more detail on how Kctd10 regulates Tbx5a, possibly by including the formation of the Kctd10-Tbx5a complex.</p> </li> </ol>"},{"location":"reviews/56170d5200000012-kctd10_in_heart_development_PMID_24430697_/#biological-process-consistency","title":"Biological Process Consistency","text":"<p>The model appropriately places the molecular activities within relevant biological processes:</p> <ul> <li>Regionalization (GO:0003002) for tbx5a and kctd10 activities</li> <li>Atrioventricular canal development (GO:0036302) for has2 activity</li> </ul> <p>These processes are consistent with the paper's findings about the roles of these genes in heart development.</p>"},{"location":"reviews/56170d5200000012-kctd10_in_heart_development_PMID_24430697_/#final-assessment","title":"Final Assessment","text":"<p>This GO-CAM model accurately captures the core regulatory relationship between kctd10, tbx5a, and has2 in zebrafish heart development, particularly in AVC formation. The model correctly represents kctd10 as a negative regulator of tbx5a that acts by direct binding, which in turn controls the expression of has2, a key factor in AVC development.</p> <p>The model follows GO-CAM best practices for representation of transcription factors and regulatory relationships. The suggested improvements would enhance the specificity and comprehensiveness of the model but do not detract from its current accuracy.</p> <p>Recommendation: The model is scientifically sound and follows GO-CAM curation practices. It could be enhanced with more specific molecular function terms for kctd10 and has2, and potentially expanded to include downstream effects on cardiac jelly formation and heart morphogenesis.</p>"},{"location":"reviews/568b0f9600000284-Antibacterial_innate_immune_response_in_the_intestine_via_MAPK_cascade__C__elegans_/","title":"568b0f9600000284 Antibacterial innate immune response in the intestine via MAPK cascade  C  elegans","text":"<p>Now that I have gathered information on the model and related literature, I'll proceed with a detailed review.</p>"},{"location":"reviews/568b0f9600000284-Antibacterial_innate_immune_response_in_the_intestine_via_MAPK_cascade__C__elegans_/#review-of-go-cam-model-gomodel568b0f9600000284","title":"Review of GO-CAM Model gomodel:568b0f9600000284","text":""},{"location":"reviews/568b0f9600000284-Antibacterial_innate_immune_response_in_the_intestine_via_MAPK_cascade__C__elegans_/#overview-of-the-model","title":"Overview of the Model","text":"<p>This GO-CAM model titled \"Antibacterial innate immune response in the intestine via MAPK cascade (C. elegans)\" represents a signaling pathway involved in innate immune response in C. elegans. The model focuses on a MAPK (Mitogen-Activated Protein Kinase) signaling cascade that mediates antibacterial defense in the worm's intestinal cells.</p>"},{"location":"reviews/568b0f9600000284-Antibacterial_innate_immune_response_in_the_intestine_via_MAPK_cascade__C__elegans_/#pathway-structure-and-components","title":"Pathway Structure and Components","text":"<p>The model depicts a complete MAPK signaling cascade consisting of:</p> <ol> <li>Initiating adaptor: TIR-1 (WB:WBGene00006575) with signaling adaptor activity (GO:0035591)</li> <li>MAPKKK: NSY-1 (WB:WBGene00003822) with MAP kinase kinase kinase activity (GO:0004709)</li> <li>MAPKK: SEK-1 (WB:WBGene00004758) with MAP kinase kinase activity (GO:0004708)</li> <li>MAPK: PMK-1 (WB:WBGene00004055) with MAP kinase activity (GO:0004707)</li> <li>Transcription factor: ATF-7 (WB:WBGene00000223) with DNA-binding transcription factor activity (GO:0000981)</li> <li>Target gene product: SYSM-1 (WB:WBGene00011979) </li> </ol> <p>The model also includes an additional regulator: - DKF-2: (WB:WBGene00012019) with protein serine/threonine kinase activity (GO:0004674) - Phosphatase VHP-1: (WB:WBGene00006923) with MAP kinase tyrosine/serine/threonine phosphatase activity (GO:0017017)</p>"},{"location":"reviews/568b0f9600000284-Antibacterial_innate_immune_response_in_the_intestine_via_MAPK_cascade__C__elegans_/#causal-relationships","title":"Causal Relationships","text":"<p>The model uses appropriate causal relationship predicates to show the flow of signaling:</p> <ol> <li>TIR-1 directly positively regulates (RO:0002629) NSY-1 </li> <li>NSY-1 directly positively regulates (RO:0002629) SEK-1</li> <li>SEK-1 directly positively regulates (RO:0002629) PMK-1</li> <li>PMK-1 directly positively regulates (RO:0002629) ATF-7</li> <li>ATF-7 directly positively regulates (RO:0002629) SYSM-1</li> <li>DKF-2 directly positively regulates (RO:0002629) PMK-1</li> <li>TPA-1 directly positively regulates (RO:0002629) DKF-2 </li> <li>VHP-1 directly negatively regulates (RO:0002630) PMK-1 and KGB-1</li> <li>VHP-1 directly negatively regulates (RO:0002630) KGB-1</li> </ol>"},{"location":"reviews/568b0f9600000284-Antibacterial_innate_immune_response_in_the_intestine_via_MAPK_cascade__C__elegans_/#cellular-components","title":"Cellular Components","text":"<p>Most activities in the model are correctly localized to appropriate cellular components: - TIR-1: cytoplasm (GO:0005737) - NSY-1: cytoplasm (GO:0005737) - SEK-1: cytoplasm (GO:0005737) - PMK-1: cytosol (GO:0005829) - DKF-2: cytoplasmic side of plasma membrane (GO:0009898) - ATF-7: nucleus (GO:0005634) - VHP-1: cytoplasm (GO:0005737)</p>"},{"location":"reviews/568b0f9600000284-Antibacterial_innate_immune_response_in_the_intestine_via_MAPK_cascade__C__elegans_/#biological-process","title":"Biological Process","text":"<p>All the activities are appropriately annotated as part of the antibacterial innate immune response (GO:0140367), which is consistent with the literature evidence from multiple papers cited in the model.</p>"},{"location":"reviews/568b0f9600000284-Antibacterial_innate_immune_response_in_the_intestine_via_MAPK_cascade__C__elegans_/#evidence","title":"Evidence","text":"<p>The model uses appropriate evidence codes and refers to relevant publications: - Most causal relationships are supported by mutant phenotype evidence (ECO:0000315) - Molecular functions are typically supported by direct assay evidence (ECO:0000314) - Cellular components are mostly supported by direct assay or orthology-based evidence</p>"},{"location":"reviews/568b0f9600000284-Antibacterial_innate_immune_response_in_the_intestine_via_MAPK_cascade__C__elegans_/#quality-assessment","title":"Quality Assessment","text":""},{"location":"reviews/568b0f9600000284-Antibacterial_innate_immune_response_in_the_intestine_via_MAPK_cascade__C__elegans_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Complete signaling cascade: The model properly represents a complete MAPK cascade from the initiating adaptor protein through transcription factor activation.</p> </li> <li> <p>Appropriate evidence: The model uses appropriate evidence codes and cites relevant literature.</p> </li> <li> <p>Correct causal relationships: The model uses the appropriate causal relationship predicates (directly positively/negatively regulates) between activities.</p> </li> <li> <p>Consistent annotation: All activities are consistently annotated as part of the same biological process (antibacterial innate immune response).</p> </li> <li> <p>Appropriate cellular components: Activities are localized to the correct cellular compartments, reflecting the biological reality of the MAPK signaling pathway.</p> </li> </ol>"},{"location":"reviews/568b0f9600000284-Antibacterial_innate_immune_response_in_the_intestine_via_MAPK_cascade__C__elegans_/#issues-and-recommendations","title":"Issues and Recommendations:","text":"<ol> <li> <p>Missing input signals: The model doesn't clearly indicate what initially activates the TIR-1 adaptor protein. Based on the literature, bacterial pathogen recognition is the likely trigger. Consider adding information about how bacterial pathogens are recognized to initiate this pathway.</p> </li> <li> <p>Molecular function for SYSM-1: The molecular function for SYSM-1 is annotated as GO:0003674 (molecular_function), which is a generic placeholder term. If more specific function information becomes available, this should be updated.</p> </li> <li> <p>Consistency with GO-CAM best practices: The model is generally consistent with GO-CAM best practices, but could potentially be enhanced by:</p> </li> <li>Adding information about any required co-factors</li> <li> <p>Including more details about the specific anti-bacterial effector mechanisms downstream of SYSM-1</p> </li> <li> <p>Additional regulatory pathway: The VHP-1 phosphatase negatively regulates both PMK-1 and KGB-1 (WB:WBGene00002187), but there's limited information about the broader role of KGB-1 and its connection to the other components in this pathway. Consider clarifying the role of KGB-1 in the context of this immune response pathway.</p> </li> <li> <p>TPA-1 regulation of DKF-2: According to the literature (PMID:19371715), TPA-1 regulates DKF-2 in the context of immune response, but this relationship is not fully represented in the model. Consider adding this regulatory relationship to complete the pathway.</p> </li> </ol>"},{"location":"reviews/568b0f9600000284-Antibacterial_innate_immune_response_in_the_intestine_via_MAPK_cascade__C__elegans_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a high-quality GO-CAM model that accurately represents the C. elegans MAPK cascade pathway in antibacterial innate immune response. The model is well-structured, uses appropriate GO terms and relationship predicates, and is supported by adequate evidence. A few minor enhancements could further improve the model, including clarification of the upstream pathogen recognition mechanism and more specific molecular function annotations for some components.</p> <p>The model provides valuable information about how C. elegans mounts antibacterial responses through MAPK signaling and highlights the conservation of innate immune signaling components between nematodes and mammals. This pathway has broader implications for understanding innate immunity across species.</p>"},{"location":"reviews/5745387b00001516-Canonical_glycolysis_1__Mouse_/","title":"5745387b00001516 Canonical glycolysis 1  Mouse","text":"<p>Based on the information gathered, I'll now review the GO-CAM model gomodel:5745387b00001516 titled \"Canonical glycolysis 1 (Mouse)\".</p>"},{"location":"reviews/5745387b00001516-Canonical_glycolysis_1__Mouse_/#go-cam-review-canonical-glycolysis-1-mouse","title":"GO-CAM Review: Canonical glycolysis 1 (Mouse)","text":""},{"location":"reviews/5745387b00001516-Canonical_glycolysis_1__Mouse_/#overview","title":"Overview","text":"<p>This model represents the canonical glycolysis pathway in mouse (NCBITaxon:10090), which was sourced from model R-HSA-70171. The model is in production status and depicts the enzymatic steps of glycolysis, showing the flow of activity through the pathway.</p>"},{"location":"reviews/5745387b00001516-Canonical_glycolysis_1__Mouse_/#structure-review","title":"Structure Review","text":"<p>The model captures the glycolytic pathway from glucokinase (HK1) to pyruvate kinase (PKM), representing all key enzymatic steps in the pathway. All enzymes are appropriately enabled by their respective mouse gene products and connected in a sequential manner using the RO:0002413 (\"provides input for\") causal relationship, which is appropriate for metabolic pathways.</p>"},{"location":"reviews/5745387b00001516-Canonical_glycolysis_1__Mouse_/#content-completeness-and-accuracy","title":"Content Completeness and Accuracy","text":"<ol> <li>Complete pathway representation: All essential enzymatic steps of canonical glycolysis are included:</li> <li> <p>Glucokinase (HK1) \u2192 Glucose-6-phosphate isomerase (GPI1) \u2192 Phosphofructokinase (PFKM) \u2192 Aldolase (ALDOA) \u2192 Triosephosphate isomerase (TPI1) \u2192 Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) \u2192 Phosphoglycerate kinase (PGK1) \u2192 Phosphoglycerate mutase (PGAM2) \u2192 Enolase (ENO3) \u2192 Pyruvate kinase (PKM)</p> </li> <li> <p>Proper evidence: Each activity is supported by appropriate experimental evidence, primarily direct assays (ECO:0000314) and mutant phenotype evidence (ECO:0000315) from relevant publications.</p> </li> <li> <p>Cellular location: All activities are properly located in the cytosol (GO:0005829), which is correct for glycolysis.</p> </li> <li> <p>Biological process: All activities are correctly annotated as part of canonical glycolysis (GO:0061621).</p> </li> </ol>"},{"location":"reviews/5745387b00001516-Canonical_glycolysis_1__Mouse_/#causal-relationships","title":"Causal Relationships","text":"<p>The model correctly uses RO:0002413 (\"provides input for\") to connect the sequential activities of the glycolytic enzymes, accurately representing the metabolic flow from glucose to pyruvate. </p> <p>An interesting aspect to note is that the model correctly represents the branching after aldolase (ALDOA), where both triose-phosphate isomerase (TPI1) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) can receive input from aldolase, reflecting the biochemical reality of the pathway.</p>"},{"location":"reviews/5745387b00001516-Canonical_glycolysis_1__Mouse_/#evidence-support","title":"Evidence Support","text":"<p>Each activity and causal relationship is adequately supported by published evidence, with multiple references for most assertions. The evidence types used (direct assay, mutant phenotype, genetic interaction) are appropriate for a metabolic pathway model.</p>"},{"location":"reviews/5745387b00001516-Canonical_glycolysis_1__Mouse_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows best practices for GO-CAM modeling: 1. Appropriate causal relationships 2. Correct representation of enzymatic activities 3. Proper evidence citation 4. Inclusion of cellular locations 5. Association with the proper biological process term</p>"},{"location":"reviews/5745387b00001516-Canonical_glycolysis_1__Mouse_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While this model is well-constructed and accurate, there are a few potential improvements:</p> <ol> <li> <p>Some evidence links, like PMID:27103217, are used across multiple activities. It may be worth verifying that this publication provides specific evidence for each assertion where it's cited.</p> </li> <li> <p>Although not required, substrate/product information could enhance the comprehensibility of the model, particularly for users less familiar with the details of glycolysis.</p> </li> </ol>"},{"location":"reviews/5745387b00001516-Canonical_glycolysis_1__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:5745387b00001516 is a high-quality representation of the canonical glycolysis pathway in mouse. It accurately captures the enzymatic activities, their sequential relationships, and provides appropriate evidence for all assertions. The model is parsimonious while being comprehensive, making it easy for users to understand the glycolytic pathway.</p> <p>The model successfully represents how glycolysis proceeds from glucose processing through ten enzymatic steps to produce pyruvate, with each step properly annotated and evidenced. No significant issues or inaccuracies were identified during this review.</p>"},{"location":"reviews/57c82fad00000695-F13a1_and_F13b_mouse_blood_clotting/","title":"57c82fad00000695 F13a1 and F13b mouse blood clotting","text":"<p>Now, let me review the GO-CAM model based on all the information gathered:</p>"},{"location":"reviews/57c82fad00000695-F13a1_and_F13b_mouse_blood_clotting/#go-cam-model-review-gomodel57c82fad00000695-f13a1-and-f13b-mouse-blood-clotting","title":"GO-CAM Model Review - gomodel:57c82fad00000695 (F13a1 and F13b-mouse-blood clotting)","text":""},{"location":"reviews/57c82fad00000695-F13a1_and_F13b_mouse_blood_clotting/#overview","title":"Overview","text":"<p>The model gomodel:57c82fad00000695 describes the roles of Factor XIII subunits (A and B) in blood coagulation in mouse. It models the interactions between Factor XIII subunits and their regulation by thrombin (F2) in the context of blood clot formation.</p>"},{"location":"reviews/57c82fad00000695-F13a1_and_F13b_mouse_blood_clotting/#molecular-components-in-the-model","title":"Molecular Components in the Model","text":"<ol> <li>F13a1 (MGI:MGI:1921395) - Coagulation factor XIII, A1 subunit, the catalytic subunit with protein-glutamine gamma-glutamyltransferase activity</li> <li>F13b (MGI:MGI:88379) - Coagulation factor XIII, B subunit, a non-catalytic subunit that binds to F13a1</li> <li>F2 (MGI:MGI:88380) - Coagulation factor II (Thrombin), with serine-type endopeptidase activity</li> </ol>"},{"location":"reviews/57c82fad00000695-F13a1_and_F13b_mouse_blood_clotting/#biological-process-and-pathway-represented","title":"Biological Process and Pathway Represented","text":"<p>The model describes blood coagulation (GO:0007596) and specifically the fibrin clot formation (GO:0072378) pathway, where thrombin (F2) activates Factor XIII by cleaving the A subunit (F13a1), while the B subunit (F13b) regulates this process. When activated, Factor XIII cross-links fibrin to stabilize blood clots.</p>"},{"location":"reviews/57c82fad00000695-F13a1_and_F13b_mouse_blood_clotting/#review-of-model-structure-and-causal-relationships","title":"Review of Model Structure and Causal Relationships","text":""},{"location":"reviews/57c82fad00000695-F13a1_and_F13b_mouse_blood_clotting/#structure-analysis","title":"Structure Analysis","text":"<p>The model includes four activity nodes: 1. F13b with unspecified molecular function (GO:0003674) - part of generic biological process (GO:0008150) 2. F2 with serine-type endopeptidase activity (GO:0004252)  3. F13a1 with protein-glutamine gamma-glutamyltransferase activity (GO:0003810) 4. F13b with protein binding activity (GO:0005515) - part of blood coagulation (GO:0007596)</p>"},{"location":"reviews/57c82fad00000695-F13a1_and_F13b_mouse_blood_clotting/#causal-relationships","title":"Causal Relationships","text":"<p>The model shows three causal relationships: 1. F2 directly positively regulates (RO:0002629) F13a1's protein-glutamine gamma-glutamyltransferase activity 2. F2 directly negatively regulates (RO:0002630) F13b's protein binding activity 3. F13b directly negatively regulates (RO:0002630) F13a1's protein-glutamine gamma-glutamyltransferase activity</p>"},{"location":"reviews/57c82fad00000695-F13a1_and_F13b_mouse_blood_clotting/#literature-support","title":"Literature Support","text":"<p>The model is supported by PMID:18224415, which describes a study of F13b knockout mice. The paper shows that F13b helps maintain F13a1 levels in circulation and that both subunits are important for normal blood clotting. The evidence indicates that thrombin activates F13a1 by cleaving an amino-terminal activation peptide, resulting in dissociation from F13b in the presence of calcium, allowing F13a1 to cross-link fibrin.</p> <p>The model is also supported by PMID:18398001 for F2's serine-type endopeptidase activity.</p>"},{"location":"reviews/57c82fad00000695-F13a1_and_F13b_mouse_blood_clotting/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li> <p>Inconsistency in F13b representation: The model has two separate activities for F13b - one with molecular function [GO:0003674] and another with protein binding [GO:0005515]. This is confusing and redundant. According to GO-CAM best practices for representing complexes, a protein should have a single molecular function node.</p> </li> <li> <p>Missing complex representation: The literature clearly indicates F13a1 and F13b form a complex (A2B2 heterotetramer), but this is not explicitly modeled. The model should include a complex formation step.</p> </li> <li> <p>Incomplete pathway representation: The model should include the downstream effects of activated F13a1 on fibrin cross-linking to better represent the full biological pathway.</p> </li> <li> <p>Evidence quality: The F13b protein binding activity is supported by \"physical interaction evidence\" (ECO:0000353) but the context of this evidence could be better clarified in the model.</p> </li> <li> <p>Biological process consistency: F13b has two activities that are part of different biological processes (GO:0008150 and GO:0007596). This is inconsistent with the known role of F13b in blood coagulation.</p> </li> </ol>"},{"location":"reviews/57c82fad00000695-F13a1_and_F13b_mouse_blood_clotting/#recommended-improvements","title":"Recommended Improvements","text":"<ol> <li> <p>Represent F13b with a single activity node related to protein binding and part of blood coagulation.</p> </li> <li> <p>Add a complex formation step showing F13a1 and F13b forming the Factor XIII complex.</p> </li> <li> <p>Include the downstream steps of the pathway to show how activated F13a1 cross-links fibrin.</p> </li> <li> <p>Clarify the evidence supporting the protein binding activity of F13b.</p> </li> <li> <p>Ensure all activities are consistently annotated to the appropriate biological processes.</p> </li> </ol>"},{"location":"reviews/57c82fad00000695-F13a1_and_F13b_mouse_blood_clotting/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides a reasonable representation of Factor XIII regulation in blood clotting, supported by relevant literature. However, it could be improved by addressing the issues noted above to better reflect the biological reality and conform to GO-CAM best practices.</p>"},{"location":"reviews/5966411600000170-Intestinal_smooth_muscle_cell_differentiation_via_foxo1a__mir145__tgfr1b__ltbp3__zeb1a__D__rerio_/","title":"5966411600000170 Intestinal smooth muscle cell differentiation via foxo1a  mir145  tgfr1b  ltbp3  zeb1a  D  rerio","text":"<p>Let me review the GO-CAM model based on the information gathered:</p>"},{"location":"reviews/5966411600000170-Intestinal_smooth_muscle_cell_differentiation_via_foxo1a__mir145__tgfr1b__ltbp3__zeb1a__D__rerio_/#go-cam-model-review-gomodel5966411600000170","title":"GO-CAM Model Review: gomodel:5966411600000170","text":""},{"location":"reviews/5966411600000170-Intestinal_smooth_muscle_cell_differentiation_via_foxo1a__mir145__tgfr1b__ltbp3__zeb1a__D__rerio_/#title","title":"Title","text":"<p>\"Intestinal smooth muscle cell differentiation via foxo1a, mir145, tgfr1b, ltbp3, zeb1a (D. rerio)\"</p>"},{"location":"reviews/5966411600000170-Intestinal_smooth_muscle_cell_differentiation_via_foxo1a__mir145__tgfr1b__ltbp3__zeb1a__D__rerio_/#overview","title":"Overview","text":"<p>This GO-CAM model represents the genetic pathway for intestinal smooth muscle cell (iSMC) differentiation in zebrafish (Danio rerio). The model describes a series of molecular interactions involving multiple genes (foxo1a, mir145, tgfr1b, ltbp3, zeb1a) that regulate the differentiation of intestinal smooth muscle cells from lateral plate mesoderm (LPM).</p>"},{"location":"reviews/5966411600000170-Intestinal_smooth_muscle_cell_differentiation_via_foxo1a__mir145__tgfr1b__ltbp3__zeb1a__D__rerio_/#evidence-analysis","title":"Evidence Analysis","text":"<p>The model is based primarily on evidence from a single publication (PMID:28049660), which describes experiments in zebrafish embryos. The evidence types used in the model include: - ECO:0000315 (mutant phenotype evidence used in manual assertion) - ECO:0000304 (author statement supported by traceable reference used in manual assertion) - ECO:0000314 (direct assay evidence used in manual assertion)</p> <p>The experimental evidence appears to be robust, including morpholino knockdowns (e.g., ZFIN:ZDB-MRPHLNO-170327-1, ZFIN:ZDB-MRPHLNO-170327-3, ZFIN:ZDB-MRPHLNO-110801-4, ZFIN:ZDB-MRPHLNO-170327-5).</p>"},{"location":"reviews/5966411600000170-Intestinal_smooth_muscle_cell_differentiation_via_foxo1a__mir145__tgfr1b__ltbp3__zeb1a__D__rerio_/#structure-and-technical-analysis","title":"Structure and Technical Analysis","text":"<p>The model includes: - 10 activities with appropriate gene products - Appropriate causal relationships between activities - A clear biological pathway from TGF\u03b2 signaling to miR-145 expression to downregulation of zeb1a and foxo1a</p>"},{"location":"reviews/5966411600000170-Intestinal_smooth_muscle_cell_differentiation_via_foxo1a__mir145__tgfr1b__ltbp3__zeb1a__D__rerio_/#issues-identified","title":"Issues Identified:","text":"<ol> <li> <p>Molecular Function Annotations: Several activities (6 out of 10) use GO:0003674 (molecular_function) as a placeholder, which is not specific. While this is acceptable when the precise function is unknown, the cited paper provides more detailed functional information for some of these gene products that could be incorporated.</p> </li> <li> <p>Overly Generic Biological Process Terms: Although GO:0007179 (transforming growth factor beta receptor signaling pathway) is used appropriately, the model could benefit from more specific biological process terms related to intestinal smooth muscle cell differentiation.</p> </li> <li> <p>No Cellular Component Annotations: There are no cellular component annotations for any of the activities, though the paper describes specific cellular locations for some of these proteins.</p> </li> </ol>"},{"location":"reviews/5966411600000170-Intestinal_smooth_muscle_cell_differentiation_via_foxo1a__mir145__tgfr1b__ltbp3__zeb1a__D__rerio_/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>The model accurately represents the key findings from the primary paper (PMID:28049660), which describes: - The role of TGF\u03b2 signaling in driving LPM ventral migration and commitment to iSMC fate - The roles of Zeb1a and Foxo1a in LPM migration around the gut - miR-145 regulation of both Zeb1a and Foxo1a - A feedback loop where TGF\u03b2 induces miR-145, which in turn downregulates Zeb1a and Foxo1a</p>"},{"location":"reviews/5966411600000170-Intestinal_smooth_muscle_cell_differentiation_via_foxo1a__mir145__tgfr1b__ltbp3__zeb1a__D__rerio_/#strengths-of-the-model","title":"Strengths of the Model:","text":"<ul> <li>Correctly captures the regulatory relationships described in the paper</li> <li>Shows the dual roles of miR-145 in targeting different genes</li> <li>Uses appropriate causal relations to show regulatory connections</li> </ul>"},{"location":"reviews/5966411600000170-Intestinal_smooth_muscle_cell_differentiation_via_foxo1a__mir145__tgfr1b__ltbp3__zeb1a__D__rerio_/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Additional Processes: The paper describes specific processes like mesenchymalization, cell migration, and proliferation that could be explicitly modeled.</p> </li> <li> <p>Incomplete Representation of Feedback Loop: The paper shows that miR-145 can target Alk5 (the TGF\u03b2 receptor) creating a negative feedback loop, but this is not represented in the model.</p> </li> <li> <p>Missing Cellular Context: The paper describes this process occurring in lateral plate mesoderm, which could be captured as cellular context.</p> </li> <li> <p>Missing Phenotypic Outcomes: The phenotypic outcomes (intestinal smooth muscle contractility issues) are not explicitly captured.</p> </li> </ol>"},{"location":"reviews/5966411600000170-Intestinal_smooth_muscle_cell_differentiation_via_foxo1a__mir145__tgfr1b__ltbp3__zeb1a__D__rerio_/#adherence-to-go-cam-best-practices","title":"Adherence to GO-CAM Best Practices","text":"<p>The model generally follows GO-CAM best practices for representing causal relationships. The use of \"directly positively regulates\" (RO:0002629) and \"directly negatively regulates\" (RO:0002630) predicates is appropriate.</p> <p>However, the model would benefit from: 1. More specific molecular function terms instead of generic GO:0003674 2. Addition of cellular component annotations 3. Inclusion of cell or tissue types as contexts</p>"},{"location":"reviews/5966411600000170-Intestinal_smooth_muscle_cell_differentiation_via_foxo1a__mir145__tgfr1b__ltbp3__zeb1a__D__rerio_/#recommendation","title":"Recommendation","text":"<p>The model provides a good representation of the key pathway described in the paper but would benefit from the following improvements:</p> <ol> <li>Add more specific molecular function terms for gene products where the paper provides this information</li> <li>Add cellular component annotations</li> <li>Include the Alk5-miR-145 negative feedback loop</li> <li>Add the cellular context (lateral plate mesoderm) for relevant activities</li> <li>Include additional biological process terms related to intestinal smooth muscle cell differentiation</li> <li>Consider representing the phenotypic outcomes (intestinal contractility)</li> </ol> <p>Overall, this is a good model that captures the main regulatory relationships described in the publication, but it could be enhanced with additional details from the paper to make it more comprehensive and informative.</p>"},{"location":"reviews/59cc772c00000000-IL1beta_mediated_signaling_pathway__Human_/","title":"59cc772c00000000 IL1beta mediated signaling pathway  Human","text":"<p>Based on my review, I'll provide a comprehensive assessment of the GO-CAM model for IL1beta-mediated signaling pathway (Human) with ID gomodel:59cc772c00000000.</p>"},{"location":"reviews/59cc772c00000000-IL1beta_mediated_signaling_pathway__Human_/#review-of-go-cam-model-il1beta-mediated-signaling-pathway-human","title":"Review of GO-CAM Model: IL1beta-mediated signaling pathway (Human)","text":""},{"location":"reviews/59cc772c00000000-IL1beta_mediated_signaling_pathway__Human_/#summary-of-the-model","title":"Summary of the Model","text":"<p>The model gomodel:59cc772c00000000 represents the IL-1\u03b2-mediated signaling pathway in humans. It captures the following key components and interactions:</p> <ol> <li>IL-1\u03b2 cytokine signaling: IL-1\u03b2 (P01584) functions as a cytokine that initiates the signaling cascade</li> <li>Receptor recognition: IL-1\u03b2 binds to and activates the IL-1 receptor type 1 (IL1R1/P14778)</li> <li>Co-receptor involvement: IL-1RAP (Q9NPH3) acts as a co-receptor</li> <li>Adaptor recruitment: MYD88 (Q99836) functions as a molecular adaptor</li> <li>Kinase activation cascade: IRAK4 (Q9NWZ3) \u2192 IRAK1 (P51617) \u2192 MAP3K7 (O43318)</li> <li>Processing component: Caspase-1 (P29466) processes pro-IL-1\u03b2 to mature IL-1\u03b2</li> </ol>"},{"location":"reviews/59cc772c00000000-IL1beta_mediated_signaling_pathway__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Proper biological pathway representation: The model correctly represents the canonical IL-1\u03b2 signaling pathway, with appropriate molecular functions assigned to each component.</p> </li> <li> <p>Appropriate use of causal relationships: The model uses the correct causal relationships (RO:0002629 \"directly positively regulates\") to connect components in the pathway.</p> </li> <li> <p>Correct subcellular localization: Components are assigned appropriate cellular locations (e.g., IL-1\u03b2 in extracellular region, IL1R1 in plasma membrane, IRAK4/IRAK1 in cytoplasm).</p> </li> <li> <p>Evidence-based annotations: Most key relationships are supported by experimental evidence with appropriate literature citations.</p> </li> <li> <p>Consistent with signaling receptor guidelines: The model follows the GO-CAM guidelines for signaling receptor activity, where:</p> </li> <li>IL-1\u03b2 has cytokine activity (GO:0005125)</li> <li>IL-1R1 has interleukin-1 receptor activity (GO:0004908)</li> <li>IL1RAP has coreceptor activity (GO:0015026)</li> </ol>"},{"location":"reviews/59cc772c00000000-IL1beta_mediated_signaling_pathway__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing NIK-IKK module: The signaling cascade typically continues through NF-\u03baB activation via NIK (MAP3K14) and IKK complex, which aren't represented in the current model.</p> </li> <li> <p>Incomplete activation cascade: The model shows IRAK1 activating MAP3K7, but doesn't show TAK1-binding proteins (TAB1/2) which are essential for MAP3K7 activation.</p> </li> <li> <p>Unconnected component in pathway: Caspase-1 (CASP1) activity is shown as processing pro-IL1\u03b2, but it appears disconnected from the main signaling cascade (this is accurate biologically as inflammasome activation is somewhat separate from IL-1 signaling).</p> </li> <li> <p>Incompletely characterized activity: MAP3K7 (O43318) activity is represented with the generic \"kinase activity\" (GO:0016301) rather than a more specific protein kinase activity term.</p> </li> <li> <p>Missing biochemical output: The model doesn't show the ultimate biochemical outputs of the pathway (e.g., NF-\u03baB activation, gene expression changes).</p> </li> <li> <p>Annotation evidence gaps: Some relationships lack full evidence annotations:</p> </li> <li>The causal association between IRAK1 (gomodel:59cc772c00000000/59cc772c00000024) and MAP3K7 (gomodel:59cc772c00000000/59cde02c00000027) lacks evidence</li> </ol>"},{"location":"reviews/59cc772c00000000-IL1beta_mediated_signaling_pathway__Human_/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<p>The model generally follows GO-CAM best practices. Particularly:</p> <ol> <li> <p>Receptor-ligand representation: Follows the signaling receptor activity guidelines with appropriate relationship between ligand (IL-1\u03b2), receptor (IL1R1), and co-receptor (IL1RAP).</p> </li> <li> <p>Molecular adaptor annotation: Correctly represents molecular adaptors (MYD88, TOLLIP) following the molecular adaptor guidelines with \"has input\" relationships to specify interacting partners.</p> </li> <li> <p>Causal relationships: Uses appropriate causal relationship predicates (RO:0002629 \"directly positively regulates\") throughout the model.</p> </li> </ol>"},{"location":"reviews/59cc772c00000000-IL1beta_mediated_signaling_pathway__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the core components of the IL-1\u03b2 signaling pathway:</p> <ol> <li> <p>IL-1\u03b2 activation: The model correctly shows CASP1 processing IL-1\u03b2, which is a key step in IL-1\u03b2 maturation.</p> </li> <li> <p>Receptor complex formation: The model appropriately shows IL-1\u03b2 binding to IL-1R1, with IL1RAP serving as co-receptor.</p> </li> <li> <p>Adaptor recruitment: The recruitment of MYD88 and TOLLIP adaptors is biologically accurate.</p> </li> <li> <p>Kinase cascade: The activation sequence IRAK4 \u2192 IRAK1 \u2192 MAP3K7 is consistent with literature evidence, including the PMID:11960013 reference that emphasizes IRAK4's role upstream of IRAK1.</p> </li> </ol>"},{"location":"reviews/59cc772c00000000-IL1beta_mediated_signaling_pathway__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Complete the signaling cascade: Add downstream components showing MAP3K7 activation of the IKK complex and subsequent NF-\u03baB activation.</p> </li> <li> <p>Add TAB1/2 adaptors: Include TAB1/2 proteins which connect IRAK1 to MAP3K7 activation.</p> </li> <li> <p>Use more specific molecular function terms: Replace generic \"kinase activity\" with more specific terms where appropriate, such as \"protein serine/threonine kinase activity\" for MAP3K7.</p> </li> <li> <p>Add pathway outcomes: Include the biological outcomes of this pathway, particularly NF-\u03baB activation and target gene expression.</p> </li> <li> <p>Complete evidence annotations: Provide missing evidence for the IRAK1-MAP3K7 connection.</p> </li> <li> <p>Consider including negative regulators: The pathway has several negative regulators (e.g., IL1RN, IRAK3) that could be added to more completely represent physiological regulation.</p> </li> </ol>"},{"location":"reviews/59cc772c00000000-IL1beta_mediated_signaling_pathway__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:59cc772c00000000 provides a solid representation of the core IL-1\u03b2 signaling pathway with appropriate molecular functions, cellular locations, and causal relationships between components. The model adheres to GO-CAM best practices for representing signaling pathways and receptor-ligand interactions. While some enhancements could be made to represent the full signaling cascade and its outcomes, the current model accurately captures the key aspects of IL-1\u03b2-mediated signaling.</p>"},{"location":"reviews/59dc728000000555-_Wnt_FGF_Notch_signaling_inregulation_of_HSC_specification_via_dlc__dld__fgfr4__wnt16__D__rerio_/","title":"59dc728000000555  Wnt FGF Notch signaling inregulation of HSC specification via dlc  dld  fgfr4  wnt16  D  rerio","text":"<p>Based on my analysis of this GO-CAM model and the relevant literature, I'll now provide a comprehensive review of the model.</p>"},{"location":"reviews/59dc728000000555-_Wnt_FGF_Notch_signaling_inregulation_of_HSC_specification_via_dlc__dld__fgfr4__wnt16__D__rerio_/#review-of-go-cam-model-59dc728000000555","title":"Review of GO-CAM Model: 59dc728000000555","text":""},{"location":"reviews/59dc728000000555-_Wnt_FGF_Notch_signaling_inregulation_of_HSC_specification_via_dlc__dld__fgfr4__wnt16__D__rerio_/#model-overview","title":"Model Overview","text":"<p>Title: Wnt-FGF-Notch signaling in regulation of HSC specification via dlc, dld, fgfr4, wnt16 (D. rerio) ID: gomodel:59dc728000000555 Taxon: Zebrafish (Danio rerio, NCBITaxon:7955) Status: Production</p>"},{"location":"reviews/59dc728000000555-_Wnt_FGF_Notch_signaling_inregulation_of_HSC_specification_via_dlc__dld__fgfr4__wnt16__D__rerio_/#summary-of-model-content","title":"Summary of Model Content","text":"<p>This model represents the genetic and molecular pathways involved in hematopoietic stem cell (HSC) specification in zebrafish. It specifically focuses on the interactions between the Wnt, FGF, and Notch signaling pathways, with key roles for wnt16, fgfr4, dlc, and dld genes. The model describes a signaling cascade that occurs in somites during mid-somitogenesis to regulate HSC fate in adjacent posterior lateral mesoderm (PLM).</p>"},{"location":"reviews/59dc728000000555-_Wnt_FGF_Notch_signaling_inregulation_of_HSC_specification_via_dlc__dld__fgfr4__wnt16__D__rerio_/#scientific-evaluation","title":"Scientific Evaluation","text":"<p>The model is based on solid research published in PMID:25428693, which demonstrates that FGF signaling through Fgfr4 functions as a molecular relay between Wnt16 and the Notch ligand Dlc in somites to specify HSCs. The paper provides strong experimental evidence for the relationships captured in the model.</p> <p>Key findings supported by the literature: 1. Wnt16 regulates fgfr4 expression in somites 2. FGF signaling via Fgfr4 regulates dlc expression but not dld 3. Both pathways are required for HSC specification in a non-cell-autonomous manner 4. The signaling occurs in specific somitic tissues adjacent to the developing HSCs</p>"},{"location":"reviews/59dc728000000555-_Wnt_FGF_Notch_signaling_inregulation_of_HSC_specification_via_dlc__dld__fgfr4__wnt16__D__rerio_/#go-cam-technical-evaluation","title":"GO-CAM Technical Evaluation","text":""},{"location":"reviews/59dc728000000555-_Wnt_FGF_Notch_signaling_inregulation_of_HSC_specification_via_dlc__dld__fgfr4__wnt16__D__rerio_/#strengths","title":"Strengths:","text":"<ol> <li>The model accurately represents the key components of the pathway described in the literature</li> <li>Appropriate molecular functions and biological processes are used for the activities</li> <li>The model correctly captures the non-cell autonomous nature of the signaling by indicating somite location for key activities</li> </ol>"},{"location":"reviews/59dc728000000555-_Wnt_FGF_Notch_signaling_inregulation_of_HSC_specification_via_dlc__dld__fgfr4__wnt16__D__rerio_/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li>Molecular Function Specificity:</li> <li> <p>Several activities use GO:0003674 (molecular_function) which is a very general term. Based on the paper, more specific functions could be assigned, particularly for:</p> <ul> <li>wnt16 (ZFIN:ZDB-GENE-040426-2330) should have Wnt signaling activity</li> <li>dlc (ZFIN:ZDB-GENE-000125-4) should have Notch ligand activity</li> <li>dld (ZFIN:ZDB-GENE-990415-47) should have Notch ligand activity</li> </ul> </li> <li> <p>Pathway Completeness:</p> </li> <li>The model does not include Wnt16 protein itself as an upstream component, despite being crucial in the paper</li> <li> <p>The mechanism of how dlc and dld affect HSC specification in the hemogenic endothelium could be more explicitly modeled</p> </li> <li> <p>Causal Relationships:</p> </li> <li> <p>The causal relationships are correctly using RO:0002304 \"causally upstream of, positive effect\" but more precise relationships like RO:0002629 \"directly positively regulates\" could be used where direct interactions are known</p> </li> <li> <p>Additional Contextual Information:</p> </li> <li>The model could benefit from more specific anatomical locations, particularly for the HSC precursors in the PLM and the hemogenic endothelium</li> <li> <p>The temporal aspect of the signaling (14-17 hpf) could be captured in annotations</p> </li> <li> <p>Evidence Quality:</p> </li> <li>Some evidence annotations reference \" ZFIN:ZDB-PUB-170214-264\" with a leading space, which should be corrected for consistency</li> </ol>"},{"location":"reviews/59dc728000000555-_Wnt_FGF_Notch_signaling_inregulation_of_HSC_specification_via_dlc__dld__fgfr4__wnt16__D__rerio_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li>Add More Specific Molecular Functions:</li> <li>Replace GO:0003674 with more specific terms from the GO hierarchy</li> <li>For wnt16: add Wnt signaling activity (GO:0005109)</li> <li> <p>For dlc and dld: add Notch binding (GO:0005112) and Delta-like protein ligand activity (GO:1904993)</p> </li> <li> <p>Expand Pathway Representation:</p> </li> <li>Include upstream wnt16 activity</li> <li>Add downstream effects on HSC specification in hemogenic endothelium</li> <li> <p>Include the parallel Wnt16\u2192dld pathway that is independent of FGF signaling</p> </li> <li> <p>Refine Cellular Contexts:</p> </li> <li>Add specific annotations for somite compartments (sclerotome)</li> <li> <p>Include hemogenic endothelium annotations for the ultimate HSC specification events</p> </li> <li> <p>Fix Evidence Annotations:</p> </li> <li> <p>Correct reference format by removing leading spaces</p> </li> <li> <p>Add Biological Process Context:</p> </li> <li>Include GO:0002244 (hematopoietic progenitor cell differentiation) for the overall process</li> <li>Include GO:0061384 (heart trabecula formation) as it was noted in the paper as being affected</li> </ol>"},{"location":"reviews/59dc728000000555-_Wnt_FGF_Notch_signaling_inregulation_of_HSC_specification_via_dlc__dld__fgfr4__wnt16__D__rerio_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model effectively captures the key aspects of the non-canonical Wnt16/FGF/Notch signaling pathway that controls HSC specification in zebrafish. The model aligns well with the cited literature and correctly represents the major causal relationships between components.</p> <p>With the suggested improvements, particularly regarding molecular function specificity and pathway completeness, the model would more comprehensively represent the biological mechanisms described in the research. The addition of more detailed cellular contexts would also enhance the model's utility for understanding the spatial organization of this signaling cascade.</p> <p>Overall, this is a valuable model that, with minor improvements, would serve as an excellent representation of this important developmental signaling pathway.</p>"},{"location":"reviews/5ae3b0f600000435-Regulation_of_sprouting_angiogenesis_via_dll4__egfl6__itgb1a__D__rerio_/","title":"5ae3b0f600000435 Regulation of sprouting angiogenesis via dll4  egfl6  itgb1a  D  rerio","text":"<p>Now that I have a better understanding of the biological context, let me review the GO-CAM model in detail:</p>"},{"location":"reviews/5ae3b0f600000435-Regulation_of_sprouting_angiogenesis_via_dll4__egfl6__itgb1a__D__rerio_/#review-of-go-cam-model-gomodel5ae3b0f600000435-regulation-of-sprouting-angiogenesis-via-dll4-egfl6-itgb1a-d-rerio","title":"Review of GO-CAM Model: gomodel:5ae3b0f600000435 \"Regulation of sprouting angiogenesis via dll4, egfl6, itgb1a (D. rerio)\"","text":""},{"location":"reviews/5ae3b0f600000435-Regulation_of_sprouting_angiogenesis_via_dll4__egfl6__itgb1a__D__rerio_/#model-overview","title":"Model Overview","text":"<p>This model represents the regulation of sprouting angiogenesis in zebrafish (Danio rerio) through the interactions between three key proteins: dll4, egfl6, and itgb1a. The model focuses on how these proteins regulate the process of sprouting angiogenesis, which is critical for proper blood vessel formation during development.</p>"},{"location":"reviews/5ae3b0f600000435-Regulation_of_sprouting_angiogenesis_via_dll4__egfl6__itgb1a__D__rerio_/#model-structure-and-biological-accuracy","title":"Model Structure and Biological Accuracy","text":"<p>The model includes four key molecular activities:</p> <ol> <li>EGFL6 (ZFIN:ZDB-GENE-040718-157) has two annotated molecular functions:</li> <li>Receptor ligand activity (GO:0048018)</li> <li>Integrin binding (GO:0005178)</li> <li>Occurs in somite (ZFA:0000155)</li> <li> <p>Part of positive regulation of cell migration involved in sprouting angiogenesis (GO:0090050)</p> </li> <li> <p>ITGB1A (ZFIN:ZDB-GENE-060803-2) has:</p> </li> <li>Signaling receptor activity (GO:0038023)</li> <li> <p>Occurs in endothelial cell (ZFA:0009065)</p> </li> <li> <p>DLL4 (ZFIN:ZDB-GENE-041014-73) has:</p> </li> <li>Notch binding (GO:0005112)</li> <li> <p>Part of Notch signaling pathway (GO:0007219)</p> </li> <li> <p>Causal Relationships:</p> </li> <li>EGFL6 directly positively regulates ITGB1A</li> <li>EGFL6 has part EGFL6 (representing its integrin binding activity)</li> <li>ITGB1A directly negatively regulates DLL4</li> </ol> <p>The biological evidence supporting these relationships is based on literature including PMID:27780917 and experimental evidence including mutant phenotype evidence (ECO:0000315).</p>"},{"location":"reviews/5ae3b0f600000435-Regulation_of_sprouting_angiogenesis_via_dll4__egfl6__itgb1a__D__rerio_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>Based on the examination of the model and the GO-CAM best practices, I've identified the following:</p>"},{"location":"reviews/5ae3b0f600000435-Regulation_of_sprouting_angiogenesis_via_dll4__egfl6__itgb1a__D__rerio_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Proper use of causal relationships: The model correctly uses RO:0002629 (directly positively regulates) to connect the ligand activity (EGFL6) to its receptor (ITGB1A).</p> </li> <li> <p>Appropriate evidence codes: The model uses appropriate evidence codes for each assertion, including experimental evidence (ECO:0000315 - mutant phenotype evidence used in manual assertion) and author statements (ECO:0000304).</p> </li> <li> <p>Cellular context: The model includes information about the cellular localization of the activities (somite for EGFL6 and endothelial cell for ITGB1A).</p> </li> <li> <p>Biological process context: Each activity is appropriately contextualized with the relevant biological process.</p> </li> </ol>"},{"location":"reviews/5ae3b0f600000435-Regulation_of_sprouting_angiogenesis_via_dll4__egfl6__itgb1a__D__rerio_/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Missing input relationships: According to the signaling receptor activity annotation guidelines, the receptor (ITGB1A) should have a \"has input\" relationship to its downstream effector. Currently, there is no specification of what molecular entity ITGB1A has as input.</p> </li> <li> <p>Regulation pathway completion: While the model shows ITGB1A negatively regulates DLL4, it's not entirely clear how DLL4's Notch binding activity fits into the larger regulatory pathway. Based on the literature, DLL4-Notch signaling plays a critical role in regulating sprouting angiogenesis, but the model doesn't completely capture the downstream effects of DLL4 activity.</p> </li> <li> <p>Limited information on specific mechanism: The model provides a high-level overview of the regulatory relationships but doesn't fully capture the details of how these activities lead to the regulation of sprouting angiogenesis.</p> </li> </ol>"},{"location":"reviews/5ae3b0f600000435-Regulation_of_sprouting_angiogenesis_via_dll4__egfl6__itgb1a__D__rerio_/#biological-content-accuracy","title":"Biological Content Accuracy","text":"<p>From the literature I retrieved, it appears that:</p> <ol> <li> <p>DLL4 is a critical Notch ligand in vascular development that is expressed in tip cells of growing blood vessel sprouts and helps regulate proper angiogenesis.</p> </li> <li> <p>EGFL6 appears to be functioning as a receptor ligand that positively regulates ITGB1A (integrin beta 1a), which is involved in signaling receptor activity.</p> </li> <li> <p>The negative regulation of DLL4 by ITGB1A aligns with literature showing complex regulatory networks in sprouting angiogenesis, where integrin signaling can modulate Notch pathway components.</p> </li> </ol> <p>The model appears to be biologically accurate in depicting a pathway where EGFL6 activates ITGB1A signaling, which in turn negatively regulates DLL4-mediated Notch signaling. This regulatory circuit would contribute to the proper control of sprouting angiogenesis during zebrafish development.</p>"},{"location":"reviews/5ae3b0f600000435-Regulation_of_sprouting_angiogenesis_via_dll4__egfl6__itgb1a__D__rerio_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add \"has input\" relationship: Add a \"has input\" relationship from ITGB1A to its downstream effector to better comply with the signaling receptor activity annotation guidelines.</p> </li> <li> <p>Complete the regulatory pathway: Consider expanding the model to show the downstream effects of DLL4-Notch binding, possibly including the effects on cxcr4a expression which was highlighted in the literature as an important factor regulated by Notch signaling during angiogenesis.</p> </li> <li> <p>Add additional biological context: The model could benefit from additional information about how this regulatory circuit fits into the broader process of sprouting angiogenesis and blood vessel formation.</p> </li> <li> <p>Include cellular details: The literature indicates specific cellular dynamics (tip cells vs. stalk cells) that are important for understanding the spatial regulation of angiogenesis. Including these details would enhance the model's biological accuracy.</p> </li> </ol>"},{"location":"reviews/5ae3b0f600000435-Regulation_of_sprouting_angiogenesis_via_dll4__egfl6__itgb1a__D__rerio_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"Regulation of sprouting angiogenesis via dll4, egfl6, itgb1a (D. rerio)\" provides a valuable representation of a key regulatory pathway in sprouting angiogenesis in zebrafish. It accurately captures the basic relationships between EGFL6, ITGB1A, and DLL4, supported by experimental evidence.</p> <p>While the model largely follows GO-CAM best practices, there are opportunities for enhancement, particularly in specifying the inputs for receptor activities and expanding the model to more fully capture the downstream effects of DLL4-Notch signaling.</p> <p>The model is biologically sound and supported by literature evidence, depicting a regulatory circuit that contributes to the control of sprouting angiogenesis during zebrafish development.</p>"},{"location":"reviews/5b528b1100000489-XBP_1_is_a_cell_nonautonomous_regulator_of_stress_resistance_and_longevity/","title":"5b528b1100000489 XBP 1 is a cell nonautonomous regulator of stress resistance and longevity","text":"<p>Now I'll review the GO-CAM model based on the documentation and literature I've gathered.</p>"},{"location":"reviews/5b528b1100000489-XBP_1_is_a_cell_nonautonomous_regulator_of_stress_resistance_and_longevity/#go-cam-model-review-for-gomodel5b528b1100000489","title":"GO-CAM Model Review for gomodel:5b528b1100000489","text":""},{"location":"reviews/5b528b1100000489-XBP_1_is_a_cell_nonautonomous_regulator_of_stress_resistance_and_longevity/#model-title","title":"Model Title:","text":"<p>\"XBP-1 is a cell-nonautonomous regulator of stress resistance and longevity\"</p>"},{"location":"reviews/5b528b1100000489-XBP_1_is_a_cell_nonautonomous_regulator_of_stress_resistance_and_longevity/#overview","title":"Overview:","text":"<p>This GO-CAM model represents the molecular pathway related to XBP-1's role in stress resistance and longevity in C. elegans. The model captures the IRE-1/XBP-1 pathway involved in the unfolded protein response (UPR), particularly focusing on how IRE-1's RNA endonuclease activity leads to XBP-1 regulation, which in turn affects neuronal function via UNC-13.</p>"},{"location":"reviews/5b528b1100000489-XBP_1_is_a_cell_nonautonomous_regulator_of_stress_resistance_and_longevity/#model-structure-assessment","title":"Model Structure Assessment:","text":"<ol> <li>Activities and connections:</li> <li>The model shows IRE-1 RNA endonuclease activity (GO:0004521) in two locations (intestine and neuronal cell body)</li> <li>IRE-1 directly positively regulates XBP-1's RNA polymerase II transcription DNA binding (GO:0000977)</li> <li>XBP-1 causally positively regulates UNC-13's syntaxin-1 binding (GO:0017075)</li> <li> <p>UNC-13 is part of synaptic vesicle exocytosis (GO:0016079)</p> </li> <li> <p>Biological validity:</p> </li> <li>The model accurately captures the IRE-1/XBP-1 pathway in the unfolded protein response</li> <li>The representation of XBP-1 as a transcription factor is appropriate</li> <li> <p>The connection to UNC-13 and synaptic function reflects the cell-nonautonomous effect described in the model title</p> </li> <li> <p>Completeness assessment:</p> </li> <li>The model includes appropriate molecular functions, cellular components, and biological processes</li> <li>Evidence codes and references are properly included</li> <li>The causal relationships use appropriate predicates</li> </ol>"},{"location":"reviews/5b528b1100000489-XBP_1_is_a_cell_nonautonomous_regulator_of_stress_resistance_and_longevity/#review-comments","title":"Review Comments:","text":"<ol> <li>Strengths:</li> <li>The model accurately represents the known biology of the IRE-1/XBP-1 pathway in C. elegans</li> <li>The causal relationships properly show that IRE-1 directly positively regulates XBP-1</li> <li> <p>The model captures cell-nonautonomous regulation by showing XBP-1 functioning in neurons while affecting intestinal processes</p> </li> <li> <p>Suggested improvements:</p> </li> <li>The model could benefit from explicitly including the IRE1-mediated unfolded protein response (GO:0036498) as a biological process associated with IRE-1's activity in the intestine, similar to how it's included for the neuronal activity</li> <li>Consider including a representation of how IRE-1 is activated during ER stress, which would provide fuller context of the pathway</li> <li> <p>The model could explicitly include how XBP-1 relates to longevity and stress resistance, which are mentioned in the title but not fully represented in the model</p> </li> <li> <p>Compliance with GO-CAM guidelines:</p> </li> <li>The transcription factor annotation aligns with the guidelines, using appropriate GO terms for DNA binding (GO:0000977)</li> <li>The RNA endonuclease activity of IRE-1 is properly represented</li> <li>The model correctly uses the \"directly positively regulates\" relationship (RO:0002629) between the activities</li> </ol>"},{"location":"reviews/5b528b1100000489-XBP_1_is_a_cell_nonautonomous_regulator_of_stress_resistance_and_longevity/#conclusion","title":"Conclusion:","text":"<p>This GO-CAM model successfully represents the IRE-1/XBP-1 pathway in C. elegans and its role in regulating UNC-13 and synaptic function. The model accurately captures the cell-nonautonomous nature of this regulation as described in the scientific literature. The causal relationships between molecular activities are appropriate, and the evidence for these assertions is well-documented with appropriate references.</p> <p>The model would benefit from minor additions to more fully represent the connection to longevity and stress resistance mentioned in the title, but overall it is a high-quality representation of this biological pathway that complies with GO-CAM best practices.</p> <p>Model ID: gomodel:5b528b1100000489</p>"},{"location":"reviews/5b91dbd100002057-Antifungal_innate_immune_response_in_the_hypodermis_via_MAPK_cascade__C__elegans_/","title":"5b91dbd100002057 Antifungal innate immune response in the hypodermis via MAPK cascade  C  elegans","text":"<p>Based on my review of the GO-CAM model \"Antifungal innate immune response in the hypodermis via MAPK cascade (C. elegans)\" (gomodel:5b91dbd100002057), here is my assessment:</p>"},{"location":"reviews/5b91dbd100002057-Antifungal_innate_immune_response_in_the_hypodermis_via_MAPK_cascade__C__elegans_/#go-cam-review-antifungal-innate-immune-response-model-gomodel5b91dbd100002057","title":"GO-CAM Review: Antifungal innate immune response model (gomodel:5b91dbd100002057)","text":""},{"location":"reviews/5b91dbd100002057-Antifungal_innate_immune_response_in_the_hypodermis_via_MAPK_cascade__C__elegans_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM represents the antifungal innate immune response in the C. elegans hypodermis involving a MAPK cascade. The model describes how C. elegans responds to fungal infection via a signaling pathway that leads to antimicrobial peptide production.</p>"},{"location":"reviews/5b91dbd100002057-Antifungal_innate_immune_response_in_the_hypodermis_via_MAPK_cascade__C__elegans_/#biological-content-assessment","title":"Biological Content Assessment","text":""},{"location":"reviews/5b91dbd100002057-Antifungal_innate_immune_response_in_the_hypodermis_via_MAPK_cascade__C__elegans_/#pathway-components-and-flow","title":"Pathway Components and Flow","text":"<p>The model successfully captures the MAPK signaling cascade involved in C. elegans antifungal innate immunity as described in the literature (PMID:19380113). The key components are properly represented:</p> <ol> <li>G-protein signaling components: </li> <li>GPA-12 (G-protein alpha subunit) and RACK-1 (G-protein beta-like)</li> <li> <p>These proteins initiate the signaling cascade upon infection</p> </li> <li> <p>Phospholipase C activities: </p> </li> <li> <p>EGL-8 and PLC-3 phospholipase C activities correctly modeled as upstream of PKC</p> </li> <li> <p>PKC signaling: </p> </li> <li>TPA-1 (PKC-delta homolog) and PKC-3 activities</li> <li> <p>Properly placed downstream of G-protein signaling</p> </li> <li> <p>MAPK cascade components: </p> </li> <li>NSY-1 (MAPKKK) \u2192 SEK-1 (MAPKK) \u2192 PMK-1 (MAPK)</li> <li> <p>The directional flow of the cascade is correctly represented</p> </li> <li> <p>Output: </p> </li> <li>The pathway appropriately ends with NLP-29, an antimicrobial peptide involved in the response</li> </ol>"},{"location":"reviews/5b91dbd100002057-Antifungal_innate_immune_response_in_the_hypodermis_via_MAPK_cascade__C__elegans_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The evidence cited in the model is strong and appropriate:</p> <ul> <li>Multiple experimental evidence codes are used (ECO:0000315 for mutant phenotype evidence, ECO:0000314 for direct assay evidence)</li> <li>Key publications like PMID:19380113 that describe the pathway are cited</li> <li>Appropriate functional annotation evidence is provided for protein activities</li> </ul>"},{"location":"reviews/5b91dbd100002057-Antifungal_innate_immune_response_in_the_hypodermis_via_MAPK_cascade__C__elegans_/#pathway-context","title":"Pathway Context","text":"<p>The model correctly places the activities in the context of the biological process GO:0061760 \"antifungal innate immune response\" and appropriate tissues (hypodermis).</p>"},{"location":"reviews/5b91dbd100002057-Antifungal_innate_immune_response_in_the_hypodermis_via_MAPK_cascade__C__elegans_/#technical-assessment","title":"Technical Assessment","text":""},{"location":"reviews/5b91dbd100002057-Antifungal_innate_immune_response_in_the_hypodermis_via_MAPK_cascade__C__elegans_/#go-cam-best-practices","title":"GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices:</p> <ul> <li>Activities are connected with appropriate causal predicates (RO:0002304 \"causally upstream of, positive effect\" and RO:0002629 \"directly positively regulates\")</li> <li>Molecular functions are properly assigned to gene products</li> <li>The biological process context is correctly specified</li> </ul>"},{"location":"reviews/5b91dbd100002057-Antifungal_innate_immune_response_in_the_hypodermis_via_MAPK_cascade__C__elegans_/#parsimonious-representation","title":"Parsimonious Representation","text":"<p>The model provides a clear and concise representation of the pathway that is easy to follow:</p> <ul> <li>The causal flow is logically organized</li> <li>Components are appropriately grouped by their role in the pathway</li> <li>No redundant or extraneous elements are included</li> </ul>"},{"location":"reviews/5b91dbd100002057-Antifungal_innate_immune_response_in_the_hypodermis_via_MAPK_cascade__C__elegans_/#technical-issues","title":"Technical Issues","text":"<p>No major technical issues were identified in the model structure or representation.</p>"},{"location":"reviews/5b91dbd100002057-Antifungal_innate_immune_response_in_the_hypodermis_via_MAPK_cascade__C__elegans_/#minor-improvement-suggestions","title":"Minor Improvement Suggestions","text":"<ol> <li> <p>Additional contextual information: While the model correctly locates activities in the hypodermis, adding more specific cellular component information for some proteins might be valuable.</p> </li> <li> <p>Publication evidence: For some activities, more recent publications could be added to strengthen the evidence base.</p> </li> <li> <p>Connection to downstream effects: The model could potentially be extended to show how NLP-29 functions to mediate fungal resistance.</p> </li> </ol>"},{"location":"reviews/5b91dbd100002057-Antifungal_innate_immune_response_in_the_hypodermis_via_MAPK_cascade__C__elegans_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model accurately represents the C. elegans antifungal immune response pathway via the MAPK cascade as described in the literature. The causal relationships between activities are well-established with appropriate evidence. The model adheres to GO-CAM best practices and presents a clear, logical representation of the biological process.</p> <p>The model successfully integrates multiple experimental findings into a coherent pathway that describes how C. elegans detects and responds to fungal pathogens through G-protein signaling, PKC activation, and MAPK cascade signaling, ultimately leading to antimicrobial peptide production.</p> <p>This is a high-quality GO-CAM model that meets the standards for biological accuracy, evidence support, and technical representation.</p>"},{"location":"reviews/5b91dbd100002241-Antifungal_innate_immune_response_in_the_hypodermis_via_transforming_growth_factor_beta_receptor_signaling_pathway__C__elegans_/","title":"5b91dbd100002241 Antifungal innate immune response in the hypodermis via transforming growth factor beta receptor signaling pathway  C  elegans","text":"<p>Based on my review of the model and the related documentation, I'll now provide a comprehensive evaluation of GO-CAM model gomodel:5b91dbd100002241.</p>"},{"location":"reviews/5b91dbd100002241-Antifungal_innate_immune_response_in_the_hypodermis_via_transforming_growth_factor_beta_receptor_signaling_pathway__C__elegans_/#review-of-go-cam-model-gomodel5b91dbd100002241","title":"Review of GO-CAM model: gomodel:5b91dbd100002241","text":""},{"location":"reviews/5b91dbd100002241-Antifungal_innate_immune_response_in_the_hypodermis_via_transforming_growth_factor_beta_receptor_signaling_pathway__C__elegans_/#model-overview","title":"Model Overview","text":"<p>Title: Antifungal innate immune response in the hypodermis via transforming growth factor beta receptor signaling pathway (C. elegans) ID: gomodel:5b91dbd100002241 Taxon: NCBITaxon:6239 (Caenorhabditis elegans) Status: Production</p>"},{"location":"reviews/5b91dbd100002241-Antifungal_innate_immune_response_in_the_hypodermis_via_transforming_growth_factor_beta_receptor_signaling_pathway__C__elegans_/#summary-of-the-model","title":"Summary of the Model","text":"<p>This model represents a key aspect of the antifungal innate immune response in C. elegans, specifically the TGF-\u03b2 pathway that regulates the expression of antimicrobial peptides in the epidermis (hypodermis) after fungal infection by Drechmeria coniospora. The model focuses on a non-canonical TGF-\u03b2 signaling pathway that functions independently of the p38 MAPK pathway to regulate caenacin (CNC) family antimicrobial peptide genes.</p>"},{"location":"reviews/5b91dbd100002241-Antifungal_innate_immune_response_in_the_hypodermis_via_transforming_growth_factor_beta_receptor_signaling_pathway__C__elegans_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Well-supported by evidence: The model is well-supported by experimental evidence from multiple publications, particularly PMID:19198592, which investigated the neuroimmune regulation of antimicrobial peptide expression.</p> </li> <li> <p>Pathway completeness: The model captures the key components of the TGF-\u03b2 signaling pathway from the ligand (DBL-1) through the receptors (DAF-4 and SMA-6) to the downstream transcription factor (SMA-3).</p> </li> <li> <p>Accurate representation of cell-to-cell signaling: The model correctly represents that DBL-1 is produced in neurons and acts non-cell-autonomously on the epidermis, which is consistent with the literature evidence.</p> </li> <li> <p>Clear biological process context: All activities are correctly annotated as part of the defense response to fungus (GO:0050832), which provides appropriate context.</p> </li> </ol>"},{"location":"reviews/5b91dbd100002241-Antifungal_innate_immune_response_in_the_hypodermis_via_transforming_growth_factor_beta_receptor_signaling_pathway__C__elegans_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing receptor complex representation: According to the \"How to annotate complexes in GO-CAM\" guidelines, the model should represent the heterodimeric receptor formed by SMA-6 (type I receptor) and DAF-4 (type II receptor). The current model shows them as separate entities but doesn't explicitly model their interaction as a complex. The literature (PMID:9847239) clearly states they form a heterodimeric receptor.</p> </li> <li> <p>Incomplete SMAD pathway representation: The model correctly shows that SMA-3 is required for this pathway but doesn't fully explain why SMA-2 and SMA-4 are not involved, despite these typically being required for canonical TGF-\u03b2 signaling. This is mentioned in the paper (PMID:19198592), but the model doesn't represent this non-canonical aspect clearly.</p> </li> <li> <p>Missing molecular function for CNC-2: The protein product of WB:WBGene00000556 (cnc-2) is annotated with molecular_function (GO:0003674), which indicates \"no evidence data found.\" Given that the paper identifies this as an antimicrobial peptide, a more specific function might be appropriate.</p> </li> <li> <p>Missing ligand-receptor interaction: According to the \"Signaling receptor activity annotation guidelines,\" the relation between a ligand and its target receptor should be captured with 'has input' and the causal relation should be 'directly positively regulates.' The model shows DBL-1 positively regulating the receptors but doesn't clearly capture the ligand-receptor binding relationship.</p> </li> <li> <p>Location information: The cellular component information could be more specific, especially for specifying that DBL-1 acts in the extracellular space and the receptors are located in the plasma membrane.</p> </li> </ol>"},{"location":"reviews/5b91dbd100002241-Antifungal_innate_immune_response_in_the_hypodermis_via_transforming_growth_factor_beta_receptor_signaling_pathway__C__elegans_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the key finding from the literature that antimicrobial peptide genes of the caenacin (CNC) family are regulated by a non-canonical TGF-\u03b2 signaling pathway during fungal infection, which is distinct from the p38 MAPK pathway that regulates other antimicrobial peptides (NLP family). </p> <p>The model correctly represents: - DBL-1 (TGF-\u03b2 homolog) acts in a paracrine manner from neurons to the epidermis - The signaling requires both the type I receptor SMA-6 and the type II receptor DAF-4 - The pathway depends on SMA-3 (SMAD) but not on other SMADs (SMA-2, SMA-4) - The pathway ultimately regulates expression of antimicrobial peptides (cnc-2)</p> <p>The use of causal relationships in the model (RO:0002304 \"causally upstream of, positive effect\" and RO:0002629 \"directly positively regulates\") is consistent with the biology described in the literature.</p>"},{"location":"reviews/5b91dbd100002241-Antifungal_innate_immune_response_in_the_hypodermis_via_transforming_growth_factor_beta_receptor_signaling_pathway__C__elegans_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add receptor complex representation: Explicitly model the SMA-6/DAF-4 heterodimeric receptor complex as described in the \"How to annotate complexes in GO-CAM\" guidelines.</p> </li> <li> <p>Expand molecular function annotations: Replace the generic molecular_function (GO:0003674) for CNC-2 with a more specific term related to antimicrobial peptide activity if evidence exists.</p> </li> <li> <p>Clarify the non-canonical nature: Add additional annotations or notes to highlight that this represents a non-canonical TGF-\u03b2 signaling pathway that doesn't require SMA-2 and SMA-4, which distinguishes it from the canonical pathway.</p> </li> <li> <p>Add cellular location information: Specify the cellular components for each activity more precisely, especially noting that DBL-1 acts in the extracellular space and the receptors are located in the plasma membrane.</p> </li> <li> <p>Enhance ligand-receptor representation: Follow the signaling receptor activity guidelines more closely to represent the relationship between DBL-1 and the receptor complex.</p> </li> </ol>"},{"location":"reviews/5b91dbd100002241-Antifungal_innate_immune_response_in_the_hypodermis_via_transforming_growth_factor_beta_receptor_signaling_pathway__C__elegans_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides a valuable representation of the non-canonical TGF-\u03b2 signaling pathway in C. elegans antifungal immunity. It captures the key components and relationships of this pathway and is well-supported by experimental evidence. With the suggested improvements, particularly in representing receptor complexes and cellular locations, the model would provide an even more comprehensive and accurate representation of this important immune signaling pathway.</p>"},{"location":"reviews/5ce58dde00001215-Mouse_Aatf_antiapoptosis/","title":"5ce58dde00001215 Mouse Aatf antiapoptosis","text":"<p>Now let me also check the information in the referenced PMID in the GO-CAM model to understand the functional relationship between these proteins:</p> <p>Let me analyze the GO-CAM model and review it based on the information I've collected and the GO-CAM guidelines.</p>"},{"location":"reviews/5ce58dde00001215-Mouse_Aatf_antiapoptosis/#review-of-go-cam-model-5ce58dde00001215-mouse-aatf-antiapoptosis","title":"Review of GO-CAM Model 5ce58dde00001215 \"Mouse-Aatf-antiapoptosis\"","text":""},{"location":"reviews/5ce58dde00001215-Mouse_Aatf_antiapoptosis/#overview-of-the-model","title":"Overview of the Model:","text":"<p>This GO-CAM model describes the role of AATF (Apoptosis Antagonizing Transcription Factor) in protecting cells from ER stress-mediated apoptosis in mouse pancreatic beta cells, primarily through regulating the transcription factor activity of a complex containing AATF and STAT3, which then activates AKT1 expression.</p>"},{"location":"reviews/5ce58dde00001215-Mouse_Aatf_antiapoptosis/#model-components","title":"Model Components:","text":"<ol> <li>Core Proteins:</li> <li>AATF (MGI:MGI:1328355): Anti-apoptotic factor that protects cells from ER stress-mediated cell death</li> <li>STAT3 (MGI:MGI:103038): Transcription factor that forms a complex with AATF</li> <li> <p>AKT1 (MGI:MGI:87986): Serine/threonine kinase with anti-apoptotic functions</p> </li> <li> <p>Biological Context:</p> </li> <li>This pathway operates in type B pancreatic cells (CL:0000169)</li> <li>It's part of the endoplasmic reticulum unfolded protein response (GO:0030968)</li> <li> <p>Leads to negative regulation of intrinsic apoptotic signaling pathway (GO:2001243)</p> </li> <li> <p>Functional Relationships:</p> </li> <li>XBP1 positively regulates AATF</li> <li>ERN1 positively regulates AATF</li> <li>AATF and ERN1 positively regulate STAT3-containing transcription complex</li> <li>EIF2AK3 positively regulates EIF2A which regulates STAT3-containing complex</li> <li>AATF-STAT3 complex directly positively regulates AKT1</li> <li>AKT1 inhibits apoptosis</li> </ol>"},{"location":"reviews/5ce58dde00001215-Mouse_Aatf_antiapoptosis/#assessment-of-model-according-to-go-cam-guidelines","title":"Assessment of Model according to GO-CAM Guidelines:","text":""},{"location":"reviews/5ce58dde00001215-Mouse_Aatf_antiapoptosis/#strengths","title":"Strengths:","text":"<ol> <li> <p>Accurate molecular functions: The transcription factor complex containing AATF and STAT3 is properly annotated with DNA-binding transcription factor activity (GO:0003700), which is appropriate based on the role of this complex in transcriptional regulation.</p> </li> <li> <p>Clear causal relationships: The model uses appropriate causal associations:</p> </li> <li>RO:0002304 \"causally upstream of, positive effect\" for upstream regulators</li> <li>RO:0002629 \"directly positively regulates\" for the STAT3 complex's effect on AKT1</li> <li> <p>RO:0004047 (which appears in the model) for EIF2A's relationship with the complex</p> </li> <li> <p>Cellular context: The model includes the cellular location (nucleus GO:0005634 for the transcription complex; pancreatic beta cells CL:0000169 for AATF).</p> </li> <li> <p>Biological process context: Components are correctly annotated as part of the ER unfolded protein response (GO:0030968).</p> </li> </ol>"},{"location":"reviews/5ce58dde00001215-Mouse_Aatf_antiapoptosis/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Complex Representation: According to the \"How to annotate complexes in GO-CAM\" document, when using a protein complex (GO:0005667 transcription regulator complex), the model should indicate which specific proteins carry the molecular activities. Here, the model correctly shows that both STAT3 and AATF are in the complex, but:</p> </li> <li> <p>The composition of the complex is incomplete, as based on the literature, this complex formation is enhanced by STAT3 binding to phosphorylated AATF, and this relationship isn't captured.</p> </li> <li> <p>According to the reference PMID:19911006, AATF and STAT3 interact directly, and this interaction enhances the binding of STAT3 to the AKT1 promoter, but this mechanistic detail isn't fully captured.</p> </li> <li> <p>Missing Phosphorylation Events: The PMID:19911006 reference emphasizes the importance of phosphorylation:</p> </li> <li>AATF is induced by ER stress through PERK-eIF2alpha phosphorylation</li> <li>STAT3 phosphorylation is enhanced by AATF</li> <li>AKT phosphorylation is also important for its activity</li> </ol> <p>These phosphorylation events are critical for the pathway functionality but aren't captured in the model.</p> <ol> <li> <p>Incomplete Biological Processes: The terminal effect of this pathway is properly captured as \"negative regulation of intrinsic apoptotic signaling pathway,\" but intermediate processes like \"transcriptional regulation of AKT1\" could have been included.</p> </li> <li> <p>Evidence Codes: While the model uses appropriate evidence codes (ECO:0000315 for mutant phenotype evidence and ECO:0000314 for direct assay evidence), some of the relationships might benefit from more specific evidence annotations.</p> </li> <li> <p>Missing Inputs for Transcription Factor Activity: According to the \"DNA-binding transcription factor activity annotation guidelines,\" the transcription factor activity should have \"has input\" relationships to the gene it regulates. The model shows that the complex directly positively regulates AKT1 activity, but doesn't explicitly show that it regulates AKT1 gene expression.</p> </li> </ol>"},{"location":"reviews/5ce58dde00001215-Mouse_Aatf_antiapoptosis/#recommendations-for-improvement","title":"Recommendations for Improvement:","text":"<ol> <li> <p>Add Phosphorylation States: Include the critical phosphorylation events (especially for STAT3 at Tyr-705 and Ser-727, and AATF phosphorylation by PERK pathway).</p> </li> <li> <p>Refine Complex Representation: Better specify the molecular interaction between AATF and STAT3 and how this interaction enhances STAT3 DNA binding.</p> </li> <li> <p>Complete the Transcriptional Regulation Representation: Add \"has input\" relationship from the transcription complex to the AKT1 gene, as per the transcription factor annotation guidelines.</p> </li> <li> <p>Add More Specific Biological Process Terms: Include intermediate processes like \"regulation of AKT1 transcription\" to better represent the mechanistic details.</p> </li> <li> <p>Enhance Cellular Context: Add more detailed subcellular localization for different components of the pathway, especially the translocation events mentioned in the paper.</p> </li> </ol>"},{"location":"reviews/5ce58dde00001215-Mouse_Aatf_antiapoptosis/#conclusion","title":"Conclusion:","text":"<p>This GO-CAM model provides a good representation of AATF's role in protecting cells from ER stress-induced apoptosis through promoting AKT1 expression via the STAT3 transcription factor complex. The model correctly captures the major players and relationships, but could be enhanced by including more mechanistic details about phosphorylation events, complex formation, and transcriptional regulation specifics.</p> <p>The model is consistent with the reference literature (PMID:19911006) and follows GO-CAM best practices, though some refinements would make it even more informative and mechanistically accurate.</p>"},{"location":"reviews/5df932e000000330-Protease_activity_in_epithelial_morphogenesis_via_f2rl1_2__spint1a__st14a__D__rerio_/","title":"5df932e000000330 Protease activity in epithelial morphogenesis via f2rl1 2  spint1a  st14a  D  rerio","text":"<p>Based on my review of the GO-CAM model gomodel:5df932e000000330 and the relevant literature, I will now provide a comprehensive assessment of this model.</p>"},{"location":"reviews/5df932e000000330-Protease_activity_in_epithelial_morphogenesis_via_f2rl1_2__spint1a__st14a__D__rerio_/#review-of-go-cam-model-gomodel5df932e000000330","title":"Review of GO-CAM Model: gomodel:5df932e000000330","text":""},{"location":"reviews/5df932e000000330-Protease_activity_in_epithelial_morphogenesis_via_f2rl1_2__spint1a__st14a__D__rerio_/#model-overview","title":"Model Overview","text":"<p>Title: Protease activity in epithelial morphogenesis via f2rl1.2, spint1a, st14a (D. rerio) Taxon: NCBITaxon:7955 (Danio rerio/zebrafish) Status: Production Model ID: https://bioregistry.io/go.model:5df932e000000330</p> <p>This model captures a signaling pathway in zebrafish involving protease activity regulation in epithelial morphogenesis, specifically focusing on the roles of f2rl1.2 (Par2b), spint1a (Hai1a), and st14a (matriptase).</p>"},{"location":"reviews/5df932e000000330-Protease_activity_in_epithelial_morphogenesis_via_f2rl1_2__spint1a__st14a__D__rerio_/#biological-context","title":"Biological Context","text":"<p>The model represents a signaling pathway described in the referenced literature (PMID:29301867), which studies the role of protease-activated receptor 2 (Par2b) in matriptase-dependent skin abnormalities in Hai1a-deficient zebrafish embryos. The paper reports that Par2b signaling regulates epithelial cell extrusion, cell-cell contacts, proliferation, and inflammation in zebrafish epidermis.</p>"},{"location":"reviews/5df932e000000330-Protease_activity_in_epithelial_morphogenesis_via_f2rl1_2__spint1a__st14a__D__rerio_/#model-evaluation","title":"Model Evaluation","text":""},{"location":"reviews/5df932e000000330-Protease_activity_in_epithelial_morphogenesis_via_f2rl1_2__spint1a__st14a__D__rerio_/#1-structural-assessment","title":"1. Structural Assessment","text":"<p>The model consists of 8 activities (molecular functions) connected by causal relationships:</p> <ul> <li>Four activities represent peptidase inhibitor activity (GO:0030414) enabled by spint1a (ZFIN:ZDB-GENE-040426-2169)</li> <li>Three activities represent peptidase activity (GO:0008233) enabled by st14a (ZFIN:ZDB-GENE-030131-6496)</li> <li>Three activities represent unspecified molecular functions (GO:0003674) enabled by f2rl1.2 (ZFIN:ZDB-GENE-070615-24)</li> </ul> <p>The activities are connected by causal relationships primarily using \"directly negatively regulates\" (RO:0002630) and \"directly positively regulates\" (RO:0002629) relationships.</p>"},{"location":"reviews/5df932e000000330-Protease_activity_in_epithelial_morphogenesis_via_f2rl1_2__spint1a__st14a__D__rerio_/#2-biological-content-assessment","title":"2. Biological Content Assessment","text":"<p>The model accurately captures several key aspects of the biological pathway:</p> <ol> <li> <p>Protease inhibition pathway: spint1a (Hai1a) inhibits st14a (matriptase) activities, represented by RO:0002630 (directly negatively regulates) relationships.</p> </li> <li> <p>Downstream regulation: st14a activities positively regulate f2rl1.2 (Par2b) activities, represented by RO:0002629 (directly positively regulates) relationships.</p> </li> <li> <p>Biological context: The peptidase activities are correctly annotated as being \"part of\" protein processing (GO:0016485).</p> </li> </ol> <p>These relationships align with the findings in the paper, which describes Hai1a as an inhibitor of matriptase (st14a), and matriptase as an activator of Par2b (f2rl1.2).</p>"},{"location":"reviews/5df932e000000330-Protease_activity_in_epithelial_morphogenesis_via_f2rl1_2__spint1a__st14a__D__rerio_/#3-evidence-assessment","title":"3. Evidence Assessment","text":"<p>The model uses appropriate evidence codes:</p> <ul> <li>ECO:0000315 (mutant phenotype evidence) with appropriate ZFIN genotype references</li> <li>ECO:0000316 (genetic interaction evidence) </li> <li>ECO:0000314 (direct assay evidence)</li> </ul> <p>All evidence is tied to PMID:29301867, which is the primary source of the assertions.</p>"},{"location":"reviews/5df932e000000330-Protease_activity_in_epithelial_morphogenesis_via_f2rl1_2__spint1a__st14a__D__rerio_/#issues-and-suggestions-for-improvement","title":"Issues and Suggestions for Improvement","text":"<ol> <li>Molecular Functions Specification:</li> <li> <p>f2rl1.2 (Par2b) is annotated with GO:0003674 (molecular_function), which is a root term. Based on the paper, Par2b functions as a G protein-coupled receptor. A more specific term such as \"G protein-coupled receptor activity\" would be more informative.</p> </li> <li> <p>Missing Biological Processes:</p> </li> <li> <p>The model could be enhanced by including additional biological processes mentioned in the paper, such as \"apical cell extrusion\" or \"epithelial cell migration,\" to better contextualize the molecular activities.</p> </li> <li> <p>Missing Cellular Components:</p> </li> <li> <p>The model lacks cellular component annotations. Given that the pathway involves membrane-localized proteins (matriptase is a membrane-tethered protease and Par2b is a transmembrane receptor), including cellular component information would strengthen the model.</p> </li> <li> <p>Pathway Completeness:</p> </li> <li> <p>The model represents a simplified version of the pathway described in the paper. Additional nodes could be included to capture:</p> <ul> <li>The role of Mmps (mentioned as being regulated by Par2b)</li> <li>The connection to Erbb2 signaling (mentioned as interacting with this pathway)</li> <li>Differential effects on periderm vs. basal keratinocytes</li> </ul> </li> <li> <p>Molecular Details:</p> </li> <li>The specific cleavage site of Par2b by matriptase (R28/M29 as described in the paper) could be more explicitly represented in the model.</li> </ol>"},{"location":"reviews/5df932e000000330-Protease_activity_in_epithelial_morphogenesis_via_f2rl1_2__spint1a__st14a__D__rerio_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:5df932e000000330 provides a reasonable representation of the protease signaling pathway involved in epithelial morphogenesis in zebrafish as described in PMID:29301867. The model correctly captures the inhibitory relationship between spint1a and st14a, and the activating relationship between st14a and f2rl1.2.</p> <p>However, the model could be improved by: 1. Using more specific molecular function terms for Par2b 2. Adding relevant biological processes and cellular components 3. Expanding the pathway to include additional components and interactions described in the literature 4. Providing more molecular details about the interactions</p> <p>Despite these limitations, the model is consistent with the biological content in the referenced literature and follows GO-CAM best practices for representing causal relationships between activities.</p>"},{"location":"reviews/5e72450500004019-SARS_COV2_HOST_/","title":"5e72450500004019 SARS COV2 HOST","text":"<p>Based on my review of the GO-CAM model and the relevant best practice documents, here is my assessment of the SARS-COV2/HOST model (gomodel:5e72450500004019):</p>"},{"location":"reviews/5e72450500004019-SARS_COV2_HOST_/#general-overview","title":"General Overview","text":"<p>This GO-CAM model represents SARS-CoV-2 viral interactions with host proteins and signaling pathways, focusing on how viral proteins interfere with the host innate immune response. The model includes:</p> <ol> <li>Host pattern recognition receptors (PRRs) like IFIH1 and RIG-I that detect viral RNA</li> <li>Downstream signaling through MAVS, TRAFs, and TBK1</li> <li>Activation of the transcription factor IRF3</li> <li>Multiple SARS-CoV-2 proteins (N, M, nsp1, nsp3, nsp6, nsp12, nsp13, nsp16, ORF6, ORF9b) that interfere with this pathway</li> </ol>"},{"location":"reviews/5e72450500004019-SARS_COV2_HOST_/#strengths","title":"Strengths","text":"<ol> <li>Comprehensive pathway representation: The model effectively captures the host innate immune signaling and viral interference mechanisms.</li> <li>Appropriate evidence associations: Each activity has supporting evidence from literature with PMIDs.</li> <li>Correct cellular compartmentalization: Activities are properly annotated with appropriate cellular locations.</li> <li>Appropriate causality relationships: The causal relationships between activities use appropriate predicates.</li> <li>Good representation of viral antagonism: The model clearly shows how different viral proteins interfere with host defense mechanisms.</li> </ol>"},{"location":"reviews/5e72450500004019-SARS_COV2_HOST_/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li>Protein sequestering activities (GO:0140311):</li> <li> <p>According to the sequestering proteins document, the relation between sequestering activity and the downstream activity should be \"directly negatively regulates\" (RO:0002630), which is correctly used in most cases. However, there is inconsistency with some protein sequestering activities.</p> </li> <li> <p>Activity <code>gomodel:5e72450500004019/6086f4f200000109</code> (nsp16 RNA binding) has a causal relation to downstream activity using RO:0002411 (causally upstream of) rather than the more specific RO:0002630 (directly negatively regulates).</p> </li> <li> <p>Missing activity inputs: </p> </li> <li> <p>For sequestering activities, the document states the relation between the protein that sequesters and its target should be \"has input\" but these are not explicitly captured in the model.</p> </li> <li> <p>Incomplete annotation: </p> </li> <li> <p>Activity <code>gomodel:5e72450500004019/5ee8120100000947</code> (nsp1 translation repressor activity) lacks cellular component annotation.</p> </li> <li> <p>PMID formatting issues:</p> </li> <li> <p>Several PMIDs have extra whitespace, e.g., \"PMID:\\n    17392790\" and \"PMID: 17392790\" which should be standardized.</p> </li> <li> <p>Automated changes noted:</p> </li> <li>The model has automated changes from 2023-03-16 where RO:0002212 was replaced by RO:0002630 and RO:0002213 was replaced by RO:0002629, which is appropriate for updating to standard relationship terms.</li> </ol>"},{"location":"reviews/5e72450500004019-SARS_COV2_HOST_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that effectively captures SARS-CoV-2 interference with host innate immune signaling. The model follows most GO-CAM best practices but would benefit from the following improvements:</p> <ol> <li>Standardize relationship predicates for protein sequestering activities</li> <li>Add explicit \"has input\" relations for sequestering activities</li> <li>Complete the cellular component annotation for nsp1 translation repressor activity</li> <li>Standardize PMID formatting</li> </ol> <p>The model provides valuable information about SARS-CoV-2 pathogenesis and successfully represents the complex interplay between viral and host proteins during infection. With the minor improvements suggested, it would fully comply with GO-CAM best practices.</p>"},{"location":"reviews/5e72450500004237-SARS_COV2_cycle/","title":"5e72450500004237 SARS COV2 cycle","text":"<p>Now let me review the GO-CAM model \"SARS-COV2/cycle\" (gomodel:5e72450500004237) based on GO-CAM best practices and standards:</p>"},{"location":"reviews/5e72450500004237-SARS_COV2_cycle/#go-cam-review-sars-cov2cycle-gomodel5e72450500004237","title":"GO-CAM Review: SARS-COV2/cycle (gomodel:5e72450500004237)","text":""},{"location":"reviews/5e72450500004237-SARS_COV2_cycle/#overview","title":"Overview","text":"<p>This model represents the SARS-CoV-2 viral life cycle, including viral entry, replication, transcription, and assembly processes. It includes both viral proteins and host factors involved in the viral life cycle.</p>"},{"location":"reviews/5e72450500004237-SARS_COV2_cycle/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Comprehensive representation: The model covers major aspects of the SARS-CoV-2 life cycle, including:</li> <li>Viral entry (S protein binding to cell surface)</li> <li>Fusion events</li> <li>RNA genome replication</li> <li>Viral protein processing</li> <li>Capsid assembly</li> <li> <p>Host-factor interactions</p> </li> <li> <p>Evidence-based assertions: Most activities and causal associations are supported by literature evidence with appropriate ECO codes and PMID references.</p> </li> <li> <p>Appropriate causal relationships: The model uses appropriate predicates for causal associations:</p> </li> <li>RO:0002629 \"directly positively regulates\" for positive regulatory interactions</li> <li>RO:0002630 \"directly negatively regulates\" for negative regulatory interactions</li> <li> <p>RO:0002411 \"causally upstream of\" for processes that are connected</p> </li> <li> <p>Cellular localization: Many activities are properly annotated with cellular locations using the \"occurs_in\" relation.</p> </li> </ol>"},{"location":"reviews/5e72450500004237-SARS_COV2_cycle/#improvement-areas","title":"Improvement Areas","text":"<ol> <li>Complex representation: </li> <li> <p>The model doesn't explicitly represent protein complexes using GO complex terms when multiple proteins work together (e.g., the replication-transcription complex). According to \"How to annotate complexes in GO-CAM,\" when the activity is shared by multiple proteins, this should be represented.</p> </li> <li> <p>Missing parts of the viral life cycle:</p> </li> <li> <p>The model appears to be missing or has limited representation of virus assembly, budding, and release phases.</p> </li> <li> <p>Causal flow clarity:</p> </li> <li> <p>Some of the causal relationships could be improved to better show the flow of the viral life cycle. For example, there are multiple upstream activities connected to \"fusogenic activity\" (GO:0140522), but the temporal sequence isn't clear.</p> </li> <li> <p>Process annotations:</p> </li> <li> <p>While most activities have \"part_of\" relationships to biological processes, some are missing these annotations, which would help contextualize the activities.</p> </li> <li> <p>Evidence codes: </p> </li> <li> <p>Some causal associations lack evidence codes, for example:</p> <ul> <li>The causal association between 60418ffa00002814 (GO:0008408 3'-5' exonuclease activity) and 5f46c3b700000325 (GO:0003968 RNA-dependent RNA polymerase activity) has no evidence code or citation.</li> <li>The causal association between 60ad85f700002547 (GO:0034736 cholesterol O-acyltransferase activity) and 5f46c3b700000583 (GO:0140522 fusogenic activity) lacks proper evidence.</li> </ul> </li> <li> <p>Automated changes note:</p> </li> <li>The model has comments indicating automated replacements of relation types (RO:0002212 replaced by RO:0002630 and RO:0002213 replaced by RO:0002629). This suggests there might have been systemic updates to the predicates.</li> </ol>"},{"location":"reviews/5e72450500004237-SARS_COV2_cycle/#specific-recommendations","title":"Specific Recommendations","text":"<ol> <li>Complete the viral life cycle representation:</li> <li>Add activities related to virion assembly, budding, and release</li> <li> <p>Ensure all key steps in the viral life cycle are represented</p> </li> <li> <p>Improve complex representation:</p> </li> <li> <p>For activities where multiple viral proteins work together (like nsp7, nsp8, and nsp12 in the replication complex), consider using appropriate GO complex terms</p> </li> <li> <p>Add missing evidence:</p> </li> <li> <p>Provide evidence codes and references for all causal associations</p> </li> <li> <p>Enhance process annotations:</p> </li> <li> <p>Ensure all activities have appropriate \"part_of\" relationships to biological processes</p> </li> <li> <p>Improve activity flow clarity:</p> </li> <li> <p>Consider adding temporal information or reorganizing the causal relationships to better represent the sequential steps in the viral life cycle</p> </li> <li> <p>Check host protein interactions:</p> </li> <li>Verify that all host-virus protein interactions are properly represented and have adequate evidence</li> </ol>"},{"location":"reviews/5e72450500004237-SARS_COV2_cycle/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"SARS-</p>"},{"location":"reviews/5ee8120100000524-SP_N4BP3on_MAVS/","title":"5ee8120100000524 SP N4BP3on MAVS","text":"<p>Based on my review and the GO-CAM documentation, I'll now provide a thorough assessment of the GO-CAM model with ID 5ee8120100000524.</p>"},{"location":"reviews/5ee8120100000524-SP_N4BP3on_MAVS/#review-of-go-cam-model-5ee8120100000524-sp_n4bp3on-mavs","title":"Review of GO-CAM Model: 5ee8120100000524 (\"SP_N4BP3on MAVS\")","text":""},{"location":"reviews/5ee8120100000524-SP_N4BP3on_MAVS/#summary-of-the-model","title":"Summary of the Model","text":"<p>This GO-CAM model represents a signaling pathway involving N4BP3 (NEDD4 binding protein 3) regulation of MAVS (Mitochondrial antiviral-signaling protein) in the context of innate immune antiviral response. The model includes:</p> <ol> <li>NEDD4 (E3 ubiquitin-protein ligase) with ubiquitin protein ligase activity</li> <li>N4BP3 with protein binding activity</li> <li>MAVS with signaling adaptor activity</li> <li>TRAF2 with ubiquitin protein ligase binding activity</li> </ol>"},{"location":"reviews/5ee8120100000524-SP_N4BP3on_MAVS/#model-structure-and-connections","title":"Model Structure and Connections","text":"<p>The model shows a linear pathway where: - N4BP3 directly positively regulates (RO:0002629) NEDD4 - NEDD4 directly positively regulates (RO:0002629) MAVS - MAVS directly positively regulates (RO:0002629) TRAF2</p> <p>All activities in the model are linked to evidence from the literature, primarily PMID:34880843, with TRAF2's activity also referencing PMID:23951545.</p>"},{"location":"reviews/5ee8120100000524-SP_N4BP3on_MAVS/#assessment-of-biological-content","title":"Assessment of Biological Content","text":"<p>The model captures key aspects of the research presented in PMID:34880843, which shows that N4BP3 positively regulates RIG-I-like receptor antiviral signaling by targeting MAVS. According to the paper, N4BP3 promotes the ubiquitination of MAVS, which enhances the interaction between MAVS and TRAF2.</p> <p>Specifically, the model represents: 1. The interaction between N4BP3 and NEDD4 (N4BP3 is a NEDD4 binding protein) 2. NEDD4's role in ubiquitinating MAVS 3. The enhanced interaction between MAVS and TRAF2</p>"},{"location":"reviews/5ee8120100000524-SP_N4BP3on_MAVS/#quality-control-assessment","title":"Quality Control Assessment","text":""},{"location":"reviews/5ee8120100000524-SP_N4BP3on_MAVS/#strengths-of-the-model","title":"Strengths of the Model:","text":"<ol> <li>Evidence-based: All activities are supported by primary literature references</li> <li>Appropriate molecular functions: Each protein is annotated with a biologically appropriate molecular function</li> <li>Logical causal relationships: The causal connections between activities make biological sense</li> <li>Parsimony: The model focuses on the key proteins and activities in the pathway without unnecessary complexity</li> </ol>"},{"location":"reviews/5ee8120100000524-SP_N4BP3on_MAVS/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li>Biological Process context:</li> <li> <p>The model includes a reference to \"innate immune response\" (GO:0045087) in the objects list, but this process isn't explicitly connected to any of the activities in the model. According to GO-CAM guidelines, molecular functions should be placed in the context of biological processes.</p> </li> <li> <p>E3 ligase representation:</p> </li> <li>Based on the E3 ubiquitin ligase guidelines, the model should indicate that NEDD4's activity \"has input\" MAVS as its substrate, which is not explicitly shown.</li> <li> <p>The biological process of ubiquitination (e.g., protein K63-linked ubiquitination) should be included to provide context for NEDD4's activity.</p> </li> <li> <p>MAVS as a signaling adaptor:</p> </li> <li>According to the paper, MAVS acts as a signaling adaptor that interacts with TRAF2, but the model doesn't show what MAVS adapts signals to or from.</li> <li> <p>The paper shows that MAVS is part of the RIG-I-like receptor antiviral signaling pathway, which could be represented more explicitly.</p> </li> <li> <p>N4BP3's functional role:</p> </li> <li> <p>While N4BP3 is shown with \"protein binding\" activity, the paper demonstrates it has a more specific role in promoting ubiquitination of MAVS, which could be better represented.</p> </li> <li> <p>Missing connection to downstream antiviral response:</p> </li> <li> <p>The model doesn't represent how this pathway connects to the ultimate outcome of enhanced antiviral response and interferon production, which is a key finding in the paper.</p> </li> <li> <p>Cellular location context:</p> </li> <li>The model doesn't include information about the cellular locations of these activities. According to the literature, MAVS is located on the mitochondrial outer membrane, which is crucial for its function.</li> </ol>"},{"location":"reviews/5ee8120100000524-SP_N4BP3on_MAVS/#specific-recommendations-for-improvement","title":"Specific Recommendations for Improvement","text":"<ol> <li>Add Biological Process context:</li> <li> <p>Connect each activity to the appropriate biological process terms, such as:</p> <ul> <li>\"innate immune response\" (GO:0045087)</li> <li>\"antiviral innate immune response\" (GO:0140374)</li> <li>\"defense response to virus\" (GO:0051607)</li> <li>\"protein ubiquitination\" (GO:0016567) or more specifically \"protein K63-linked ubiquitination\" (GO:0070534)</li> </ul> </li> <li> <p>Improve E3 ligase annotation:</p> </li> <li>Add \"has input\" relation from NEDD4's ubiquitin protein ligase activity to MAVS</li> <li> <p>Include the biological process of ubiquitination as part of NEDD4's activity context</p> </li> <li> <p>Clarify MAVS signaling adaptor role:</p> </li> <li>Show that MAVS adapts signals from RIG-I-like receptors to downstream effectors</li> <li> <p>Add a \"has input\" relation for MAVS's signaling adaptor activity</p> </li> <li> <p>Refine N4BP3 annotation:</p> </li> <li>Consider annotating N4BP3 with a more specific function, if supported by the evidence</li> <li> <p>Clearly indicate its role in enhancing MAVS ubiquitination</p> </li> <li> <p>Add downstream signaling:</p> </li> <li>Extend the model to show how TRAF2 activation leads to activation of the type I interferon pathway</li> <li> <p>Include IRF3 activation and/or NF-\u03baB activation, which are key outcomes mentioned in the paper</p> </li> <li> <p>Add cellular location information:</p> </li> <li>Include \"occurs in\" relations to specify the cellular locations of the activities</li> <li>Particularly important for MAVS (mitochondrial outer membrane)</li> </ol>"},{"location":"reviews/5ee8120100000524-SP_N4BP3on_MAVS/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model 5ee8120100000524 provides a foundation for representing the N4BP3-MAVS-TRAF2 signaling pathway in antiviral response. It captures key aspects of the pathway but would benefit from additional context and refinement to fully represent the biological insights from the supporting literature. With the recommended improvements, the model would be more comprehensive and aligned with GO-CAM best practices.</p> <p>The model represents an important innate immune signaling pathway that contributes to our understanding of antiviral responses, particularly how N4BP3 positively regulates MAVS-mediated signaling through promoting MAVS ubiquitination and enhancing its interaction with TRAF2.</p>"},{"location":"reviews/5ee8120100001898-Migrasome_signaling_involved_in_organ_morphogenesis_via_cxcl12a__cxcr4b__tspan4a__tspan7__D__rerio_/","title":"5ee8120100001898 Migrasome signaling involved in organ morphogenesis via cxcl12a  cxcr4b  tspan4a  tspan7  D  rerio","text":"<p>Based on my review of the GO-CAM model gomodel:5ee8120100001898 \"Migrasome signaling involved in organ morphogenesis via cxcl12a, cxcr4b, tspan4a, tspan7 (D. rerio)\" and the related publications, here is my comprehensive evaluation:</p>"},{"location":"reviews/5ee8120100001898-Migrasome_signaling_involved_in_organ_morphogenesis_via_cxcl12a__cxcr4b__tspan4a__tspan7__D__rerio_/#go-cam-model-review-gomodel5ee8120100001898","title":"GO-CAM Model Review: gomodel:5ee8120100001898","text":""},{"location":"reviews/5ee8120100001898-Migrasome_signaling_involved_in_organ_morphogenesis_via_cxcl12a__cxcr4b__tspan4a__tspan7__D__rerio_/#overview","title":"Overview","text":"<p>This GO-CAM model represents a signaling pathway in zebrafish (Danio rerio) involving migrasomes and chemokine signaling that regulates organ morphogenesis. The model focuses on interactions between Cxcl12a (a chemokine), Cxcr4b (its receptor), and tetraspanin proteins (Tspan4a and Tspan7) in the context of cell migration and organ development.</p>"},{"location":"reviews/5ee8120100001898-Migrasome_signaling_involved_in_organ_morphogenesis_via_cxcl12a__cxcr4b__tspan4a__tspan7__D__rerio_/#strengths","title":"Strengths","text":"<ol> <li> <p>Scientific validity: The model is well-supported by the primary literature, particularly PMID:31371827, which describes migrasomes as vesicular organelles that form on retraction fibers behind migrating cells and their role in embryonic development. Additional references (PMID:15081362, PMID:15340012) support the role of Cxcl12a-Cxcr4b signaling in chemotaxis and cell migration.</p> </li> <li> <p>Biological process representation: The model correctly captures that Cxcl12a functions as a chemoattractant (GO:0042056) that affects the G protein-coupled chemoattractant receptor activity of Cxcr4b (GO:0001637), which is part of cell localization (GO:0051674).</p> </li> <li> <p>Contextual accuracy: The model appropriately places Cxcl12a in migrasomes (GO:0140494) and Cxcr4b in forerunner cells (ZFA:0000023), reflecting the biological context described in the literature.</p> </li> <li> <p>Evidence documentation: Each activity and causal relationship is supported with proper evidence codes and literature references.</p> </li> </ol>"},{"location":"reviews/5ee8120100001898-Migrasome_signaling_involved_in_organ_morphogenesis_via_cxcl12a__cxcr4b__tspan4a__tspan7__D__rerio_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Incomplete molecular function annotation: While tspan4a (ZFIN:ZDB-GENE-040718-38) and tspan7 (ZFIN:ZDB-GENE-030131-5435) are included in the model, they are both annotated with a generic \"molecular_function\" (GO:0003674) rather than specific functions. The referenced paper indicates these tetraspanins are required for migrasome formation, but this function is not clearly represented in the model.</p> </li> <li> <p>Redundant activities: There are two nearly identical activities for Cxcl12a (gomodel:5ee8120100001898/5ee8120100002541 and gomodel:5ee8120100001898/60747c4200000449), both performing the same function in the same location with the same downstream target. This redundancy could be confusing and should be merged.</p> </li> <li> <p>Causal relationship clarification: The model shows tetraspanins (tspan4a and tspan7) positively regulating Cxcl12a activity, but the exact mechanism (whether they regulate Cxcl12a secretion, localization to migrasomes, or its activity) is not clearly specified.</p> </li> <li> <p>Biological process context: While the model title mentions \"organ morphogenesis,\" the specific organ development processes (like Kupffer's vesicle development or left/right asymmetry determination) are included as objects but not directly connected to activities in the model.</p> </li> </ol>"},{"location":"reviews/5ee8120100001898-Migrasome_signaling_involved_in_organ_morphogenesis_via_cxcl12a__cxcr4b__tspan4a__tspan7__D__rerio_/#technical-review","title":"Technical Review","text":"<ol> <li> <p>Predicate usage: The model correctly uses RO:0002304 (causally upstream of, positive effect) and RO:0002629 (directly positively regulates) for causal relationships between activities.</p> </li> <li> <p>Evidence codes: Appropriate evidence codes are used - ECO:0000315 (mutant phenotype evidence) and ECO:0000314 (direct assay evidence).</p> </li> <li> <p>Ontology term selection: The model uses appropriate GO terms for molecular functions, cellular components, and biological processes.</p> </li> </ol>"},{"location":"reviews/5ee8120100001898-Migrasome_signaling_involved_in_organ_morphogenesis_via_cxcl12a__cxcr4b__tspan4a__tspan7__D__rerio_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Specify tetraspanin functions: Rather than using the generic GO:0003674 (molecular_function), annotate tspan4a and tspan7 with more specific molecular functions based on their role in migrasome formation, if available in the GO.</p> </li> <li> <p>Consolidate redundant activities: The duplicate Cxcl12a activities should be merged into a single activity node.</p> </li> <li> <p>Connect to biological processes: Explicitly connect the activities to relevant biological processes like GO:0070121 (Kupffer's vesicle development) or GO:0007368 (determination of left/right symmetry) to better reflect the model title's emphasis on organ morphogenesis.</p> </li> <li> <p>Clarify mechanism: Consider adding annotations to explain how tetraspanins regulate Cxcl12a activity - whether through enabling migrasome formation, facilitating Cxcl12a localization, or other mechanisms.</p> </li> <li> <p>Add specific downstream effects: Consider extending the model to show how Cxcr4b activity in forerunner cells leads to specific developmental outcomes mentioned in the title.</p> </li> </ol>"},{"location":"reviews/5ee8120100001898-Migrasome_signaling_involved_in_organ_morphogenesis_via_cxcl12a__cxcr4b__tspan4a__tspan7__D__rerio_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides a valuable representation of migrasome signaling through the Cxcl12a-Cxcr4b axis in zebrafish development. It is scientifically sound and supported by published literature. With the suggested improvements, particularly in specifying tetraspanin functions and connecting activities to developmental outcomes, the model would more comprehensively represent the biological system described in the title.</p> <p>The model is acceptable in its current form but would benefit from the recommended revisions to improve clarity and completeness.</p>"},{"location":"reviews/5ee8120100002841-Inflammatory_signaling_involved_in_regulation_of_hematopoietic_stem_cell_differentiation_via_notch1a__tnfa__tnfrsf1b__jag1a__D_rerio_/","title":"5ee8120100002841 Inflammatory signaling involved in regulation of hematopoietic stem cell differentiation via notch1a  tnfa  tnfrsf1b  jag1a  D rerio","text":"<p>Now, let me review the GO-CAM model based on the information I've gathered and best practices for GO-CAM curation.</p>"},{"location":"reviews/5ee8120100002841-Inflammatory_signaling_involved_in_regulation_of_hematopoietic_stem_cell_differentiation_via_notch1a__tnfa__tnfrsf1b__jag1a__D_rerio_/#go-cam-model-review-gomodel5ee8120100002841","title":"GO-CAM Model Review: gomodel:5ee8120100002841","text":""},{"location":"reviews/5ee8120100002841-Inflammatory_signaling_involved_in_regulation_of_hematopoietic_stem_cell_differentiation_via_notch1a__tnfa__tnfrsf1b__jag1a__D_rerio_/#summary-of-the-model","title":"Summary of the Model","text":"<p>Model ID: gomodel:5ee8120100002841 Title: \"Inflammatory signaling involved in regulation of hematopoietic stem cell differentiation via notch1a, tnfa, tnfrsf1b, jag1a (D.rerio)\"</p> <p>This GO-CAM model describes a signaling pathway in zebrafish (Danio rerio) where inflammation-related signaling regulates hematopoietic stem cell (HSC) differentiation. The model captures the interaction between Tumor Necrosis Factor alpha (Tnfa), its receptor Tnfrsf1b, and downstream activation of Notch signaling through Jag1a (Jagged1a) and Notch1a.</p>"},{"location":"reviews/5ee8120100002841-Inflammatory_signaling_involved_in_regulation_of_hematopoietic_stem_cell_differentiation_via_notch1a__tnfa__tnfrsf1b__jag1a__D_rerio_/#model-components","title":"Model Components","text":"<p>The model includes four main molecular activities:</p> <ol> <li>Tnfa (ZFIN:ZDB-GENE-050317-1) with receptor ligand activity (GO:0048018)</li> <li>Occurs in extracellular space (GO:0005615)</li> <li>Part of positive regulation of HSC differentiation (GO:1902038)</li> <li> <p>Directly positively regulates Tnfrsf1b activity</p> </li> <li> <p>Tnfrsf1b (ZFIN:ZDB-GENE-070410-133) with signaling receptor activity (GO:0038023)</p> </li> <li>Occurs in plasma membrane (GO:0005886)</li> <li>Part of positive regulation of HSC differentiation (GO:1902038)</li> <li> <p>Causally upstream of Jag1a activity with positive effect</p> </li> <li> <p>Jag1a (ZFIN:ZDB-GENE-011128-2) with receptor ligand activity (GO:0048018)</p> </li> <li>Occurs in plasma membrane (GO:0005886)</li> <li>Part of positive regulation of HSC differentiation (GO:1902038)</li> <li> <p>Directly positively regulates Notch1a activity</p> </li> <li> <p>Notch1a (ZFIN:ZDB-GENE-990415-173) with signaling receptor activity (GO:0038023)</p> </li> <li>Occurs in plasma membrane (GO:0005886)</li> <li>Part of Notch signaling pathway (GO:0007219) for one node and not annotated to a BP for the other node</li> </ol>"},{"location":"reviews/5ee8120100002841-Inflammatory_signaling_involved_in_regulation_of_hematopoietic_stem_cell_differentiation_via_notch1a__tnfa__tnfrsf1b__jag1a__D_rerio_/#evaluation-of-the-model","title":"Evaluation of the Model","text":""},{"location":"reviews/5ee8120100002841-Inflammatory_signaling_involved_in_regulation_of_hematopoietic_stem_cell_differentiation_via_notch1a__tnfa__tnfrsf1b__jag1a__D_rerio_/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>The biological pathway represented in this model is well-supported by the literature. The PMID:25416946 reference provides extensive evidence for the role of inflammatory signaling, particularly TNF-alpha, in HSC specification in zebrafish. Key findings include:</p> <ol> <li>Tnfa signals through Tnfr2 (Tnfrsf1b) to upregulate the Notch ligand Jag1a on endothelial cells.</li> <li>Jag1a activates Notch1a, leading to HSC specification.</li> <li>Primitive neutrophils are the key source of Tnfa in this developmental process.</li> <li>This pathway is essential for HSC generation and is independent of its role in vascular development.</li> </ol> <p>The model accurately captures the central aspect of this pathway, showing the signaling flow from Tnfa \u2192 Tnfrsf1b \u2192 Jag1a \u2192 Notch1a, which aligns with the biological mechanism described in the literature.</p>"},{"location":"reviews/5ee8120100002841-Inflammatory_signaling_involved_in_regulation_of_hematopoietic_stem_cell_differentiation_via_notch1a__tnfa__tnfrsf1b__jag1a__D_rerio_/#go-cam-structure-and-compliance-assessment","title":"GO-CAM Structure and Compliance Assessment","text":""},{"location":"reviews/5ee8120100002841-Inflammatory_signaling_involved_in_regulation_of_hematopoietic_stem_cell_differentiation_via_notch1a__tnfa__tnfrsf1b__jag1a__D_rerio_/#strengths","title":"Strengths:","text":"<ol> <li>The model correctly uses receptor ligand activity (GO:0048018) for the ligands (Tnfa and Jag1a) and signaling receptor activity (GO:0038023) for receptors (Tnfrsf1b and Notch1a).</li> <li>Appropriate cellular components are used (extracellular space for secreted Tnfa, plasma membrane for receptors and membrane-bound ligand).</li> <li>The causal relations between activities are appropriate, using \"directly positively regulates\" (RO:0002629) for the ligand-receptor interactions.</li> <li>The model is grounded in strong experimental evidence from PMID:25416946.</li> </ol>"},{"location":"reviews/5ee8120100002841-Inflammatory_signaling_involved_in_regulation_of_hematopoietic_stem_cell_differentiation_via_notch1a__tnfa__tnfrsf1b__jag1a__D_rerio_/#issues-and-recommendations","title":"Issues and Recommendations:","text":"<ol> <li>Inconsistent biological process annotations:</li> <li>Notch1a has two activity nodes in the model. One is part of \"Notch signaling pathway\" (GO:0007219) and one has no biological process annotation.</li> <li> <p>Recommendation: Both Notch1a activities should be annotated with the same biological process since they represent the same activity in the same pathway.</p> </li> <li> <p>Missing downstream effects:</p> </li> <li>The model ends with Notch1a activation but doesn't capture the downstream effectors like NF-\u03baB activation, which the paper identifies as a critical component of the pathway.</li> <li> <p>Recommendation: Add NF-\u03baB activation as a downstream effect of Notch1a signaling.</p> </li> <li> <p>Incomplete representation of the pathway:</p> </li> <li>The model doesn't represent the role of primitive neutrophils as the source of Tnfa, which is a key finding in the paper.</li> <li> <p>Recommendation: Consider adding this information to provide a more complete representation of the biological context.</p> </li> <li> <p>Redundant Notch1a nodes:</p> </li> <li>There are two separate nodes for Notch1a activity with different causal connections, which isn't necessary and may create confusion.</li> <li> <p>Recommendation: Consolidate into a single Notch1a activity node with appropriate connections.</p> </li> <li> <p>Missing \"has input\" relations:</p> </li> <li>According to the GO-CAM guidelines for signaling receptors, there should be \"has input\" relations between receptors and their targets. These appear to be missing in the model.</li> <li>Recommendation: Add the appropriate \"has input\" relations according to the guidelines.</li> </ol>"},{"location":"reviews/5ee8120100002841-Inflammatory_signaling_involved_in_regulation_of_hematopoietic_stem_cell_differentiation_via_notch1a__tnfa__tnfrsf1b__jag1a__D_rerio_/#specific-annotation-review","title":"Specific Annotation Review:","text":"<p>For each activity node, I've noted specific issues:</p> <ol> <li>Tnfa (ZFIN:ZDB-GENE-050317-1):</li> <li>Correctly annotated with receptor ligand activity and appropriate cellular component</li> <li> <p>The causal relation to Tnfrsf1b is correct</p> </li> <li> <p>Tnfrsf1b (ZFIN:ZDB-GENE-070410-133):</p> </li> <li>Correctly annotated with signaling receptor activity</li> <li> <p>Missing \"has input\" relation to downstream targets according to GO-CAM guidelines</p> </li> <li> <p>Jag1a (ZFIN:ZDB-GENE-011128-2):</p> </li> <li>Correctly annotated with receptor ligand activity</li> <li> <p>Missing \"has input\" relation to Notch1a according to guidelines</p> </li> <li> <p>Notch1a (ZFIN:ZDB-GENE-990415-173):</p> </li> <li>Redundant activity nodes (two separate nodes for the same protein)</li> <li>One activity node lacks biological process annotation</li> <li>Missing downstream connections to effectors like NF-\u03baB</li> </ol>"},{"location":"reviews/5ee8120100002841-Inflammatory_signaling_involved_in_regulation_of_hematopoietic_stem_cell_differentiation_via_notch1a__tnfa__tnfrsf1b__jag1a__D_rerio_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model (gomodel:5ee8120100002841) accurately captures the core signaling pathway where inflammatory signaling through Tnfa/Tnfrsf1b activates Notch signaling via Jag1a to regulate hematopoietic stem cell differentiation in zebrafish. The model is based on strong experimental evidence and uses appropriate GO terms and relations for most components.</p> <p>To improve the model, I recommend: 1. Consolidating the redundant Notch1a activity nodes 2. Adding appropriate \"has input\" relations per GO-CAM guidelines 3. Including NF-\u03baB activation as a downstream effect 4. Considering the addition of contextual information about primitive neutrophils as the source of Tnfa 5. Ensuring consistent biological process annotations across related activities</p> <p>These improvements would make the model more complete and consistent with GO-CAM best practices while accurately representing the underlying biological mechanism.</p>"},{"location":"reviews/5f46c3b700001031-MYD88_dependent_TLR4_signaling_pathway_leading_to_NF_kappa_B_activation__Human_/","title":"5f46c3b700001031 MYD88 dependent TLR4 signaling pathway leading to NF kappa B activation  Human","text":"<p>Now that I've gathered information on the model and relevant guidelines, I'll provide a detailed review of GO-CAM model \"gomodel:5f46c3b700001031\" titled \"MYD88-dependent TLR4 signaling pathway leading to NF-kappa-B activation (Human)\".</p>"},{"location":"reviews/5f46c3b700001031-MYD88_dependent_TLR4_signaling_pathway_leading_to_NF_kappa_B_activation__Human_/#go-cam-model-review-myd88-dependent-tlr4-signaling-pathway-leading-to-nf-kappa-b-activation-human","title":"GO-CAM Model Review: MYD88-dependent TLR4 signaling pathway leading to NF-kappa-B activation (Human)","text":""},{"location":"reviews/5f46c3b700001031-MYD88_dependent_TLR4_signaling_pathway_leading_to_NF_kappa_B_activation__Human_/#model-summary","title":"Model Summary","text":"<p>This model represents the TLR4 signaling pathway that occurs in response to LPS (lipopolysaccharide) stimulation, leading to NF-kappa-B activation via the MYD88-dependent pathway in humans. The model captures the molecular activities and causal relationships starting from LPS transport by CD14 and LBP, through TLR4 receptor activation, the signaling cascade through adaptor proteins, kinase activities, and culminating in NF-kappa-B transcription factor activity.</p>"},{"location":"reviews/5f46c3b700001031-MYD88_dependent_TLR4_signaling_pathway_leading_to_NF_kappa_B_activation__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Pathway completeness: The model captures the key components of the MYD88-dependent TLR4 signaling pathway from initial LPS recognition to NF-kappa-B activation.</p> </li> <li> <p>Correct use of molecular carrier activity: The annotation of CD14 (P08571) and LBP (P18428) with \"molecular carrier activity\" (GO:0140104) accurately depicts their role in transporting LPS, consistent with the guidelines and the referenced literature (PMID:1698311).</p> </li> <li> <p>Appropriate signaling receptor activity: TLR4 (O00206) is correctly annotated with \"signaling receptor activity\" (GO:0038023) and the proper cellular location (plasma membrane).</p> </li> <li> <p>Proper adaptor protein annotation: The model correctly represents the signaling adaptors TIRAP (P58753) and MYD88 (Q99836) with \"signaling adaptor activity\" (GO:0035591).</p> </li> <li> <p>Appropriate causal relationships: The causal relationships between activities use the appropriate predicates. For example, \"directly positively regulates\" (RO:0002629) is used for the activation cascade.</p> </li> <li> <p>Detailed kinase cascade: The model correctly captures the sequence of kinase activities (IRAK4, IRAK2, MAP3K7, CHUK) that occurs downstream of TLR4 activation.</p> </li> <li> <p>Correct ubiquitin ligase annotation: TRAF6 (Q9Y4K3) is annotated with \"ubiquitin protein ligase activity\" (GO:0061630) and part of \"protein K63-linked ubiquitination\" (GO:0070534), which is consistent with its biological role in the pathway.</p> </li> <li> <p>Proper molecular adaptor annotation: ECSIT (Q9BQ95) is correctly annotated as having \"molecular adaptor activity\" (GO:0060090) which is consistent with the guidelines.</p> </li> </ol>"},{"location":"reviews/5f46c3b700001031-MYD88_dependent_TLR4_signaling_pathway_leading_to_NF_kappa_B_activation__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Missing CD14-TLR4 relationship: According to the examined literature (PMID:1698311), CD14 directly interacts with TLR4 to facilitate LPS recognition. The model should include a causal relationship from CD14's molecular carrier activity to TLR4's signaling receptor activity.</p> </li> <li> <p>LBP and CD14 coordination: The model shows LBP and CD14 as separate activities handling LPS, but the literature indicates they work in coordination, with LBP forming complexes with LPS that are then recognized by CD14. The relationship between these two activities could be more explicitly modeled.</p> </li> <li> <p>NFKBIA activity annotation: NFKBIA (P25963) is annotated with \"molecular sequestering activity\" (GO:0140313), which is correct, but the model could benefit from adding its target (RELA) as an input to better represent the sequestering relationship.</p> </li> <li> <p>Evidence for some causal relationships: One relationship in the model (from TIRAP to MYD88) lacks specific evidence annotations. All relationships should ideally have supporting evidence.</p> </li> <li> <p>Potential missing components: The model focuses on the MYD88-dependent pathway but doesn't include some components known to be involved in this pathway such as IRAK1, which is typically involved between IRAK2 and TRAF6.</p> </li> </ol>"},{"location":"reviews/5f46c3b700001031-MYD88_dependent_TLR4_signaling_pathway_leading_to_NF_kappa_B_activation__Human_/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":"<ol> <li> <p>LPS handling: The model correctly represents LPS (CHEBI:16412) as both input and output for CD14 and LBP, consistent with their role as carriers rather than modifiers of LPS.</p> </li> <li> <p>TLR4 signaling initiation: The activation of TLR4 by LPS is biologically accurate, though as mentioned, the model could better represent how CD14/LBP present LPS to TLR4.</p> </li> <li> <p>Adaptor recruitment: The recruitment of TIRAP and MYD88 to activated TLR4 reflects the established biology of TLR4 signaling.</p> </li> <li> <p>Kinase cascade: The sequential activation of IRAK4, IRAK2, MAP3K7 (TAK1), and CHUK (IKK\u03b1) reflects the established signaling cascade in the pathway.</p> </li> <li> <p>NF-kappa-B regulation: The model correctly represents how NFKBIA (I\u03baB\u03b1) sequesters RELA (p65) in the cytoplasm and how phosphorylation of NFKBIA leads to its degradation, allowing RELA to translocate to the nucleus.</p> </li> <li> <p>Correct cellular locations: The model correctly annotates the cellular locations for each activity: extracellular space for LPS carriers, plasma membrane for receptor activities, cytoplasm for signaling components, and nucleus for transcription factor activity.</p> </li> </ol>"},{"location":"reviews/5f46c3b700001031-MYD88_dependent_TLR4_signaling_pathway_leading_to_NF_kappa_B_activation__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model accurately represents the MYD88-dependent TLR4 signaling pathway leading to NF-kappa-B activation in humans. The model adheres to GO-CAM best practices in terms of activity representation, causal relationships, and contextual annotations. The few suggestions for improvement are relatively minor and would enhance the model's completeness rather than correct significant errors.</p> <p>The representation of LPS handling by LBP and CD14, TLR4 signaling, adaptor protein recruitment, and downstream signaling cascade are all biologically accurate and supported by the literature. The model effectively captures the key molecular activities and their relationships in this important immune signaling pathway.</p>"},{"location":"reviews/5f46c3b700001407-TBK1_activation_via_TRAF3_autoubiquitination__Human_/","title":"5f46c3b700001407 TBK1 activation via TRAF3 autoubiquitination  Human","text":"<p>Based on all the information gathered, I'll now provide a review of GO-CAM model gomodel:5f46c3b700001407, titled \"TBK1 activation via TRAF3 autoubiquitination (Human)\".</p>"},{"location":"reviews/5f46c3b700001407-TBK1_activation_via_TRAF3_autoubiquitination__Human_/#review-of-go-cam-model-tbk1-activation-via-traf3-autoubiquitination-human","title":"Review of GO-CAM Model: TBK1 activation via TRAF3 autoubiquitination (Human)","text":""},{"location":"reviews/5f46c3b700001407-TBK1_activation_via_TRAF3_autoubiquitination__Human_/#model-id-gomodel5f46c3b700001407","title":"Model ID: gomodel:5f46c3b700001407","text":""},{"location":"reviews/5f46c3b700001407-TBK1_activation_via_TRAF3_autoubiquitination__Human_/#overview","title":"Overview","text":"<p>This model represents the signaling pathway leading to TBK1 activation through TRAF3 autoubiquitination in human cells. It focuses on positive regulation of type I interferon production (GO:0032481), which is a critical process in innate immune responses to viral and bacterial infections.</p>"},{"location":"reviews/5f46c3b700001407-TBK1_activation_via_TRAF3_autoubiquitination__Human_/#model-structure","title":"Model Structure","text":"<p>The model consists of 7 activities connected through causal relationships:</p> <ol> <li>TICAM2 (UniProtKB:Q86XR7) - Molecular adaptor activity (GO:0060090) occurring in endosome (GO:0005768)</li> <li>TICAM1 (UniProtKB:Q8IUC6) - Molecular adaptor activity (GO:0060090) occurring in endosome (GO:0005768)</li> <li>TRAF3 (UniProtKB:Q13114) - Ubiquitin protein ligase activity (GO:0061630) occurring in endosome (GO:0005768)</li> <li>MAVS (UniProtKB:Q7Z434) - Molecular adaptor activity (GO:0060090) occurring in mitochondrion (GO:0005739)</li> <li>TRAF3IP3 (UniProtKB:Q9Y228) - Molecular adaptor activity (GO:0060090) occurring in mitochondrion (GO:0005739)</li> <li>TRAF3 (UniProtKB:Q13114) - Ubiquitin protein ligase activity (GO:0061630) occurring in mitochondrion (GO:0005739)</li> <li>TBK1 (UniProtKB:Q9UHD2) - Protein serine/threonine kinase activity (GO:0004674) occurring in cytoplasm (GO:0005737)</li> </ol>"},{"location":"reviews/5f46c3b700001407-TBK1_activation_via_TRAF3_autoubiquitination__Human_/#causal-flow-analysis","title":"Causal Flow Analysis","text":"<p>The causal flow in this model follows two main pathways:</p> <ol> <li>Endosomal pathway: TICAM2 \u2192 TICAM1 \u2192 TRAF3 (endosomal) \u2192 TBK1</li> <li>Mitochondrial pathway: MAVS \u2192 TRAF3IP3 \u2192 TRAF3 (mitochondrial) \u2192 TBK1</li> </ol> <p>Both pathways converge on TBK1 activation, which leads to type I interferon production. The causal connections use RO:0002629 (directly positively regulates), indicating direct positive regulation.</p>"},{"location":"reviews/5f46c3b700001407-TBK1_activation_via_TRAF3_autoubiquitination__Human_/#scientific-accuracy-assessment","title":"Scientific Accuracy Assessment","text":"<p>Based on the published literature provided (PMID:19898473 and PMID:14703513), the model appears scientifically accurate. The papers describe:</p> <ol> <li>TRAF3's critical role in type I interferon responses</li> <li>The importance of TRAF3 ubiquitination in regulating IFN production</li> <li>TBK1's function as a protein serine/threonine kinase that phosphorylates IRF3</li> <li>The involvement of adaptor proteins like TICAM1/TICAM2 (also known as TRIF/TRAM) in engaging TRAF3</li> <li>MAVS as a mitochondrial adaptor for TRAF3 in virus-induced signaling</li> </ol>"},{"location":"reviews/5f46c3b700001407-TBK1_activation_via_TRAF3_autoubiquitination__Human_/#adherence-to-go-cam-best-practices","title":"Adherence to GO-CAM Best Practices","text":"<p>Overall, the model follows GO-CAM best practices:</p> <ol> <li> <p>Molecular adaptor annotation: The model correctly represents molecular adaptor activities (GO:0060090) for TICAM1, TICAM2, MAVS, and TRAF3IP3. According to guidelines, these adaptors should use \"directly positively regulates\" (RO:0002629) relations to downstream activities, which is correctly implemented.</p> </li> <li> <p>E3 ubiquitin ligase representation: TRAF3 is appropriately annotated with ubiquitin protein ligase activity (GO:0061630). The guidelines indicate E3 ligases should be connected to downstream processes they regulate.</p> </li> <li> <p>Cellular component annotation: Each activity is correctly annotated with its cellular location (endosome, mitochondrion, or cytoplasm).</p> </li> <li> <p>Biological process annotation: All activities are properly connected to their biological process, \"positive regulation of type I interferon production\" (GO:0032481).</p> </li> <li> <p>Evidence annotation: Each activity is supported by experimental evidence (ECO:0000314 - direct assay evidence) with appropriate PMID references.</p> </li> </ol>"},{"location":"reviews/5f46c3b700001407-TBK1_activation_via_TRAF3_autoubiquitination__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Add inputs to molecular adaptors: According to the guidelines, molecular adaptors should have inputs specified (the molecules they bring together). The current model doesn't specify inputs for any of the adaptor proteins.</p> </li> <li> <p>Clarify TRAF3 autoubiquitination: The title mentions TRAF3 autoubiquitination, but this is not explicitly modeled. The model could more clearly show that TRAF3 ubiquitin ligase activity is self-directed, perhaps by adding TRAF3 as an input to its own activity.</p> </li> <li> <p>Include IRF3 activation: Given that TBK1 ultimately phosphorylates and activates IRF3 leading to IFN production (as shown in PMID:14703513), the model could be extended to include this final step in the pathway.</p> </li> <li> <p>Distinguish K63 vs K48 ubiquitination: The paper (PMID:19898473) discusses distinct modes of TRAF3 ubiquitination (K63-linked for the IFN pathway vs. K48-linked for degradation). This distinction could be made clearer in the model.</p> </li> </ol>"},{"location":"reviews/5f46c3b700001407-TBK1_activation_via_TRAF3_autoubiquitination__Human_/#conclusion","title":"Conclusion","text":"<p>GO-CAM model gomodel:5f46c3b700001407 accurately represents the signaling pathway for TBK1 activation via TRAF3 autoubiquitination. It correctly implements GO-CAM best practices for molecular adaptor and E3 ligase annotation. The model effectively captures two distinct pathways (endosomal and mitochondrial) leading to TBK1 activation in type I interferon production. With minor enhancements to specify inputs for adaptors and more explicitly model TRAF3 autoubiquitination, this would be an exemplary representation of this signaling pathway.</p>"},{"location":"reviews/5f46c3b700001570-SPModule_TBK1_IRF3/","title":"5f46c3b700001570 SPModule TBK1 IRF3","text":"<p>Based on all of the information I've gathered, I'll now review the GO-CAM model gomodel:5f46c3b700001570 titled \"SPModule TBK1-IRF3\".</p>"},{"location":"reviews/5f46c3b700001570-SPModule_TBK1_IRF3/#review-of-go-cam-model-spmodule-tbk1-irf3-gomodel5f46c3b700001570","title":"Review of GO-CAM Model: SPModule TBK1-IRF3 (gomodel:5f46c3b700001570)","text":""},{"location":"reviews/5f46c3b700001570-SPModule_TBK1_IRF3/#overview","title":"Overview","text":"<p>This model represents a signaling pathway involving TBK1 (TANK-binding kinase 1) and IRF3 (Interferon Regulatory Factor 3), which are key proteins in the innate immune response against viruses. The model describes the phosphorylation cascade where TBK1 activates IRF3, leading to IRF3's DNA-binding and transcriptional activation activities.</p>"},{"location":"reviews/5f46c3b700001570-SPModule_TBK1_IRF3/#model-structure","title":"Model Structure","text":"<p>The model consists of 5 activities: 1. TBK1 protein serine/threonine kinase activity 2. IRF3 protein homodimerization activity 3. IRF3 protein binding activity 4. IRF3 sequence-specific DNA binding activity 5. IRF3 DNA-binding transcription activator activity</p> <p>The causal flow follows: TBK1 kinase activity \u2192 IRF3 homodimerization \u2192 IRF3 protein binding \u2192 IRF3 DNA binding \u2192 IRF3 transcriptional activation</p>"},{"location":"reviews/5f46c3b700001570-SPModule_TBK1_IRF3/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Accurate biological process representation: The model correctly represents the established pathway of TBK1-mediated phosphorylation of IRF3, leading to IRF3 homodimerization, nuclear translocation, and activation of interferon gene transcription.</p> </li> <li> <p>Correct causal associations: The model uses the appropriate causal relation \"directly positively regulates\" (RO:0002629) between activities, which correctly represents the flow of the signaling cascade.</p> </li> <li> <p>Appropriate cellular locations: The model correctly localizes TBK1 kinase activity in the cytoplasm (GO:0005737) and IRF3's DNA binding and transcriptional activities in the nucleus (GO:0005634).</p> </li> <li> <p>Solid evidence basis: Each activity and causal relation is supported by primary research literature with proper evidence codes (ECO:0000314 - direct assay evidence used in manual assertion).</p> </li> </ol>"},{"location":"reviews/5f46c3b700001570-SPModule_TBK1_IRF3/#issues-and-suggested-improvements","title":"Issues and Suggested Improvements","text":"<ol> <li> <p>Phosphorylation representation: While the model shows TBK1 kinase activity leading to IRF3 homodimerization, it doesn't explicitly represent the phosphorylation of IRF3 at serine residues 385 and 386, which is a critical step. Consider adding this detail as it's a key molecular event in this pathway.</p> </li> <li> <p>Missing adaptor proteins: The literature indicates that adaptor proteins like MAVS, STING1, or TICAM1 are first phosphorylated by TBK1 on their pLxIS motif, leading to recruitment of IRF3, which enables IRF3 phosphorylation by TBK1. These adaptor proteins are missing from the model, making the pathway representation incomplete.</p> </li> <li> <p>IRF3 nuclear translocation: The model shows IRF3 binding to DNA in the nucleus after homodimerization, but it doesn't explicitly represent IRF3's translocation from cytoplasm to nucleus. While this can be inferred, explicitly representing this step would improve clarity.</p> </li> <li> <p>Downstream gene activation: The model ends with IRF3's transcriptional activator activity but doesn't represent the activation of specific downstream genes like IFNB (interferon beta) and other interferon-stimulated genes (ISGs). Adding these would complete the biological story.</p> </li> <li> <p>Complex representation: According to the GO-CAM guidelines for complexes, when the subunit that carries the activity is known (as in this case), the activities should be represented by the specific proteins carrying them. The model follows this guideline correctly.</p> </li> </ol>"},{"location":"reviews/5f46c3b700001570-SPModule_TBK1_IRF3/#technical-aspects","title":"Technical Aspects","text":"<ol> <li> <p>Evidence codes: All assertions use the ECO:0000314 (direct assay evidence used in manual assertion), which is appropriate since the evidence is from experimental publications.</p> </li> <li> <p>Protein identity: The model correctly identifies the proteins using UniProtKB accessions (Q9UHD2 for TBK1 and Q14653 for IRF3).</p> </li> <li> <p>Ontology term usage: The molecular functions and cellular components are represented using appropriate GO terms.</p> </li> </ol>"},{"location":"reviews/5f46c3b700001570-SPModule_TBK1_IRF3/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the TBK1-IRF3 signaling pathway central to antiviral immune responses. The main areas for improvement are the inclusion of adaptor proteins that facilitate IRF3 recruitment and phosphorylation, explicit representation of IRF3 phosphorylation and nuclear translocation, and extension to downstream gene activation events. These additions would make the model more complete and informative.</p> <p>The model is consistent with current knowledge about TBK1 and IRF3 function in antiviral responses and follows GO-CAM annotation guidelines appropriately.</p>"},{"location":"reviews/5f46c3b700002102-SPModule_TIRAP_MYDDOSOME/","title":"5f46c3b700002102 SPModule TIRAP MYDDOSOME","text":"<p>Based on a thorough review of the model and associated information, I'll now provide a comprehensive review of the GO-CAM model \"gomodel:5f46c3b700002102\" titled \"SPModule-TIRAP-MYDDOSOME\".</p>"},{"location":"reviews/5f46c3b700002102-SPModule_TIRAP_MYDDOSOME/#review-of-go-cam-model-spmodule-tirap-myddosome-gomodel5f46c3b700002102","title":"Review of GO-CAM Model: SPModule-TIRAP-MYDDOSOME (gomodel:5f46c3b700002102)","text":""},{"location":"reviews/5f46c3b700002102-SPModule_TIRAP_MYDDOSOME/#1-model-overview","title":"1. Model Overview","text":"<p>This GO-CAM model represents the TIRAP-MYDDOSOME signaling complex, which is a key component in TLR/IL-1R signaling. The model shows a sequential recruitment and activation pathway involving four proteins:</p> <ol> <li>TIRAP/MAL (UniProtKB:P58753) - Toll/IL-1 receptor domain-containing adapter protein</li> <li>MYD88 (UniProtKB:Q99836) - Myeloid differentiation primary response protein</li> <li>IRAK4 (UniProtKB:Q9NWZ3) - Interleukin-1 receptor-associated kinase 4</li> <li>IRAK1 (UniProtKB:P51617) - Interleukin-1 receptor-associated kinase 1</li> <li>TRAF6 (UniProtKB:Q9Y4K3) - TNF receptor-associated factor 6</li> </ol> <p>The model depicts a signaling cascade where each protein in the pathway directly positively regulates (RO:0002629) the next protein in the sequence, ultimately leading to TRAF6 ubiquitin-ubiquitin ligase activity.</p>"},{"location":"reviews/5f46c3b700002102-SPModule_TIRAP_MYDDOSOME/#2-scientific-accuracy","title":"2. Scientific Accuracy","text":"<p>The model accurately represents the known biology of the TIRAP-MYDDOSOME signaling pathway:</p> <ul> <li>The model correctly shows TIRAP initiating the signaling cascade at the cell surface, which matches its known role as a TLR adaptor protein that recruits MYD88 to TLR2 and TLR4 complexes.</li> <li>The sequential assembly of the Myddosome complex with MYD88 recruiting IRAK4, and IRAK4 recruiting IRAK1 is consistent with the literature (PMID:20485341).</li> <li>The kinase activities of IRAK4 and IRAK1 are accurately represented.</li> <li>The model appropriately ends with TRAF6 ubiquitin-ubiquitin ligase activity, which is consistent with TRAF6's role in this pathway.</li> </ul>"},{"location":"reviews/5f46c3b700002102-SPModule_TIRAP_MYDDOSOME/#3-completeness-and-molecular-function-annotations","title":"3. Completeness and Molecular Function Annotations","text":"<p>Each protein in the model is annotated with its appropriate molecular function:</p> <ul> <li>TIRAP: Annotated with \"molecular adaptor activity\" (GO:0060090), which is appropriate for its role in recruiting MYD88.</li> <li>MYD88: Annotated with \"molecular adaptor activity\" (GO:0060090), consistent with its role in TLR signaling.</li> <li>IRAK4: Annotated with \"kinase activity\" (GO:0016301), which correctly represents its enzymatic function.</li> <li>IRAK1: Annotated with \"kinase activity\" (GO:0016301), which correctly represents its enzymatic function.</li> <li>TRAF6: Annotated with \"ubiquitin-ubiquitin ligase activity\" (GO:0034450), which is appropriate for its E3 ligase function.</li> </ul>"},{"location":"reviews/5f46c3b700002102-SPModule_TIRAP_MYDDOSOME/#4-cellular-component-annotations","title":"4. Cellular Component Annotations","text":"<p>All proteins are annotated with appropriate cellular locations:</p> <ul> <li>TIRAP: Located at \"cell surface\" (GO:0009986), which is appropriate as it recruits MyD88 to cell surface TLR complexes.</li> <li>MYD88: Located at \"cell surface\" (GO:0009986), consistent with its recruitment by TIRAP.</li> <li>IRAK4: Located at \"cell surface\" (GO:0009986), which is appropriate for its recruitment to the receptor complex.</li> <li>IRAK1: Located at \"cell surface\" (GO:0009986), correctly reflecting its location in the Myddosome complex.</li> <li>TRAF6: Located at \"cytoplasm\" (GO:0005737), which is appropriate as TRAF6 dissociates from the receptor complex following activation.</li> </ul>"},{"location":"reviews/5f46c3b700002102-SPModule_TIRAP_MYDDOSOME/#5-causal-relations","title":"5. Causal Relations","text":"<p>The causal relationships in the model use the appropriate relation (RO:0002629 \"directly positively regulates\"), which correctly captures the direct positive regulatory relationships between the proteins in this signaling cascade:</p> <ul> <li>TIRAP directly positively regulates MYD88</li> <li>MYD88 directly positively regulates IRAK4</li> <li>IRAK4 directly positively regulates IRAK1</li> <li>IRAK1 directly positively regulates TRAF6</li> </ul>"},{"location":"reviews/5f46c3b700002102-SPModule_TIRAP_MYDDOSOME/#6-evidence","title":"6. Evidence","text":"<p>Each activity and causal relation is supported by appropriate experimental evidence:</p> <ul> <li>Evidence codes used are primarily ECO:0000314 (direct assay evidence used in manual assertion)</li> <li>Literature references are provided for each assertion (e.g., PMID:14625308, PMID:22851693, PMID:9734363, PMID:11960013, PMID:20485341, PMID:15465037)</li> <li>All assertions have appropriate provenance information with contributor ORCID and dates</li> </ul>"},{"location":"reviews/5f46c3b700002102-SPModule_TIRAP_MYDDOSOME/#7-compliance-with-go-cam-best-practices","title":"7. Compliance with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices for representing protein complexes as outlined in the document \"How_to_annotate_complexes_in_GO-CAM\":</p> <ul> <li>The model correctly uses individual proteins when the subunits that carry specific molecular activities are known, rather than using a complex ID.</li> <li>The model appropriately represents the sequential assembly and activation of the complex through causal relations between the individual proteins.</li> </ul>"},{"location":"reviews/5f46c3b700002102-SPModule_TIRAP_MYDDOSOME/#8-areas-for-improvement","title":"8. Areas for Improvement","text":"<p>While the model is scientifically accurate and well-constructed, I have a few minor suggestions for improvement:</p> <ol> <li> <p>Additional Context: The model could potentially benefit from additional context by connecting to upstream TLR activation or downstream events beyond TRAF6.</p> </li> <li> <p>Complex Formation: While the model implies complex formation through the causal relations, it might be valuable to explicitly annotate the formation of the Myddosome complex.</p> </li> <li> <p>Additional TRAF6 Relations: TRAF6 activates multiple downstream pathways (NF-\u03baB, MAP kinases). Including some of these downstream targets could enhance the model's biological completeness.</p> </li> </ol>"},{"location":"reviews/5f46c3b700002102-SPModule_TIRAP_MYDDOSOME/#9-conclusion","title":"9. Conclusion","text":"<p>The GO-CAM model \"gomodel:5f46c3b700002102\" (SPModule-TIRAP-MYDDOSOME) is a scientifically accurate, well-constructed representation of the TIRAP-MYDDOSOME signaling pathway. It correctly captures the sequential assembly and activation of this important signaling complex in TLR/IL-1R pathways, with appropriate molecular functions, cellular components, causal relations, and supporting evidence.</p> <p>The model effectively represents how TIRAP recruits MYD88 to TLR signaling complexes, which then recruits IRAK4, leading to the recruitment and activation of IRAK1, and ultimately activating TRAF6. This accurately reflects our current understanding of this signaling pathway as supported by the primary literature.</p>"},{"location":"reviews/5f46c3b700002685-IL6_sIL6R_Trans_signaling_pathway__Human_/","title":"5f46c3b700002685 IL6 sIL6R Trans signaling pathway  Human","text":"<p>Based on my review of the model and supporting information, I'll now provide a comprehensive review of gomodel:5f46c3b700002685 \"IL6:sIL6R Trans-signaling pathway (Human)\".</p>"},{"location":"reviews/5f46c3b700002685-IL6_sIL6R_Trans_signaling_pathway__Human_/#review-of-go-cam-model-il6sil6r-trans-signaling-pathway-human","title":"Review of GO-CAM Model: IL6:sIL6R Trans-signaling pathway (Human)","text":""},{"location":"reviews/5f46c3b700002685-IL6_sIL6R_Trans_signaling_pathway__Human_/#model-summary","title":"Model Summary","text":"<p>Model ID: gomodel:5f46c3b700002685 Species: Human (NCBITaxon:9606) Status: Production Title: IL6:sIL6R Trans-signaling pathway (Human)</p> <p>This model represents the interleukin-6 (IL6) trans-signaling pathway in humans, focusing on the interaction between IL6, the soluble IL6 receptor (sIL6R), and the signal transducer glycoprotein 130 (gp130/IL6ST). The model captures the key molecular events in this signaling pathway, from ligand-receptor binding to downstream activation of JAK/STAT signaling, as well as negative regulation by SOCS3.</p>"},{"location":"reviews/5f46c3b700002685-IL6_sIL6R_Trans_signaling_pathway__Human_/#model-structure-and-accuracy","title":"Model Structure and Accuracy","text":""},{"location":"reviews/5f46c3b700002685-IL6_sIL6R_Trans_signaling_pathway__Human_/#pathway-representation","title":"Pathway Representation","text":"<p>The model correctly captures the main components of IL6 trans-signaling:</p> <ol> <li> <p>IL6 cytokine activity: IL6 (UniProtKB:P05231) with its cytokine activity (GO:0005125) occurring in extracellular space (GO:0005615), which positively regulates soluble IL6R.</p> </li> <li> <p>Soluble IL6R activity: IL6R (UniProtKB:P08887-2, isoform 2 representing the soluble form) with cytokine receptor activity (GO:0004896) occurring in extracellular space (GO:0005615), which positively regulates IL6ST/gp130.</p> </li> <li> <p>IL6ST/gp130 activity: IL6ST (UniProtKB:P40189) with protein tyrosine kinase activator activity (GO:0030296) occurring at the plasma membrane (GO:0005886), which positively regulates JAK1 kinase activity.</p> </li> <li> <p>JAK1 kinase activity: JAK1 (UniProtKB:P23458) with protein tyrosine kinase activity (GO:0004713) occurring at the cytoplasmic side of plasma membrane (GO:0009898), which positively regulates STAT3 activity.</p> </li> <li> <p>STAT3 activity: STAT3 (UniProtKB:P40763) with DNA-binding transcription factor activity (GO:0003700) occurring in the nucleus (GO:0005634).</p> </li> <li> <p>Negative regulation by SOCS3: SOCS3 (UniProtKB:O14543) with protein kinase inhibitor activity (GO:0004860) occurring at the cytoplasmic side of plasma membrane (GO:0009898), which negatively regulates JAK1 activity.</p> </li> </ol>"},{"location":"reviews/5f46c3b700002685-IL6_sIL6R_Trans_signaling_pathway__Human_/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model is scientifically accurate based on current knowledge of IL6 signaling:</p> <ol> <li> <p>Trans-signaling mechanism: The model correctly represents IL6 trans-signaling where IL6 first forms a complex with soluble IL6R, and this complex then engages gp130/IL6ST to initiate signaling. This is supported by the PMID:12829785 reference which describes the hexameric structure of this complex.</p> </li> <li> <p>Signaling cascade: The downstream activation of JAK1 and subsequently STAT3 is accurately represented, which is the canonical signaling pathway activated by IL6.</p> </li> <li> <p>Negative feedback: The negative regulation by SOCS3 of JAK1 kinase represents an essential feedback mechanism for controlling IL6 signaling, referenced by PMID:9727029.</p> </li> <li> <p>Biological process annotations: All activities are appropriately placed within their respective biological processes - IL6-mediated signaling pathway (GO:0070102) for the cytokine and receptors, and JAK-STAT cascade (GO:0007259) for the downstream components.</p> </li> </ol>"},{"location":"reviews/5f46c3b700002685-IL6_sIL6R_Trans_signaling_pathway__Human_/#relationship-to-literature","title":"Relationship to Literature","text":"<p>The model is well-supported by the scientific literature:</p> <ul> <li>The structure of the IL6/IL6R/IL6ST complex as described in PMID:12829785 (Boulanger et al., 2003) is correctly represented in</li> </ul>"},{"location":"reviews/5f46c3b700003802-dGMP_catabolic_process_to_allantoin__Mouse_/","title":"5f46c3b700003802 dGMP catabolic process to allantoin  Mouse","text":""},{"location":"reviews/5f46c3b700003802-dGMP_catabolic_process_to_allantoin__Mouse_/#detailed-review","title":"Detailed Review","text":"<p>After examining the model in detail along with GO-CAM guidelines, I conclude that this model (gomodel:5f46c3b700003802) generally follows GO-CAM best practices for metabolic pathway representation. The model accurately captures the purine catabolism pathway from dGMP to allantoin in mice with appropriate causal connections.</p>"},{"location":"reviews/5f46c3b700003802-dGMP_catabolic_process_to_allantoin__Mouse_/#strengths","title":"Strengths:","text":"<ol> <li>Causal connectivity: The model properly represents the metabolic flow using the appropriate predicate \"provides input for\" (RO:0002413).</li> <li>Cell compartmentalization: Correct subcellular localization for each enzymatic activity.</li> <li>Evidence support: Most assertions are backed by appropriate evidence and literature references.</li> <li>Clear biological process context: All activities are placed in the context of \"dGMP catabolic process\" (GO:0046055).</li> <li>Gene product annotation: Each activity is enabled by the appropriate gene product.</li> </ol>"},{"location":"reviews/5f46c3b700003802-dGMP_catabolic_process_to_allantoin__Mouse_/#improvements-needed","title":"Improvements Needed:","text":"<ol> <li>Missing evidence: One causal association lacks evidence annotation and should be completed.</li> <li>Duplicate causal link: There is a redundant causal association that should be removed.</li> <li>Intermediate metabolites: While the final product (allantoin) is annotated as an output, annotating intermediate metabolites as inputs and outputs of each step would improve the model's completeness.</li> </ol>"},{"location":"reviews/5f46c3b700003802-dGMP_catabolic_process_to_allantoin__Mouse_/#biological-accuracy","title":"Biological Accuracy:","text":"<p>The pathway representation is consistent with the known purine catabolism pathway in mammals. The progression from nucleotide (dGMP) through purine base, xanthine, uric acid, and finally to allantoin follows the established biochemical understanding of this process.</p>"},{"location":"reviews/5f46c3b700003802-dGMP_catabolic_process_to_allantoin__Mouse_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model is a well-constructed representation of the dGMP catabolic process to allantoin in mice. It follows GO-CAM best practices for pathway representation and is biologically accurate. The few minor issues identified (missing evidence, duplicate link) should be addressed, but they don't significantly impact the overall quality or utility of the model.</p>"},{"location":"reviews/5f46c3b700003884-AMP_catabolic_process_to_allantoin__Mouse_/","title":"5f46c3b700003884 AMP catabolic process to allantoin  Mouse","text":"<p>Let me analyze the GO-CAM model and provide a comprehensive review based on the information gathered:</p>"},{"location":"reviews/5f46c3b700003884-AMP_catabolic_process_to_allantoin__Mouse_/#review-of-go-cam-model-for-amp-catabolic-process-to-allantoin-mouse","title":"Review of GO-CAM Model for AMP Catabolic Process to Allantoin (Mouse)","text":"<p>Model ID: gomodel:5f46c3b700003884</p>"},{"location":"reviews/5f46c3b700003884-AMP_catabolic_process_to_allantoin__Mouse_/#overview","title":"Overview","text":"<p>This GO-CAM model represents the AMP catabolic process to allantoin in mouse. The model captures the complete degradation pathway of AMP to allantoin, including all intermediate steps and enzymes involved in the process.</p>"},{"location":"reviews/5f46c3b700003884-AMP_catabolic_process_to_allantoin__Mouse_/#model-structure-and-content","title":"Model Structure and Content","text":""},{"location":"reviews/5f46c3b700003884-AMP_catabolic_process_to_allantoin__Mouse_/#pathway-representation","title":"Pathway Representation","text":"<p>The model correctly represents the sequential enzymatic steps in AMP degradation: 1. AMP is first converted to adenosine by 5'-nucleotidase activity 2. Adenosine is converted to inosine by adenosine deaminase 3. Inosine is converted to hypoxanthine by purine-nucleoside phosphorylase 4. Hypoxanthine is converted to xanthine by xanthine dehydrogenase/oxidase 5. Xanthine is further converted to urate by xanthine dehydrogenase/oxidase 6. Urate is oxidized to 5-hydroxyisourate (HIU) by urate oxidase 7. HIU is converted to OHCU (2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline) by HIU hydrolase 8. OHCU is finally converted to allantoin by OHCU decarboxylase</p>"},{"location":"reviews/5f46c3b700003884-AMP_catabolic_process_to_allantoin__Mouse_/#causal-connections","title":"Causal Connections","text":"<p>The model correctly uses the <code>RO:0002413</code> (provides input for) predicate to connect the sequential activities in the pathway, which is appropriate for metabolic pathways where the product of one reaction becomes the substrate for the next.</p>"},{"location":"reviews/5f46c3b700003884-AMP_catabolic_process_to_allantoin__Mouse_/#cellular-location","title":"Cellular Location","text":"<p>The model appropriately captures the subcellular locations of the enzymes: - Cytosolic enzymes (GO:0005829): adenosine deaminase, 5'-nucleotidase, purine-nucleoside phosphorylase - Peroxisomal enzymes (GO:0005777): urate oxidase, HIU hydrolase, and OHCU decarboxylase</p>"},{"location":"reviews/5f46c3b700003884-AMP_catabolic_process_to_allantoin__Mouse_/#evidence","title":"Evidence","text":"<p>The model uses appropriate evidence codes: - ECO:0000314 (direct assay evidence used in manual assertion) - ECO:0000315 (mutant phenotype evidence used in manual assertion) - ECO:0000266 (sequence orthology evidence used in manual assertion)</p>"},{"location":"reviews/5f46c3b700003884-AMP_catabolic_process_to_allantoin__Mouse_/#quality-assessment","title":"Quality Assessment","text":""},{"location":"reviews/5f46c3b700003884-AMP_catabolic_process_to_allantoin__Mouse_/#strengths","title":"Strengths","text":"<ol> <li>Completeness: The model captures the entire pathway from AMP to allantoin with all intermediate steps.</li> <li>Evidential Support: Each activity is supported by literature evidence with citations to relevant PMIDs.</li> <li>Cellular Compartmentalization: The model correctly represents the subcellular locations of different enzymatic activities.</li> <li>Proper Causal Relationships: The model uses the appropriate causal relation predicates.</li> <li>Species Specificity: The model is properly designated for mouse (NCBITaxon:10090).</li> </ol>"},{"location":"reviews/5f46c3b700003884-AMP_catabolic_process_to_allantoin__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Redundancy in Xanthine Oxidase/Dehydrogenase Representation: The same gene product (Xdh, MGI:MGI:98973) is represented with multiple activities (hypoxanthine dehydrogenase, hypoxanthine oxidase, xanthine dehydrogenase, and xanthine oxidase activities) in multiple instances. While technically correct as Xdh can function in both modes, this creates some redundancy and complexity in the model representation. Consider consolidating these activities for clarity.</p> </li> <li> <p>Missing Output Annotations: While the final output (allantoin, CHEBI:15676) is correctly noted for the OHCU decarboxylase activity, other intermediates in the pathway are not explicitly annotated as outputs of their respective enzymatic reactions. Adding these would improve the completeness of the model.</p> </li> <li> <p>Multiple 5'-Nucleotidase Activities: The model contains two instances of 5'-nucleotidase activity (encoded by Nt5c1b and Nt5c1a). The documentation could clarify if these represent tissue-specific isoforms, or if they have different substrate preferences.</p> </li> </ol>"},{"location":"reviews/5f46c3b700003884-AMP_catabolic_process_to_allantoin__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>Based on the PMID:16462750</p>"},{"location":"reviews/5fa76ad400000018-AMP_catabolic_process_2__Mouse_/","title":"5fa76ad400000018 AMP catabolic process 2  Mouse","text":"<p>Now, let me review the model based on the information provided.</p>"},{"location":"reviews/5fa76ad400000018-AMP_catabolic_process_2__Mouse_/#go-cam-model-review-gomodel5fa76ad400000018-amp-catabolic-process-2-mouse","title":"GO-CAM Model Review: gomodel:5fa76ad400000018 \"AMP catabolic process 2 (Mouse)\"","text":""},{"location":"reviews/5fa76ad400000018-AMP_catabolic_process_2__Mouse_/#overview","title":"Overview","text":"<p>This model (gomodel:5fa76ad400000018) describes the AMP catabolic process in mouse, focusing on the pathway components involved in AMP metabolism and transport. The model involves several key proteins:</p> <ol> <li>Nt5e (CD73, 5'-nucleotidase) - MGI:MGI:99782</li> <li>Entpd1 (CD39, ectonucleoside triphosphate diphosphohydrolase 1) - MGI:MGI:102805</li> <li>Slc29a1 (ENT1, equilibrative nucleoside transporter 1) - MGI:MGI:1927073</li> <li>Slc29a2 (ENT2, equilibrative nucleoside transporter 2) - MGI:MGI:1345278</li> <li>Ampd3 (AMP deaminase 3) - MGI:MGI:1096344</li> </ol>"},{"location":"reviews/5fa76ad400000018-AMP_catabolic_process_2__Mouse_/#key-model-elements-and-activities","title":"Key Model Elements and Activities","text":"<p>The model includes the following activities:</p> <ol> <li>5'-nucleotidase activity (GO:0008253) performed by Nt5e (CD73) - converts AMP to adenosine</li> <li>ADP phosphatase activity (GO:0043262) performed by Entpd1 (CD39) - converts ADP to AMP</li> <li>AMP deaminase activity (GO:0003876) performed by Ampd3 - involved in AMP catabolism</li> <li>Purine nucleoside transmembrane transporter activity (GO:0015211) performed by both Slc29a1 (ENT1) and Slc29a2 (ENT2)</li> </ol> <p>The activities are connected through causal associations with the predicate \"provides input for\" (RO:0002413), describing a metabolic pathway where ADP is converted to AMP, which is then either transported or further metabolized.</p>"},{"location":"reviews/5fa76ad400000018-AMP_catabolic_process_2__Mouse_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model is supported by multiple scientific publications, primarily: - PMID:28746349 - Details AMP metabolism in erythrocytes, specifically discussing the roles of CD73, AMPD3, and nucleoside transporters - PMID:28069792 - Referenced for evidence about Slc29a1 and Slc29a2 activity - PMID:17502665 - Provides evidence for Entpd1 function - PMID:20430891 - Supports evidence for Nt5e function</p> <p>The literature strongly supports the molecular functions and biological processes represented in this model. PMID:28746349 in particular provides detailed information about the interplay between these enzymes in regulating the adenine nucleotide pool in erythrocytes.</p>"},{"location":"reviews/5fa76ad400000018-AMP_catabolic_process_2__Mouse_/#model-correctness-assessment","title":"Model Correctness Assessment","text":""},{"location":"reviews/5fa76ad400000018-AMP_catabolic_process_2__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the AMP catabolic pathway according to the current scientific knowledge. Key points:</p> <ol> <li>Entpd1 (CD39) correctly shown hydrolyzing ADP to AMP on the external side of the plasma membrane</li> <li>Nt5e (CD73) correctly shown hydrolyzing AMP to adenosine on the external side of the plasma membrane</li> <li>Nucleoside transporters (Slc29a1/ENT1 and Slc29a2/ENT2) correctly shown transporting nucleosides</li> <li>Ampd3 correctly shown as involved in intracellular AMP catabolism</li> </ol> <p>The UniProt entries confirm the molecular functions assigned to each protein in the model.</p>"},{"location":"reviews/5fa76ad400000018-AMP_catabolic_process_2__Mouse_/#go-cam-standards-compliance","title":"GO-CAM Standards Compliance","text":"<p>The model follows GO-CAM best practices:</p> <ol> <li>Activities are connected through appropriate causal associations</li> <li>Molecular functions are correctly associated with gene products</li> <li>Input and output molecules are properly specified</li> <li>Cellular locations are accurately annotated</li> <li>Biological processes are appropriately associated with activities</li> </ol>"},{"location":"reviews/5fa76ad400000018-AMP_catabolic_process_2__Mouse_/#areas-for-potential-improvement","title":"Areas for Potential Improvement","text":"<ol> <li>Subcellular Localization: While the model includes some localization information (e.g., CD73 at GO:0009897 \"external side of plasma membrane\"), some additional specificity might be beneficial for Ampd3, which is shown to be in cytosol (</li> </ol>"},{"location":"reviews/5fa76ad400000110-GMP_catabolic_process_to_allantoin__Mouse_/","title":"5fa76ad400000110 GMP catabolic process to allantoin  Mouse","text":"<p>Based on the information available, I'll now provide a detailed review of the GO-CAM model with ID 5fa76ad400000110.</p>"},{"location":"reviews/5fa76ad400000110-GMP_catabolic_process_to_allantoin__Mouse_/#review-of-go-cam-model-5fa76ad400000110-gmp-catabolic-process-to-allantoin-mouse","title":"Review of GO-CAM Model: 5fa76ad400000110 (\"GMP catabolic process to allantoin (Mouse)\")","text":""},{"location":"reviews/5fa76ad400000110-GMP_catabolic_process_to_allantoin__Mouse_/#overview","title":"Overview","text":"<p>This GO-CAM model represents the GMP catabolic pathway in mouse leading to allantoin production. This is an important pathway for purine catabolism where GMP is broken down to guanine, then to xanthine, urate, and finally to allantoin through several enzymatic steps.</p>"},{"location":"reviews/5fa76ad400000110-GMP_catabolic_process_to_allantoin__Mouse_/#biological-content-review","title":"Biological Content Review","text":""},{"location":"reviews/5fa76ad400000110-GMP_catabolic_process_to_allantoin__Mouse_/#pathway-overview","title":"Pathway Overview","text":"<p>The model correctly represents the GMP catabolic pathway in mice that leads to allantoin formation. This pathway consists of several key steps: 1. PNP (Purine nucleoside phosphorylase) converting GMP to guanine 2. GDA (Guanine deaminase) converting guanine to xanthine 3. XDH/XO (Xanthine dehydrogenase/oxidase) converting xanthine to urate 4. UOX (Urate oxidase) converting urate to 5-hydroxyisourate 5. URAH (HIU hydrolase) converting 5-hydroxyisourate to OHCU 6. URAD (OHCU decarboxylase) converting OHCU to allantoin</p> <p>The model captures this sequence correctly with appropriate causal relationships.</p>"},{"location":"reviews/5fa76ad400000110-GMP_catabolic_process_to_allantoin__Mouse_/#evidence-and-references","title":"Evidence and References","text":"<p>The model includes appropriate evidence codes and literature references for most annotations: - ECO:0000315 (mutant phenotype evidence) and ECO:0000314 (direct assay evidence) are used - Key publications such as PMID:11783524, PMID:8064675, PMID:8226898, and PMID:16462750 are cited - These references are appropriate for the specific interactions being modeled</p>"},{"location":"reviews/5fa76ad400000110-GMP_catabolic_process_to_allantoin__Mouse_/#cellular-locations","title":"Cellular Locations","text":"<p>The model correctly specifies cellular locations for activities: - Some activities occur in the cytosol (GO:0005829) - Later steps in the pathway occur in peroxisomes (GO:0005777) - This is consistent with the known biology of purine degradation</p>"},{"location":"reviews/5fa76ad400000110-GMP_catabolic_process_to_allantoin__Mouse_/#key-molecular-activities","title":"Key Molecular Activities","text":"<p>The model accurately represents the molecular functions: - GO:0050484 (GMP 5'-nucleotidase activity) - GO:0004731 (purine-nucleoside phosphorylase activity) - GO:0008892 (guanine deaminase activity) - GO:0004854/GO:0004855 (xanthine dehydrogenase/oxidase activities) - GO:0004846 (urate oxidase activity) - GO:0033971 (hydroxyisourate hydrolase activity) - GO:0051997 (2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase activity)</p>"},{"location":"reviews/5fa76ad400000110-GMP_catabolic_process_to_allantoin__Mouse_/#technical-assessment","title":"Technical Assessment","text":""},{"location":"reviews/5fa76ad400000110-GMP_catabolic_process_to_allantoin__Mouse_/#activity-flow","title":"Activity Flow","text":"<p>The model uses appropriate causal connections (RO:0002413 \"provides input for\") to link activities in the pathway. The flow from initial GMP catabolism through each step to allantoin production is represented in a logical sequence that accurately reflects the biological process.</p>"},{"location":"reviews/5fa76ad400000110-GMP_catabolic_process_to_allantoin__Mouse_/#entity-representation","title":"Entity Representation","text":"<p>The model correctly uses MGI identifiers for mouse gene products: - MGI:MGI:2178563 (Nt5c2) - GMP 5'-nucleotidase - MGI:MGI:97365 (Pnp) - Purine nucleoside phosphorylase - MGI:MGI:95678 (Gda) - Guanine deaminase - MGI:MGI:98973 (Xdh) - Xanthine dehydrogenase/oxidase - MGI:MGI:98907 (Uox) - Urate oxidase - MGI:MGI:1916142 (Urah) - Hydroxyisourate hydrolase - MGI:MGI:3647519 (Urad) - OHCU decarboxylase</p>"},{"location":"reviews/5fa76ad400000110-GMP_catabolic_process_to_allantoin__Mouse_/#part-of-process-associations","title":"Part of Process Associations","text":"<p>All molecular activities are correctly associated with GO:0046038 (GMP catabolic process).</p>"},{"location":"reviews/5fa76ad400000110-GMP_catabolic_process_to_allantoin__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Pathway Completeness: The model covers the complete pathway from GMP to allantoin, including all intermediate</li> </ol>"},{"location":"reviews/5fa76ad400000265-dAMP_catabolic_process_to_allantoin__Mouse_/","title":"5fa76ad400000265 dAMP catabolic process to allantoin  Mouse","text":"<p>Now I'll review the GO-CAM model in detail.</p>"},{"location":"reviews/5fa76ad400000265-dAMP_catabolic_process_to_allantoin__Mouse_/#review-of-go-cam-model-5fa76ad400000265-damp-catabolic-process-to-allantoin-mouse","title":"Review of GO-CAM Model: 5fa76ad400000265 - dAMP catabolic process to allantoin (Mouse)","text":""},{"location":"reviews/5fa76ad400000265-dAMP_catabolic_process_to_allantoin__Mouse_/#overview","title":"Overview","text":"<p>This GO-CAM model (gomodel:5fa76ad400000265) describes the dAMP catabolic pathway in mouse (Mus musculus), showing the breakdown of dAMP to allantoin. The model captures a sequential enzymatic pathway with multiple activities connected through causal associations, primarily using the \"provides input for\" (RO:0002413) predicate.</p>"},{"location":"reviews/5fa76ad400000265-dAMP_catabolic_process_to_allantoin__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Well-structured pathway: The model presents a clear flow of activities from dAMP degradation to the final product allantoin, with appropriate causal connections between activities.</p> </li> <li> <p>Appropriate evidence citations: Each activity is supported by experimental evidence with relevant PMID citations.</p> </li> <li> <p>Proper cellular localization: The activities are appropriately localized to either cytosol (GO:0005829) or peroxisome (GO:0005777), which is consistent with current knowledge of purine metabolism.</p> </li> <li> <p>Clear molecular functions: Each activity has a well-defined molecular function term that accurately captures the enzymatic activity.</p> </li> <li> <p>Correct biological process assignment: All activities are correctly annotated as part of the dAMP catabolic process (GO:0046059).</p> </li> <li> <p>Proper representation of final output: The model correctly shows allantoin (CHEBI:15676) as the final product of the pathway.</p> </li> </ol>"},{"location":"reviews/5fa76ad400000265-dAMP_catabolic_process_to_allantoin__Mouse_/#suggested-improvements","title":"Suggested Improvements","text":"<ol> <li> <p>Missing transport activity: The model shows activities occurring in both cytosol and peroxisome, but there's no representation of how the metabolites are transported between these compartments. Consider adding the relevant transport activities.</p> </li> <li> <p>Missing molecular inputs: While the causal connections between activities are clear, the model lacks explicit representation of the input molecules for each reaction. Adding the chemical entities as inputs would improve the representation of the pathway.</p> </li> <li> <p>Additional evidence for some causal associations: Some causal associations lack evidence citations (e.g., the connection from activity 5fa76ad400000265/5fa76ad400000281 to 5fa76ad400000265/5fa76ad400000286). These should be supported by evidence.</p> </li> <li> <p>Xanthine dehydrogenase/oxidase representation: Xanthine dehydrogenase (XDH) can function as both a dehydrogenase and an oxidase. The model correctly represents this with multiple activities (GO:0070674, GO:0070675, GO:0004854, GO:0004855) enabled by the same gene product (MGI:MGI:98973). However, it might be useful to add annotations explaining the interconversion between these forms, as this is regulated by post-translational modifications.</p> </li> </ol>"},{"location":"reviews/5fa76ad400000265-dAMP_catabolic_process_to_allantoin__Mouse_/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":"<ol> <li> <p>Pathway representation: The model accurately represents the degradation of dAMP to allantoin in mouse as described in the literature. The sequence starts with 2'-deoxyadenosine deaminase activity (ADA), continues through nucleotidase and purine-nucleoside phosphorylase activities, then through the xanthine dehydrogenase/oxidase system, urate oxidase, and finally to hydroxyisourate hydrolase and 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase activities.</p> </li> <li> <p>Recent findings incorporation: The model correctly incorporates the findings from Ramazzina et al. (PMID:16462750) regarding the final steps of the pathway. This paper identified two additional enzymes (HIU hydrolase and OHCU decarboxylase) needed for the efficient conversion of uric acid to allantoin.</p> </li> <li> <p>Species-specific representation: The model correctly represents the mouse pathway, which differs from humans as mice retain the ability to degrade uric acid to allantoin, while humans have lost this ability due to pseudogenization of the urate oxidase gene.</p> </li> </ol>"},{"location":"reviews/5fa76ad400000265-dAMP_catabolic_process_to_allantoin__Mouse_/#conclusion","title":"Conclusion","text":"<p>This is a well-constructed GO-CAM model that accurately represents the dAMP catabolic pathway in mouse, leading to allantoin production. The model follows best practices for GO-CAM construction, with appropriate use of causal relationships, evidence citations, and cellular component annotations. The minor improvements suggested would enhance the completeness of the model but don't detract from</p>"},{"location":"reviews/5fa76ad400000374-IMP_catabolic_process_to_allantoin__Mouse_/","title":"5fa76ad400000374 IMP catabolic process to allantoin  Mouse","text":"<p>Based on the information I've gathered, I'll now provide a comprehensive review of the GO-CAM model gomodel:5fa76ad400000374.</p>"},{"location":"reviews/5fa76ad400000374-IMP_catabolic_process_to_allantoin__Mouse_/#review-of-go-cam-model-gomodel5fa76ad400000374","title":"Review of GO-CAM Model gomodel:5fa76ad400000374","text":""},{"location":"reviews/5fa76ad400000374-IMP_catabolic_process_to_allantoin__Mouse_/#model-overview","title":"Model Overview","text":"<p>Title: IMP catabolic process to allantoin (Mouse) ID: gomodel:5fa76ad400000374 Taxon: NCBITaxon:10090 (Mouse) Status: Production</p>"},{"location":"reviews/5fa76ad400000374-IMP_catabolic_process_to_allantoin__Mouse_/#summary","title":"Summary","text":"<p>This model represents the IMP catabolic pathway leading to allantoin in mouse, depicting the sequential enzymatic reactions that convert IMP (inosine monophosphate) to the final product allantoin. The model captures a well-established biochemical pathway with clear causal relationships between molecular activities connected by the \"provides input for\" (RO:0002413) causal predicate.</p>"},{"location":"reviews/5fa76ad400000374-IMP_catabolic_process_to_allantoin__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the purine degradation pathway, specifically the breakdown of IMP to allantoin. This pathway is well-documented in the literature, as shown in the referenced publication (PMID:16462750). The key molecular functions and their sequence in the pathway appear to be correctly depicted:</p> <ol> <li>IMP is converted to hypoxanthine by nucleotidase activity</li> <li>Hypoxanthine is oxidized to xanthine by xanthine dehydrogenase/oxidase</li> <li>Xanthine is further oxidized to uric acid</li> <li>Uric acid is degraded to allantoin through a series of enzymatic reactions</li> </ol> <p>The model correctly represents multiple subcellular locations for these activities, including cytosol (GO:0005829) and peroxisome (GO:0005777), which is consistent with the literature.</p>"},{"location":"reviews/5fa76ad400000374-IMP_catabolic_process_to_allantoin__Mouse_/#go-cam-best-practices","title":"GO-CAM Best Practices","text":"<p>The model follows most GO-CAM best practices:</p> <ol> <li> <p>Causal connections: The model uses appropriate causal relationships (RO:0002413 \"provides input for\") to connect molecular activities, properly representing the flow of the biochemical pathway.</p> </li> <li> <p>Evidence: Each assertion has appropriate evidence codes and literature references. Most activities are supported by experimental evidence (ECO:0000314 - direct assay evidence).</p> </li> <li> <p>Subcellular locations: Activities are correctly annotated with their subcellular locations.</p> </li> <li> <p>Part-of relationships: Activities are properly placed in the context of the broader biological process (GO:0006204 - IMP catabolic process).</p> </li> <li> <p>Activity flow: The model correctly shows the sequential nature of the pathway from IMP to allantoin.</p> </li> </ol>"},{"location":"reviews/5fa76ad400000374-IMP_catabolic_process_to_allantoin__Mouse_/#specific-assessment","title":"Specific Assessment","text":""},{"location":"reviews/5fa76ad400000374-IMP_catabolic_process_to_allantoin__Mouse_/#strengths","title":"Strengths","text":"<ol> <li> <p>Complete pathway representation: The model provides a comprehensive view of the entire IMP to allantoin catabolic pathway.</p> </li> <li> <p>Detailed molecular activities: The model correctly represents the different activities of Xanthine dehydrogenase/oxidase (Xdh) protein, including hypoxanthine dehydrogenase (GO:0070674), hypoxanthine oxidase (GO:0070675), xanthine dehydrogenase (GO:0004854), and xanthine oxidase (GO:0004855) activities.</p> </li> <li> <p>Accurate cellular locations: The model correctly places the early steps (nucleotidase, early Xdh activities) in the cytosol and the later steps (uricase, etc.) in the peroxisome, which matches the known biology.</p> </li> <li> <p>Final output: The model correctly identifies allantoin (CHEBI:15676) as the end product of the pathway.</p> </li> </ol>"},{"location":"reviews/5fa76ad400000374-IMP_catabolic_process_to_allantoin__Mouse_/#potential-issues-and-recommendations","title":"Potential Issues and Recommendations","text":"<ol> <li> <p>Multiple nucleotidase enzymes: The model shows three different IMP 5'-nucleotidase activities (Nt5c, Nt5c2, and Nt5c1a) that all provide input to the same downstream activity. While not necessarily incorrect, it would be helpful to clarify if these enzymes act redundantly, in different contexts, or have different specificities. </p> </li> <li> <p>Evidence gaps: One causal association (60418ffa00001817 to 5fa76ad400000376) lacks evidence annotations, which should be added for completeness.</p> </li> <li> <p>Xanthine dehydrogenase/oxidase connections: The model shows multiple paths from the Xdh enzyme to downstream reactions. While this does represent the complexity of the enzyme's activities, the representation could potentially be streamlined for clarity</p> </li> </ol>"},{"location":"reviews/5fadbcf000000317-Fzd3_function_in_Cranial_neural_crest_cells/","title":"5fadbcf000000317 Fzd3 function in Cranial neural crest cells","text":"<p>Based on all the information I've reviewed, I can now provide a comprehensive evaluation of GO-CAM model 5fadbcf000000317:</p>"},{"location":"reviews/5fadbcf000000317-Fzd3_function_in_Cranial_neural_crest_cells/#review-of-go-cam-model-gomodel5fadbcf000000317","title":"Review of GO-CAM Model: gomodel:5fadbcf000000317","text":""},{"location":"reviews/5fadbcf000000317-Fzd3_function_in_Cranial_neural_crest_cells/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model titled \"Fzd3 function in Cranial neural crest cells\" represents signaling pathways involving Frizzled receptors (particularly Fzd3 and Fzd7) in Xenopus (frog) cranial neural crest cells. The model focuses on the Wnt signaling pathway, specifically the planar cell polarity (PCP) pathway, which is a non-canonical Wnt pathway involved in cell migration and tissue organization. The model was created in 2020 with some automated updates in 2023.</p>"},{"location":"reviews/5fadbcf000000317-Fzd3_function_in_Cranial_neural_crest_cells/#model-structure-and-biological-content","title":"Model Structure and Biological Content","text":"<p>The model depicts several key components:</p> <ol> <li>Wnt Receptor Activities: </li> <li>Fzd3 (fzd3.L) and Fzd7 (fzd7.L) are shown with Wnt receptor activity (GO:0042813)</li> <li> <p>These receptors also display Wnt-protein binding activity (GO:0017147)</p> </li> <li> <p>Wnt Ligands:</p> </li> <li>Wnt11 (wnt11.L) with frizzled binding activity (GO:0005109)</li> <li> <p>The model shows extracellular Wnt signaling molecules binding to membrane-bound receptors</p> </li> <li> <p>Downstream Signaling:</p> </li> <li>RhoA (rhoa.L) with protein kinase binding (GO:0019901)</li> <li>Rac1 (rac1.L) with GTPase activity (GO:0003924)</li> <li>JNK/MAPK8 with JNK kinase activity (GO:0004705)</li> <li>ROCK1 kinase with Rho-dependent protein serine/threonine kinase activity (GO:0072518)</li> <li> <p>Dishevelled (dvl1.L) with frizzled binding activity (GO:0005109)</p> </li> <li> <p>Cellular Contexts:</p> </li> <li>Activities occur in specific cellular compartments (extracellular region, plasma membrane, cytosol, nucleus)</li> <li>Specialized context of cranial neural crest cells (XAO:0001001)</li> </ol>"},{"location":"reviews/5fadbcf000000317-Fzd3_function_in_Cranial_neural_crest_cells/#evaluation-against-go-cam-best-practices","title":"Evaluation Against GO-CAM Best Practices","text":""},{"location":"reviews/5fadbcf000000317-Fzd3_function_in_Cranial_neural_crest_cells/#strengths","title":"Strengths:","text":"<ol> <li> <p>Appropriate Context Annotations: The model correctly specifies cellular locations for proteins (e.g., extracellular for Wnt ligands, membrane for receptors).</p> </li> <li> <p>Causal Relationships: The model uses appropriate causal relationship predicates between activities, including:</p> </li> <li>RO:0002304 (causally upstream of, positive effect)</li> <li>RO:0002629 (directly positively regulates)</li> <li> <p>RO:0002630 (directly negatively regulates)</p> </li> <li> <p>Pathway Integrity: The model builds a coherent pathway with logical flow from extracellular Wnt signals to intracellular effects, capturing the non-canonical Wnt/PCP pathway.</p> </li> <li> <p>Biological Process Integration: Activities are appropriately tied to biological processes (e.g., GO:0060071 \"Wnt signaling pathway, planar cell polarity pathway\").</p> </li> </ol>"},{"location":"reviews/5fadbcf000000317-Fzd3_function_in_Cranial_neural_crest_cells/#issues-and-recommendations","title":"Issues and Recommendations:","text":"<ol> <li>Biological Accuracy Concerns:</li> <li> <p>The model correctly depicts Fzd3's role in neural crest development, which is supported by the literature. The paper I found (PNAS article) confirms that FZD3 is \"one of the few FZD family members that are predominantly expressed at the dorsal site of the neural tube, coinciding with neural crest appearance\" and \"injection of FZD3 mRNA can induce formation of the neural crest in embryos and explants.\"</p> </li> <li> <p>Model Completeness:</p> </li> <li>The model includes a deprecated term: GO:1904929 \"obsolete coreceptor activity involved in Wnt signaling pathway, planar cell polarity pathway.\" This should be updated with the current appropriate term.</li> <li> <p>The downstream transcriptional effects of the pathway are not fully modeled - according to the literature, FZD3 ultimately influences transcription of genes important for neural crest development and migration.</p> </li> <li> <p>Technical Structure:</p> </li> <li>Some activities lack evidence annotations for their causal</li> </ol>"},{"location":"reviews/5fadbcf000000480-UMP_catabolic_process__Mouse_/","title":"5fadbcf000000480 UMP catabolic process  Mouse","text":"<p>Based on the information available, I'll now review the GO-CAM model gomodel:5fadbcf000000480 - \"UMP catabolic process (Mouse)\".</p>"},{"location":"reviews/5fadbcf000000480-UMP_catabolic_process__Mouse_/#go-cam-model-review-gomodel5fadbcf000000480","title":"GO-CAM Model Review: gomodel:5fadbcf000000480","text":""},{"location":"reviews/5fadbcf000000480-UMP_catabolic_process__Mouse_/#basic-information","title":"Basic Information","text":"<ul> <li>Title: UMP catabolic process (Mouse)</li> <li>ID: gomodel:5fadbcf000000480</li> <li>Taxon: NCBITaxon:10090 (Mouse)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/5fadbcf000000480-UMP_catabolic_process__Mouse_/#overview","title":"Overview","text":"<p>This model describes the UMP (uridine monophosphate) catabolic process in mouse cells, involving multiple gene products working in a cascade to break down UMP. The pathway spans from initial 5'-nucleotidase activities through to the final degradation steps of pyrimidine catabolism.</p>"},{"location":"reviews/5fadbcf000000480-UMP_catabolic_process__Mouse_/#model-structure-and-flow","title":"Model Structure and Flow","text":"<p>The model has a well-defined causal flow with appropriate use of the \"provides input for\" predicate (RO:0002413) to connect activities in the pathway. The model represents 7 different molecular activities carried out by different gene products, primarily in the cytosol.</p>"},{"location":"reviews/5fadbcf000000480-UMP_catabolic_process__Mouse_/#molecular-activities-and-connections","title":"Molecular Activities and Connections","text":"<ol> <li>Two 5'-nucleotidase activities:</li> <li>MGI:MGI:1354954 (Nt5c) - 5'-nucleotidase activity (GO:0008253)</li> <li>MGI:MGI:1927186 (Nt5c3) - 5'-nucleotidase activity (GO:0008253)</li> </ol> <p>Both provide input for uridine phosphorylase activities.</p> <ol> <li>Two uridine phosphorylase activities:</li> <li>MGI:MGI:1097668 (Upp1) - uridine phosphorylase activity (GO:0004850)</li> <li>MGI:MGI:1923904 (Upp2) - uridine phosphorylase activity (GO:0004850)</li> </ol> <p>Both provide input for dihydropyrimidine dehydrogenase activity.</p> <ol> <li>Subsequent catabolic steps:</li> <li>MGI:MGI:2139667 (Dpyd) - dihydropyrimidine dehydrogenase activity (GO:0017113)</li> <li>MGI:MGI:1928679 (Dpys) - dihydropyrimidinase activity (GO:0004157)</li> <li>MGI:MGI:2143535 (Upb1) - beta-ureidopropionase activity (GO:0003837)</li> <li>MGI:MGI:2146052 (Agxt2) - beta-alanine:pyruvate transaminase activity (GO:0016223)</li> </ol>"},{"location":"reviews/5fadbcf000000480-UMP_catabolic_process__Mouse_/#consistency-and-scientific-accuracy","title":"Consistency and Scientific Accuracy","text":"<p>The model accurately represents the known steps in pyrimidine/UMP catabolism, with the pathway being consistent with the biochemical knowledge about UMP degradation. The pathway begins with the hydrolysis of UMP to uridine by 5'-nucleotidases, followed by phosphorolysis of uridine to uracil by uridine phosphorylases, and then proceeds through the established pyrimidine degradation pathway.</p> <p>The model is consistent with the Uniprot entry for NT5C (Q8TCD5), which confirms its role as a cytosolic 5\u2032(3\u2032)-deoxyribonucleotidase with a preference for dUMP and dTMP.</p>"},{"location":"reviews/5fadbcf000000480-UMP_catabolic_process__Mouse_/#subcellular-localization","title":"Subcellular Localization","text":"<p>Most activities are appropriately localized to the cytosol (GO:0005829), with one activity (beta-alanine:pyruvate transaminase) correctly localized to the</p>"},{"location":"reviews/5fadbcf000000868-dUMP_catabolic_process__Mouse_/","title":"5fadbcf000000868 dUMP catabolic process  Mouse","text":"<p>Based on my review of the GO-CAM model with ID 5fadbcf000000868, titled \"dUMP catabolic process (Mouse),\" here is my comprehensive assessment:</p>"},{"location":"reviews/5fadbcf000000868-dUMP_catabolic_process__Mouse_/#go-cam-review-dump-catabolic-process-mouse-gomodel5fadbcf000000868","title":"GO-CAM Review: dUMP catabolic process (Mouse) - gomodel:5fadbcf000000868","text":""},{"location":"reviews/5fadbcf000000868-dUMP_catabolic_process__Mouse_/#overall-model-description","title":"Overall Model Description","text":"<p>This GO-CAM model represents the dUMP catabolic process in mouse (NCBITaxon:10090), showing the enzymatic pathway for the breakdown of deoxyuridine monophosphate (dUMP). The model includes 7 molecular activities carried out by different proteins, primarily located in the cytosol, with one activity in the mitochondrion.</p>"},{"location":"reviews/5fadbcf000000868-dUMP_catabolic_process__Mouse_/#strengths","title":"Strengths","text":"<ol> <li> <p>Clear causal flow: The model demonstrates a logical sequence of molecular activities with appropriate causal connections using the \"provides input for\" (RO:0002413) predicate.</p> </li> <li> <p>Consistent subcellular localization: Most activities are appropriately annotated to occur in the cytosol (GO:0005829), with one mitochondrial activity correctly distinguished.</p> </li> <li> <p>Evidence support: Each activity is supported by experimental evidence, primarily direct assay evidence (ECO:0000314) with appropriate PMID references.</p> </li> <li> <p>Taxonomic consistency: All annotations are specific to mouse proteins, maintaining taxonomic consistency throughout the model.</p> </li> </ol>"},{"location":"reviews/5fadbcf000000868-dUMP_catabolic_process__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Incomplete activity flow: The model includes one activity (GO:0016223 beta-alanine:pyruvate transaminase activity by MGI:MGI:2146052/Agxt2) that is not connected to the main causal chain, making its role in the pathway unclear.</p> </li> <li> <p>Missing chemical inputs/outputs: While the causal connections between activities are present, the model would benefit from explicitly representing the chemical entities being transformed at each step.</p> </li> <li> <p>Limited evidence for one activity: The annotation for Nt5c3 (MGI:MGI:1927186) relies on sequence orthology evidence (ECO:0000266) rather than direct experimental evidence, which is less robust than the evidence used for other activities.</p> </li> </ol>"},{"location":"reviews/5fadbcf000000868-dUMP_catabolic_process__Mouse_/#biological-accuracy-review","title":"Biological Accuracy Review","text":"<p>The model represents the pyrimidine degradation pathway, specifically focusing on dUMP catabolism. The sequence of enzymatic activities is biologically accurate:</p> <ol> <li> <p>The pathway begins with 5'-nucleotidase activities (GO:0008253) by Nt5c3 and Nt5c, which provide input for deoxyuridine phosphorylase activity.</p> </li> <li> <p>This is followed by deoxyuridine phosphorylase activity (GO:0047847) by Upp1, dihydropyrimidine dehydrogenase activity (GO:0017113) by Dpyd, dihydropyrimidinase activity (GO:0004157) by Dpys, and beta-ureidopropionase activity (GO:0003837) by Upb1.</p> </li> <li> <p>The final step involving beta-alanine:pyruvate transaminase activity (GO:0016223) by Agxt2 is correctly localized to the mitochondrion but lacks causal connection to the other activities.</p> </li> </ol>"},{"location":"reviews/5fadbcf000000868-dUMP_catabolic_process__Mouse_/#compliance-with-go-cam-guidelines","title":"Compliance with GO-CAM Guidelines","text":"<p>The model generally follows GO-CAM best practices:</p> <ol> <li> <p>Molecular activities: Each protein is annotated with a specific molecular function, appropriate for its role in the pathway.</p> </li> <li> <p>Causal relationships: The model uses the appropriate causal predicate (RO:0002413 - \"provides input for\") for connecting sequential enzymatic activities.</p> </li> <li> <p>Process annotation: Activities are correctly annotated as being part of the dUMP catabolic process (GO:0046079).</p> </li> </ol>"},{"location":"reviews/5fadbcf000000868-dUMP_catabolic_process__Mouse_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Connect isolated activity: The beta-alanine:pyruvate transaminase activity should be causally connected to the beta-ureidopropionase activity, as beta-alanine is a product of beta-ureidopropionase that serves as a substrate for the transaminase.</p> </li> <li> <p>Add missing chemical entities: Consider including the chemical entities being transformed at each step to make the model more complete and informative.</p> </li> <li> <p>Strengthen evidence: If possible, replace the sequence orthology evidence for Nt5c3 with direct experimental evidence.</p> </li> <li> <p>Consider complex representation: For any enzymes that function as complexes, review the</p> </li> </ol>"},{"location":"reviews/5fadbcf000000942-dTMP_catabolic_process__Mouse_/","title":"5fadbcf000000942 dTMP catabolic process  Mouse","text":"<p>Based on my review of the GO-CAM model and the information I've gathered, I can now provide a comprehensive review of gomodel:5fadbcf000000942, which represents the \"dTMP catabolic process (Mouse)\" pathway.</p>"},{"location":"reviews/5fadbcf000000942-dTMP_catabolic_process__Mouse_/#go-cam-model-review-dtmp-catabolic-process-mouse-gomodel5fadbcf000000942","title":"GO-CAM Model Review: dTMP catabolic process (Mouse) - gomodel:5fadbcf000000942","text":""},{"location":"reviews/5fadbcf000000942-dTMP_catabolic_process__Mouse_/#overview","title":"Overview","text":"<p>This GO-CAM model depicts the dTMP (thymidine monophosphate) catabolic process in mouse. The model shows the sequential enzymatic activities involved in breaking down thymidine to products that can enter central metabolism.</p>"},{"location":"reviews/5fadbcf000000942-dTMP_catabolic_process__Mouse_/#model-structure-and-contents","title":"Model Structure and Contents","text":"<p>The model includes 7 activities (functions) enabled by different gene products: 1. 5'-nucleotidase activity (GO:0008253) - enabled by Nt5c and Nt5c3 2. Thymidine phosphorylase activity (GO:0009032) - enabled by Tymp and Upp1 3. Dihydropyrimidine dehydrogenase [NADP+] activity (GO:0017113) - enabled by Dpyd 4. Dihydropyrimidinase activity (GO:0004157) - enabled by Dpys 5. Beta-ureidopropionase activity (GO:0003837) - enabled by Upb1 6. (R)-3-amino-2-methylpropionate-pyruvate transaminase activity (GO:0047305) - enabled by Agxt2</p> <p>The model uses causal relationships (RO:0002413 \"provides input for\") to connect the activities in a logical sequence for the breakdown pathway.</p>"},{"location":"reviews/5fadbcf000000942-dTMP_catabolic_process__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Complete pathway representation: The model captures the entire thymidine degradation pathway from dTMP to beta-alanine and other end products.</p> </li> <li> <p>Appropriate causal connections: The model correctly uses \"provides input for\" (RO:0002413) to connect activities in a metabolic pathway.</p> </li> <li> <p>Correct subcellular locations: Most activities have appropriate cellular locations specified (e.g., cytosol - GO:0005829).</p> </li> <li> <p>Evidence quality: The model includes evidence codes with proper references to literature.</p> </li> </ol>"},{"location":"reviews/5fadbcf000000942-dTMP_catabolic_process__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Incomplete subcellular localization: Not all activities have a specified cellular location. For example, the beta-ureidopropionase activity doesn't have an explicit cellular location. According to UniProt entry for Upb1 (Q9UBR1), this activity occurs in the cytoplasm, so GO:0005829 (cytosol) should be added.</p> </li> <li> <p>Missing biological process for an activity: The beta-ureidopropionase activity (gomodel:5fadbcf000000942/5fadbcf000000998) enabled by Upb1 lacks a part_of relationship to the dTMP catabolic process. It should be associated with GO:0046074 (dTMP catabolic process) like the other activities in the model.</p> </li> <li> <p>Activity of Agxt2: The Agxt2 enzyme is correctly included, but it represents a branch point of the pathway. It might be beneficial to clarify in the model that this represents a terminal step in one branch of the pathway.</p> </li> <li> <p>Evidence for subcellular locations: Some of the subcellular locations lack evidence annotations, which would strengthen the model.</p> </li> </ol>"},{"location":"reviews/5fadbcf000000942-dTMP_catabolic_process__Mouse_/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model accurately represents the thymidine degradation pathway as described in the literature:</p> <ol> <li> <p>The pathway begins with the conversion of dTMP to thymidine by 5'-nucleotidases (Nt5c and Nt5c3)</p> </li> <li> <p>Thymidine is then converted to thymine by thymidine phosphorylases (Tymp and Upp1). This step is supported by the literature, including the PMID:12077348 paper which discusses the role of these enzymes.</p> </li> <li> <p>Thymine is then reduced to dihydrothymine by dihydropyrimidine dehydrogenase (Dpyd), as confirmed by UniProt data for Q12882 (human DPYD).</p> </li> <li> <p>Dihydrothymine is hydrolyzed to N-carbamoyl-beta-alanine by dihydropyrimidinase (</p> </li> </ol>"},{"location":"reviews/5fadbcf000001101-SPModule_IFIH1_MAVS/","title":"5fadbcf000001101 SPModule IFIH1 MAVS","text":"<p>Based on all the information collected, I'll now provide a comprehensive review of GO-CAM model gomodel:5fadbcf000001101:</p>"},{"location":"reviews/5fadbcf000001101-SPModule_IFIH1_MAVS/#review-of-go-cam-model-gomodel5fadbcf000001101-spmodule-ifih1-mavs","title":"Review of GO-CAM model: gomodel:5fadbcf000001101 \"SPModule IFIH1-MAVS\"","text":""},{"location":"reviews/5fadbcf000001101-SPModule_IFIH1_MAVS/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (gomodel:5fadbcf000001101) represents the signaling interactions between IFIH1 (MDA5) and MAVS proteins in the innate immune pathway, particularly focused on viral RNA sensing and signal transduction. The model contains 5 activities connected through causal relations.</p>"},{"location":"reviews/5fadbcf000001101-SPModule_IFIH1_MAVS/#model-content-summary","title":"Model Content Summary","text":"<p>The model depicts a signaling cascade where: 1. IFIH1 engages in pattern recognition receptor activity (GO:0038187) 2. This provides input for PPP1CA phosphatase activity (GO:0016791) 3. PPP1CA dephosphorylates IFIH1, which enables IFIH1 to form a homodimer (identical protein binding, GO:0042802) 4. Active IFIH1 directly positively regulates MAVS (GO:0042802, identical protein binding) 5. MAVS then exerts signaling adaptor activity (GO:0035591) to propagate the antiviral response</p>"},{"location":"reviews/5fadbcf000001101-SPModule_IFIH1_MAVS/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Accurately represents scientific knowledge: The model correctly depicts the key interactions between IFIH1/MDA5 and MAVS in viral sensing, which agrees with the literature showing IFIH1 acts as a pattern recognition receptor for viral dsRNA.</p> </li> <li> <p>Includes the critical regulatory mechanism: The model correctly includes the important role of PPP1CA (PP1-alpha) in dephosphorylating IFIH1/MDA5, which is essential for its activation as demonstrated in the literature (PMID:23499489).</p> </li> <li> <p>Proper subcellular localization: The model appropriately indicates that IFIH1/MDA5 functions in the cytoplasm (GO:0005737) and that MAVS functions in the mitochondrial outer membrane (GO:0005741), which matches their known biological locations.</p> </li> <li> <p>Captures ATP interaction: The model properly shows that ATP (CHEBI:15422) is an input for IFIH1's identical protein binding activity, which is consistent with the literature showing that ATP is involved in IFIH1/MDA5 function.</p> </li> </ol>"},{"location":"reviews/5fadbcf000001101-SPModule_IFIH1_MAVS/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li> <p>Missing filament formation: The literature (particularly PMID:22314235) indicates that MDA5 forms filaments along viral dsRNA, which is a crucial step in its activation mechanism. This cooperative assembly into filaments is not represented in the model. I recommend adding this as an additional activity or clarifying the existing \"identical protein binding\" activity to reflect filament formation.</p> </li> <li> <p>Incomplete representation of RNA binding: Though the model includes ATP as an input for IFIH1, it doesn't specify the involvement of viral dsRNA, which is the primary ligand for IFIH1/MDA5. I recommend adding dsRNA (like double-stranded RNA, CHEBI:67208) as an additional input for IFIH1's pattern recognition receptor activity.</p> </li> <li> <p>Missing CARD domains interaction: The literature highlights the importance of the CARD domains in IFIH1/MDA5 for interacting with the CARD domain of MAVS, triggering downstream signaling. The precise mechanism of this CARD-CARD interaction should be more explicitly represented.</p> </li> <li> <p>Regulatory dynamics of phosphorylation: While the model includes PPP1CA's role in dephosphorylating IFIH1, it would be more complete if it also indicated which residue(s) are dephosphorylated. According to PMID:23499489, Ser-88 dephosphorylation is particularly important for MDA5 activation.</p> </li> <li> <p>Simplified representation of MAVS activation: The model shows MAVS as simply conducting signaling adapter activity, but the literature indicates that MAVS forms prion-like aggregates at the mitochondrial membrane following interaction with MDA5. This oligomerization is an important mechanistic detail that should be included.</p> </li> <li> <p>Consider adding downstream effects: For completeness, the model could be extended to include downstream components such as the activation of IRF3 and NF-\u03baB, leading to type I interferon</p> </li> </ol>"},{"location":"reviews/5fadbcf000001646-SP_SIK2_actvity_on_P300/","title":"5fadbcf000001646 SP SIK2 actvity on P300","text":"<p>I'm now going to review GO-CAM model 5fadbcf000001646 based on the information I've gathered. This model represents the relationship between SIK2 activity and p300/ChREBP in relation to fatty acid metabolism in the liver.</p>"},{"location":"reviews/5fadbcf000001646-SP_SIK2_actvity_on_P300/#review-of-go-cam-model-5fadbcf000001646-sp_sik2-actvity-on-p300","title":"Review of GO-CAM Model: 5fadbcf000001646 (SP_SIK2-actvity-on-P300)","text":""},{"location":"reviews/5fadbcf000001646-SP_SIK2_actvity_on_P300/#overview","title":"Overview","text":"<p>This GO-CAM model (gomodel:5fadbcf000001646) describes the regulatory relationships between Salt-inducible kinase 2 (SIK2), the transcriptional coactivator p300, and Carbohydrate-responsive element-binding protein (ChREBP/MLXIPL) in the context of hepatic lipid metabolism.</p>"},{"location":"reviews/5fadbcf000001646-SP_SIK2_actvity_on_P300/#model-components","title":"Model Components","text":"<p>The model includes the following molecular activities:</p> <ol> <li>SIK2 (UniProtKB:Q9H0K1) - Protein serine/threonine kinase activity (GO:0004674)</li> <li> <p>This activity negatively regulates two downstream activities:</p> <ul> <li>p300 (UniProtKB:Q09472) acetyltransferase activity (GO:0016407)</li> <li>p300 (UniProtKB:Q09472) protein binding activity (GO:0005515)</li> </ul> </li> <li> <p>p300 (UniProtKB:Q09472)</p> </li> <li>Acetyltransferase activity (GO:0016407) occurring in chromatin (GO:0000785)</li> <li>Protein binding activity (GO:0005515)</li> <li> <p>Both activities positively regulate ChREBP/MLXIPL activities</p> </li> <li> <p>ChREBP/MLXIPL (UniProtKB:Q9NP71)</p> </li> <li>DNA-binding transcription activator activity (GO:0001216) occurring in chromatin (GO:0000785) and part of lipid biosynthetic process (GO:0008610)</li> <li>DNA-binding transcription factor binding (GO:0140297) occurring in chromatin (GO:0000785)</li> </ol>"},{"location":"reviews/5fadbcf000001646-SP_SIK2_actvity_on_P300/#evidence-evaluation","title":"Evidence Evaluation","text":"<p>The model is supported by primary literature evidence, particularly:</p> <ol> <li>Bricambert et al., 2010 demonstrating that:</li> <li>SIK2 phosphorylates p300 at Ser89, inhibiting its HAT activity</li> <li>p300 acetylates ChREBP at Lys672, which enhances its DNA binding and transcriptional activity</li> <li> <p>This pathway regulates hepatic lipid metabolism and steatosis</p> </li> <li> <p>Zhang et al., 2016 showing that:</p> </li> <li>SIK2 regulates p300 activity through phosphorylation</li> <li>p300 acts as a coactivator for transcription factors involved in lipid metabolism</li> <li>SIK2-mediated inhibition of p300 affects metabolic pathways</li> </ol>"},{"location":"reviews/5fadbcf000001646-SP_SIK2_actvity_on_P300/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<p>After reviewing the model, I find that it generally follows GO-CAM best practices:</p> <ol> <li> <p>Molecular Activities: Each protein is appropriately associated with its molecular functions.</p> </li> <li> <p>Causal Relations: The causal relationships use appropriate relation types:</p> </li> <li>RO:0002630 (directly negatively regulates) for SIK2's inhibition of p300</li> <li> <p>RO:0002629 (directly positively regulates) for p300's activation of ChREBP</p> </li> <li> <p>Cellular Context: Activities are appropriately localized to chromatin (GO:0000785).</p> </li> <li> <p>Biological Process: ChREBP's activity is correctly associated with lipid biosynthetic process (GO:0008610).</p> </li> <li> <p>Evidence: All activities and relationships are supported by experimental evidence from peer-reviewed literature with appropriate ECO codes (ECO:0000314 - direct assay evidence used in manual assertion).</p> </li> </ol>"},{"location":"reviews/5fadbcf000001646-SP_SIK2_actvity_on_P300/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model follows most GO-CAM best practices, I have a few suggestions for improvement:</p> <ol> <li>Cellular Component Annotation: The SIK2 kinase activity is not annotated with a cellular component. Based on the literature, SIK2 acts on p300</li> </ol>"},{"location":"reviews/5fadbcf000001962-T_helper_17_cell_lineage_commitment_by_IL6_cluster__Human_/","title":"5fadbcf000001962 T helper 17 cell lineage commitment by IL6 cluster  Human","text":"<p>Now, let me review the GO-CAM model that was requested:</p> <p>Based on the information I've gathered, I'll now review the GO-CAM model gomodel:5fadbcf000001962 - \"T-helper 17 cell lineage commitment by IL6 cluster (Human)\".</p>"},{"location":"reviews/5fadbcf000001962-T_helper_17_cell_lineage_commitment_by_IL6_cluster__Human_/#go-cam-model-review-t-helper-17-cell-lineage-commitment-by-il6-cluster-human","title":"GO-CAM Model Review: T-helper 17 cell lineage commitment by IL6 cluster (Human)","text":""},{"location":"reviews/5fadbcf000001962-T_helper_17_cell_lineage_commitment_by_IL6_cluster__Human_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (gomodel:5fadbcf000001962) represents the IL-6 signaling pathway in the context of T-helper 17 (Th17) cell lineage commitment in humans. The model captures the key components involved in IL-6 signaling, including:</p> <ol> <li>IL-6 (UniProtKB:P05231) acting as a cytokine</li> <li>IL-6 receptor components:</li> <li>Membrane-bound IL-6R alpha (UniProtKB:P08887-2)</li> <li>gp130/IL6ST (UniProtKB:P40189-2)</li> <li>JAK1 kinase (UniProtKB:P23458)</li> <li>STAT3 transcription factor (UniProtKB:P40763)</li> <li>SOCS3 (UniProtKB:O14543) as a negative regulator</li> </ol> <p>The model traces the signaling cascade from IL-6 binding to its receptor, through JAK1 activation, STAT3 phosphorylation and nuclear translocation, to the final outcome of Th17 cell lineage commitment.</p>"},{"location":"reviews/5fadbcf000001962-T_helper_17_cell_lineage_commitment_by_IL6_cluster__Human_/#model-evaluation","title":"Model Evaluation","text":""},{"location":"reviews/5fadbcf000001962-T_helper_17_cell_lineage_commitment_by_IL6_cluster__Human_/#accuracy-of-biological-content","title":"Accuracy of Biological Content","text":"<p>The biological content of the model is generally accurate and aligns with current understanding of IL-6 signaling in Th17 differentiation:</p> <ol> <li>The model correctly represents IL-6 acting as a cytokine in the extracellular space (GO:0005615)</li> <li>The signaling begins with IL-6 binding to membrane-bound IL-6R (P08887-2) at the plasma membrane</li> <li>The model correctly shows the sequential activation of JAK1 and STAT3</li> <li>STAT3 is appropriately located in the nucleus where it acts as a DNA-binding transcription factor</li> <li>The inclusion of SOCS3 as a negative regulator of this pathway is biologically accurate</li> <li>The model appropriately designates this pathway as part of the JAK-STAT signaling pathway (GO:0007259)</li> <li>The final outcome of Th17 cell lineage commitment (GO:0072540) is correctly represented</li> </ol>"},{"location":"reviews/5fadbcf000001962-T_helper_17_cell_lineage_commitment_by_IL6_cluster__Human_/#go-cam-structure-and-best-practices","title":"GO-CAM Structure and Best Practices","text":"<p>The model follows most GO-CAM best practices for representing signaling pathways:</p> <ol> <li>Causal relationships: The model uses appropriate causal relationship predicates:</li> <li>RO:0002629 (directly positively regulates) for direct activation</li> <li> <p>RO:0002407 (contributes to) for downstream effects</p> </li> <li> <p>Localization: Cellular components are correctly assigned:</p> </li> <li>IL-6 in extracellular space (GO:0005615)</li> <li>IL-6R and gp130 at plasma membrane (GO:0005886)</li> <li>JAK1 at the cytoplasmic side of plasma membrane (GO:0009898)</li> <li> <p>STAT3 in the nucleus (GO:0005634)</p> </li> <li> <p>Activity flow: The pathway flow is logical and sequential, following the known biology of IL-6 signaling.</p> </li> </ol>"},{"location":"reviews/5fadbcf000001962-T_helper_17_cell_lineage_commitment_by_IL6_cluster__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<p>While the model is generally well-constructed, I identified several areas for improvement:</p> <ol> <li> <p>Incomplete molecular function annotation for IL-6R: IL-6R (P08887-2) has been annotated with \"molecular adaptor activity\" (GO:0030296) but would be more accurately annotated with \"interleukin-6 receptor activity\" (GO:0004915).</p> </li> <li> <p>Missing complex representation: According to the best practices for annotating complexes, the IL-6/IL-6R/gp130 hexameric complex should be properly represented. The current model shows individual components but doesn't properly show the formation of this complex.</p> </li> <li> <p>Missing TGF-beta component: The literature clearly indicates that TGF-beta signaling works together with IL-6 to induce Th17 differentiation. The model focuses only on IL-6 signaling without representing the crucial contribution of TGF-beta, which is essential for complete and accurate representation</p> </li> </ol>"},{"location":"reviews/5fadbcf000002042-CMP_catabolic_process__Mouse_/","title":"5fadbcf000002042 CMP catabolic process  Mouse","text":"<p>Based on all the information I've gathered, I will now provide a comprehensive review of the GO-CAM model with ID 5fadbcf000002042, titled \"CMP catabolic process (Mouse)\".</p>"},{"location":"reviews/5fadbcf000002042-CMP_catabolic_process__Mouse_/#go-cam-model-review-cmp-catabolic-process-mouse","title":"GO-CAM Model Review: CMP catabolic process (Mouse)","text":"<p>Model ID: 5fadbcf000002042 Title: CMP catabolic process (Mouse) Taxon: Mouse (NCBITaxon:10090) Status: Production</p>"},{"location":"reviews/5fadbcf000002042-CMP_catabolic_process__Mouse_/#overview","title":"Overview","text":"<p>This model represents the CMP (cytidine monophosphate) catabolic pathway in mouse. The model traces the enzymatic degradation of CMP through multiple steps involving several enzymes. The pathway is represented as a series of molecular activities connected by causal relationships.</p>"},{"location":"reviews/5fadbcf000002042-CMP_catabolic_process__Mouse_/#model-structure","title":"Model Structure","text":"<p>The model contains 7 molecular activities connected in a linear pathway, with each activity enabled by a different mouse gene product:</p> <ol> <li>Cytidine deaminase activity (GO:0004126) - Cda (MGI:MGI:1919519)</li> <li>5'-nucleotidase activity (GO:0008253) - Nt5c3 (MGI:MGI:1927186)</li> <li>Uridine phosphorylase activity (GO:0004850) - Upp1 (MGI:MGI:1097668) and Upp2 (MGI:MGI:1923904)</li> <li>Dihydropyrimidine dehydrogenase (NADP+) activity (GO:0017113) - Dpyd (MGI:MGI:2139667)</li> <li>Dihydropyrimidinase activity (GO:0004157) - Dpys (MGI:MGI:1928679)</li> <li>Beta-ureidopropionase activity (GO:0003837) - Upb1 (MGI:MGI:2143535)</li> </ol> <p>All of these activities are part of the \"CMP catabolic process\" (GO:0006248).</p>"},{"location":"reviews/5fadbcf000002042-CMP_catabolic_process__Mouse_/#pathway-logic","title":"Pathway Logic","text":"<p>The model accurately represents the degradation pathway of CMP: 1. Initial activity by 5'-nucleotidase (Nt5c3) which provides input for cytidine deaminase 2. Cytidine deaminase (Cda) which converts cytidine to uridine  3. Uridine phosphorylases (Upp1 and Upp2) catalyze the phosphorolytic cleavage of uridine 4. Dihydropyrimidine dehydrogenase (Dpyd) reduces the pyrimidine ring 5. Dihydropyrimidinase (Dpys) catalyzes the hydrolytic opening of the pyrimidine ring 6. Finally, beta-ureidopropionase (Upb1) completes the degradation</p> <p>The causal links between activities are properly represented using RO:0002413 (provides input for).</p>"},{"location":"reviews/5fadbcf000002042-CMP_catabolic_process__Mouse_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model is supported by empirical evidence, primarily from experimental literature: - Direct assay evidence (ECO:0000314) from PMID:14715930, PMID:7744869, PMID:5472365 - Sequence orthology evidence (ECO:0000266) from GO_REF:0000008</p> <p>Each activity is appropriately annotated with the supporting evidence.</p>"},{"location":"reviews/5fadbcf000002042-CMP_catabolic_process__Mouse_/#cellular-context","title":"Cellular Context","text":"<p>The model includes appropriate cellular context information: - Cytidine deaminase and 5'-nucleotidase activities are specified to occur in the cytosol (GO:0005829)</p>"},{"location":"reviews/5fadbcf000002042-CMP_catabolic_process__Mouse_/#quality-assessment","title":"Quality Assessment","text":""},{"location":"reviews/5fadbcf000002042-CMP_catabolic_process__Mouse_/#strengths","title":"Strengths:","text":"<ol> <li>The model accurately represents the known CMP catabolic pathway in mouse</li> <li>Appropriate evidence codes and references are provided for most assertions</li> <li>The causal connections between activities follow the biochemical logic of the pathway</li> <li>Cellular localization is specified for key activities</li> </ol>"},{"location":"reviews/5fadbcf000002042-CMP_catabolic_process__Mouse_/#minor-issues","title":"Minor Issues:","text":"<ol> <li>While the model represents the canonical pathway well, it might benefit from including any known regulatory mechanisms that affect this pathway</li> <li>Some evidence is from older literature (PMID:5472365 from 1970s) - it would be valuable to include more recent confirmatory evidence if available</li> </ol>"},{"location":"reviews/5fadbcf000002042-CMP_catabolic_process__Mouse_/#recommendations","title":"Recommendations","text":"<p>The model is of high quality and accurately represents the CMP catabolic pathway in</p>"},{"location":"reviews/5fadbcf000002129-Sphingomyelin_phosphodiesterase_activity_involved_in_viral_entry__Human_Sars_Cov_2_/","title":"5fadbcf000002129 Sphingomyelin phosphodiesterase activity involved in viral entry  Human Sars Cov 2","text":"<p>Now, I'll review the GO-CAM model based on all the information gathered:</p>"},{"location":"reviews/5fadbcf000002129-Sphingomyelin_phosphodiesterase_activity_involved_in_viral_entry__Human_Sars_Cov_2_/#review-of-go-cam-model-gomodel5fadbcf000002129","title":"Review of GO-CAM Model: gomodel:5fadbcf000002129","text":""},{"location":"reviews/5fadbcf000002129-Sphingomyelin_phosphodiesterase_activity_involved_in_viral_entry__Human_Sars_Cov_2_/#title-sphingomyelin-phosphodiesterase-activity-involved-in-viral-entry-human-sars-cov-2","title":"Title: Sphingomyelin phosphodiesterase activity involved in viral entry (Human-Sars-Cov-2)","text":""},{"location":"reviews/5fadbcf000002129-Sphingomyelin_phosphodiesterase_activity_involved_in_viral_entry__Human_Sars_Cov_2_/#summary-of-model-content","title":"Summary of Model Content","text":"<p>This GO-CAM model describes a molecular pathway involved in SARS-CoV-2 viral entry, focusing on the role of acid sphingomyelinase (SMPD1) and cholesterol transfer activity (NPC2) in this process. The model also includes the viral receptor ACE2.</p> <p>The model contains the following key activities:</p> <ol> <li>SMPD1 (Acid Sphingomyelinase) - UniProtKB:P17405</li> <li>Molecular function: Sphingomyelin phosphodiesterase activity (GO:0004767)</li> <li>Occurs in: Lysosome (GO:0005764) and Extracellular space (GO:0005615)</li> <li>Biological process: Ceramide biosynthetic process (GO:0046513)</li> <li> <p>Regulates: NPC2's cholesterol transfer activity</p> </li> <li> <p>NPC2 (Niemann-Pick Disease Type C2 Protein) - UniProtKB:P61916</p> </li> <li>Molecular function: Cholesterol transfer activity (GO:0120020)</li> <li>Occurs in: Lysosome (GO:0005764)</li> <li> <p>Biological process: Cholesterol efflux (GO:0033344)</p> </li> <li> <p>ACE2 (Angiotensin-converting enzyme 2) - UniProtKB:Q9BYF1</p> </li> <li>Molecular function: Virus receptor activity (GO:0001618)</li> <li>Occurs in: Plasma membrane (GO:0005886)</li> <li>Biological process: Symbiont entry into host cell (GO:0046718)</li> </ol> <p>The causal relationships in the model describe how: - SMPD1 provides input for itself in different locations - SMPD1 directly positively regulates NPC2's cholesterol transfer activity - ACE2 directly positively regulates SMPD1's activity in the extracellular space</p>"},{"location":"reviews/5fadbcf000002129-Sphingomyelin_phosphodiesterase_activity_involved_in_viral_entry__Human_Sars_Cov_2_/#assessment-of-model-structure","title":"Assessment of Model Structure","text":"<ol> <li> <p>General Model Structure: The model correctly demonstrates a pathway for SARS-CoV-2 entry by connecting ACE2 (the viral receptor) to SMPD1 and subsequently to NPC2, showing the sequence of molecular events during viral entry.</p> </li> <li> <p>Evidential Support: All activities are supported by experimental evidence (ECO:0000314 - direct assay evidence used in manual assertion) with proper reference to the literature (PMID:33163980 and PMID:25339683).</p> </li> <li> <p>Causal Relationships: The causal relationships (RO:0002413 - provides input for, RO:0002629 - directly positively regulates) are appropriately used to connect the activities.</p> </li> <li> <p>Cellular Components: Activities are properly localized to relevant cellular compartments (lysosome, extracellular space, plasma membrane).</p> </li> </ol>"},{"location":"reviews/5fadbcf000002129-Sphingomyelin_phosphodiesterase_activity_involved_in_viral_entry__Human_Sars_Cov_2_/#literature-validation","title":"Literature Validation","text":"<p>The main reference (PMID:33163980) strongly supports the model, showing: 1. SARS-CoV-2 activates the acid sphingomyelinase/ceramide system during viral entry 2. Acid sphingomyelinase (SMPD1) converts sphingomyelin to ceramide in the plasma membrane 3. This activity is essential for SARS-CoV-2 infection 4. Inhibition of SMPD1 prevents SARS-CoV-2 entry</p> <p>The model correctly reflects these key findings from the literature, showing how ACE2 (the viral receptor) activates SMPD1, which then affects NPC2 and cholesterol transport, a process important for viral entry.</p>"},{"location":"reviews/5fadbcf000002129-Sphingomyelin_phosphodiesterase_activity_involved_in_viral_entry__Human_Sars_Cov_2_/#consistency-with-best-practices","title":"Consistency with Best Practices","text":"<p>The model follows GO-CAM best practices for representing complexes and molecular activities: 1. Individual proteins with defined activities are correctly represented 2. Activities are accurately localized to cellular compartments 3. Causal relationships correctly represent the flow of events in the literature</p>"},{"location":"reviews/5fadbcf000002129-Sphingomyelin_phosphodiesterase_activity_involved_in_viral_entry__Human_Sars_Cov_2_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li>Additional Context: The model could be enhanced by including more details about how ceramide production from SMPD1 affects membrane properties that facilitate viral</li> </ol>"},{"location":"reviews/5fadbcf000002236-dCMP_catabolic_process__Mouse_/","title":"5fadbcf000002236 dCMP catabolic process  Mouse","text":"<p>Now that I have gathered information about the model and relevant best practices, I'll provide a comprehensive review of GO-CAM model gomodel:5fadbcf000002236.</p>"},{"location":"reviews/5fadbcf000002236-dCMP_catabolic_process__Mouse_/#review-of-go-cam-model-gomodel5fadbcf000002236","title":"Review of GO-CAM Model: gomodel:5fadbcf000002236","text":""},{"location":"reviews/5fadbcf000002236-dCMP_catabolic_process__Mouse_/#model-overview","title":"Model Overview","text":"<ul> <li>Title: dCMP catabolic process (Mouse)</li> <li>Taxon: NCBITaxon:10090 (Mouse)</li> <li>Status: Production</li> <li>Process: GO:0006249 dCMP catabolic process</li> </ul>"},{"location":"reviews/5fadbcf000002236-dCMP_catabolic_process__Mouse_/#summary","title":"Summary","text":"<p>This GO-CAM model represents the catabolic pathway for 2'-deoxycytidine (dCMP) in mouse. The model shows a sequence of enzymatic activities that constitute the dCMP catabolic process, with all activities occurring in the cytosol GO:0005829.</p>"},{"location":"reviews/5fadbcf000002236-dCMP_catabolic_process__Mouse_/#detailed-review","title":"Detailed Review","text":""},{"location":"reviews/5fadbcf000002236-dCMP_catabolic_process__Mouse_/#pathway-structure","title":"Pathway Structure","text":"<p>The model correctly represents a linear metabolic pathway with appropriate causal connections using the \"provides input for\" (RO:0002413) relationship between activities. The pathway includes several key enzymes involved in dCMP catabolism:</p> <ol> <li>5'-nucleotidase activities (provided by Nt5c3 and Nt5c)</li> <li>Cytidine deaminase (provided by Cda)</li> <li>Deoxyuridine phosphorylase activities (provided by Upp1 and Upp2)</li> <li>Dihydropyrimidine dehydrogenase activity (provided by Dpyd)</li> <li>Dihydropyrimidinase activity (provided by Dpys)</li> <li>Beta-ureidopropionase activity (provided by Upb1)</li> </ol>"},{"location":"reviews/5fadbcf000002236-dCMP_catabolic_process__Mouse_/#strengths","title":"Strengths","text":"<ol> <li>The model correctly represents the sequential enzymatic reactions in the dCMP catabolic pathway.</li> <li>All molecular functions are properly enabled by the appropriate gene products.</li> <li>The model correctly uses the \"provides input for\" (RO:0002413) causal relation to connect activities in sequence.</li> <li>All activities are properly located in the cytosol, which is biologically accurate.</li> <li>Evidence is provided for most associations using appropriate ECO codes and references.</li> <li>The model has a clear biological focus on a specific metabolic pathway.</li> <li>The input molecule (2'-deoxycytidine, CHEBI:15698) is correctly specified.</li> </ol>"},{"location":"reviews/5fadbcf000002236-dCMP_catabolic_process__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing output molecules: While the model correctly identifies the input molecule (2'-deoxycytidine), it would be beneficial to include the outputs for each enzymatic step as has_output associations to provide a more complete picture of the metabolic pathway.</p> </li> <li> <p>Parallel pathways representation: The model shows two potential entry points (with Nt5c3 and Nt5c) and two parallel paths with Upp1 and Upp2. While this appears to be biologically accurate, a brief annotation explaining the biological significance of these parallel routes would enhance clarity.</p> </li> <li> <p>Final activity without causal associations: The beta-ureidopropionase activity (Upb1) is the final step in the pathway but lacks any outgoing causal associations. It would be better to specify the final product of the pathway as a has_output association.</p> </li> <li> <p>Evidence completeness: Some of the activities have evidence annotations while others do not. For completeness, all activities should have evidence annotations.</p> </li> <li> <p>Part_of associations: While most activities have part_of associations to the dCMP catabolic process, the final activity (beta-ureidopropionase activity) does not. For consistency, this should be added.</p> </li> </ol>"},{"location":"reviews/5fadbcf000002236-dCMP_catabolic_process__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model appears to be biologically accurate and aligns with current knowledge of the dCMP catabolic pathway. The evidence is predominantly based on sequence orthology (ECO:0000266) from human to mouse and direct assays (ECO:0000314), which is appropriate for this type of model.</p> <p>The function of cytidine deaminase (verified through UniProt entry P32320) is correctly represented as catalyzing the deamination of cytidine and 2'-deoxycytidine, which is consistent with the reaction in this pathway.</p>"},{"location":"reviews/5fadbcf000002236-dCMP_catabolic_process__Mouse_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Add output molecules: Include has_output associations for each enzymatic step to complete the metabolic flow representation.</p> </li> <li> <p>Complete evidence annotations: Ensure all activities have appropriate evidence annotations.</p> </li> <li> <p>Add part_of association for the final activity: Add a part_of association to GO:0006249 for the beta-ureidopropionase activity.</p> </li> <li> <p>Clarify parallel pathways: Consider adding a comment or note explaining the biological significance of the parallel enzymatic routes with Nt5c3/Nt5c and Upp1/Upp2.</p> </li> <li> <p>Specify final product: Add the final product of the pathway as an output of the beta-ureidopropionase activity.</p> </li> </ol>"},{"location":"reviews/5fadbcf000002236-dCMP_catabolic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, gomodel:5fadbcf000002236 is a well-constructed GO-CAM model that accurately represents the dCMP catabolic process in mouse. The model follows GO-CAM best practices for representing enzymatic activities in a pathway. With a few minor improvements as suggested above, the model would provide a more complete representation of this biological process.</p> <p>The model meets the standards for a production-level GO-CAM and demonstrates appropriate use of causal relations to connect molecular activities into a coherent biological pathway.</p>"},{"location":"reviews/5fb9cc0600000156-circadian_rhythm_and_hematopoiesis_via_ezh2__per1b__cry1a_etc___D__rerio_/","title":"5fb9cc0600000156 circadian rhythm and hematopoiesis via ezh2  per1b  cry1a etc   D  rerio","text":"<p>Now that I have reviewed the model and related resources, I'll conduct a comprehensive review of the GO-CAM model gomodel:5fb9cc0600000156.</p>"},{"location":"reviews/5fb9cc0600000156-circadian_rhythm_and_hematopoiesis_via_ezh2__per1b__cry1a_etc___D__rerio_/#review-of-go-cam-model-gomodel5fb9cc0600000156","title":"Review of GO-CAM Model: gomodel:5fb9cc0600000156","text":""},{"location":"reviews/5fb9cc0600000156-circadian_rhythm_and_hematopoiesis_via_ezh2__per1b__cry1a_etc___D__rerio_/#model-overview","title":"Model Overview","text":"<ul> <li>Title: \"circadian rhythm and hematopoiesis via ezh2, per1b, cry1a etc. (D. rerio)\"</li> <li>Taxon: Zebrafish (Danio rerio) - NCBITaxon:7955</li> <li>Status: Production</li> <li>Primary Focus: Interactions between circadian rhythm regulation and hematopoiesis mediated by Ezh2 and other factors</li> </ul>"},{"location":"reviews/5fb9cc0600000156-circadian_rhythm_and_hematopoiesis_via_ezh2__per1b__cry1a_etc___D__rerio_/#biological-background","title":"Biological Background","text":"<p>This model illustrates the intersection of circadian rhythm regulation and hematopoiesis in zebrafish, based primarily on the findings from Zhang et al. (2018). Their study showed that Ezh2, a histone methyltransferase, positively regulates both circadian rhythms and hematopoiesis through non-canonical mechanisms. This work is significant because it reveals a previously unknown connection between these two processes and describes how Ezh2 enhances the expression of key genes in both pathways independent of its canonical histone methyltransferase activity.</p>"},{"location":"reviews/5fb9cc0600000156-circadian_rhythm_and_hematopoiesis_via_ezh2__per1b__cry1a_etc___D__rerio_/#major-components-of-the-model","title":"Major Components of the Model","text":"<ol> <li>CLOCK-BMAL Transcription Complex - Core circadian clock component</li> <li>Ezh2 - Histone methyltransferase involved in both pathways</li> <li>Cry1a - Circadian clock gene</li> <li>Per1b - Circadian clock gene</li> <li>Myb - Transcription factor involved in hematopoiesis</li> <li>Lck - Involved in hematopoiesis</li> </ol>"},{"location":"reviews/5fb9cc0600000156-circadian_rhythm_and_hematopoiesis_via_ezh2__per1b__cry1a_etc___D__rerio_/#review-comments","title":"Review Comments","text":""},{"location":"reviews/5fb9cc0600000156-circadian_rhythm_and_hematopoiesis_via_ezh2__per1b__cry1a_etc___D__rerio_/#strengths","title":"Strengths","text":"<ol> <li> <p>Clear Pathway Representation: The model effectively captures the dual role of Ezh2 in regulating both circadian rhythm and hematopoiesis as described in the primary publication.</p> </li> <li> <p>Complex Handling: The CLOCK-BMAL transcription complex (GO:1990513) is properly represented according to GO-CAM guidelines, with appropriate molecular functions.</p> </li> <li> <p>Evidence Quality: Most assertions are backed by high-quality experimental evidence (ECO:0000314 - direct assay evidence and ECO:0000315 - mutant phenotype evidence).</p> </li> <li> <p>Causal Relations: The causal relationships between activities use appropriate relationships (RO:0002629 \"directly positively regulates\" and RO:0002630 \"directly negatively regulates\").</p> </li> </ol>"},{"location":"reviews/5fb9cc0600000156-circadian_rhythm_and_hematopoiesis_via_ezh2__per1b__cry1a_etc___D__rerio_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Redundant Activities: There are some potentially redundant or very similar activities in the model, particularly for Ezh2:</li> <li>Activities 5fb9cc0600000200, 60747c4200000590, and 60747c4200000606 all represent Ezh2 with transcription coactivator activity (GO:0003713)</li> <li>Activities 5fb9cc0600000176, 5fb9cc0600000185 represent Ezh2 with transcription coregulator activity (GO:0003712)</li> </ol> <p>These could potentially be consolidated to improve model parsimony.</p> <ol> <li> <p>Missing Cellular Components: None of the activities have cellular component annotations, which would provide important spatial context for these activities. Given that the CLOCK-BMAL complex functions in the nucleus, this information should be added.</p> </li> <li> <p>Incomplete Evidence: Some activities (like 5fb9cc0600000185 and 5fb9cc0600000173) have causal associations but no evidence for these associations.</p> </li> <li> <p>Activity Flow Clarity: While the causal connections between individual activities are appropriate, the overall flow could be clarified to better represent the main message from the paper about how Ezh2 contributes to both circadian rhythm and hematopoiesis simultaneously.</p> </li> <li> <p>Missing Molecular Mechanisms: The paper describes how Ezh2 functions independent of its histone methyltransferase activity, but this specific mechanism isn't clearly represented in the model.</p> </li> </ol>"},{"location":"reviews/5fb9cc0600000156-circadian_rhythm_and_hematopoiesis_via_ezh2__per1b__cry1a_etc___D__rerio_/#specific-go-cam-guideline-issues","title":"Specific GO-CAM Guideline Issues","text":"<ol> <li> <p>Complex Annotation: The model correctly uses GO:1990513 (CLOCK-BMAL transcription complex) and appropriately lists the complex members. This follows the guidance in \"How to annotate complexes in GO-CAM\" for cases where the precise activity-carrying subunit isn't known.</p> </li> <li> <p>Regulatory Relationships: The model appropriately uses RO:0002629 (directly positively regulates) and RO:0002630 (directly negatively regulates) to connect activities, consistent with the guidance in \"WIP - Regulation and Regulatory Processes in GO-CAM\".</p> </li> <li> <p>Tissue Context: The model doesn't specify the tissue context for these activities, which would be valuable given that the paper discusses these pathways in specific tissues.</p> </li> </ol>"},{"location":"reviews/5fb9cc0600000156-circadian_rhythm_and_hematopoiesis_via_ezh2__per1b__cry1a_etc___D__rerio_/#suggested-improvements","title":"Suggested Improvements","text":"<ol> <li> <p>Add Missing Cellular Components: Add appropriate cellular component annotations to activities, particularly nuclear localization for transcription-related activities.</p> </li> <li> <p>Consolidate Redundant Activities: Consider consolidating similar activities of the same proteins to improve model clarity.</p> </li> <li> <p>Complete Evidence Annotations: Add evidence for all causal associations that are currently missing it.</p> </li> <li> <p>Clarify Non-canonical Mechanism: Add annotations to better represent how Ezh2 functions independent of its histone methyltransferase activity, as this is a key finding from the paper.</p> </li> <li> <p>Add Tissue Context: Consider adding tissue context information to better represent where these activities occur.</p> </li> </ol>"},{"location":"reviews/5fb9cc0600000156-circadian_rhythm_and_hematopoiesis_via_ezh2__per1b__cry1a_etc___D__rerio_/#conclusion","title":"Conclusion","text":"<p>GO-CAM model 5fb9cc0600000156 successfully captures the dual regulatory role of Ezh2 in circadian rhythm and hematopoiesis in zebrafish. The model follows most GO-CAM best practices, particularly for representing complexes and causal relationships. With some refinements to reduce redundancy, add cellular component information, and clarify the non-canonical mechanism of Ezh2, the model could even more effectively represent the biological findings presented in the source publication.</p>"},{"location":"reviews/5fb9cc0600000627-Regulation_of_macrophage_differntiation_via_irf2bp2b__cebpa__spi1b__D__rerio_/","title":"5fb9cc0600000627 Regulation of macrophage differntiation via irf2bp2b  cebpa  spi1b  D  rerio","text":"<p>Based on my review of the GO-CAM model gomodel:5fb9cc0600000627 and the relevant literature, I'll now provide a comprehensive review of this model.</p>"},{"location":"reviews/5fb9cc0600000627-Regulation_of_macrophage_differntiation_via_irf2bp2b__cebpa__spi1b__D__rerio_/#review-of-go-cam-model-gomodel5fb9cc0600000627","title":"Review of GO-CAM Model: gomodel:5fb9cc0600000627","text":""},{"location":"reviews/5fb9cc0600000627-Regulation_of_macrophage_differntiation_via_irf2bp2b__cebpa__spi1b__D__rerio_/#model-title-and-overview","title":"Model Title and Overview","text":"<p>Title: \"Regulation of macrophage differentiation via irf2bp2b, cebpa, spi1b (D. rerio)\" Taxon: Danio rerio (Zebrafish) - NCBITaxon:7955 Status: Production  </p> <p>This model represents the transcriptional regulatory network governing neutrophil-macrophage progenitor (NMP) cell fate decision in zebrafish, specifically focusing on how irf2bp2b (Interferon regulatory factor 2 binding protein 2b) acts as a mediator between cebpa (CCAAT enhancer binding protein alpha) and spi1b (spleen focus forming virus proviral integration oncogene) to regulate macrophage differentiation.</p>"},{"location":"reviews/5fb9cc0600000627-Regulation_of_macrophage_differntiation_via_irf2bp2b__cebpa__spi1b__D__rerio_/#biological-content-assessment","title":"Biological Content Assessment","text":"<p>The model captures a regulatory cascade where: 1. cebpa enables DNA-binding transcription activator activity that is part of a transcriptional activation process 2. irf2bp2b enables DNA-binding transcription repressor activity that negatively regulates macrophage differentiation 3. spi1b (PU.1) is involved in macrophage differentiation</p> <p>The model accurately represents findings from the primary paper (PMID:31123027), which shows that: - Irf2bp2b acts as a downstream target of C/ebp\u03b1 - Irf2bp2b represses PU.1 expression - Depletion of irf2bp2b results in biased neutrophil-macrophage progenitor cell fate in favor of macrophages at the expense of neutrophils - C/ebp\u03b1 regulates neutrophil versus macrophage fate through irf2bp2b</p>"},{"location":"reviews/5fb9cc0600000627-Regulation_of_macrophage_differntiation_via_irf2bp2b__cebpa__spi1b__D__rerio_/#technical-assessment","title":"Technical Assessment","text":""},{"location":"reviews/5fb9cc0600000627-Regulation_of_macrophage_differntiation_via_irf2bp2b__cebpa__spi1b__D__rerio_/#strengths","title":"Strengths:","text":"<ol> <li>The model correctly uses appropriate molecular function terms:</li> <li>GO:0000978 (RNA polymerase II cis-regulatory region sequence-specific DNA binding)</li> <li>GO:0001227 (DNA-binding transcription repressor activity, RNA polymerase II-specific)</li> <li> <p>GO:0001228 (DNA-binding transcription activator activity, RNA polymerase II-specific)</p> </li> <li> <p>The model correctly represents the biological process:</p> </li> <li>GO:0030225 (macrophage differentiation)</li> <li> <p>GO:0045650 (negative regulation of macrophage differentiation)</p> </li> <li> <p>Evidence codes are appropriately used:</p> </li> <li>ECO:0000314 (direct assay evidence used in manual assertion)</li> <li>ECO:0000315 (mutant phenotype evidence used in manual assertion)</li> <li> <p>All evidence is linked to PMID:31123027</p> </li> <li> <p>The causal relationships are correctly represented using appropriate relationship terms:</p> </li> <li>BFO:0000050 (part of)</li> <li>RO:0002407 (positively regulates)</li> <li>RO:0002409 (negatively regulates)</li> </ol>"},{"location":"reviews/5fb9cc0600000627-Regulation_of_macrophage_differntiation_via_irf2bp2b__cebpa__spi1b__D__rerio_/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Missing Molecular Function for spi1b: The spi1b gene product (activity 5fb9cc0600000658) is annotated with GO:0003674 (molecular_function), which is a placeholder term. Based on the literature, spi1b functions as a DNA-binding transcription factor, so it should be annotated with a more specific term such as GO:0001228 (DNA-binding transcription activator activity, RNA polymerase II-specific).</p> </li> <li> <p>Incomplete Causal Chain: The model shows cebpa positively regulating irf2bp2b, and irf2bp2b negatively regulating macrophage differentiation, but there's no direct causal connection shown between cebpa activity (5fb9cc0600000633) and irf2bp2b's repressor activity (5fb9cc0600000628). According to the literature, cebpa activates irf2bp2b expression, which then represses pu.1.</p> </li> <li> <p>No Input Specification: According to the GO-CAM best practices for transcription factors, the relation between a DNA-binding transcription factor activity and the gene it regulates should be captured with \"has input.\" The model doesn't explicitly show which genes are the targets of each transcription factor.</p> </li> <li> <p>No Cellular Component: The GO-CAM best practices recommend including 'occurs in' nucleus (GO:0005634) for transcription factor activities, which is missing in this model.</p> </li> </ol>"},{"location":"reviews/5fb9cc0600000627-Regulation_of_macrophage_differntiation_via_irf2bp2b__cebpa__spi1b__D__rerio_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Update spi1b Molecular Function: Change GO:0003674 (molecular_function) to a more specific transcription factor activity term, likely GO:0001228 (DNA-binding transcription activator activity, RNA polymerase II-specific).</p> </li> <li> <p>Complete the Causal Chain: Add a causal relationship between cebpa's transcription activator activity and irf2bp2b's expression/activity to clearly show the complete regulatory cascade.</p> </li> <li> <p>Add Input Relations: For each transcription factor activity, specify the target gene using the \"has input\" relation.</p> </li> <li> <p>Add Cellular Component: Add 'occurs in' nucleus (GO:0005634) for all transcription factor activities.</p> </li> <li> <p>Consider Adding More Detail: If possible, add more specific details about the mechanisms of regulation, such as the binding of cebpa to the irf2bp2b promoter and the binding of irf2bp2b to the pu.1 promoter, as described in the paper.</p> </li> </ol>"},{"location":"reviews/5fb9cc0600000627-Regulation_of_macrophage_differntiation_via_irf2bp2b__cebpa__spi1b__D__rerio_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model effectively captures the key regulatory relationship between cebpa, irf2bp2b, and spi1b in controlling macrophage differentiation in zebrafish. The model is supported by appropriate evidence and correctly represents the biological findings described in the primary literature. </p> <p>With the suggested improvements, this model could more completely represent the molecular mechanisms involved in neutrophil-macrophage progenitor cell fate determination and better align with GO-CAM best practices for transcription factor annotation.</p>"},{"location":"reviews/5fb9cc0600000727-Triacyl_lipopetide_activation_of_TLR1_TLR2_complex__Human_/","title":"5fb9cc0600000727 Triacyl lipopetide activation of TLR1 TLR2 complex  Human","text":"<p>Now I'll examine this model in detail and provide my review:</p>"},{"location":"reviews/5fb9cc0600000727-Triacyl_lipopetide_activation_of_TLR1_TLR2_complex__Human_/#go-cam-model-review-gomodel5fb9cc0600000727","title":"GO-CAM Model Review: gomodel:5fb9cc0600000727","text":""},{"location":"reviews/5fb9cc0600000727-Triacyl_lipopetide_activation_of_TLR1_TLR2_complex__Human_/#model-overview","title":"Model Overview","text":"<p>Title: Triacyl lipopetide activation of TLR1-TLR2 complex (Human) Taxon: Human (NCBITaxon:9606) Status: Production Model ID: gomodel:5fb9cc0600000727</p> <p>This model represents the activation of the TLR1-TLR2 receptor complex by triacyl lipopeptide, involving key molecular carriers and adaptor proteins in the signaling pathway.</p>"},{"location":"reviews/5fb9cc0600000727-Triacyl_lipopetide_activation_of_TLR1_TLR2_complex__Human_/#model-structure-and-components","title":"Model Structure and Components","text":"<p>The model contains 4 major activities:</p> <ol> <li>LBP (Lipopolysaccharide-binding protein) activity:</li> <li>Protein: UniProtKB:P18428</li> <li>Function: Molecular carrier activity (GO:0140104)</li> <li>Location: Extracellular space (GO:0005615)</li> <li>Input: Triacyl lipopeptide (CHEBI:60192)</li> <li> <p>Provides input for: TLR1-TLR2 receptor complex</p> </li> <li> <p>CD14 activity:</p> </li> <li>Protein: UniProtKB:P08571</li> <li>Function: Molecular carrier activity (GO:0140104)</li> <li>Location: Extracellular space (GO:0005615)</li> <li>Input: Triacyl lipopeptide (CHEBI:60192)</li> <li> <p>Provides input for: TLR1-TLR2 receptor complex</p> </li> <li> <p>TLR1-TLR2 receptor complex activity:</p> </li> <li>Complex: Toll-like receptor 1-Toll-like receptor 2 protein complex (GO:0035354)</li> <li>Members: TLR1 UniProtKB:Q15399 and TLR2 UniProtKB:O60603</li> <li>Function: Transmembrane signaling receptor activity (GO:0004888)</li> <li>Location: Plasma membrane raft (GO:0044853)</li> <li>Part of: Toll-like receptor TLR1:TLR2 signaling pathway (GO:0038123)</li> <li> <p>Directly positively regulates: TIRAP activity</p> </li> <li> <p>TIRAP activity:</p> </li> <li>Protein: UniProtKB:P58753</li> <li>Function: Protein-macromolecule adaptor activity (GO:0030674)</li> <li>Location: Plasma membrane (GO:0005886)</li> <li>Part of: Toll-like receptor TLR1:TLR2 signaling pathway (GO:0038123)</li> </ol>"},{"location":"reviews/5fb9cc0600000727-Triacyl_lipopetide_activation_of_TLR1_TLR2_complex__Human_/#review-assessment","title":"Review Assessment","text":""},{"location":"reviews/5fb9cc0600000727-Triacyl_lipopetide_activation_of_TLR1_TLR2_complex__Human_/#biological-content-accuracy","title":"Biological Content Accuracy","text":"<ul> <li>The model accurately represents the roles of LBP and CD14 as molecular carriers that transfer triacyl lipopeptide to the TLR1-TLR2 receptor complex, consistent with literature (PMID:15294986, PMID:23430250, PMID:16848791).</li> <li>The model correctly represents TLR1-TLR2 complex as a heterodimer receptor complex for triacylated lipopeptides, consistent with literature (PMID:16880211, PMID:17889651).</li> <li>The placement of TIRAP (also known as MAL) as the adaptor protein downstream of TLR1-TLR2 is biologically accurate (PMID:17322885).</li> <li>The cellular locations for each component are accurately represented, with the carrier proteins in extracellular space, the receptor complex in membrane rafts, and the adaptor in the plasma membrane.</li> </ul>"},{"location":"reviews/5fb9cc0600000727-Triacyl_lipopetide_activation_of_TLR1_TLR2_complex__Human_/#go-cam-best-practices","title":"GO-CAM Best Practices","text":"<ol> <li>Complex Representation:</li> <li> <p>The TLR1-TLR2 heterodimer is correctly represented using the appropriate GO complex term (GO:0035354) with both component proteins listed (TLR1 and TLR2), following the guidelines for annotating complexes in GO-CAM.</p> </li> <li> <p>Signaling Receptor Activity:</p> </li> <li> <p>The model follows the \"Signaling receptor activity annotation guidelines\" by correctly representing:</p> <ul> <li>The molecular carrier proteins (LBP, CD14) with \"provides input for\" relations to the receptor complex</li> <li>The receptor complex with appropriate signaling receptor activity (GO:0004888)</li> <li>The adaptor protein (TIRAP) as the downstream target of the receptor complex</li> <li>The relationship between the receptor and adaptor using \"directly positively regulates\"</li> </ul> </li> <li> <p>Causal Relationships:</p> </li> <li> <p>The causal relationships in the model use appropriate predicates:</p> <ul> <li>\"provides input for\" (RO:0002413) between carriers and receptor</li> <li>\"directly positively regulates\" (RO:0002629) between receptor and adaptor</li> </ul> </li> <li> <p>Pathway Representation:</p> </li> <li>The model correctly represents the flow of information from extracellular ligand binding to intracellular signaling via the adaptor protein.</li> <li>All activities are appropriately associated with the TLR1:TLR2 signaling pathway (GO:0038123).</li> </ol>"},{"location":"reviews/5fb9cc0600000727-Triacyl_lipopetide_activation_of_TLR1_TLR2_complex__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Missing Downstream Signaling:</li> <li> <p>The model stops at TIRAP and does not include downstream components like MyD88, IRAK family kinases, and NF-\u03baB activation, which would complete the signaling pathway representation.</p> </li> <li> <p>Evidence Consistency:</p> </li> <li> <p>Some of the evidence citations have been updated in May 2024, suggesting recent revisions, but the model would benefit from more detailed evidence citations for specific aspects of the pathway.</p> </li> <li> <p>Activity Completeness:</p> </li> <li>The model could be expanded to include the endocytosis and Golgi trafficking of the receptor complex after activation, which is mentioned in PMID:16880211 as an important aspect of TLR1-TLR2 signaling.</li> </ol>"},{"location":"reviews/5fb9cc0600000727-Triacyl_lipopetide_activation_of_TLR1_TLR2_complex__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:5fb9cc0600000727) accurately represents the triacyl lipopeptide activation of the TLR1-TLR2 complex in humans, following GO-CAM best practices for representing complexes and signaling receptor activities. The model is biologically accurate and supported by literature evidence.</p> <p>The model is concise and effectively represents the initial steps of the pathway, capturing the key molecular events in triacyl lipopeptide recognition and initial signal transduction. It could be enhanced by extending the pathway to include downstream signaling events and trafficking of the activated receptor complex.</p> <p>Overall, this is a high-quality GO-CAM model that accurately represents this part of the innate immune signaling pathway.</p>"},{"location":"reviews/5fce9b7300000367-BMP2_SMAD_signaling_mouse/","title":"5fce9b7300000367 BMP2 SMAD signaling mouse","text":"<p>Let me fetch the GO-CAM best practice document on complexes to better understand how to evaluate this model:</p> <p>Now I'll review the GO-CAM model gomodel:5fce9b7300000367 \"BMP2-SMAD signaling mouse\" based on the information I've gathered.</p>"},{"location":"reviews/5fce9b7300000367-BMP2_SMAD_signaling_mouse/#go-cam-review-gomodel5fce9b7300000367-bmp2-smad-signaling-mouse","title":"GO-CAM Review: gomodel:5fce9b7300000367 (BMP2-SMAD signaling mouse)","text":""},{"location":"reviews/5fce9b7300000367-BMP2_SMAD_signaling_mouse/#general-overview","title":"General Overview","text":"<p>This GO-CAM model represents the BMP2-SMAD signaling pathway in mouse (NCBITaxon:10090). It depicts the signaling cascade involved in the BMP (Bone Morphogenetic Protein) pathway, which is crucial for bone development, chondrogenesis (cartilage formation), and many other developmental processes.</p>"},{"location":"reviews/5fce9b7300000367-BMP2_SMAD_signaling_mouse/#model-structure-and-content","title":"Model Structure and Content","text":"<p>The model contains: - 10 activities represented - 9 distinct gene products - Key components of BMP signaling including BMP2 ligand, BMP receptors (Type I and Type II), and SMAD transcription factors - Causal relationships between activities using BFO:0000051 (has_part) and RO:0002629 (directly positively regulates)</p>"},{"location":"reviews/5fce9b7300000367-BMP2_SMAD_signaling_mouse/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Well-defined molecular pathway: The model captures the basic components of the BMP-SMAD signaling pathway, showing the flow from ligand binding through receptor activation to downstream signaling.</p> </li> <li> <p>Evidence base: Most activities and causal relationships are supported by appropriate evidence with PMIDs.</p> </li> <li> <p>Subcellular localization: Some activities include cellular localization information (such as plasma membrane, nucleus, clathrin-coated pit).</p> </li> <li> <p>Biological process context: Activities are placed within the appropriate biological process context (GO:0030509 - BMP signaling pathway).</p> </li> </ol>"},{"location":"reviews/5fce9b7300000367-BMP2_SMAD_signaling_mouse/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Protein binding activity representation: The model includes a protein binding activity (GO:0005515) for Eps15l1 (MGI:MGI:104582) that binds to the BMPR2 protein (as shown in the SPR function call). According to the complexes document, when the subunit that carries the molecular activity is known, the activity should be represented by the specific protein carrying that activity. In this case, it appears more information may be needed about the specific activity of Eps15l1 beyond simply binding.</p> </li> <li> <p>Missing molecular function annotation: One activity (gomodel:5fce9b7300000367/5fce9b7300000819) is enabled by Eps15l1 (MGI:MGI:104582) but has molecular function GO:0003674 (molecular_function), which is a generic placeholder term indicating the function is not known. Based on the UniProt information retrieved, Eps15l1 is involved in clathrin-mediated endocytosis, which could be more specifically annotated.</p> </li> <li> <p>Inconsistent evidence: Some activities and causal associations lack evidence annotations, including the activity enabled by Eps15l1 mentioned above.</p> </li> <li> <p>BMPR2 binding and endocytosis: Based on the literature I reviewed (PMID:21976273), there appears to be a relationship between BMPR2 binding and endocytosis that isn't fully captured in the model. The binding of Eps15l1 to BMPR2 might be part of the receptor endocytosis process, which could be represented more explicitly.</p> </li> <li> <p>Missing details in signaling cascade: The model shows protein binding between BMPR1a and Eps15l1, but doesn't fully show how this interaction contributes to the regulation of SMAD signaling. Based on the literature, clathrin-dependent endocytosis may regulate the availability or activity of BMP receptors.</p> </li> </ol>"},{"location":"reviews/5fce9b7300000367-BMP2_SMAD_signaling_mouse/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Update Eps15l1 activity: Replace the generic molecular_function annotation with a more specific term reflecting its role in clathrin-mediated endocytosis, such as \"clathrin-dependent endocytic adaptor activity.\" Add appropriate evidence for this annotation.</p> </li> <li> <p>Complete the signaling pathway: Consider adding additional causal relationships showing how the clathrin-dependent endocytosis affects BMP receptor activity or availability, potentially via negative regulation.</p> </li> <li> <p>Add missing evidence: Ensure all activities and causal associations have appropriate evidence annotations with PMIDs.</p> </li> <li> <p>Clarify the role of protein binding: For the protein binding activity between Eps15l1 and BMPR2, clarify whether this is a transient interaction or part of a complex formation that affects receptor signaling or trafficking.</p> </li> <li> <p>Consider adding additional regulation: The literature indicates that noggin acts as an antagonist of BMP signaling, which could be included to provide a more complete representation of pathway regulation.</p> </li> </ol>"},{"location":"reviews/5fce9b7300000367-BMP2_SMAD_signaling_mouse/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model provides a valuable representation of the BMP2-SMAD signaling pathway in mouse, capturing key components and relationships. With some refinements, particularly around the role of Eps15l1 in receptor trafficking and more complete evidence annotations, it could more accurately represent the current understanding of this important developmental pathway.</p>"},{"location":"reviews/5fce9b7300000434-BMP2_MAPK_signaling_mouse/","title":"5fce9b7300000434 BMP2 MAPK signaling mouse","text":"<p>Based on my review of the GO-CAM model \"gomodel:5fce9b7300000434\" titled \"BMP2-MAPK signaling mouse\" and the relevant literature, I'll provide a comprehensive evaluation:</p>"},{"location":"reviews/5fce9b7300000434-BMP2_MAPK_signaling_mouse/#go-cam-review-bmp2-mapk-signaling-mouse-gomodel5fce9b7300000434","title":"GO-CAM Review: BMP2-MAPK signaling mouse (gomodel:5fce9b7300000434)","text":""},{"location":"reviews/5fce9b7300000434-BMP2_MAPK_signaling_mouse/#overview-of-the-model","title":"Overview of the Model","text":"<p>This GO-CAM model represents the BMP2-MAPK signaling pathway in mouse, focusing on how BMP2 signals through its receptors and activates downstream MAPK pathways to regulate osteoblast differentiation and bone formation.</p>"},{"location":"reviews/5fce9b7300000434-BMP2_MAPK_signaling_mouse/#biological-content-and-scientific-accuracy","title":"Biological Content and Scientific Accuracy","text":"<p>The model appropriately captures the key molecular events in BMP2 signaling as supported by the scientific literature:</p> <ol> <li> <p>BMP2 ligand signaling: The model correctly shows BMP2 (MGI:MGI:88177) with receptor ligand activity (GO:0048018) occurring in the extracellular region (GO:0005576) and participating in BMP signaling pathway (GO:0030509).</p> </li> <li> <p>BMP receptor activation: BMP2 directly positively regulates (RO:0002629) BMP receptor activities of BMPR1A (MGI:MGI:1338938) and BMPR1B (MGI:MGI:107191) which both enable BMP receptor activity (GO:0098821).</p> </li> <li> <p>Downstream signaling cascade: The model accurately represents the sequential activation of:</p> </li> <li>BMPR2 (MGI:MGI:1095407) protein serine/threonine kinase activity</li> <li>MAP3K7/TAK1 (MGI:MGI:1346877) MAP kinase kinase kinase kinase activity </li> <li>MAP2K6 (MGI:MGI:1346870) MAP kinase kinase activity</li> <li>MAPK11 (MGI:MGI:1338024) and MAPK14 (MGI:MGI:1346865) MAP kinase activities</li> <li> <p>RUNX2 (MGI:MGI:99829) DNA-binding transcription factor activity</p> </li> <li> <p>Terminal outcomes: The model includes appropriate terminal effector genes regulated by RUNX2, including:</p> </li> <li>SP7/Osterix (MGI:MGI:2153568) </li> <li>Integrin-binding sialoprotein (MGI:MGI:96389)</li> <li>Alkaline phosphatase (MGI:MGI:87983)</li> <li>Osteocalcin (MGI:MGI:88156)</li> </ol> <p>The model is consistent with the published literature, particularly with the papers cited in the evidence (PMID:21976273, PMID:11714695, PMID:20551513). The model accurately represents how BMP2 activates the p38 MAPK pathway through TAK1 to promote RUNX2 activity and osteoblast differentiation.</p>"},{"location":"reviews/5fce9b7300000434-BMP2_MAPK_signaling_mouse/#evaluation-based-on-go-cam-best-practices","title":"Evaluation Based on GO-CAM Best Practices","text":""},{"location":"reviews/5fce9b7300000434-BMP2_MAPK_signaling_mouse/#structural-assessment","title":"Structural Assessment","text":"<ol> <li>Connectivity: The model is well-connected with appropriate causal relationships between activities, using the correct predicates:</li> <li>RO:0002629 (directly positively regulates) for direct activation</li> <li> <p>BFO:0000051 (has part) for complex subunit relationships</p> </li> <li> <p>Biological Process Context: Each activity is appropriately placed in the relevant biological process context:</p> </li> <li>BMP signaling pathway (GO:0030509)</li> <li>MAPK cascade (GO:0000165)</li> <li> <p>Osteoblast differentiation (GO:0001649)</p> </li> <li> <p>Cellular Component Localization: Activities are correctly localized to appropriate cellular locations:</p> </li> <li>Extracellular region for BMP2</li> <li> <p>Cytosol for MAPK pathway components</p> </li> <li> <p>Completeness: The model includes the major components from ligand to transcription factors and their targets, creating a complete representation of the pathway.</p> </li> </ol>"},{"location":"reviews/5fce9b7300000434-BMP2_MAPK_signaling_mouse/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Potential for Additional Contextual Information: The model could benefit from more detailed context about the specific stage of osteoblast differentiation or bone development where this pathway is most active.</p> </li> <li> <p>Regulatory Feedback Loops: While the model captures the forward signaling, it doesn't include any negative feedback mechanisms that may regulate this pathway, such as inhibitory SMADs or phosphatases that terminate the signal.</p> </li> <li> <p>Potential Additional Interactions: The model focuses primarily on the MAPK pathway downstream of BMP receptors but doesn't include the parallel SMAD pathway, which is also important in BMP signaling. Including the SMAD pathway would provide a more comprehensive view of BMP signaling.</p> </li> <li> <p>Evidence Support: While the model includes appropriate citations, some connections lack evidence codes or references (for example, some of the BFO:0000051 relationships lack evidence codes).</p> </li> </ol>"},{"location":"reviews/5fce9b7300000434-BMP2_MAPK_signaling_mouse/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"BMP2-MAPK signaling mouse\" (gomodel:5fce9b7300000434) is a scientifically accurate and well-structured representation of the BMP2-induced MAPK signaling pathway in mouse. It follows GO-CAM best practices for representing signaling pathways, with appropriate use of molecular functions, biological processes, cellular components, and causal relationships.</p> <p>The model's strength lies in its clear depiction of the sequential activation steps from the BMP2 ligand through the receptors and kinase cascade to the transcription factor RUNX2 and its downstream targets. This accurately represents our current understanding of how BMP2 signals promote osteoblast differentiation and bone formation through the MAPK pathway.</p> <p>Minor improvements could include more contextual information, representation of regulatory feedback mechanisms, and more comprehensive evidence documentation for some relationships. Additionally, including the parallel SMAD pathway would provide a more complete picture of BMP signaling.</p> <p>Overall, this is a high-quality GO-CAM model that effectively captures the essential elements of BMP2-MAPK signaling in osteoblast differentiation.</p>"},{"location":"reviews/5fce9b7300001590-SPModule_PGLYRP1_HSP701A/","title":"5fce9b7300001590 SPModule PGLYRP1 HSP701A","text":"<p>Let me now review the GO-CAM model with ID \"5fce9b7300001590\" based on the information I've gathered:</p>"},{"location":"reviews/5fce9b7300001590-SPModule_PGLYRP1_HSP701A/#review-of-go-cam-model-gomodel5fce9b7300001590-spmodule-pglyrp1hsp701a","title":"Review of GO-CAM Model: gomodel:5fce9b7300001590 (SPModule-PGLYRP1/HSP701A)","text":""},{"location":"reviews/5fce9b7300001590-SPModule_PGLYRP1_HSP701A/#model-overview","title":"Model Overview","text":"<p>This is a GO-CAM model titled \"SPModule-PGLYRP1/HSP701A\" that describes interactions between several proteins in human cells (NCBITaxon:9606). The model focuses on HSPA1A (Heat shock 70 kDa protein 1A), HSPBP1 (Hsp70-binding protein 1), PGLYRP1 (Peptidoglycan recognition protein 1), and TNFRSF1A (Tumor necrosis factor receptor superfamily member 1A).</p>"},{"location":"reviews/5fce9b7300001590-SPModule_PGLYRP1_HSP701A/#key-components-and-activities","title":"Key Components and Activities","text":""},{"location":"reviews/5fce9b7300001590-SPModule_PGLYRP1_HSP701A/#1-hspa1a-uniprotkbp0dmv8","title":"1. HSPA1A (UniProtKB:P0DMV8)","text":"<ul> <li>Molecular Function: Receptor ligand activity (GO:0048018)</li> <li>Cellular Location: Extracellular space (GO:0005615)</li> <li>Causal Relationship: Directly positively regulates (RO:0002629) TNFRSF1A activity</li> </ul>"},{"location":"reviews/5fce9b7300001590-SPModule_PGLYRP1_HSP701A/#2-hspbp1-uniprotkbq9nzl4","title":"2. HSPBP1 (UniProtKB:Q9NZL4)","text":"<ul> <li>Molecular Function: Molecular sequestering activity (GO:0140313)</li> <li>Cellular Location: Extracellular space (GO:0005615)</li> <li>Causal Relationship: Directly negatively regulates (RO:0002630) PGLYRP1 activity</li> </ul>"},{"location":"reviews/5fce9b7300001590-SPModule_PGLYRP1_HSP701A/#3-tnfrsf1a-uniprotkbp19438-1","title":"3. TNFRSF1A (UniProtKB:P19438-1)","text":"<ul> <li>Molecular Function: Tumor necrosis factor receptor activity (GO:0005031)</li> <li>Cellular Location: Cell surface (GO:0009986)</li> </ul>"},{"location":"reviews/5fce9b7300001590-SPModule_PGLYRP1_HSP701A/#4-pglyrp1-uniprotkbo75594","title":"4. PGLYRP1 (UniProtKB:O75594)","text":"<ul> <li>Molecular Function: Hsp70 protein binding (GO:0030544)</li> <li>Cellular Location: Extracellular space (GO:0005615)</li> <li>Causal Relationship: Directly positively regulates (RO:0002629) HSPA1A activity</li> </ul>"},{"location":"reviews/5fce9b7300001590-SPModule_PGLYRP1_HSP701A/#model-flow-and-logic","title":"Model Flow and Logic","text":"<p>The model describes how:</p> <ol> <li>PGLYRP1 (Tag7) has Hsp70 protein binding activity, which directly positively regulates HSPA1A's receptor ligand activity.</li> <li>HSPA1A's receptor ligand activity directly positively regulates TNFRSF1A's tumor necrosis factor receptor activity.</li> <li>HSPBP1 has molecular sequestering activity that directly negatively regulates PGLYRP1's Hsp70 protein binding activity.</li> </ol> <p>This regulatory network shows how HSPBP1 can inhibit the PGLYRP1-HSPA1A complex formation, which would otherwise activate TNFRSF1A receptor signaling.</p>"},{"location":"reviews/5fce9b7300001590-SPModule_PGLYRP1_HSP701A/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model is supported by several research publications: - PMID:26183779 provides evidence for HSPA1A's interaction with TNFRSF1A - PMID:21247889 supports HSPBP1's negative regulation of PGLYRP1 - PMID:14585845 provides evidence for PGLYRP1's interaction with HSPA1A</p>"},{"location":"reviews/5fce9b7300001590-SPModule_PGLYRP1_HSP701A/#consistency-with-literature","title":"Consistency with Literature","text":"<p>According to the literature, PGLYRP1 (also known as Tag7) forms a complex with HSPA1A (Hsp70), and this complex can activate TNFRSF1A to induce cell death in tumor cells. HSPBP1 can block this cytotoxic action by binding to PGLYRP1, preventing the formation of the PGLYRP1-HSPA1A complex.</p> <p>This is consistent with the interactions depicted in the model.</p>"},{"location":"reviews/5fce9b7300001590-SPModule_PGLYRP1_HSP701A/#model-quality-assessment","title":"Model Quality Assessment","text":""},{"location":"reviews/5fce9b7300001590-SPModule_PGLYRP1_HSP701A/#strengths","title":"Strengths:","text":"<ol> <li>The model correctly captures the core regulatory mechanism where HSPBP1 inhibits PGLYRP1-HSPA1A complex formation.</li> <li>The molecular functions assigned to each protein are appropriate.</li> <li>The cellular locations are correctly annotated.</li> <li>The causal relationships between activities are logically consistent.</li> <li>Evidence is properly cited with PMIDs.</li> </ol>"},{"location":"reviews/5fce9b7300001590-SPModule_PGLYRP1_HSP701A/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li>The model could benefit from including more details about downstream signaling events after TNFRSF1A activation.</li> <li>While the model shows PGLYRP1 positively regulating HSPA1A, the literature suggests they form a complex. According to the GO-CAM best practices for complexes, when two proteins form a complex where both activities are important, this could potentially be modeled differently.</li> </ol>"},{"location":"reviews/5fce9b7300001590-SPModule_PGLYRP1_HSP701A/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>Based on the \"How to annotate complexes in GO-CAM\" document, this model falls mostly under the first scenario, where \"the subunit that carries the molecular activity is known.\" Each protein is represented with its specific molecular function, which is appropriate.</p> <p>The interaction between PGLYRP1 and HSPA1A could arguably be represented as a case where \"activities are shared by several proteins\" (scenario 3), but the current representation is also valid and clearly shows the regulatory relationship.</p>"},{"location":"reviews/5fce9b7300001590-SPModule_PGLYRP1_HSP701A/#conclusion","title":"Conclusion","text":"<p>This is a well-constructed GO-CAM model that accurately represents the biological system based on current knowledge. It correctly depicts how HSPBP1 can protect cells against the cytotoxic action of the PGLYRP1-HSPA1A complex by inhibiting the interaction between PGLYRP1 and HSPA1A, thereby preventing activation of TNFRSF1A signaling.</p> <p>The model uses appropriate GO terms for molecular functions and cellular components, and the causal relationships are well-supported by the literature. The evidence is properly cited, and the model provides a clear representation of this specific signaling pathway.</p>"},{"location":"reviews/5fce9b7300001616-SPModule_PGRP1_S100A4/","title":"5fce9b7300001616 SPModule PGRP1 S100A4","text":"<p>Based on all the information gathered, I'll now provide a comprehensive review of the GO-CAM model with ID 5fce9b7300001616:</p>"},{"location":"reviews/5fce9b7300001616-SPModule_PGRP1_S100A4/#review-of-go-cam-model-gomodel5fce9b7300001616-spmodule-pgrp1-s100a4","title":"Review of GO-CAM Model gomodel:5fce9b7300001616 (SPModule-PGRP1-S100A4)","text":""},{"location":"reviews/5fce9b7300001616-SPModule_PGRP1_S100A4/#overview","title":"Overview","text":"<p>This model describes a chemotactic signaling pathway in humans (Homo sapiens) involving PGLYRP1 (also known as Tag7), S100A4 (also known as Mts1), and the chemokine receptors CCR5 and CXCR3. The core of the model represents how the PGLYRP1-S100A4 complex functions as a chemoattractant that induces lymphocyte migration through activation of the CCR5 and CXCR3 receptors.</p>"},{"location":"reviews/5fce9b7300001616-SPModule_PGRP1_S100A4/#model-components","title":"Model Components","text":"<p>The model contains four main molecular activities:</p> <ol> <li>O75594 (PGLYRP1) - enables molecular adaptor activity (GO:0060090) occurring in extracellular space (GO:0005615)</li> <li>P26447 (S100A4) - enables chemoattractant activity (GO:0042056) occurring in extracellular space (GO:0005615)</li> <li>P49682 (CXCR3) - enables C-C chemokine receptor activity (GO:0016493) occurring on cell surface (GO:0009986)</li> <li>P51681 (CCR5) - enables C-C chemokine receptor activity (GO:0016493) occurring on cell surface (GO:0009986)</li> </ol>"},{"location":"reviews/5fce9b7300001616-SPModule_PGRP1_S100A4/#causal-relationships","title":"Causal Relationships","text":"<p>The model includes the following causal relationships: - PGLYRP1's molecular adaptor activity directly positively regulates (RO:0002629) S100A4's chemoattractant activity - S100A4's chemoattractant activity directly positively regulates (RO:0002629) CCR5's C-C chemokine receptor activity - S100A4's chemoattractant activity directly positively regulates (RO:0002629) CXCR3's C-C chemokine receptor activity</p>"},{"location":"reviews/5fce9b7300001616-SPModule_PGRP1_S100A4/#evidence-base","title":"Evidence Base","text":"<p>The model is supported by multiple experimental papers, primarily: - PMID:26654597 - Shows the formation of the Tag7-Mts1 complex and its role in lymphocyte migration - PMID:30713770 - Demonstrates that Tag7-Mts1 complex induces lymphocyte migration via CCR5 and CXCR3 receptors - Other PMIDs supporting specific activities of individual proteins</p>"},{"location":"reviews/5fce9b7300001616-SPModule_PGRP1_S100A4/#assessment","title":"Assessment","text":""},{"location":"reviews/5fce9b7300001616-SPModule_PGRP1_S100A4/#strengths","title":"Strengths","text":"<ol> <li> <p>Biological accuracy: The model correctly represents a novel chemotactic pathway that has been experimentally validated. The literature supports that PGLYRP1 (Tag7) forms a complex with S100A4 (Mts1) that can induce lymphocyte migration through CCR5 and CXCR3.</p> </li> <li> <p>Evidence-based: Each activity and relationship in the model is supported by published evidence with appropriate ECO codes.</p> </li> <li> <p>Cellular context: The model appropriately places the activities in their correct cellular compartments (extracellular space for the secreted proteins and cell surface for the receptors).</p> </li> </ol>"},{"location":"reviews/5fce9b7300001616-SPModule_PGRP1_S100A4/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Molecular Function Accuracy: While CXCR3 is annotated with \"C-C chemokine receptor activity\" (GO:0016493), it should more accurately be annotated with \"C-X-C chemokine receptor activity\" (GO:0016494) since CXCR3 is a CXC-type receptor, not a CC-type receptor.</p> </li> <li> <p>Missing Activity Flow: The model doesn't capture what happens downstream of the receptor activation. According to the literature (PMID:30713770), receptor activation leads to G-protein signaling and calcium mobilization, which ultimately results in lymphocyte migration. These downstream effects would enhance the completeness of the pathway.</p> </li> <li> <p>Complex Representation: According to best practices for annotating complexes in GO-CAM, when the activity is shared by several proteins in a complex, both should be shown with their respective activities. The model correctly shows PGLYRP1 as having molecular adaptor activity and S100A4 as having chemoattractant activity, but could more explicitly represent their complex formation.</p> </li> <li> <p>Molecular Adaptor Annotation: According to the guidelines for annotating molecular adaptor activity, the relation between the adaptor activity and the molecules it brings together should be 'has input'. The model could be improved by adding S100A4 and possibly CCR5/CXCR3 as inputs to PGLYRP1's adaptor activity.</p> </li> <li> <p>Biological Process Context: The model could benefit from including a biological process context for each activity, such as \"cell chemotaxis\" (GO:0060326) or \"lymphocyte chemotaxis\" (GO:0048247).</p> </li> </ol>"},{"location":"reviews/5fce9b7300001616-SPModule_PGRP1_S100A4/#recommended-revisions","title":"Recommended Revisions","text":"<ol> <li> <p>Change the molecular function of CXCR3 from \"C-C chemokine receptor activity\" (GO:0016493) to \"C-X-C chemokine receptor activity\" (GO:0016494).</p> </li> <li> <p>Add downstream activities that occur after receptor activation, including G-protein signaling, calcium mobilization, and ultimately cell migration.</p> </li> <li> <p>Add \"has input\" relationships from PGLYRP1's adaptor activity to S100A4 to better represent how the adaptor brings molecules together.</p> </li> <li> <p>Add biological process contexts for each activity, specifically linking them to \"lymphocyte chemotaxis\" (GO:0048247) or similar processes.</p> </li> <li> <p>Consider adding additional information about the specificity of the receptor binding, as the literature indicates the Tag7-Mts1 complex has higher affinity for CCR5 than CXCR3.</p> </li> </ol>"},{"location":"reviews/5fce9b7300001616-SPModule_PGRP1_S100A4/#summary","title":"Summary","text":"<p>The GO-CAM model gomodel:5fce9b7300001616 successfully captures a novel chemotactic pathway involving the PGLYRP1-S100A4 complex and its activation of CCR5 and CXCR3 receptors. The model is well-supported by published evidence and correctly represents the core signaling relationships. With a few refinements, particularly in the accuracy of molecular function assignments and the addition of downstream signaling events, this model could provide an even more complete representation of this important pathway in immune cell migration.</p>"},{"location":"reviews/5fce9b7300001742-Strap_in_alternative_splicing_mouse/","title":"5fce9b7300001742 Strap in alternative splicing mouse","text":"<p>Now let me analyze the GO-CAM model and provide a detailed review.</p>"},{"location":"reviews/5fce9b7300001742-Strap_in_alternative_splicing_mouse/#go-cam-model-review-gomodel5fce9b7300001742","title":"GO-CAM Model Review: gomodel:5fce9b7300001742","text":""},{"location":"reviews/5fce9b7300001742-Strap_in_alternative_splicing_mouse/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model titled \"Strap in alternative splicing-mouse\" describes molecular interactions related to retinoic acid (RA) signaling in mouse, particularly focusing on the role of Strap (Serine-threonine kinase receptor-associated protein) in regulating retinoic acid metabolism and signaling pathways.</p>"},{"location":"reviews/5fce9b7300001742-Strap_in_alternative_splicing_mouse/#model-content-analysis","title":"Model Content Analysis","text":"<p>The model contains 6 molecular activities with causal connections between them:</p> <ol> <li>Strap (MGI:MGI:1329037) is shown with two different molecular functions:</li> <li>U2 snRNP binding (GO:1990447) in the nucleus</li> <li>mRNA binding (GO:0003729)</li> <li> <p>An unspecified molecular function (GO:0003674) that negatively regulates transcription factors</p> </li> <li> <p>Transcription factors:</p> </li> <li>Klf9 (MGI:MGI:1333856) - DNA-binding transcription factor activity (GO:0003700)</li> <li> <p>Sp1 (MGI:MGI:98372) - DNA-binding transcription factor activity (GO:0003700)</p> </li> <li> <p>Cyp26a1 (MGI:MGI:1096359) - retinoic acid 4-hydroxylase activity (GO:0008401)</p> </li> <li> <p>Causal relationships:</p> </li> <li>Klf9 and Sp1 both directly positively regulate (RO:0002629) Cyp26a1</li> <li> <p>Strap directly negatively regulates (RO:0002630) both Klf9 and Sp1</p> </li> <li> <p>Biological processes:</p> </li> <li>Strap is involved in alternative mRNA splicing (GO:0000380) and protein-RNA complex assembly (GO:0022618)</li> <li>Cyp26a1 is involved in retinoic acid catabolic process (GO:0034653)</li> </ol>"},{"location":"reviews/5fce9b7300001742-Strap_in_alternative_splicing_mouse/#literature-verification","title":"Literature Verification","text":"<p>The model is primarily based on two publications:</p> <ol> <li> <p>PMID:29781215 - Describes how Strap deletion attenuates intracellular RA signaling in embryoid bodies by selectively inducing Cyp26A1 expression. It identifies that KLF9 binding motifs are critical for RA-induced transactivation of Cyp26A1, and increased KLF9 expression in the absence of STRAP is partially responsible for Cyp26A1 induction.</p> </li> <li> <p>PMID:9250660 - Describes Cyp26a1 (P450RA) as an RA-catabolizing enzyme that converts biologically active retinoic acid into inactive forms, specifically 5,8-epoxy all-trans RA. The paper shows that P450RA is expressed differentially during mouse development and may establish the uneven distribution of active RA in embryos.</p> </li> </ol>"},{"location":"reviews/5fce9b7300001742-Strap_in_alternative_splicing_mouse/#model-quality-assessment","title":"Model Quality Assessment","text":""},{"location":"reviews/5fce9b7300001742-Strap_in_alternative_splicing_mouse/#strengths","title":"Strengths:","text":"<ol> <li> <p>The model accurately captures the core regulatory relationship described in the literature, where STRAP negatively regulates the transcription factors KLF9 and SP1, which in turn positively regulate CYP26A1 expression.</p> </li> <li> <p>The inclusion of specific molecular functions is accurate: Strap as an RNA-binding protein, KLF9 and SP1 as transcription factors, and CYP26A1 as a retinoic acid metabolizing enzyme.</p> </li> <li> <p>The model correctly associates CYP26A1 with retinoic acid catabolism, which is well-supported by the literature.</p> </li> </ol>"},{"location":"reviews/5fce9b7300001742-Strap_in_alternative_splicing_mouse/#issues-and-recommendations","title":"Issues and Recommendations:","text":"<ol> <li> <p>Incomplete molecular function for Strap: The model uses GO:0003674 (molecular function) for one of Strap's activities, which is a very general term. Based on the literature, this could be refined to a more specific molecular function term related to its role in transcriptional regulation.</p> </li> <li> <p>Missing contextual information: While the paper PMID:29781215 discusses Strap's role in embryonic stem cells and development, the model doesn't include the cellular or developmental context for these interactions.</p> </li> <li> <p>Missing related biological processes: The paper describes Strap's role in ESC differentiation and retinoic acid signaling, but the model doesn't include biological processes related to development or cellular differentiation.</p> </li> <li> <p>Incomplete representation of Strap functions: From the literature, Strap has multiple roles in RNA processing and transcriptional regulation, but only some of these are represented in the model.</p> </li> <li> <p>Sp1 involvement: While the PMID:29781215 paper mentions Sp1, the evidence for its direct role in regulating Cyp26a1 in this context is not as strongly established as for Klf9, yet the model represents them with equal causal relationships.</p> </li> </ol>"},{"location":"reviews/5fce9b7300001742-Strap_in_alternative_splicing_mouse/#go-cam-best-practices-recommendations","title":"GO-CAM Best Practices Recommendations","text":"<p>Based on GO-CAM best practices, I recommend the following improvements:</p> <ol> <li> <p>Use more specific molecular function terms: Replace GO:0003674 (molecular function) with a more specific term that better represents Strap's activity in transcriptional regulation.</p> </li> <li> <p>Add cellular context: Add appropriate cell type or developmental stage contextual information to better represent the embryonic stem cell context described in the paper.</p> </li> <li> <p>Include relevant biological processes: Add biological processes related to embryonic development and cellular differentiation to provide a more complete biological context.</p> </li> <li> <p>Clarify the mechanism: The model could be improved by adding more detail about how Strap regulates the transcription factors - through direct binding or through other mechanisms described in the paper.</p> </li> <li> <p>Consider evidence codes: Ensure appropriate evidence codes are used for each assertion, particularly distinguishing between experimental evidence and inferences.</p> </li> </ol>"},{"location":"reviews/5fce9b7300001742-Strap_in_alternative_splicing_mouse/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model accurately represents the core regulatory pathway where Strap negatively regulates transcription factors (Klf9 and Sp1) that positively regulate Cyp26a1, an enzyme involved in retinoic acid metabolism. The model is well-supported by the literature but could be enhanced with more specific terms for molecular functions, additional biological context, and a more detailed representation of the mechanisms involved.</p> <p>The model provides a valuable representation of a regulatory pathway in retinoic acid signaling and metabolism that is important for embryonic development and cell differentiation.</p>"},{"location":"reviews/5fce9b7300002336-SPModule_TREM1_DAP12/","title":"5fce9b7300002336 SPModule TREM1 DAP12","text":"<p>Based on my review of the GO-CAM model and the reference documentation, I'll now provide a structured assessment of the model gomodel:5fce9b7300002336 \"SPModule-TREM1-DAP12\".</p>"},{"location":"reviews/5fce9b7300002336-SPModule_TREM1_DAP12/#go-cam-review-spmodule-trem1-dap12-gomodel5fce9b7300002336","title":"GO-CAM Review: SPModule-TREM1-DAP12 (gomodel:5fce9b7300002336)","text":""},{"location":"reviews/5fce9b7300002336-SPModule_TREM1_DAP12/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents the TREM1-DAP12 signaling pathway in human cells. The model focuses on the triggering receptor expressed on myeloid cells 1 (TREM1) and its interaction with the TYRO protein tyrosine kinase-binding protein (TYROBP/DAP12) adaptor molecule, as well as upstream ligands and downstream effects.</p>"},{"location":"reviews/5fce9b7300002336-SPModule_TREM1_DAP12/#activities-in-the-model","title":"Activities in the Model","text":"<ol> <li>TREM1 (UniProtKB:Q9NP99) transmembrane signaling receptor activity (GO:0004888) on the cell surface (GO:0009986)</li> <li>DAP12/TYROBP (UniProtKB:O43914) molecular adaptor activity (GO:0060090) on the cell surface (GO:0009986)</li> <li>SYK (UniProtKB:P43405) kinase activity (GO:0016301)</li> <li>PGLYRP1 (UniProtKB:O75594) receptor ligand activity (GO:0048018) in extracellular space (GO:0005615)</li> <li>HMGB1 (UniProtKB:P09429) receptor ligand activity (GO:0048018) in extracellular space (GO:0005615)</li> <li>HSPA1A (UniProtKB:P0DMV8) receptor ligand activity (GO:0048018) in extracellular space (GO:0005615)</li> <li>TREM1-2/sTREM1 (UniProtKB:Q9NP99-2) receptor decoy activity (GO:0140319) in extracellular space (GO:0005615)</li> </ol>"},{"location":"reviews/5fce9b7300002336-SPModule_TREM1_DAP12/#causal-relationships","title":"Causal Relationships","text":"<ol> <li>PGLYRP1 receptor ligand activity directly positively regulates (RO:0002629) TREM1 receptor activity</li> <li>HMGB1 receptor ligand activity directly positively regulates (RO:0002629) TREM1 receptor activity</li> <li>HSPA1A receptor ligand activity directly positively regulates (RO:0002629) TREM1 receptor activity</li> <li>TREM1 receptor activity directly positively regulates (RO:0002629) DAP12 adaptor activity</li> <li>DAP12 adaptor activity directly positively regulates (RO:0002629) SYK kinase activity</li> <li>TREM1 soluble isoform (sTREM1) receptor decoy activity directly negatively regulates (RO:0002630) TREM1 receptor activity</li> </ol>"},{"location":"reviews/5fce9b7300002336-SPModule_TREM1_DAP12/#assessment","title":"Assessment","text":""},{"location":"reviews/5fce9b7300002336-SPModule_TREM1_DAP12/#correctness-of-biological-content","title":"Correctness of Biological Content","text":"<ol> <li> <p>TREM1 signaling: The model correctly represents TREM1 as a transmembrane receptor that signals through DAP12, which is consistent with the literature. TREM1 is indeed expressed on myeloid cells (especially neutrophils and monocytes) and associates with DAP12 to mediate immune cell activation.</p> </li> <li> <p>TREM1 ligands: The model includes three confirmed ligands for TREM1:</p> </li> <li>PGLYRP1 (peptidoglycan recognition protein 1) - validated in PMID:25595774</li> <li>HMGB1 (high mobility group box 1 protein) - validated in PMID:17568691  </li> <li> <p>HSPA1A (heat shock 70 kDa protein) - validated in PMID:17568691</p> </li> <li> <p>DAP12-SYK signaling pathway: The model correctly shows DAP12 acting as an adaptor molecule that signals downstream to SYK kinase, which is well-established in the literature.</p> </li> <li> <p>sTREM1 as decoy receptor: The model appropriately includes the soluble form of TREM1 (sTREM1/TREM1-2) as a decoy receptor that negatively regulates TREM1 signaling, which is consistent with the literature (PMID:26561551).</p> </li> </ol>"},{"location":"reviews/5fce9b7300002336-SPModule_TREM1_DAP12/#adherence-to-go-cam-best-practices","title":"Adherence to GO-CAM Best Practices","text":"<ol> <li> <p>Evidence codes and references: Each activity in the model includes appropriate evidence codes (ECO:0000314 - direct assay evidence used in manual assertion) and PMID references.</p> </li> <li> <p>Cellular components: The model correctly specifies the locations of proteins:</p> </li> <li>TREM1 and DAP12 on the cell surface (GO:0009986)</li> <li>Ligands (PGLYRP1, HMGB1, HSPA1A) in extracellular space (GO:0005615)</li> <li> <p>sTREM1 in extracellular space (GO:0005615)</p> </li> <li> <p>Activity representation: The model uses appropriate molecular function terms:</p> </li> <li>GO:0004888 (transmembrane signaling receptor activity) for TREM1</li> <li>GO:0060090 (molecular adaptor activity) for DAP12</li> <li>GO:0016301 (kinase activity) for SYK</li> <li>GO:0048018 (receptor ligand activity) for TREM1 ligands</li> <li> <p>GO:0140319 (receptor decoy activity) for sTREM1</p> </li> <li> <p>Causal relations: The model uses appropriate causal relations:</p> </li> <li>RO:0002629 (directly positively regulates) for activating relationships</li> <li> <p>RO:0002630 (directly negatively regulates) for inhibitory relationships</p> </li> <li> <p>Molecular adaptor representation: The model follows the guidelines for representing molecular adaptors, with DAP12 using the molecular adaptor activity (GO:0060090) term and the relation \"directly positively regulates\" to its downstream target.</p> </li> </ol>"},{"location":"reviews/5fce9b7300002336-SPModule_TREM1_DAP12/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Missing Biological Process annotations: The model doesn't include any biological process terms for the activities. Adding relevant BP terms (e.g., immune response, innate immune response, signal transduction) would improve the annotation.</p> </li> <li> <p>Elaboration of SYK pathway: The downstream effects of SYK activation could be further elaborated to include the phosphorylation of PLC\u03b3 and ERK1/2 as shown in the literature (PMID:10799849).</p> </li> <li> <p>Missing ITAM domain information: The molecular mechanism by which DAP12 signals through its ITAM domain could be more explicitly represented.</p> </li> <li> <p>Additional receptors: Consider adding other known TREM1 complexes, such as its interaction with TLR4 mentioned in the literature (PMID:17098818, PMID:21393102).</p> </li> <li> <p>Functional outcomes: The model could be expanded to include functional outcomes of TREM1 signaling (e.g., cytokine production, immune cell activation).</p> </li> </ol>"},{"location":"reviews/5fce9b7300002336-SPModule_TREM1_DAP12/#summary","title":"Summary","text":"<p>The GO-CAM model gomodel:5fce9b7300002336 provides a solid representation of the TREM1-DAP12 signaling module with accurate molecular functions, cellular locations, and causal relationships that are well-supported by the literature. The model correctly represents the TREM1 ligands, the adaptor role of DAP12, the involvement of SYK kinase, and the regulatory role of sTREM1. While the model could be enhanced with additional details on downstream signaling and biological processes, it provides a clear and accurate representation of the core TREM1-DAP12 signaling pathway.</p> <p>This model should be approved as it follows GO-CAM guidelines and accurately represents the biology of TREM1-DAP12 signaling. The annotations are well-supported by evidence from the literature and follow the appropriate guidelines for representing molecular adaptors and signaling pathways.</p>"},{"location":"reviews/5fce9b7300002436-TREM2_activated_by_APP/","title":"5fce9b7300002436 TREM2 activated by APP","text":"<p>Now I'll review the GO-CAM model with ID gomodel:5fce9b7300002436.</p>"},{"location":"reviews/5fce9b7300002436-TREM2_activated_by_APP/#review-of-go-cam-model-gomodel5fce9b7300002436","title":"Review of GO-CAM Model (gomodel:5fce9b7300002436)","text":""},{"location":"reviews/5fce9b7300002436-TREM2_activated_by_APP/#model-overview","title":"Model Overview","text":"<p>This model titled \"TREM2 activated by APP\" describes a signaling pathway involving TREM2 (Triggering Receptor Expressed on Myeloid cells 2), its adaptor protein DAP12 (TYROBP), and downstream tyrosine kinase SYK in human cells (NCBITaxon:9606).</p>"},{"location":"reviews/5fce9b7300002436-TREM2_activated_by_APP/#components-and-structure","title":"Components and Structure","text":"<p>The model contains four main molecular activities:</p> <ol> <li>APP (UniProtKB:P05067) with receptor ligand activity (GO:0048018) occurring in extracellular space (GO:0005615), part of cellular response to amyloid-beta (GO:1904646)</li> <li>TREM2 (UniProtKB:Q9NZC2) with transmembrane signaling receptor activity (GO:0004888) occurring in plasma membrane (GO:0005886), part of cellular response to amyloid-beta (GO:1904646)</li> <li>TYROBP/DAP12 (UniProtKB:O43914) with protein-macromolecule adaptor activity (GO:0030674) occurring in plasma membrane (GO:0005886), part of cellular response to amyloid-beta (GO:1904646)</li> <li>SYK (UniProtKB:P43405) with protein tyrosine kinase activity (GO:0004713) occurring in cytoplasm (GO:0005737), part of cellular response to amyloid-beta (GO:1904646)</li> </ol>"},{"location":"reviews/5fce9b7300002436-TREM2_activated_by_APP/#causal-relationships","title":"Causal Relationships","text":"<p>The model represents the following causal flow: - APP directly positively regulates (RO:0002629) TREM2 - TREM2 directly positively regulates (RO:0002629) TYROBP/DAP12 - TYROBP/DAP12 directly positively regulates (RO:0002629) SYK</p>"},{"location":"reviews/5fce9b7300002436-TREM2_activated_by_APP/#evidence","title":"Evidence","text":"<p>Each activity and causal relationship is supported by experimental evidence from peer-reviewed literature (ECO:0000314 - direct assay evidence used in manual assertion), primarily from PMID:29518356 for most connections and additional PMID:24078628 for TREM2 localization and PMID:23459077 for TYROBP/DAP12 activity and localization.</p>"},{"location":"reviews/5fce9b7300002436-TREM2_activated_by_APP/#assessment-and-recommendations","title":"Assessment and Recommendations","text":""},{"location":"reviews/5fce9b7300002436-TREM2_activated_by_APP/#strengths-of-the-model","title":"Strengths of the model:","text":"<ul> <li>The model accurately captures the molecular function of each protein</li> <li>The causal relationships are appropriately represented with the correct relationship types</li> <li>All activities are properly classified as part of the same biological process</li> <li>Evidence is well-documented for each assertion</li> <li>The model aligns with current literature showing TREM2 as a receptor for amyloid-beta (supported by PMID:29518356)</li> </ul>"},{"location":"reviews/5fce9b7300002436-TREM2_activated_by_APP/#areas-for-improvement","title":"Areas for improvement:","text":"<ol> <li>Complex representation:</li> <li> <p>The model currently doesn't indicate that TREM2 and DAP12/TYROBP form a complex, which is critical for signaling. According to GO-CAM complex guidelines, this should be represented since they function together to transmit the signal to SYK.</p> </li> <li> <p>Physical interactions:</p> </li> <li> <p>The direct physical interaction between TREM2 and its adaptor DAP12/TYROBP should be more explicitly represented, as this binding is crucial for signal transduction.</p> </li> <li> <p>Additional downstream effects:</p> </li> <li> <p>The model could be extended to include downstream effects after SYK activation, such as phosphorylation of specific targets and activation of inflammatory responses.</p> </li> <li> <p>Specificity of cellular context:</p> </li> <li> <p>While the model indicates that TREM2 is in the plasma membrane, it would be useful to specify that this is occurring specifically in microglial cells (or other myeloid cells), which is the primary cell type expressing TREM2 in the brain.</p> </li> <li> <p>Additional evidence:</p> </li> <li>The model could benefit from including more recent publications that further support the interactions between A\u03b2, TREM2, and downstream signaling.</li> </ol>"},{"location":"reviews/5fce9b7300002436-TREM2_activated_by_APP/#suggested-updates","title":"Suggested Updates","text":"<ol> <li> <p>Add a relationship indicating that TREM2 and DAP12/TYROBP form a functional complex through their physical association.</p> </li> <li> <p>Consider adding details about the specific molecular mechanisms of activation, such as:</p> </li> <li>Phosphorylation of ITAM domains in DAP12/TYROBP following ligand binding to TREM2</li> <li> <p>Recruitment of SYK to phosphorylated ITAM domains</p> </li> <li> <p>Include more specific cellular context information about the pathway occurring in microglia.</p> </li> <li> <p>Extend the model to capture downstream effects of SYK activation in the context of amyloid-beta response.</p> </li> </ol>"},{"location":"reviews/5fce9b7300002436-TREM2_activated_by_APP/#conclusion","title":"Conclusion","text":"<p>Overall, the model gomodel:5fce9b7300002436 provides a solid representation of the TREM2 signaling pathway activated by APP/amyloid-beta, which is consistent with current literature. The model accurately captures the main molecular players in the pathway and their causal relationships. The suggested improvements would enhance the model's completeness and provide a more comprehensive view of the biological mechanisms involved in TREM2-mediated responses to amyloid-beta, which is relevant for understanding microglial function in Alzheimer's disease.</p> <p>The model correctly follows GO-CAM best practices in terms of evidence documentation and causal relationship representation. The suggested addition of complex information would further align the model with GO-CAM guidelines for representing protein complexes in signaling pathways.</p>"},{"location":"reviews/600ced8500002343-BMP9_signaling_pathway__Human_/","title":"600ced8500002343 BMP9 signaling pathway  Human","text":"<p>Let me review the GO-CAM model for BMP9 signaling pathway (Human) by analyzing its structure, consistency with GO-CAM guidelines, and biological accuracy.</p>"},{"location":"reviews/600ced8500002343-BMP9_signaling_pathway__Human_/#review-of-go-cam-model-gomodel600ced8500002343","title":"Review of GO-CAM model: gomodel:600ced8500002343","text":""},{"location":"reviews/600ced8500002343-BMP9_signaling_pathway__Human_/#model-overview","title":"Model Overview","text":"<p>This model represents the BMP9 signaling pathway in humans (NCBITaxon:9606) and depicts the key molecular activities and causal relationships in this pathway.</p>"},{"location":"reviews/600ced8500002343-BMP9_signaling_pathway__Human_/#components-and-structure","title":"Components and Structure","text":"<p>The model includes 5 activities: 1. GDF2/BMP9 (Q9UK05) with growth factor activity in extracellular space 2. ACVR2B (Q13705) with activin receptor type II activity in plasma membrane 3. ACVRL1/ALK1 (P37023) with activin receptor type I activity in plasma membrane 4. BMPR2 (Q13873) with activin receptor type II activity in plasma membrane 5. SMAD1 (Q15797) with DNA-binding transcription factor activity in chromatin</p>"},{"location":"reviews/600ced8500002343-BMP9_signaling_pathway__Human_/#causal-relationships","title":"Causal Relationships","text":"<ul> <li>GDF2/BMP9 directly positively regulates (RO:0002629) both BMPR2 and ACVR2B</li> <li>ACVR2B directly positively regulates (RO:0002629) ACVRL1</li> <li>BMPR2 directly positively regulates (RO:0002629) ACVRL1</li> <li>ACVRL1 directly positively regulates (RO:0002629) SMAD1</li> </ul>"},{"location":"reviews/600ced8500002343-BMP9_signaling_pathway__Human_/#evaluation","title":"Evaluation","text":""},{"location":"reviews/600ced8500002343-BMP9_signaling_pathway__Human_/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<p>The model follows the signaling receptor activity guidelines: - Ligand (GDF2/BMP9) has growth factor activity (GO:0008083) located in extracellular space (GO:0005615) - GDF2/BMP9 directly positively regulates receptors (BMPR2, ACVR2B) - Type II receptors (ACVR2B, BMPR2) directly positively regulate the Type I receptor (ACVRL1) - Type I receptor (ACVRL1) directly positively regulates the downstream effector (SMAD1) - All membrane receptors are correctly located in plasma membrane (GO:0005886) - All activities are part of the BMP signaling pathway (GO:0030509)</p>"},{"location":"reviews/600ced8500002343-BMP9_signaling_pathway__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the BMP9 signaling pathway based on literature evidence:</p> <ol> <li>GDF2/BMP9 as ligand:</li> <li>Correctly annotated as a secreted growth factor in extracellular space</li> <li>UniProt entry confirms it's a potent circulating BMP that signals through ACVRL1</li> <li> <p>Evidence from multiple PMIDs including 7664647 and 19366699</p> </li> <li> <p>Receptor Complex:</p> </li> <li>Correctly shows both ACVR2B and BMPR2 as type II receptors that phosphorylate ACVRL1</li> <li>Follows the known mechanism where BMP9 binds type II receptors, which then activate type I receptors</li> <li> <p>Evidence from PMID:22718755 as cited in the model</p> </li> <li> <p>ACVRL1/ALK1 as Type I receptor:</p> </li> <li>Correctly annotated as an activin receptor type I in the plasma membrane</li> <li>UniProt confirms it's a type I receptor for BMP9/GDF2 and BMP10</li> <li> <p>Evidence from PMID:22718755</p> </li> <li> <p>SMAD1 as downstream effector:</p> </li> <li>Correctly shown as a DNA-binding transcription factor in chromatin</li> <li>Represents the correct SMAD pathway activation following receptor activation</li> <li>Evidence from multiple papers including PMID:8653785</li> </ol>"},{"location":"reviews/600ced8500002343-BMP9_signaling_pathway__Human_/#qa-checks","title":"QA Checks","text":"<ol> <li>Contextual annotations: All activities have appropriate cellular location annotations.</li> <li>Evidence codes: All relationships have appropriate evidence codes and citations.</li> <li>Pathway consistency: All activities are part of the BMP signaling pathway.</li> <li>Activity flow: The model correctly depicts the sequential activation in BMP signaling:</li> <li>Ligand \u2192 Type II receptors \u2192 Type I receptor \u2192 SMAD transcription factor</li> </ol>"},{"location":"reviews/600ced8500002343-BMP9_signaling_pathway__Human_/#suggested-improvements","title":"Suggested Improvements","text":"<p>While the model is scientifically accurate and follows GO-CAM guidelines, a few minor enhancements could be considered:</p> <ol> <li>Additional components: The model could be expanded to include:</li> <li>SMAD4 which forms a complex with phosphorylated SMAD1</li> <li>Nuclear translocation of the SMAD1/SMAD4 complex</li> <li> <p>Target genes regulated by the SMAD complex</p> </li> <li> <p>Regulatory mechanisms: The model could include negative regulators such as:</p> </li> <li>SMAD6 which can inhibit SMAD1 activation</li> <li> <p>SMURF1/2 which can ubiquitinate and degrade pathway components</p> </li> <li> <p>Alternative receptors: The model could incorporate alternative type I receptors that can respond to BMP9 in different contexts.</p> </li> </ol>"},{"location":"reviews/600ced8500002343-BMP9_signaling_pathway__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model (gomodel:600ced8500002343) representing the BMP9 signaling pathway in humans is biologically accurate and follows GO-CAM best practices. It correctly depicts the key molecular activities and causal relationships in the pathway, with appropriate evidence citations.</p> <p>The model represents a high-quality representation of the core BMP9 signaling pathway and successfully captures the essential elements of activin/BMP receptor signaling as described in the \"Signaling receptor activity annotation guidelines\" document.</p> <p>No critical errors or inconsistencies were identified in the model structure, relationships, or biological content.</p>"},{"location":"reviews/60418ffa00000327-Xanthine_catabolic_process__Mouse_/","title":"60418ffa00000327 Xanthine catabolic process  Mouse","text":"<p>Based on all the information I've gathered, I'll now review the GO-CAM model with ID 60418ffa00000327.</p>"},{"location":"reviews/60418ffa00000327-Xanthine_catabolic_process__Mouse_/#review-of-go-cam-model-gomodel60418ffa00000327-xanthine-catabolic-process-in-mouse","title":"Review of GO-CAM Model: gomodel:60418ffa00000327 (Xanthine catabolic process in Mouse)","text":""},{"location":"reviews/60418ffa00000327-Xanthine_catabolic_process__Mouse_/#overview","title":"Overview","text":"<p>This GO-CAM model (gomodel:60418ffa00000327) represents the \"Xanthine catabolic process\" in mouse (NCBI Taxon: 10090). The model describes the enzymatic pathway for the degradation of xanthine to allantoin, which is part of purine catabolism.</p>"},{"location":"reviews/60418ffa00000327-Xanthine_catabolic_process__Mouse_/#model-components-and-structure","title":"Model Components and Structure","text":"<p>The model contains 6 molecular activities connected in a pathway:</p> <ol> <li>Xanthine dehydrogenase activity (GO:0004854) - enabled by Xdh protein (MGI:MGI:98973)</li> <li>Xanthine oxidase activity (GO:0004855) - enabled by Xdh protein (MGI:MGI:98973)</li> <li>Xanthine oxidase activity (GO:0004855) - enabled by Xdh protein (MGI:MGI:98973) - another instance</li> <li>Urate oxidase activity (GO:0004846) - enabled by Uox protein (MGI:MGI:98907)</li> <li>Hydroxyisourate hydrolase activity (GO:0033971) - enabled by Urah protein (MGI:MGI:1916142)</li> <li>2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase activity (GO:0051997) - enabled by Urad protein (MGI:MGI:3647519)</li> </ol> <p>The activities are connected via causal associations using the \"provides input for\" predicate (RO:0002413), forming a linear metabolic pathway.</p>"},{"location":"reviews/60418ffa00000327-Xanthine_catabolic_process__Mouse_/#subcellular-locations","title":"Subcellular Locations","text":"<p>The model correctly annotates subcellular locations: - Xanthine dehydrogenase/oxidase activities occur in the cytosol (GO:0005829) and peroxisome (GO:0005777) - Urate oxidase, hydroxyisourate hydrolase, and OHCU decarboxylase activities occur in the peroxisome (GO:0005777)</p>"},{"location":"reviews/60418ffa00000327-Xanthine_catabolic_process__Mouse_/#evidence","title":"Evidence","text":"<p>The model is supported by experimental evidence from multiple publications: - PMID:1590774 (molecular cloning of xanthine dehydrogenase in mouse) - PMID:16462750 (identification of the complete uric acid degradation pathway) - PMID:4207016 (developmental changes of enzymes in mouse tissues)</p>"},{"location":"reviews/60418ffa00000327-Xanthine_catabolic_process__Mouse_/#output","title":"Output","text":"<p>The model correctly indicates allantoin (CHEBI:15676) as the final output of the pathway.</p>"},{"location":"reviews/60418ffa00000327-Xanthine_catabolic_process__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Complete pathway representation: The model captures the entire xanthine degradation pathway from xanthine to allantoin.</p> </li> <li> <p>Accurate molecular functions: All enzymes are assigned their correct molecular function terms.</p> </li> <li> <p>Proper cellular locations: The model correctly represents that xanthine oxidase/dehydrogenase activities occur in both cytosol and peroxisome, while the later steps (urate oxidation and subsequent steps) occur in the peroxisome.</p> </li> <li> <p>Sound causal relationships: The activities are connected appropriately through \"provides input for\" (RO:0002413) relationships, reflecting the sequential nature of the metabolic pathway.</p> </li> <li> <p>Strong evidence basis: The model uses appropriate experimental evidence from publications that specifically study these enzymes in mice.</p> </li> </ol>"},{"location":"reviews/60418ffa00000327-Xanthine_catabolic_process__Mouse_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Metabolic intermediates: The model could be improved by explicitly showing the intermediate metabolites in the pathway (hypoxanthine \u2192 xanthine \u2192 uric acid \u2192 5-hydroxyisourate \u2192 OHCU \u2192 allantoin).</p> </li> <li> <p>Xanthine dehydrogenase/oxidase clarification: The model represents both xanthine dehydrogenase (GO:0004854) and xanthine oxidase (GO:0004855) activities, which is accurate since they are different activities of the same protein. However, it has two instances of xanthine oxidase activity that could be consolidated, as one appears to be in the cytosol and one in the peroxisome.</p> </li> <li> <p>Molecular details: The model could include additional molecular details about the cofactors involved (e.g., NAD+ for xanthine dehydrogenase, molecular oxygen for xanthine oxidase).</p> </li> <li> <p>Developmental context: Based on PMID:4207016, there are developmental changes in the expression of these enzymes that could be noted in the model description.</p> </li> </ol>"},{"location":"reviews/60418ffa00000327-Xanthine_catabolic_process__Mouse_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices for representing enzyme activities and pathways:</p> <ol> <li> <p>Correct representation of complexes: The model correctly represents individual protein activities rather than complexes, as these are all single-protein enzymes.</p> </li> <li> <p>Causal connections: The model uses appropriate causal connections between activities using \"provides input for\" (RO:0002413).</p> </li> <li> <p>Biological process association: Each activity is correctly associated with the xanthine catabolic process (GO:0009115).</p> </li> <li> <p>Cellular component annotation: The model correctly annotates the cellular components for each activity.</p> </li> </ol>"},{"location":"reviews/60418ffa00000327-Xanthine_catabolic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model (gomodel:60418ffa00000327) is a well-constructed representation of the xanthine catabolic pathway in mouse. It accurately captures the molecular functions, causal relationships, cellular locations, and is supported by appropriate evidence. The model could be enhanced with additional details about metabolic intermediates and cofactors, but these are minor suggestions for an already solid model.</p> <p>The model is consistent with current knowledge about purine catabolism and follows GO-CAM best practices. It provides a clear view of the enzymatic pathway leading from xanthine to allantoin in mouse, which is important for understanding purine metabolism and potentially relevant to conditions involving uric acid accumulation.</p>"},{"location":"reviews/60418ffa00000414-Adenosine_catabolic_process__Mouse_/","title":"60418ffa00000414 Adenosine catabolic process  Mouse","text":"<p>Based on my review of the GO-CAM model (gomodel:60418ffa00000414) and the supporting documentation, here is my assessment:</p>"},{"location":"reviews/60418ffa00000414-Adenosine_catabolic_process__Mouse_/#go-cam-review-adenosine-catabolic-process-mouse-gomodel60418ffa00000414","title":"GO-CAM Review: Adenosine catabolic process (Mouse) - gomodel:60418ffa00000414","text":""},{"location":"reviews/60418ffa00000414-Adenosine_catabolic_process__Mouse_/#overview","title":"Overview","text":"<p>This model represents the adenosine catabolic pathway in mouse, describing the enzymatic conversion of adenosine to allantoin. The model includes several enzymes and their activities involved in this degradation pathway.</p>"},{"location":"reviews/60418ffa00000414-Adenosine_catabolic_process__Mouse_/#model-structure-analysis","title":"Model Structure Analysis","text":"<p>The model includes the following key components: 1. Adenosine deaminase (Ada) - converting adenosine to inosine 2. Purine-nucleoside phosphorylase (Pnp) - converting inosine to hypoxanthine 3. Xanthine dehydrogenase/oxidase (Xdh) with multiple activities:    - Hypoxanthine dehydrogenase activity    - Hypoxanthine oxidase activity    - Xanthine dehydrogenase activity    - Xanthine oxidase activity 4. Urate oxidase (Uox) - converting urate to 5-hydroxyisourate 5. Hydroxyisourate hydrolase (Urah) - converting 5-hydroxyisourate to OHCU 6. 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase (Urad) - converting OHCU to allantoin</p>"},{"location":"reviews/60418ffa00000414-Adenosine_catabolic_process__Mouse_/#strengths","title":"Strengths","text":"<ol> <li>The model correctly captures the full pathway of adenosine degradation to allantoin in mouse.</li> <li>The dual enzymatic activities of Xanthine dehydrogenase/oxidase (Xdh) are properly represented.</li> <li>The model appropriately uses the <code>RO:0002413</code> (\"provides input for\") predicate to connect the sequential activities.</li> <li>Most activities have appropriate cellular locations (cytosol and peroxisome).</li> <li>The model includes appropriate references to evidence from the literature.</li> <li>The inclusion of the final steps of urate degradation (Urah and Urad) is consistent with the literature (PMID:16462750).</li> </ol>"},{"location":"reviews/60418ffa00000414-Adenosine_catabolic_process__Mouse_/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li> <p>Subcellular location inconsistency: Some Xdh activities are annotated as occurring in the cytosol (GO:0005829) while others are in the peroxisome (GO:0005777). While Xdh can be found in both locations, the UniProt entry indicates that Xdh is primarily cytoplasmic with some peroxisomal localization. The model should ensure consistency in subcellular localization for related activities of the same protein, or provide clear evidence for the differential localization.</p> </li> <li> <p>Missing has_input annotations: While the model correctly uses causal associations to connect activities, some activities are missing explicit <code>has_input</code> annotations that would make the model clearer. For example, the xanthine dehydrogenase activity should explicitly have xanthine as input.</p> </li> <li> <p>Terminal output annotation: The model shows allantoin (CHEBI:15676) as the output of the OHCU decarboxylase activity (Urad), which is correct. However, to improve clarity, the model could indicate this is the final product of the pathway.</p> </li> <li> <p>Evidence consistency: Some activities have more extensive evidence citations than others. It would be beneficial to ensure consistent evidence documentation across all parts of the model.</p> </li> </ol>"},{"location":"reviews/60418ffa00000414-Adenosine_catabolic_process__Mouse_/#biological-content-validation","title":"Biological Content Validation","text":"<p>The model correctly represents the adenosine catabolic pathway as described in the literature. The inclusion of the full urate degradation pathway (including Urah and Urad) is consistent with the findings in PMID:16462750, which identified these enzymes as essential for the stereospecific conversion of urate to S-(+)-allantoin.</p> <p>The dual function of Xanthine dehydrogenase/oxidase (Xdh) as both a dehydrogenase and oxidase is correctly represented, which is important because the enzyme can switch between these two forms depending on cellular conditions.</p>"},{"location":"reviews/60418ffa00000414-Adenosine_catabolic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the adenosine catabolic pathway in mouse. The model follows most GO-CAM best practices and is biologically sound. The minor issues noted regarding subcellular localization consistency and explicit input/output annotations could be addressed to further improve the model's clarity and completeness.</p>"},{"location":"reviews/60418ffa00000811-Inosine_catabolic_process__Mouse_/","title":"60418ffa00000811 Inosine catabolic process  Mouse","text":"<p>Based on the information I've gathered, I will now conduct a comprehensive review of the GO-CAM model with ID 60418ffa00000811 \"Inosine catabolic process (Mouse)\".</p>"},{"location":"reviews/60418ffa00000811-Inosine_catabolic_process__Mouse_/#review-of-go-cam-model-inosine-catabolic-process-mouse","title":"Review of GO-CAM Model: Inosine catabolic process (Mouse)","text":""},{"location":"reviews/60418ffa00000811-Inosine_catabolic_process__Mouse_/#model-overview","title":"Model Overview","text":"<p>The GO-CAM model:60418ffa00000811 represents the inosine catabolic pathway in mice, which is part of purine metabolism. This model describes the sequence of enzymatic reactions that convert inosine to allantoin, with all the intermediary steps.</p>"},{"location":"reviews/60418ffa00000811-Inosine_catabolic_process__Mouse_/#biological-context","title":"Biological Context","text":"<p>The model captures the well-established purine catabolism pathway that leads from inosine to allantoin in mouse. This pathway is important for purine metabolism and involves several key enzymes:</p> <ol> <li>Purine nucleoside phosphorylase (Pnp) - Converts inosine to hypoxanthine</li> <li>Xanthine dehydrogenase/oxidase (Xdh) - Converts hypoxanthine to xanthine and then xanthine to uric acid</li> <li>Urate oxidase (Uox) - Converts uric acid to 5-hydroxyisourate</li> <li>Hydroxyisourate hydrolase (Urah) - Converts 5-hydroxyisourate to 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline (OHCU)</li> <li>2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase (Urad) - Converts OHCU to allantoin</li> </ol> <p>This pathway is particularly interesting because humans lack functional urate oxidase and thus cannot convert uric acid to allantoin, making them susceptible to gout and urate kidney stones. Mice, in contrast, can fully degrade uric acid to allantoin.</p>"},{"location":"reviews/60418ffa00000811-Inosine_catabolic_process__Mouse_/#review-of-model-components","title":"Review of Model Components","text":""},{"location":"reviews/60418ffa00000811-Inosine_catabolic_process__Mouse_/#activities-and-evidence","title":"Activities and Evidence","text":"<p>The model includes 8 distinct activities carried out by 5 different proteins:</p> <ol> <li>MGI:MGI:97365 (Pnp): Correctly annotated with purine-nucleoside phosphorylase activity (GO:0004731)</li> <li>Evidence is well supported by literature references (PMID:8064675, PMID:11783524)</li> <li>Occurs in cytosol (GO:0005829)</li> <li> <p>Properly linked to inosine catabolic process (GO:0006148)</p> </li> <li> <p>MGI:MGI:98973 (Xdh): Annotated with multiple activities:</p> </li> <li>Hypoxanthine dehydrogenase activity (GO:0070674)</li> <li>Hypoxanthine oxidase activity (GO:0070675)</li> <li>Xanthine dehydrogenase activity (GO:0004854)</li> <li>Xanthine oxidase activity (GO:0004855)</li> <li>Evidence comes from multiple sources and publications (PMID:30936145, PMID:12502743, PMID:1590774, PMID:29895374, PMID:8226898)</li> <li> <p>Correctly shows dual localization in cytosol (GO:0005829) and peroxisome (GO:0005777)</p> </li> <li> <p>MGI:MGI:98907 (Uox): Annotated with urate oxidase activity (GO:0004846)</p> </li> <li>Evidence supported by PMID:16462750</li> <li> <p>Correctly localized to peroxisome (GO:0005777)</p> </li> <li> <p>MGI:MGI:1916142 (Urah): Annotated with hydroxyisourate hydrolase activity (GO:0033971)</p> </li> <li>Evidence from PMID:16462750</li> <li> <p>Correctly localized to peroxisome (GO:0005777)</p> </li> <li> <p>MGI:MGI:3647519 (Urad): Annotated with 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase activity (GO:0051997)</p> </li> <li>Evidence from PMID:16462750</li> <li>Correctly localized to peroxisome (GO:0005777)</li> <li>Has output allantoin (CHEBI:15676)</li> </ol>"},{"location":"reviews/60418ffa00000811-Inosine_catabolic_process__Mouse_/#causal-relationships","title":"Causal Relationships","text":"<p>The model accurately represents the sequence of events in the inosine catabolic pathway using the \"RO:0002413\" (provides input for) relation:</p> <ol> <li>Pnp (GO:0004731) \u2192 Xdh (GO:0070674/GO:0070675)</li> <li>Xdh (GO:0070674) \u2192 Xdh (GO:0004854)</li> <li>Xdh (GO:0070675) \u2192 Xdh (GO:0004855)</li> <li>Xdh (GO:0004854/GO:0004855) \u2192 Uox (GO:0004846)</li> <li>Uox (GO:0004846) \u2192 Urah (GO:0033971)</li> <li>Urah (GO:0033971) \u2192 Urad (GO:0051997)</li> </ol>"},{"location":"reviews/60418ffa00000811-Inosine_catabolic_process__Mouse_/#cellular-localization","title":"Cellular Localization","text":"<p>The model correctly represents: - Pnp and some of Xdh activities in the cytosol (GO:0005829) - Some of Xdh activities, Uox, Urah, and Urad in the peroxisome (GO:0005777)</p> <p>This is consistent with what we know about the subcellular location of these enzymes from the literature.</p>"},{"location":"reviews/60418ffa00000811-Inosine_catabolic_process__Mouse_/#model-assessment","title":"Model Assessment","text":""},{"location":"reviews/60418ffa00000811-Inosine_catabolic_process__Mouse_/#strengths","title":"Strengths","text":"<ol> <li> <p>Completeness: The model comprehensively captures the entire inosine catabolic pathway from inosine to allantoin.</p> </li> <li> <p>Evidential Support: Each activity is backed by multiple pieces of evidence from the literature.</p> </li> <li> <p>Dual Forms of Xdh: The model correctly represents that Xdh can function both as a dehydrogenase and an oxidase, with different subcellular localizations.</p> </li> <li> <p>Accurate Localization: The correct subcellular locations are assigned to each activity.</p> </li> <li> <p>Causal Flow: The sequential nature of the catabolic pathway is clearly represented through \"provides input for\" causal relations.</p> </li> </ol>"},{"location":"reviews/60418ffa00000811-Inosine_catabolic_process__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Substrate/Product Representation: While the pathway ends with allantoin as the output, the other intermediate metabolites (hypoxanthine, xanthine, uric acid, 5-hydroxyisourate, OHCU) are not explicitly represented as inputs/outputs. Adding these could enhance the model's completeness.</p> </li> <li> <p>Regulatory Information: The model doesn't include any regulation of enzyme activities, such as the known interconversion between XDH and XO forms of Xanthine dehydrogenase/oxidase, which is highlighted in the literature (PMID:31659168).</p> </li> <li> <p>Complex Representation: Xanthine dehydrogenase/oxidase functions as a homodimer, as indicated in the UniProt entry (Q00519), but this is not represented in the model. According to the GO-CAM guidance on complex annotation, this could be explicitly represented.</p> </li> </ol>"},{"location":"reviews/60418ffa00000811-Inosine_catabolic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model 60418ffa00000811 \"Inosine catabolic process (Mouse)\" is a well-constructed representation of the inosine degradation pathway in mice. It accurately captures the key enzymes, their activities, subcellular locations, and sequential relationships in this metabolic pathway. </p> <p>The model is consistent with current understanding of purine metabolism and is backed by strong evidential support from the literature. The few suggestions for improvement relate to more explicit representation of substrates/products and regulatory mechanisms, but these are not critical gaps.</p> <p>This model serves as an excellent resource for researchers interested in purine metabolism and provides a clear visualization of how mice (unlike humans) can fully degrade uric acid to allantoin.</p>"},{"location":"reviews/60418ffa00001019-NLRP3_inflammasome_in_pyroptosis_via_nlrp3__caspa__caspb_etc___D__rerio_/","title":"60418ffa00001019 NLRP3 inflammasome in pyroptosis via nlrp3  caspa  caspb etc   D  rerio","text":"<p>Based on my analysis of the GO-CAM model and the relevant literature, I'll now provide a comprehensive review of GO-CAM model 60418ffa00001019, \"NLRP3 inflammasome in pyroptosis via nlrp3, caspa, caspb etc. (D. rerio)\".</p>"},{"location":"reviews/60418ffa00001019-NLRP3_inflammasome_in_pyroptosis_via_nlrp3__caspa__caspb_etc___D__rerio_/#review-of-go-cam-model-60418ffa00001019","title":"Review of GO-CAM Model 60418ffa00001019","text":""},{"location":"reviews/60418ffa00001019-NLRP3_inflammasome_in_pyroptosis_via_nlrp3__caspa__caspb_etc___D__rerio_/#overview","title":"Overview","text":"<p>The GO-CAM model 60418ffa00001019 represents the NLRP3 inflammasome pathway in zebrafish (Danio rerio), focusing on the process of pyroptosis mediated by NLRP3, caspases (caspa and caspb), and other related proteins. This model was created to capture the molecular mechanisms of inflammasome formation and pyroptotic cell death in this teleost fish model.</p>"},{"location":"reviews/60418ffa00001019-NLRP3_inflammasome_in_pyroptosis_via_nlrp3__caspa__caspb_etc___D__rerio_/#biological-context-and-accuracy","title":"Biological Context and Accuracy","text":"<p>The model accurately represents the zebrafish NLRP3 inflammasome as described in the literature, particularly in the paper by Li et al. (2020). The paper identifies a functional NLRP3 inflammasome in zebrafish that shares conserved mechanisms with mammalian inflammasomes but also has some distinct features.</p> <p>The model correctly captures: - The role of DrNLRP3 (ZFIN:ZDB-GENE-070424-110) in inflammasome assembly - The involvement of zebrafish ASC adapter protein (not explicitly included in the model) - The sequential activation of inflammatory caspases (caspa and caspb) - The regulatory role in programmed cell death (GO:0043067) - The downstream impact on gasdermin proteins that execute pyroptosis</p>"},{"location":"reviews/60418ffa00001019-NLRP3_inflammasome_in_pyroptosis_via_nlrp3__caspa__caspb_etc___D__rerio_/#structural-analysis-of-the-model","title":"Structural Analysis of the Model","text":""},{"location":"reviews/60418ffa00001019-NLRP3_inflammasome_in_pyroptosis_via_nlrp3__caspa__caspb_etc___D__rerio_/#components-and-activities","title":"Components and Activities","text":"<p>The model includes the following key components: 1. NLRP3 (ZFIN:ZDB-GENE-070424-110) - involved in NLRP3 inflammasome complex assembly (GO:0044546) 2. Caspa (ZFIN:ZDB-GENE-000616-3) - hydrolase activity (GO:0016787), part of self proteolysis (GO:0097264) 3. Caspb (ZFIN:ZDB-GENE-020812-1) - involved in regulation of programmed cell death (GO:0043067) 4. Gsdmea (ZFIN:ZDB-GENE-120215-186) - gasdermin E protein a 5. Gsdmeb (ZFIN:ZDB-GENE-030131-7662) - gasdermin E protein b 6. NLRP3 inflammasome complex (GO:0072559) - represented as a complex entity</p>"},{"location":"reviews/60418ffa00001019-NLRP3_inflammasome_in_pyroptosis_via_nlrp3__caspa__caspb_etc___D__rerio_/#causal-relationships","title":"Causal Relationships","text":"<p>The model includes appropriate causal relationships: 1. Caspb directly positively regulates (RO:0002629) gsdmeb 2. Caspb directly positively regulates (RO:0002629) gsdmea 3. NLRP3 inflammasome complex directly positively regulates (RO:0002629) caspa and caspb 4. Nlrp3 causally upstream, positive effect (RO:0002304) on caspb</p>"},{"location":"reviews/60418ffa00001019-NLRP3_inflammasome_in_pyroptosis_via_nlrp3__caspa__caspb_etc___D__rerio_/#evidence-and-references","title":"Evidence and References","text":"<p>The model is well-supported by experimental evidence, primarily from: - Direct assay evidence (ECO:0000314) from PMID:31852739 - Mutant phenotype evidence (ECO:0000315) from PMID:31852739</p>"},{"location":"reviews/60418ffa00001019-NLRP3_inflammasome_in_pyroptosis_via_nlrp3__caspa__caspb_etc___D__rerio_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":""},{"location":"reviews/60418ffa00001019-NLRP3_inflammasome_in_pyroptosis_via_nlrp3__caspa__caspb_etc___D__rerio_/#complex-representation","title":"Complex Representation","text":"<p>The model follows good practices for representing complexes. It uses the GO term for the NLRP3 inflammasome complex (GO:0072559) as described in the \"How to annotate complexes in GO-CAM\" document. This approach is appropriate since the precise subunit that carries some activities within the complex isn't always specified in the literature.</p>"},{"location":"reviews/60418ffa00001019-NLRP3_inflammasome_in_pyroptosis_via_nlrp3__caspa__caspb_etc___D__rerio_/#causal-relationships_1","title":"Causal Relationships","text":"<p>The causal relationships in the model follow the recommendations in the \"Regulation and Regulatory Processes in GO-CAM\" document. The model correctly uses: - RO:0002629 (directly positively regulates) for direct regulatory relationships - RO:0002304 (causally upstream of, positive effect) for positive regulatory relationships</p>"},{"location":"reviews/60418ffa00001019-NLRP3_inflammasome_in_pyroptosis_via_nlrp3__caspa__caspb_etc___D__rerio_/#areas-for-improvement","title":"Areas for Improvement","text":"<p>While the model captures key aspects of the zebrafish NLRP3 inflammasome pathway, there are several areas that could be enhanced:</p> <ol> <li> <p>Missing ASC Component: The model doesn't explicitly include the ASC adaptor protein (pycard in zebrafish), which the paper identifies as crucial for inflammasome assembly. Adding this component would more accurately represent the complete pathway.</p> </li> <li> <p>Incomplete Representation of IL-1\u03b2 Processing: The model doesn't fully capture the maturation of zebrafish IL-1\u03b2 (DrIL-1\u03b2), which according to the paper is processed in two steps: first by caspa (at Asp104) and then by caspb (at Asp122). This sequential processing is a unique aspect of the zebrafish inflammasome.</p> </li> <li> <p>ASC-Independent Pathway: The paper identifies both ASC-dependent and ASC-independent pathways for caspase activation and pyroptosis. The model could be enhanced by clearly distinguishing these two mechanisms.</p> </li> <li> <p>Activation Triggers: The model doesn't include the initial triggers for inflammasome activation (such as LPS and H\u2082O\u2082), which the paper identifies as important for activating the zebrafish NLRP3 inflammasome.</p> </li> <li> <p>Additional Molecular Functions: Some proteins in the model have generic molecular functions (GO:0003674, molecular function) that could be specified based on the detailed functional characterization in the paper.</p> </li> </ol>"},{"location":"reviews/60418ffa00001019-NLRP3_inflammasome_in_pyroptosis_via_nlrp3__caspa__caspb_etc___D__rerio_/#recommendations","title":"Recommendations","text":"<p>To improve the model, I recommend:</p> <ol> <li> <p>Add the ASC adaptor protein (ZFIN:ZDB-GENE-000511-2) with its role in mediating the interaction between NLRP3 and caspa/caspb.</p> </li> <li> <p>Include IL-1\u03b2 (ZFIN:ZDB-GENE-040702-2) and its maturation process with the correct sequence of cleavage by caspa and caspb.</p> </li> <li> <p>Enhance the representation of molecular functions for proteins currently annotated with generic GO:0003674 terms.</p> </li> <li> <p>Consider representing both the ASC-dependent pathway (for IL-1\u03b2 maturation) and ASC-independent pathway (for gasdermin cleavage and pyroptosis).</p> </li> <li> <p>Add relevant upstream activators of the NLRP3 inflammasome (e.g., LPS, H\u2082O\u2082) if appropriate for the model's scope.</p> </li> <li> <p>Ensure that the gasdermin-mediated membrane pore formation activity is correctly represented as part of the pyroptotic process.</p> </li> </ol>"},{"location":"reviews/60418ffa00001019-NLRP3_inflammasome_in_pyroptosis_via_nlrp3__caspa__caspb_etc___D__rerio_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model 60418ffa00001019 provides a valuable representation of the zebrafish NLRP3 inflammasome pathway, capturing the key molecular components and relationships. The model is generally consistent with GO-CAM best practices and the current scientific literature. With the suggested enhancements, it could become a more comprehensive and precise representation of this important inflammatory pathway in zebrafish.</p> <p>This model is particularly valuable as it documents an evolutionarily ancient form of the NLRP3 inflammasome, highlighting both conserved features and unique aspects compared to mammalian systems, which advances our understanding of the evolution of innate immune mechanisms.</p>"},{"location":"reviews/60418ffa00001124-Hypoxanthine_catabolic_process__Mouse_/","title":"60418ffa00001124 Hypoxanthine catabolic process  Mouse","text":"<p>Based on my analysis of the model and the literature, I'm now ready to provide a comprehensive review.</p>"},{"location":"reviews/60418ffa00001124-Hypoxanthine_catabolic_process__Mouse_/#review-of-go-cam-model-gomodel60418ffa00001124","title":"Review of GO-CAM Model: gomodel:60418ffa00001124","text":""},{"location":"reviews/60418ffa00001124-Hypoxanthine_catabolic_process__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (gomodel:60418ffa00001124) represents \"Hypoxanthine catabolic process (Mouse)\" in Mus musculus (Mouse). The model describes the enzymatic pathway for the conversion of hypoxanthine to allantoin, which is a key part of purine catabolism.</p>"},{"location":"reviews/60418ffa00001124-Hypoxanthine_catabolic_process__Mouse_/#biological-process-represented","title":"Biological Process Represented","text":"<p>The model depicts the enzymatic pathway for purine degradation, specifically the catabolism of hypoxanthine to allantoin. This is a crucial metabolic pathway in mice (and many other mammals) that allows them to eliminate excess purines as the highly soluble allantoin rather than the poorly soluble uric acid, which can form crystals leading to gout and kidney stones in species (like humans) that lack this complete pathway.</p> <p>The pathway consists of several sequential enzymatic reactions: 1. Conversion of hypoxanthine to xanthine 2. Oxidation of xanthine to uric acid 3. Conversion of uric acid to 5-hydroxyisourate (HIU) 4. Hydrolysis of HIU to 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline (OHCU) 5. Decarboxylation of OHCU to allantoin</p>"},{"location":"reviews/60418ffa00001124-Hypoxanthine_catabolic_process__Mouse_/#model-structure-and-components","title":"Model Structure and Components","text":"<p>The model contains 8 activity nodes representing various molecular functions enabled by 4 different gene products:</p> <ol> <li>Xdh (MGI:MGI:98973) - Xanthine dehydrogenase/oxidase, which performs multiple functions:</li> <li>Hypoxanthine dehydrogenase activity (GO:0070674)</li> <li>Hypoxanthine oxidase activity (GO:0070675)</li> <li>Xanthine dehydrogenase activity (GO:0004854)</li> <li> <p>Xanthine oxidase activity (GO:0004855)</p> </li> <li> <p>Uox (MGI:MGI:98907) - Urate oxidase with:</p> </li> <li> <p>Urate oxidase activity (GO:0004846)</p> </li> <li> <p>Urah (MGI:MGI:1916142) - Hydroxyisourate hydrolase with:</p> </li> <li> <p>Hydroxyisourate hydrolase activity (GO:0033971)</p> </li> <li> <p>Urad (MGI:MGI:3647519) - OHCU decarboxylase with:</p> </li> <li>2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase activity (GO:0051997)</li> </ol> <p>The model correctly uses causal relationships with the predicate \"RO:0002413\" (provides input for) to connect the activities in the proper sequence of the metabolic pathway.</p>"},{"location":"reviews/60418ffa00001124-Hypoxanthine_catabolic_process__Mouse_/#evaluation","title":"Evaluation","text":""},{"location":"reviews/60418ffa00001124-Hypoxanthine_catabolic_process__Mouse_/#strengths","title":"Strengths","text":"<ol> <li> <p>Completeness: The model represents the complete hypoxanthine catabolic pathway from hypoxanthine to allantoin, including all necessary enzymatic activities.</p> </li> <li> <p>Correct activity flow: The activities are properly connected with causal associations that reflect the correct metabolic flow in the pathway, with each reaction providing the substrate for the next step.</p> </li> <li> <p>Subcellular localization: The model appropriately includes subcellular localization information, differentiating between activities that occur in the cytosol (GO:0005829) and those that occur in peroxisomes (GO:0005777).</p> </li> <li> <p>Evidence quality: The model uses high-quality evidence codes (ECO:0000314 - direct assay evidence used in manual assertion) and provides references to primary literature.</p> </li> <li> <p>Molecular output: The model correctly identifies allantoin (CHEBI:15676) as an output of the pathway.</p> </li> </ol>"},{"location":"reviews/60418ffa00001124-Hypoxanthine_catabolic_process__Mouse_/#potential-improvements","title":"Potential Improvements","text":"<ol> <li> <p>Molecular Inputs: The model could be more explicit about the inputs for each activity. While the causal connections imply that the output of one activity is the input for the next, explicitly stating the molecular inputs (e.g., hypoxanthine, xanthine, urate) for each activity would enhance clarity.</p> </li> <li> <p>Dual Localization: According to UniProt data for Uox (P25688), the protein is localized to both peroxisomes and mitochondria. The model currently only shows the peroxisomal localization. Consider adding the mitochondrial localization as well.</p> </li> <li> <p>Alternative Forms of XDH: The model correctly shows different activities of the Xdh protein (dehydrogenase vs. oxidase forms), but could potentially clarify the relationship between these activities. The UniProt entry indicates that XDH can be converted from the dehydrogenase form to the oxidase form by proteolysis or oxidation of sulfhydryl groups.</p> </li> <li> <p>Regulators: If known, the model could include regulatory relationships that affect this pathway.</p> </li> </ol>"},{"location":"reviews/60418ffa00001124-Hypoxanthine_catabolic_process__Mouse_/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model is scientifically accurate and consistent with the latest literature. The pathway described is well-established in mouse metabolism and the causal relationships between activities reflect the true metabolic flow.</p> <p>The model correctly represents the findings from the papers cited, particularly the key role of Urah and Urad in the complete conversion of uric acid to allantoin as described in the 2006 paper by Ramazzina et al. (PMID:16462750). This paper was crucial in identifying the complete uric acid degradation pathway, revealing that urate oxidase is not the only enzyme involved, but rather part of a three-enzyme system.</p>"},{"location":"reviews/60418ffa00001124-Hypoxanthine_catabolic_process__Mouse_/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices, including:</p> <ol> <li>Appropriate use of causal relations to connect activities</li> <li>Proper annotation of cellular locations for activities</li> <li>Inclusion of high-quality evidence codes and references</li> <li>Integration of gene products, molecular functions, and biological processes</li> </ol>"},{"location":"reviews/60418ffa00001124-Hypoxanthine_catabolic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>Gomodel:60418ffa00001124 is a well-constructed GO-CAM model that accurately represents the hypoxanthine catabolic pathway in mouse. The model provides a clear depiction of the enzymatic conversion of hypoxanthine to allantoin through the sequential activities of Xdh, Uox, Urah, and Urad. The connections between activities are logically structured and scientifically sound.</p> <p>The pathway is particularly interesting from an evolutionary perspective, as humans and other primates have lost the ability to degrade uric acid beyond the initial oxidation step due to the inactivation of the urate oxidase gene. This has clinical significance in terms of human susceptibility to gout and kidney stones.</p> <p>Overall, this model effectively captures the current knowledge of hypoxanthine catabolism in mice and serves as a valuable resource for understanding this metabolic pathway.</p>"},{"location":"reviews/60418ffa00001200-Guanine_catabolic_process__Mouse_/","title":"60418ffa00001200 Guanine catabolic process  Mouse","text":"<p>Now that I've reviewed the model and related literature, I'll analyze the GO-CAM model for guanine catabolic process in mouse (gomodel:60418ffa00001200). </p>"},{"location":"reviews/60418ffa00001200-Guanine_catabolic_process__Mouse_/#go-cam-review-guanine-catabolic-process-mouse-gomodel60418ffa00001200","title":"GO-CAM Review: Guanine catabolic process (Mouse) - gomodel:60418ffa00001200","text":""},{"location":"reviews/60418ffa00001200-Guanine_catabolic_process__Mouse_/#overview","title":"Overview","text":"<p>This model represents the guanine catabolic process in mice, demonstrating how guanine is metabolized to allantoin through a series of enzymatic steps. The pathway involves multiple enzymes that catalyze consecutive reactions in this purine degradation pathway.</p>"},{"location":"reviews/60418ffa00001200-Guanine_catabolic_process__Mouse_/#pathway-analysis","title":"Pathway Analysis","text":"<p>The model describes the following sequence of enzymatic activities:</p> <ol> <li> <p>Guanine deaminase (Gda/MGI:MGI:95678) in the cytosol catalyzes the first step, which feeds into two separate activities of xanthine dehydrogenase/oxidase (Xdh/MGI:MGI:98973).</p> </li> <li> <p>Xanthine dehydrogenase/oxidase (Xdh) has dual enzymatic activities:</p> </li> <li>Xanthine dehydrogenase activity (GO:0004854) in the cytosol</li> <li> <p>Xanthine oxidase activity (GO:0004855) in both the cytosol and peroxisome</p> </li> <li> <p>These activities provide input for urate oxidase (Uox/MGI:MGI:98907) with urate oxidase activity (GO:0004846) in the peroxisome.</p> </li> <li> <p>Urate oxidase provides input for hydroxyisourate hydrolase (Urah/MGI:MGI:1916142) with hydroxyisourate hydrolase activity (GO:0033971) in the peroxisome.</p> </li> <li> <p>Finally, 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase (Urad/MGI:MGI:3647519) with decarboxylase activity (GO:0051997) in the peroxisome produces allantoin (CHEBI:15676).</p> </li> </ol>"},{"location":"reviews/60418ffa00001200-Guanine_catabolic_process__Mouse_/#literature-support","title":"Literature Support","text":"<p>The model is well-supported by the literature. The PMID:16462750 paper clearly describes the complete uric acid degradation pathway through a series of enzymatic steps, specifically identifying Urah and Urad as the enzymes involved in the final steps leading to allantoin production. The paper confirms that this pathway converts uric acid to dextrorotatory allantoin on a time scale of seconds, which is the biologically relevant form.</p> <p>PMID:1590774 provides important information about xanthine dehydrogenase/oxidase and its role in purine metabolism, supporting the dual activity (dehydrogenase and oxidase) represented in the model.</p>"},{"location":"reviews/60418ffa00001200-Guanine_catabolic_process__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Accurate enzyme localization: The model correctly represents the subcellular localization of enzymes - with early steps occurring in the cytosol and later steps in the peroxisome, consistent with the literature.</p> </li> <li> <p>Well-connected causal relationships: The model uses \"provides input for\" (RO:0002413) predicates appropriately to show the sequential nature of the metabolic pathway.</p> </li> <li> <p>Representation of dual enzymatic activities: The model correctly represents that Xdh has both dehydrogenase and oxidase activities.</p> </li> <li> <p>Complete metabolic pathway: The model captures the entire pathway from guanine to allantoin.</p> </li> <li> <p>Strong evidence basis: Each activity is supported by literature evidence with appropriate ECO codes.</p> </li> </ol>"},{"location":"reviews/60418ffa00001200-Guanine_catabolic_process__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing molecular inputs/outputs: While the final product (allantoin) is represented as an output, the intermediate metabolites in the pathway (xanthine, uric acid, etc.) are not explicitly shown as outputs and inputs between the steps. These could be added to make the molecular transformations clearer.</p> </li> <li> <p>Incomplete biological process associations: While some of the activities are correctly associated with \"guanine catabolic process\" (GO:0006147), not all are. The guanine deaminase activity is not explicitly linked to this process.</p> </li> <li> <p>Alternative pathways: The model represents multiple inputs from Xdh activities to Uox, which is correct, but it's not entirely clear if this represents alternative routes or concurrent mechanisms.</p> </li> </ol>"},{"location":"reviews/60418ffa00001200-Guanine_catabolic_process__Mouse_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Add molecular outputs and inputs: Consider adding the specific small-molecule products and reactants for each step to fully document the chemical transformations.</p> </li> <li> <p>Ensure biological process consistency: All activities involved should be explicitly associated with \"guanine catabolic process\" (GO:0006147) where appropriate.</p> </li> <li> <p>Check alternative mechanisms: Clarify whether the multiple inputs to Uox represent alternative routes or concurrent mechanisms.</p> </li> <li> <p>Verify enzyme structures: While not critical, it could be useful to note if any of these enzymes function as complexes, especially given the information about enzyme structures in PMID:16462750.</p> </li> </ol>"},{"location":"reviews/60418ffa00001200-Guanine_catabolic_process__Mouse_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices by: - Using appropriate predicates for causal relationships (RO:0002413) - Correctly representing subcellular localization - Including appropriate evidence codes and references - Representing the biological process context</p>"},{"location":"reviews/60418ffa00001200-Guanine_catabolic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>This is a high-quality GO-CAM model that accurately represents the guanine catabolic pathway in mouse. It is well-supported by the literature and follows GO-CAM best practices. The minor improvement suggestions would enhance the model's clarity and completeness but do not detract significantly from its current value.</p> <p>The model successfully captures the key findings from the research papers, particularly the complete uric acid degradation pathway described in PMID:16462750, which was an important discovery showing how the conversion from uric acid to allantoin occurs through specific enzymatic steps rather than spontaneous decay.</p>"},{"location":"reviews/60418ffa00001258-Deoxyadenosine_catabolic_process__Mouse_/","title":"60418ffa00001258 Deoxyadenosine catabolic process  Mouse","text":"<p>Based on my analysis of the GO-CAM model and the relevant information about the proteins involved, I'll provide a comprehensive review of the model.</p>"},{"location":"reviews/60418ffa00001258-Deoxyadenosine_catabolic_process__Mouse_/#go-cam-review-deoxyadenosine-catabolic-process-mouse-gomodel60418ffa00001258","title":"GO-CAM Review: Deoxyadenosine catabolic process (Mouse) - gomodel:60418ffa00001258","text":""},{"location":"reviews/60418ffa00001258-Deoxyadenosine_catabolic_process__Mouse_/#overview","title":"Overview","text":"<p>This GO-CAM model represents the deoxyadenosine catabolic process in mouse (Taxon: Mus musculus). The model describes the enzymatic pathway for the degradation of deoxyadenosine through a series of molecular functions connected via causal associations (primarily \"provides input for\" relationships).</p>"},{"location":"reviews/60418ffa00001258-Deoxyadenosine_catabolic_process__Mouse_/#model-structure-and-biological-accuracy","title":"Model Structure and Biological Accuracy","text":"<p>The model captures the following key activities:</p> <ol> <li>Adenosine deaminase (Ada) catalyzes the deamination of 2'-deoxyadenosine to 2'-deoxyinosine</li> <li>Enabled by MGI:MGI:87916 (Ada)</li> <li>Function: GO:0046936 (2'-deoxyadenosine deaminase activity)</li> <li>Located in the cytosol (GO:0005829)</li> <li> <p>Evidence supported by experimental data (ECO:0000315, PMID:10720488)</p> </li> <li> <p>Purine-nucleoside phosphorylase (Pnp) converts 2'-deoxyinosine to hypoxanthine</p> </li> <li>Enabled by MGI:MGI:97365 (Pnp)</li> <li>Function: GO:0004731 (purine-nucleoside phosphorylase activity)</li> <li>Located in the cytosol (GO:0005829)</li> <li> <p>Evidence from multiple sources (PMID:11783524, PMID:6771276)</p> </li> <li> <p>Xanthine dehydrogenase/oxidase (Xdh) carries out multiple enzymatic activities:</p> </li> <li>Hypoxanthine dehydrogenase activity (GO:0070674)</li> <li>Hypoxanthine oxidase activity (GO:0070675)</li> <li>Xanthine dehydrogenase activity (GO:0004854)</li> <li>Xanthine oxidase activity (GO:0004855)</li> <li>Located in both cytosol and peroxisome</li> <li> <p>Well-supported by experimental evidence</p> </li> <li> <p>Urate oxidase (Uox) activity</p> </li> <li>Enabled by MGI:MGI:98907 (Uox)</li> <li>Function: GO:0004846 (urate oxidase activity)</li> <li> <p>Located in the peroxisome (GO:0005777)</p> </li> <li> <p>Final steps with hydroxyisourate hydrolase (Urah) and 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase (Urad) activities lead to allantoin production.</p> </li> </ol>"},{"location":"reviews/60418ffa00001258-Deoxyadenosine_catabolic_process__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Pathway Completeness: The model successfully captures the complete deoxyadenosine degradation pathway from Ada's initial activity through to the production of allantoin.</p> </li> <li> <p>Evidence Quality: Each activity is well-supported by experimental evidence with appropriate citations.</p> </li> <li> <p>Cellular Localization: Subcellular locations are properly annotated for each activity (cytosol vs. peroxisome).</p> </li> <li> <p>Causal Connections: The activities are correctly connected with \"provides input for\" (RO:0002413) relationships that accurately reflect the biochemical sequence.</p> </li> <li> <p>Biological Accuracy: The model correctly represents the dual activities of Xdh as both dehydrogenase and oxidase forms, which aligns with the known biology that Xdh can be converted between forms.</p> </li> </ol>"},{"location":"reviews/60418ffa00001258-Deoxyadenosine_catabolic_process__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Xanthine dehydrogenase/oxidase representation: The model represents multiple activities of Xdh (hypoxanthine dehydrogenase, hypoxanthine oxidase, xanthine dehydrogenase, and xanthine oxidase) separately, which seems appropriate given that Xdh is known to have these specific activities. However, according to the \"How to annotate complexes in GO-CAM\" document, it may be worth considering if these should be represented as activities of a single enzyme or if any of these activities occur within a complex context.</p> </li> <li> <p>Tissue specificity: The model does not capture tissue-specific differences in this pathway that might be relevant. The PMID:10720488 reference indicates there are tissue-specific aspects of this pathway, particularly in the gastrointestinal tract.</p> </li> <li> <p>Regulatory relationships: While the model captures the core catalytic pathway, it doesn't include any regulatory relationships (e.g., feedback inhibition) that might be present in this pathway. For a more comprehensive model, such regulatory mechanisms could be incorporated using the appropriate regulatory predicates (RO:0002629, RO:0002630).</p> </li> </ol>"},{"location":"reviews/60418ffa00001258-Deoxyadenosine_catabolic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:60418ffa00001258 is a well-constructed representation of the deoxyadenosine catabolic pathway in mouse. It accurately captures the enzymatic activities, their subcellular locations, and the causal relationships between them. The model is supported by high-quality evidence from the literature. </p> <p>From a curation standpoint, the model appears to follow GO-CAM best practices and provides a clear, parsimony-oriented representation of the pathway that would be understandable to researchers studying purine metabolism.</p> <p>The completeness of the pathway from deoxyadenosine through to allantoin makes this model particularly valuable as a reference for understanding this metabolic process and its potential role in various physiological and pathological contexts, such as the immunological defects described in the associated literature.</p>"},{"location":"reviews/60418ffa00001536-Deoxyguanosine_catabolic_process__Mouse_/","title":"60418ffa00001536 Deoxyguanosine catabolic process  Mouse","text":"<p>After reviewing the model and relevant documentation, I'll now provide a comprehensive review of GO-CAM model 60418ffa00001536.</p>"},{"location":"reviews/60418ffa00001536-Deoxyguanosine_catabolic_process__Mouse_/#review-of-go-cam-model-60418ffa00001536","title":"Review of GO-CAM Model: 60418ffa00001536","text":""},{"location":"reviews/60418ffa00001536-Deoxyguanosine_catabolic_process__Mouse_/#model-overview","title":"Model Overview","text":"<p>Title: Deoxyguanosine catabolic process (Mouse) Taxon: Mus musculus (Mouse) Status: Production ID: gomodel:60418ffa00001536</p> <p>This model represents the deoxyguanosine catabolic process in mouse, showing the pathway from deoxyguanosine to allantoin through a series of enzymatic steps. The model captures the purine degradation pathway, with a focus on the catabolism of deoxyguanosine and the subsequent conversion of xanthine to uric acid and eventually to allantoin.</p>"},{"location":"reviews/60418ffa00001536-Deoxyguanosine_catabolic_process__Mouse_/#model-components","title":"Model Components","text":"<p>The model includes the following key gene products and their molecular functions:</p> <ol> <li>Purine-nucleoside phosphorylase (Pnp/MGI:MGI:97365): </li> <li>GO:0004731 - purine-nucleoside phosphorylase activity</li> <li> <p>Located in GO:0005829 (cytosol)</p> </li> <li> <p>Guanine deaminase (Gda/MGI:MGI:95678):</p> </li> <li>GO:0008892 - guanine deaminase activity</li> <li>Located in GO:0005829 (cytosol)</li> <li> <p>Part of GO:0006161 (deoxyguanosine catabolic process)</p> </li> <li> <p>Xanthine oxidoreductase (Xdh/MGI:MGI:98973):</p> </li> <li>Has multiple activities:<ul> <li>GO:0004855 - xanthine oxidase activity (in peroxisome)</li> <li>GO:0004854 - xanthine dehydrogenase activity (in cytosol)</li> </ul> </li> <li> <p>Part of GO:0006161 (deoxyguanosine catabolic process)</p> </li> <li> <p>Urate oxidase (Uox/MGI:MGI:98907):</p> </li> <li>GO:0004846 - urate oxidase activity</li> <li>Located in GO:0005777 (peroxisome)</li> <li> <p>Part of GO:0006161 (deoxyguanosine catabolic process)</p> </li> <li> <p>Hydroxyisourate hydrolase (Urah/MGI:MGI:1916142):</p> </li> <li>GO:0033971 - hydroxyisourate hydrolase activity</li> <li>Located in GO:0005777 (peroxisome)</li> <li> <p>Part of GO:0006161 (deoxyguanosine catabolic process)</p> </li> <li> <p>2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase (Urad/MGI:MGI:3647519):</p> </li> <li>GO:0051997 - 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase activity</li> <li>Located in GO:0005777 (peroxisome)</li> </ol>"},{"location":"reviews/60418ffa00001536-Deoxyguanosine_catabolic_process__Mouse_/#pathway-flow","title":"Pathway Flow","text":"<p>The model represents the sequential flow of metabolites through the deoxyguanosine catabolic pathway with the following causal connections:</p> <ol> <li>Pnp (purine-nucleoside phosphorylase) provides input for Gda (guanine deaminase)</li> <li>Gda provides input for Xdh (xanthine dehydrogenase activity)</li> <li>Xdh (xanthine oxidase and dehydrogenase activities) provides input for Uox (urate oxidase)</li> <li>Uox provides input for Urah (hydroxyisourate hydrolase)</li> <li>Urah provides input for Urad (2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase)</li> </ol> <p>All causal relationships use the \"provides input for\" (RO:0002413) predicate, indicating that the output of one activity serves as the substrate for the next.</p>"},{"location":"reviews/60418ffa00001536-Deoxyguanosine_catabolic_process__Mouse_/#evidence-and-references","title":"Evidence and References","text":"<p>The model is well-supported by experimental evidence, primarily from direct assays (ECO:0000314) and the following publications:</p> <ul> <li>PMID:16462750 - Identifies the enzymes involved in the uric acid degradation pathway</li> <li>PMID:8226898, PMID:4207016, PMID:29895374 - Supporting xanthine oxidoreductase activities</li> <li>PMID:10075721, PMID:8064675 - Supporting guanine deaminase activity</li> <li>PMID:109081, PMID:11783524 - Supporting purine-nucleoside phosphorylase localization and activity</li> </ul>"},{"location":"reviews/60418ffa00001536-Deoxyguanosine_catabolic_process__Mouse_/#review-assessment","title":"Review Assessment","text":""},{"location":"reviews/60418ffa00001536-Deoxyguanosine_catabolic_process__Mouse_/#strengths","title":"Strengths","text":"<ol> <li> <p>Completeness: The model provides a comprehensive representation of the deoxyguanosine catabolic pathway, from deoxyguanosine to allantoin.</p> </li> <li> <p>Subcellular Localization: The model correctly captures the differential localization of enzymes, with Xdh exhibiting both cytosolic (dehydrogenase) and peroxisomal (oxidase) activities, and the terminal steps (Uox, Urah, Urad) occurring in the peroxisome.</p> </li> <li> <p>Evidence Base: The model is well-supported by multiple sources of experimental evidence, particularly the key paper by Ramazzina et al. (PMID:16462750) which elucidated the complete uric acid degradation pathway.</p> </li> <li> <p>Causal Connections: The causal connections between activities correctly use the \"provides input for\" predicate (RO:0002413), which is appropriate for a metabolic pathway where the product of one reaction becomes the substrate for the next.</p> </li> <li> <p>Biological Accuracy: The model captures the recently discovered enzymatic steps beyond urate oxidase (Uox), including the conversion of 5-hydroxyisourate (HIU) to 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline (OHCU) by hydroxyisourate hydrolase (Urah), and the final conversion to S-(+)-allantoin by OHCU decarboxylase (Urad). This reflects current understanding of the pathway as described in the cited literature.</p> </li> </ol>"},{"location":"reviews/60418ffa00001536-Deoxyguanosine_catabolic_process__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Molecular Inputs/Outputs: The model would benefit from explicitly capturing the small molecule inputs and outputs for each reaction, which would make the biochemical details of the pathway clearer to readers.</p> </li> <li> <p>Compartmental Transport: The model doesn't explicitly capture the transport of metabolites between cellular compartments (e.g., cytosol to peroxisome), which is necessary for this pathway to function. This is particularly relevant for the transition from cytosolic xanthine dehydrogenase activity to peroxisomal xanthine oxidase activity.</p> </li> <li> <p>Alternative Starting Points: While the model focuses on deoxyguanosine catabolism, the purine degradation pathway has multiple entry points. It might be useful to indicate that this pathway can process other purines (e.g., adenosine), perhaps through future linked models.</p> </li> <li> <p>Xanthine Oxidoreductase Dual Role: The dual functionality of Xdh as both dehydrogenase and oxidase is represented through two separate activities, but the model doesn't capture the relationship between these two activities of the same enzyme. It would be helpful to link these activities or provide some annotation to clarify their relationship.</p> </li> <li> <p>Regulatory Mechanisms: The model doesn't include any regulatory mechanisms that might control flux through this pathway. If known, adding inhibitory or activating relationships would enhance the biological representation.</p> </li> </ol>"},{"location":"reviews/60418ffa00001536-Deoxyguanosine_catabolic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a high-quality GO-CAM model that accurately represents the deoxyguanosine catabolic pathway in mouse. It follows GO-CAM best practices in terms of causal relationships and evidence, and it incorporates recently discovered enzymes in the uric acid degradation pathway.</p> <p>The model effectively captures the sequential enzymatic activities from deoxyguanosine to allantoin, with appropriate subcellular localization. The evidence base is strong, drawing from multiple primary research papers.</p> <p>The minor suggested improvements would enhance the model's completeness and clarity but don't detract significantly from its current value. This model serves as a valuable resource for understanding purine catabolism in mouse and demonstrates the power of GO-CAM for representing metabolic pathways with precise molecular and cellular details.</p>"},{"location":"reviews/60418ffa00001643-Deoxyinosine_catabolic_process__Mouse_/","title":"60418ffa00001643 Deoxyinosine catabolic process  Mouse","text":"<p>Now that I have the necessary information, I'll review the GO-CAM model:</p>"},{"location":"reviews/60418ffa00001643-Deoxyinosine_catabolic_process__Mouse_/#go-cam-review-deoxyinosine-catabolic-process-mouse","title":"GO-CAM Review: Deoxyinosine catabolic process (Mouse)","text":""},{"location":"reviews/60418ffa00001643-Deoxyinosine_catabolic_process__Mouse_/#model-overview","title":"Model Overview","text":"<ul> <li>ID: gomodel:60418ffa00001643</li> <li>Title: Deoxyinosine catabolic process (Mouse)</li> <li>Taxon: Mouse (NCBITaxon:10090)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/60418ffa00001643-Deoxyinosine_catabolic_process__Mouse_/#pathway-description","title":"Pathway Description","text":"<p>This GO-CAM model represents the deoxyinosine catabolic pathway in mouse, showing how deoxyinosine is metabolized through several enzymatic steps into allantoin. The model includes:</p> <ol> <li>Purine-nucleoside phosphorylase (Pnp) - converts deoxyinosine to hypoxanthine</li> <li>Xanthine dehydrogenase/oxidase (Xdh) - converts hypoxanthine to xanthine, then xanthine to uric acid</li> <li>Urate oxidase (Uox) - converts uric acid to 5-hydroxyisourate</li> <li>Hydroxyisourate hydrolase (Urah) - converts 5-hydroxyisourate to 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline</li> <li>2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase (Urad) - converts 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline to allantoin</li> </ol>"},{"location":"reviews/60418ffa00001643-Deoxyinosine_catabolic_process__Mouse_/#key-proteins-and-activities","title":"Key Proteins and Activities","text":"<ol> <li>PNP (Pnp) - MGI:MGI:97365</li> <li>GO:0004731 (purine-nucleoside phosphorylase activity)</li> <li>Part of GO:0006149 (deoxyinosine catabolic process)</li> <li> <p>Provides input for Xdh hypoxanthine dehydrogenase and oxidase activities</p> </li> <li> <p>XDH (Xdh) - MGI:MGI:98973</p> </li> <li>Multiple activities:<ul> <li>GO:0070674 (hypoxanthine dehydrogenase activity)</li> <li>GO:0070675 (hypoxanthine oxidase activity)</li> <li>GO:0004854 (xanthine dehydrogenase activity)</li> <li>GO:0004855 (xanthine oxidase activity)</li> </ul> </li> <li>Part of GO:0006149 (deoxyinosine catabolic process)</li> <li> <p>Activities sequentially provide input for each other and ultimately for urate oxidase</p> </li> <li> <p>UOX (Uox) - MGI:MGI:98907</p> </li> <li>GO:0004846 (urate oxidase activity)</li> <li>Occurs in GO:0005777 (peroxisome)</li> <li>Part of GO:0006149 (deoxyinosine catabolic process)</li> <li> <p>Provides input for hydroxyisourate hydrolase activity</p> </li> <li> <p>URAH (Urah) - MGI:MGI:1916142</p> </li> <li>GO:0033971 (hydroxyisourate hydrolase activity)</li> <li>Occurs in GO:0005777 (peroxisome)</li> <li>Part of GO:0006149 (deoxyinosine catabolic process)</li> <li> <p>Provides input for 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase activity</p> </li> <li> <p>URAD (Urad) - MGI:MGI:3647519</p> </li> <li>GO:0051997 (2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase activity)</li> <li>Occurs in GO:0005777 (peroxisome)</li> <li>Has output CHEBI:15676 (allantoin)</li> </ol>"},{"location":"reviews/60418ffa00001643-Deoxyinosine_catabolic_process__Mouse_/#review-assessment","title":"Review Assessment","text":""},{"location":"reviews/60418ffa00001643-Deoxyinosine_catabolic_process__Mouse_/#strengths","title":"Strengths","text":"<ol> <li> <p>Biological accuracy: The model accurately represents the known deoxyinosine catabolic pathway in mouse, with all the key enzymatic steps properly connected by causal relationships.</p> </li> <li> <p>Appropriate evidence: The model uses appropriate evidence codes (ECO:0000314 - direct assay evidence, ECO:0000315 - mutant phenotype evidence, and ECO:0000266 - sequence orthology evidence) and cites relevant literature to support the annotations.</p> </li> <li> <p>Subcellular localization: The model correctly annotates peroxisome localization for the enzymes that operate in this compartment.</p> </li> <li> <p>Causal connections: The causal flow using RO:0002413 (provides input for) is used appropriately to connect the activities in sequence.</p> </li> <li> <p>Comprehensive representation: The model includes all major steps of the pathway from deoxyinosine to the final product allantoin.</p> </li> </ol>"},{"location":"reviews/60418ffa00001643-Deoxyinosine_catabolic_process__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Multiple pathway entries for Xdh: The model shows several parallel entries for Xdh activities rather than showing them as a single linear pathway. While this accurately reflects that Xdh has multiple activities, it creates some visual complexity that could be streamlined.</p> </li> <li> <p>Molecular function clarity: For Xdh, the distinction between dehydrogenase and oxidase activities could be clearer. In mammals, XDH exists in two forms - the dehydrogenase (XD) that uses NAD+ as an electron acceptor and the oxidase (XO) that uses O2. This interconversion is biologically significant and could be more explicitly modeled.</p> </li> <li> <p>Output entity specification: The final product allantoin is correctly specified as an output, but intermediate metabolites (hypoxanthine, xanthine, uric acid, etc.) are not explicitly represented as outputs/inputs between steps. Adding these molecular entities would improve the model's clarity.</p> </li> <li> <p>Location completeness: While peroxisomal location is correctly specified for several enzymes, the location information for Pnp is missing even though it's known to be cytosolic.</p> </li> </ol>"},{"location":"reviews/60418ffa00001643-Deoxyinosine_catabolic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the deoxyinosine catabolic pathway in mouse. The model correctly captures the sequence of enzymatic activities leading from deoxyinosine to allantoin, with appropriate evidence and references to support the annotations.</p> <p>The model could be enhanced by: 1. More explicit representation of the intermediate metabolites 2. Adding cytosolic location for Pnp 3. Possibly streamlining the multiple parallel pathways for Xdh to improve visual clarity</p> <p>These minor improvements would make the model even more informative and easier to interpret, but even in its current form, it's a biologically accurate and valuable representation of the pathway.</p>"},{"location":"reviews/6086f4f200000223-canonical_Wnt_signaling_pathway_via_wg_fz2__D_mel_/","title":"6086f4f200000223 canonical Wnt signaling pathway via wg fz2  D mel","text":"<p>Now, let me review the GO-CAM model \"gomodel:6086f4f200000223\" titled \"canonical Wnt signaling pathway via wg-fz2 (D.mel)\" which focuses on the Wnt signaling pathway in Drosophila melanogaster.</p>"},{"location":"reviews/6086f4f200000223-canonical_Wnt_signaling_pathway_via_wg_fz2__D_mel_/#go-cam-review-analysis","title":"GO-CAM Review Analysis","text":""},{"location":"reviews/6086f4f200000223-canonical_Wnt_signaling_pathway_via_wg_fz2__D_mel_/#general-overview","title":"General Overview","text":"<p>This model represents the canonical Wnt signaling pathway in Drosophila melanogaster, focusing on negative regulation of the pathway via various protein activities. The model includes: - 10 activities carried out by different gene products - Causal relationships between these activities - Cellular locations (cytosol, plasma membrane, extracellular space, nucleus) - Evidence from multiple scientific publications</p>"},{"location":"reviews/6086f4f200000223-canonical_Wnt_signaling_pathway_via_wg_fz2__D_mel_/#biological-content-accuracy","title":"Biological Content Accuracy","text":"<p>The model appears to correctly represent the canonical Wnt signaling pathway components and their relationships:</p> <ol> <li>Wingless (wg/Wnt) Signaling: FB:FBgn0284084 (wg) with receptor ligand activity in extracellular space</li> <li>Receptor Components: </li> <li>FB:FBgn0016797 (fz2) with Wnt receptor activity on plasma membrane</li> <li>FB:FBgn0000119 (arrow/arr) with coreceptor activity</li> <li>Downstream Components:</li> <li>FB:FBgn0000499 (dishevelled/dsh) as adaptor</li> <li>FB:FBgn0003371 (shaggy/sgg, GSK3\u03b2 ortholog) as protein kinase</li> <li>FB:FBgn0026597 (Axin/Axn) with beta-catenin binding</li> <li>FB:FBgn0025638 (Roc1a) with ubiquitin ligase activity</li> <li>FB:FBgn0003371 (sgg) with protein kinase activity</li> <li>FB:FBgn0000117 (armadillo/arm, \u03b2-catenin ortholog) as transcription coactivator</li> <li>FB:FBgn0026598 (Apc2) with molecular adaptor activity</li> <li>FB:FBgn0015024 (CkIalpha) with protein kinase activity</li> </ol> <p>The model accurately shows: - Wnt signaling activating its receptor Frizzled (fz2) - Arrow (arr) functioning as co-receptor - Dishevelled (dsh) mediating signal transduction  - The destruction complex components (Axin, GSK3\u03b2/shaggy, Apc2, CkIalpha) negatively regulating \u03b2-catenin (armadillo) - The relationship between these activities in the context of negative regulation of canonical Wnt signaling</p>"},{"location":"reviews/6086f4f200000223-canonical_Wnt_signaling_pathway_via_wg_fz2__D_mel_/#activity-flow-and-causal-relationships","title":"Activity Flow and Causal Relationships","text":"<p>The causal relationships in the model follow a logical flow: 1. Wnt ligand (wg) activates its receptor (fz2) 2. fz2 activates the adaptor protein Dishevelled (dsh) 3. dsh negatively regulates shaggy/GSK3\u03b2 kinase activity 4. In the absence of Wnt signaling, kinases (sgg and CkIalpha) and adaptors (Axn and Apc2) form a destruction complex 5. This complex leads to \u03b2-catenin degradation via ubiquitin ligase (Roc1a)</p>"},{"location":"reviews/6086f4f200000223-canonical_Wnt_signaling_pathway_via_wg_fz2__D_mel_/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li>Missing Evidence: </li> <li>Activity of FB:FBgn0000117 (arm/\u03b2-catenin) as transcription coactivator lacks evidence details</li> <li> <p>Some causal relationships lack evidence</p> </li> <li> <p>Cellular Location Consistency:</p> </li> <li> <p>Most activities have appropriate cellular locations, but FB:FBgn0015024 (CkIalpha) is missing a cellular location</p> </li> <li> <p>Redundant Causal Relationships:</p> </li> <li> <p>There appears to be duplicate relationships between dsh and sgg (the same relationship is listed twice)</p> </li> <li> <p>Complex Representation:</p> </li> <li>The model doesn't explicitly represent the \u03b2-catenin destruction complex as a complex entity, but this is acceptable since the individual component activities are represented according to the GO-CAM guidelines</li> </ol>"},{"location":"reviews/6086f4f200000223-canonical_Wnt_signaling_pathway_via_wg_fz2__D_mel_/#qc-recommendations","title":"QC Recommendations:","text":"<ol> <li>Add missing evidence for the transcription coactivator activity of armadillo/\u03b2-catenin</li> <li>Specify cellular location for CkIalpha kinase activity</li> <li>Remove duplicate causal relationship between dsh and sgg</li> <li>Consider clarifying the role of Axin as a scaffold for the destruction complex</li> </ol>"},{"location":"reviews/6086f4f200000223-canonical_Wnt_signaling_pathway_via_wg_fz2__D_mel_/#summary","title":"Summary","text":"<p>Overall, this GO-CAM model effectively represents the canonical Wnt signaling pathway in Drosophila melanogaster with a focus on the negative regulation aspect. The biological content is accurate and well-supported by evidence from the literature. The minor issues identified should be addressed to improve the completeness and clarity of the model, but they don't significantly detract from its scientific value.</p> <p>The model is available at: https://bioregistry.io/go.model:6086f4f200000223</p>"},{"location":"reviews/60897d8500000494-IMP_salvage__Mouse_/","title":"60897d8500000494 IMP salvage  Mouse","text":"<p>Based on my review of this GO-CAM model (gomodel:60897d8500000494), I can provide the following assessment:</p>"},{"location":"reviews/60897d8500000494-IMP_salvage__Mouse_/#go-cam-review-imp-salvage-mouse-model-gomodel60897d8500000494","title":"GO-CAM Review: IMP Salvage (Mouse) Model - gomodel:60897d8500000494","text":""},{"location":"reviews/60897d8500000494-IMP_salvage__Mouse_/#overview","title":"Overview","text":"<p>This model represents the IMP (inosine monophosphate) salvage pathway in mouse (NCBITaxon:10090). It illustrates how IMP is synthesized or recovered through various enzymatic activities in cellular metabolism.</p>"},{"location":"reviews/60897d8500000494-IMP_salvage__Mouse_/#model-structure-and-content","title":"Model Structure and Content","text":"<p>The model contains 11 distinct activities that contribute to the IMP salvage process, with multiple genes/proteins performing similar functions in parallel routes within the pathway:</p> <ol> <li>Three distinct AMP deaminase activities (enabled by Ampd1, Ampd2, and Ampd3) converting AMP to IMP</li> <li>Two GMP reductase activities (enabled by Gmpr and Gmpr2) converting GMP to IMP</li> <li>Hypoxanthine phosphoribosyltransferase activity (Hprt1)</li> <li>Adenosine kinase activity (Adk)</li> <li>2'-deoxyadenosine deaminase activity (Ada)</li> <li>Purine-nucleoside phosphorylase activity (Pnp)</li> <li>Two 5'-nucleotidase activities (Nt5c and Nt5c2)</li> <li>Adenine phosphoribosyltransferase activity (Aprt)</li> </ol> <p>All activities are appropriately labeled as part of the biological process \"GO:0032264 - IMP salvage\".</p>"},{"location":"reviews/60897d8500000494-IMP_salvage__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Well-documented evidence: Each activity is supported by appropriate evidence types and PMIDs, providing strong scientific backing.</p> </li> <li> <p>Causal connections: Appropriate causal relationships are established using RO:0002413 \"provides input for\" to show the flow of metabolites through the pathway.</p> </li> <li> <p>Molecular specificity: The model clearly identifies inputs and outputs of reactions with specific ChEBI terms for metabolites.</p> </li> <li> <p>Cellular component annotation: Where relevant, subcellular locations are specified (e.g., cytosol/GO:0005829 for some activities).</p> </li> <li> <p>Parallel pathways: The model captures the biological reality that multiple enzymes can perform similar functions in the IMP salvage pathway.</p> </li> </ol>"},{"location":"reviews/60897d8500000494-IMP_salvage__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Input molecules missing: Some activities (like in Gmpr and Gmpr2) have output molecules (IMP) specified but seem to be missing input molecules required for the reaction.</p> </li> <li> <p>Compartmentalization: Only some activities have cellular location specified. For consistency, all activities should have cellular locations if known.</p> </li> <li> <p>Missing connections: Although there are several causal connections established, some potential connections between related activities seem to be missing. For example, the relationship between the 5'-nucleotidase activities and other steps could be better defined.</p> </li> <li> <p>Visualization limitations: The model is complex with many parallel activities, which might make it difficult to interpret visually, though this is inherent to the complexity of the biological process.</p> </li> </ol>"},{"location":"reviews/60897d8500000494-IMP_salvage__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>From a biological perspective, the model accurately represents the IMP salvage pathway as documented in the literature. The inclusion of three AMP deaminase isoforms is consistent with the literature, as indicated in PMID:24940686, which discusses how these enzymes convert AMP to IMP.</p> <p>The pathway connections are also biologically sound, showing how adenine, adenosine, and other purines can be metabolized to produce IMP through various enzymatic activities.</p>"},{"location":"reviews/60897d8500000494-IMP_salvage__Mouse_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Add any missing input molecules for activities where they're known but not specified</p> </li> <li> <p>Ensure cellular compartmentalization is consistently annotated for all activities</p> </li> <li> <p>Complete any missing causal connections to better show the flow of metabolites through the pathway</p> </li> <li> <p>Consider adding annotations for regulatory aspects of the pathway if known (such as feedback inhibition)</p> </li> </ol>"},{"location":"reviews/60897d8500000494-IMP_salvage__Mouse_/#conclusion","title":"Conclusion","text":"<p>This is a high-quality GO-CAM model that accurately represents the IMP salvage pathway in mice. It adheres to GO-CAM best practices and provides a detailed representation of the pathway with strong literature support. With minor improvements as suggested, it would be an excellent reference model for IMP metabolism.</p> <p>The model can be accessed at: https://bioregistry.io/go.model:60897d8500000494</p>"},{"location":"reviews/60897d8500000531-AMP_salvage__Mouse_/","title":"60897d8500000531 AMP salvage  Mouse","text":"<p>After a thorough review of GO-CAM model 60897d8500000531 (AMP salvage in Mouse), I can now provide a comprehensive assessment of the model's quality, consistency with GO-CAM standards, and biological accuracy.</p>"},{"location":"reviews/60897d8500000531-AMP_salvage__Mouse_/#model-summary","title":"Model Summary","text":"<p>GO-CAM model:60897d8500000531 titled \"AMP salvage (Mouse)\" represents the AMP (adenosine monophosphate) salvage pathway in mouse. This pathway is crucial for recycling adenine-containing nucleotides and bases to regenerate AMP, rather than synthesizing it de novo, which is energetically more costly.</p>"},{"location":"reviews/60897d8500000531-AMP_salvage__Mouse_/#model-structure-and-activities","title":"Model Structure and Activities","text":"<p>The model consists of 6 activities connected in a pathway, all part of GO:0044209 (AMP salvage):</p> <ol> <li>HPRT1 activity (Hypoxanthine phosphoribosyltransferase) - MGI:MGI:96217</li> <li>Function: GO:0004422 (hypoxanthine phosphoribosyltransferase activity)</li> <li>Input: CHEBI:17368 (hypoxanthine)</li> <li> <p>Provides input for two downstream activities:</p> <ul> <li>ADSS1 (adenylosuccinate synthase 1)</li> <li>ADSS2 (adenylosuccinate synthase 2)</li> </ul> </li> <li> <p>APRT activity (Adenine phosphoribosyltransferase) - MGI:MGI:88061</p> </li> <li>Function: GO:0003999 (adenine phosphoribosyltransferase activity)</li> <li>Input: CHEBI:16708 (adenine)</li> <li> <p>Output: CHEBI:16027 (AMP)</p> </li> <li> <p>ADK activity (Adenosine kinase) - MGI:MGI:87930</p> </li> <li>Function: GO:0004001 (adenosine kinase activity)</li> <li>Input: CHEBI:16335 (adenosine)</li> <li> <p>Output: CHEBI:16027 (AMP)</p> </li> <li> <p>ADSS1 activity (Adenylosuccinate synthase 1) - MGI:MGI:87947</p> </li> <li>Function: GO:0004019 (adenylosuccinate synthase activity)</li> <li> <p>Provides input for ADSL activity</p> </li> <li> <p>ADSS2 activity (Adenylosuccinate synthase 2) - MGI:MGI:87948</p> </li> <li>Function: GO:0004019 (adenylosuccinate synthase activity)</li> <li> <p>Provides input for ADSL activity</p> </li> <li> <p>ADSL activity (Adenylosuccinate lyase) - MGI:MGI:103202</p> </li> <li>Function: GO:0004018 (N6-(1,2-dicarboxyethyl)AMP AMP-lyase (fumarate-forming) activity)</li> <li>Output: CHEBI:16027 (AMP)</li> </ol>"},{"location":"reviews/60897d8500000531-AMP_salvage__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Appropriate biological process annotation: All activities are correctly annotated with GO:0044209 (AMP salvage).</p> </li> <li> <p>Correct causal connections: The model uses RO:0002413 (provides input for) to connect upstream to downstream activities, which is appropriate for metabolic pathways.</p> </li> <li> <p>Comprehensive representation: The model captures multiple routes for AMP salvage (via adenine, adenosine, and hypoxanthine), providing a complete picture of the pathway.</p> </li> <li> <p>Well-supported evidence: Each activity has proper evidence codes and literature references.</p> </li> <li> <p>Accurately annotated enzymes: The enzymes are correctly matched to their appropriate activities with correct GO terms for molecular functions.</p> </li> <li> <p>Proper chemical entities: The model uses appropriate ChEBI terms for metabolites.</p> </li> </ol>"},{"location":"reviews/60897d8500000531-AMP_salvage__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing substrate/product annotations: For ADSS1 and ADSS2, there are no annotated input substrates (should be IMP) or output products (should be adenylosuccinate). These missing annotations would make the model more complete.</p> </li> <li> <p>Missing full reaction details for ADSL: While ADSL is shown to produce AMP (output), it's missing the input annotation for adenylosuccinate.</p> </li> <li> <p>Evidence distribution: Evidence for some activities is more comprehensive than others. For example, HPRT1 activity has multiple lines of evidence from different PMIDs, while some of the other activities have more limited evidence.</p> </li> <li> <p>Relation between ADSS1 and ADSS2: The model doesn't clarify the functional difference or tissue specificity between ADSS1 and ADSS2 (muscle vs. liver isozymes in mammals).</p> </li> </ol>"},{"location":"reviews/60897d8500000531-AMP_salvage__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the AMP salvage pathway in mouse. The key enzymes involved in this process are all present and correctly connected. The pathway is consistent with the literature:</p> <ol> <li> <p>HPRT1 role: Literature (PMIDs 8878108, 10037486) confirms HPRT1's role in converting hypoxanthine to IMP, which is a precursor for AMP synthesis.</p> </li> <li> <p>Multiple salvage routes: The model correctly shows that AMP can be produced through multiple routes:</p> </li> <li>Directly from adenine via APRT</li> <li>From adenosine via ADK</li> <li> <p>From hypoxanthine via HPRT1\u2192ADSS1/2\u2192ADSL pathway</p> </li> <li> <p>Enzyme functions: All enzymes are annotated with their correct molecular functions according to their UniProt entries.</p> </li> </ol>"},{"location":"reviews/60897d8500000531-AMP_salvage__Mouse_/#consistency-with-go-cam-standards","title":"Consistency with GO-CAM Standards","text":"<p>The model follows GO-CAM best practices by:</p> <ol> <li> <p>Using appropriate relation predicates: \"provides input for\" (RO:0002413) is correctly used to connect metabolic reactions.</p> </li> <li> <p>Proper annotation of molecular activities: Each gene product is annotated with its molecular function.</p> </li> <li> <p>Proper input/output annotations: Most activities have appropriate input and output molecules annotated.</p> </li> <li> <p>Well-defined biological process: All activities are appropriately connected to the overarching biological process GO:0044209 (AMP salvage).</p> </li> </ol>"},{"location":"reviews/60897d8500000531-AMP_salvage__Mouse_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li>Complete the substrate/product annotations:</li> <li>Add IMP as input for ADSS1 and ADSS2</li> <li>Add adenylosuccinate as output for ADSS1 and ADSS2</li> <li> <p>Add adenylosuccinate as input for ADSL</p> </li> <li> <p>Add tissue specificity information: Consider annotating the ADSS1 and ADSS2 activities with tissue specificity information, as they are known to be expressed differently (muscle vs. liver).</p> </li> <li> <p>Balance evidence: Consider adding more supporting evidence for some of the less well-documented activities.</p> </li> </ol>"},{"location":"reviews/60897d8500000531-AMP_salvage__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, GO-CAM model 60897d8500000531 is a high-quality representation of the AMP salvage pathway in mouse. It accurately captures the key enzymes and their connections in this metabolic pathway. The model would benefit from adding the missing substrate/product annotations for some reactions, but it is fundamentally sound and biologically accurate. The model is consistent with GO-CAM best practices and the available literature on AMP salvage.</p>"},{"location":"reviews/60ad85f700000058-Atf2_mouse/","title":"60ad85f700000058 Atf2 mouse","text":"<p>Let me now analyze the GO-CAM model to provide a comprehensive review:</p>"},{"location":"reviews/60ad85f700000058-Atf2_mouse/#go-cam-model-review-gomodel60ad85f700000058-atf2-mouse","title":"GO-CAM Model Review: gomodel:60ad85f700000058 (Atf2 mouse)","text":""},{"location":"reviews/60ad85f700000058-Atf2_mouse/#overview","title":"Overview","text":"<p>This model focuses on ATF2 (Activating Transcription Factor 2), a transcription factor in mouse. The model encompasses multiple activities of ATF2 across various cellular contexts and biological processes, supported by evidence from numerous publications.</p>"},{"location":"reviews/60ad85f700000058-Atf2_mouse/#structure-analysis","title":"Structure Analysis","text":"<p>The model contains 66 activities, predominantly involving ATF2 (MGI:MGI:109349) but also including interactions with numerous other proteins such as JDP2, JUN, CREB5, MAPK14, and others. The model covers ATF2's involvement in: - Transcriptional regulation - DNA binding - Protein-protein interactions - Various signaling pathways - Different cell types and developmental processes</p>"},{"location":"reviews/60ad85f700000058-Atf2_mouse/#strengths","title":"Strengths","text":"<ol> <li>Evidence Base: The model is well-supported by numerous scientific publications (at least 15 different PMIDs referenced).</li> <li>Molecular Function Detail: Correctly represents ATF2's key molecular functions such as:</li> <li>DNA binding (GO:0000978)</li> <li>Protein binding (GO:0005515)</li> <li>cAMP response element binding (GO:0035497)</li> <li>Leucine zipper domain binding (GO:0043522)</li> <li>Protein homodimerization (GO:0042803) and heterodimerization (GO:0046982)</li> <li> <p>Promoter-specific chromatin binding (GO:1990841)</p> </li> <li> <p>Subcellular Localization: Appropriately represents ATF2's activities in relevant cellular compartments, including:</p> </li> <li>Nucleus</li> <li>CCAAT-binding factor complex</li> <li> <p>Various cell types (melanocytes, fibroblasts, etc.)</p> </li> <li> <p>Biological Processes: Captures numerous biological processes in which ATF2 is involved, aligning with the UniProt functional annotation.</p> </li> </ol>"},{"location":"reviews/60ad85f700000058-Atf2_mouse/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Causal Relations: While the model includes some causal associations (7 instances using RO:0002418 \"activates\"), it lacks comprehensive causal connections between many activities. Most activities stand alone without connecting to each other in a pathway-like manner.</p> </li> <li> <p>Use of Generic MF: Many activities (27) use the generic \"molecular_function\" (GO:0003674) rather than more specific molecular functions. This makes it difficult to understand the precise role of ATF2 in those contexts.</p> </li> <li> <p>Complex Representation: ATF2 forms complexes with other proteins (as indicated in UniProt), but the model doesn't fully capture this using the standard complex annotation patterns described in the GO-CAM guidelines for complexes.</p> </li> <li> <p>Transcription Factor Activity Representation: Based on the \"DNA-binding transcription factor activity annotation guidelines\", the model should ideally:</p> </li> <li>Use more specific transcription factor terms like GO:0001228 (DNA-binding transcription activator activity) instead of generic terms</li> <li>Include causal relationships (\"indirectly positively regulates\" or \"indirectly negatively regulates\") to connect the transcription factor activity to the activities of target genes</li> <li> <p>Include \"has input\" relations to target genes or regulatory regions</p> </li> <li> <p>Redundancy: There appear to be some redundant or highly similar activity nodes that could be consolidated.</p> </li> <li> <p>Visual Organization: With 66 activities, the model is complex and would benefit from better organization by pathway or process context to improve comprehensibility.</p> </li> </ol>"},{"location":"reviews/60ad85f700000058-Atf2_mouse/#specific-issues","title":"Specific Issues","text":"<ol> <li> <p>Missing Phosphorylation Context: ATF2 is regulated by phosphorylation (as shown in UniProt), but this regulatory mechanism isn't clearly represented in the model.</p> </li> <li> <p>Incomplete pathway representation: Activities are often not connected into coherent pathways, making it difficult to understand the flow of biological information.</p> </li> <li> <p>Generic BP terms: Some biological process terms are very general (e.g., GO:0010467 \"gene expression\") and could be replaced with more specific terms.</p> </li> <li> <p>Unclear contexts: For some activities, the biological context is unclear - while the cell type might be specified, the broader biological context isn't provided.</p> </li> </ol>"},{"location":"reviews/60ad85f700000058-Atf2_mouse/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Add Causal Connections: Connect more activities with appropriate causal relations to create coherent pathways rather than isolated activities.</p> </li> <li> <p>Specify Molecular Functions: Replace generic molecular function terms (GO:0003674) with specific functions based on the evidence.</p> </li> <li> <p>Improve Complex Representation: Follow the GO-CAM guidelines for representing complexes more explicitly where ATF2 is part of a protein complex.</p> </li> <li> <p>Apply Transcription Factor Guidelines: Implement the specific patterns from the transcription factor guidelines, especially for causal relationships and input specification.</p> </li> <li> <p>Consolidate Redundant Activities: Review similar activities to determine if they can be consolidated.</p> </li> <li> <p>Organize by Pathway/Process: Consider reorganizing the model by pathway or biological process for better comprehensibility.</p> </li> <li> <p>Add Regulatory Context: Include the phosphorylation regulation of ATF2 that is well-documented.</p> </li> </ol>"},{"location":"reviews/60ad85f700000058-Atf2_mouse/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model for ATF2 (gomodel:60ad85f700000058) provides a comprehensive representation of ATF2's activities across various biological contexts, supported by substantial evidence. However, the model would benefit from improved causal connectivity between activities, more specific molecular function terms, better representation of complex formation, and implementation of transcription factor-specific annotation patterns. These improvements would make the model more biologically informative and easier to interpret as a coherent representation of ATF2's roles in cellular processes.</p>"},{"location":"reviews/60ad85f700000110-receptor_signaling_pathway_via_JAK_STAT_via_upd2_dome__D_mel_/","title":"60ad85f700000110 receptor signaling pathway via JAK STAT via upd2 dome  D mel","text":"<p>Based on all the information gathered, I'll now provide a thorough review of the GO-CAM model gomodel:60ad85f700000110.</p>"},{"location":"reviews/60ad85f700000110-receptor_signaling_pathway_via_JAK_STAT_via_upd2_dome__D_mel_/#review-of-go-cam-model-60ad85f700000110","title":"Review of GO-CAM model 60ad85f700000110","text":""},{"location":"reviews/60ad85f700000110-receptor_signaling_pathway_via_JAK_STAT_via_upd2_dome__D_mel_/#model-overview","title":"Model Overview","text":"<ul> <li>Title: \"Receptor signaling pathway via JAK-STAT via upd2-dome (D.mel)\"</li> <li>Taxon: Drosophila melanogaster (NCBITaxon:7227)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/60ad85f700000110-receptor_signaling_pathway_via_JAK_STAT_via_upd2_dome__D_mel_/#model-content","title":"Model Content","text":"<p>This model represents the JAK-STAT signaling pathway in Drosophila melanogaster, specifically focusing on the signaling initiated by the cytokine Unpaired-2 (Upd2) through the Domeless (Dome) receptor. The model consists of 4 activities in a signaling cascade:</p> <ol> <li>Upd2 (FB:FBgn0030904) - cytokine activity (GO:0005125) in the extracellular region</li> <li>Dome (FB:FBgn0043903) - cytokine receptor activity (GO:0004896) at the apical plasma membrane</li> <li>Hopscotch (FB:FBgn0004864) - non-membrane spanning protein tyrosine kinase activity (GO:0004715) at the cytoplasmic side of plasma membrane</li> <li>Stat92E (FB:FBgn0016917) - DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228) in the nucleus</li> </ol>"},{"location":"reviews/60ad85f700000110-receptor_signaling_pathway_via_JAK_STAT_via_upd2_dome__D_mel_/#evaluation-of-the-model","title":"Evaluation of the Model","text":""},{"location":"reviews/60ad85f700000110-receptor_signaling_pathway_via_JAK_STAT_via_upd2_dome__D_mel_/#pathway-accuracy-and-consistency","title":"Pathway Accuracy and Consistency","text":"<p>The model correctly captures the canonical JAK-STAT signaling pathway in Drosophila. The sequence of events is biologically accurate: 1. Upd2 cytokine is secreted into the extracellular space 2. Upd2 activates the Dome receptor at the plasma membrane 3. Activated Dome directly positively regulates Hop (JAK kinase) 4. Hop phosphorylates and activates Stat92E, which moves to the nucleus to activate transcription</p> <p>This is consistent with the literature on JAK-STAT signaling in Drosophila, as shown in the PMID:32917740 paper that describes this pathway in detail.</p>"},{"location":"reviews/60ad85f700000110-receptor_signaling_pathway_via_JAK_STAT_via_upd2_dome__D_mel_/#compliance-with-go-cam-guidelines","title":"Compliance with GO-CAM Guidelines","text":"<ol> <li>Molecular Functions and Context:</li> <li>Each protein has the correct molecular function assigned</li> <li>Each activity includes proper cellular context (occurs_in)</li> <li> <p>All activities are part of the same biological process (GO:0007259 - cell surface receptor signaling pathway via JAK-STAT)</p> </li> <li> <p>Causal Relations:</p> </li> <li>The model correctly uses RO:0002629 (directly positively regulates) for causal links between activities</li> <li> <p>The sequence Upd2 \u2192 Dome \u2192 Hop \u2192 Stat92E follows the correct signaling flow</p> </li> <li> <p>Evidence:</p> </li> <li>Each activity and causal relation is supported by evidence from published literature</li> <li>Multiple PMIDs are cited where appropriate (e.g., PMID:32917740, PMID:23885117, PMID:9032284)</li> <li>Evidence uses proper ECO codes (ECO:0000314 - direct assay evidence used in manual assertion)</li> </ol>"},{"location":"reviews/60ad85f700000110-receptor_signaling_pathway_via_JAK_STAT_via_upd2_dome__D_mel_/#specific-assessment-based-on-go-cam-best-practices","title":"Specific Assessment Based on GO-CAM Best Practices","text":"<p>Based on the \"Signaling receptor activity annotation guidelines\" document, this model adheres well to the recommended structure for signaling receptor pathways:</p> <ol> <li>Ligand Annotation:</li> <li>Upd2 is correctly annotated with \"cytokine activity\" (GO:0005125)</li> <li>It is properly placed in the extracellular region (GO:0005576)</li> <li> <p>The causal relation between Upd2 and Dome uses \"directly positively regulates\"</p> </li> <li> <p>Receptor Annotation:</p> </li> <li>Dome is correctly annotated with \"cytokine receptor activity\" (GO:0004896)</li> <li>It is properly placed at the apical plasma membrane (GO:0016324)</li> <li> <p>The relationship between Dome and its downstream target (Hop) uses \"directly positively regulates\"</p> </li> <li> <p>Downstream Signaling Components:</p> </li> <li>The JAK kinase (Hop) and transcription factor (Stat92E) components are properly represented</li> <li>Subcellular locations are accurate (cytoplasmic side for Hop, nucleus for Stat92E)</li> </ol>"},{"location":"reviews/60ad85f700000110-receptor_signaling_pathway_via_JAK_STAT_via_upd2_dome__D_mel_/#cellular-localization-accuracy","title":"Cellular Localization Accuracy","text":"<p>The subcellular locations in the model are accurate: - Upd2 in extracellular region (GO:0005576) - Dome at apical plasma membrane (GO:0016324) - Hop at cytoplasmic side of plasma membrane (GO:0009898) - Stat92E in nucleus (GO:0005634)</p> <p>These locations align with our understanding of the JAK-STAT pathway components and their functions.</p>"},{"location":"reviews/60ad85f700000110-receptor_signaling_pathway_via_JAK_STAT_via_upd2_dome__D_mel_/#suggested-improvements","title":"Suggested Improvements","text":"<p>While the model is generally well-constructed, I have a few minor suggestions for enhancement:</p> <ol> <li> <p>Additional Biological Context: The model could potentially include information about the specific biological processes regulated by this pathway in Drosophila, such as immune response, cell proliferation, or development.</p> </li> <li> <p>Pathway Regulation: The model might benefit from including negative regulators of the pathway, such as SOCS proteins (Suppressor of Cytokine Signaling), which provide negative feedback regulation of JAK-STAT signaling.</p> </li> <li> <p>Mechanistic Details: While not required, additional details about the phosphorylation events (particularly the phosphorylation of Stat92E at Tyr704 and Thr702 as identified in PMID:32917740) could strengthen the model.</p> </li> </ol>"},{"location":"reviews/60ad85f700000110-receptor_signaling_pathway_via_JAK_STAT_via_upd2_dome__D_mel_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model 60ad85f700000110 representing the JAK-STAT signaling pathway via Upd2-Dome in Drosophila melanogaster is biologically accurate, well-evidenced, and compliant with GO-CAM best practices for representing signaling pathways. The model effectively captures the core components and causal relationships of this important signaling cascade.</p> <p>The model meets all quality standards for a production-ready GO-CAM and provides a useful resource for researchers interested in JAK-STAT signaling in Drosophila.</p>"},{"location":"reviews/60ad85f700000189-BMP_signaling_pathway_via_dpp_tkv_put__D_mel_/","title":"60ad85f700000189 BMP signaling pathway via dpp tkv put  D mel","text":"<p>Now I have a better understanding of the guidelines. Let me analyze the GO-CAM model 60ad85f700000189 in detail to check if it follows all best practices:</p>"},{"location":"reviews/60ad85f700000189-BMP_signaling_pathway_via_dpp_tkv_put__D_mel_/#review-of-go-cam-model-gomodel60ad85f700000189","title":"Review of GO-CAM Model: gomodel:60ad85f700000189","text":""},{"location":"reviews/60ad85f700000189-BMP_signaling_pathway_via_dpp_tkv_put__D_mel_/#title-bmp-signaling-pathway-via-dpp-tkvput-dmel","title":"Title: \"BMP signaling pathway via dpp-tkv/put (D.mel)\"","text":""},{"location":"reviews/60ad85f700000189-BMP_signaling_pathway_via_dpp_tkv_put__D_mel_/#biological-overview","title":"Biological Overview:","text":"<p>This model represents the BMP (Bone Morphogenetic Protein) signaling pathway in Drosophila melanogaster, specifically through the dpp (decapentaplegic) ligand and tkv/put (thick veins/punt) receptors. </p>"},{"location":"reviews/60ad85f700000189-BMP_signaling_pathway_via_dpp_tkv_put__D_mel_/#model-components-analysis","title":"Model Components Analysis:","text":"<ol> <li>Ligand: dpp (FB:FBgn0000490)</li> <li>MF: Receptor ligand activity (GO:0048018) \u2713</li> <li>CC: Occurs in extracellular space (GO:0005615) \u2713</li> <li>BP: Part of BMP signaling pathway (GO:0030509) \u2713</li> <li> <p>Causal relation: Directly positively regulates (RO:0002629) the receptor activity of put \u2713</p> </li> <li> <p>Type II BMP Receptor: punt (FB:FBgn0003169)</p> </li> <li>MF: BMP receptor activity (GO:0098821) \u2713</li> <li>CC: Occurs in plasma membrane (GO:0005886) \u2713</li> <li>BP: Part of BMP signaling pathway (GO:0030509) \u2713</li> <li> <p>Causal relation: Directly positively regulates (RO:0002629) the receptor activity of tkv \u2713</p> </li> <li> <p>Type I BMP Receptor: thick veins (FB:FBgn0003716)</p> </li> <li>MF: BMP receptor activity (GO:0098821) \u2713</li> <li>CC: Occurs in plasma membrane (GO:0005886) \u2713</li> <li>BP: Part of BMP signaling pathway (GO:0030509) \u2713</li> <li> <p>Causal relation: Directly positively regulates (RO:0002629) Mad's co-SMAD binding activity \u2713</p> </li> <li> <p>SMAD transcription factor: Mad (FB:FBgn0011648)</p> </li> <li>MF1: co-SMAD binding (GO:0070410) \u2713</li> <li>CC1: Occurs in cytosol (GO:0005829) \u2713</li> <li>BP: Part of BMP signaling pathway (GO:0030509) \u2713</li> <li> <p>Causal relation: Directly positively regulates (RO:0002629) Med's DNA-binding transcription activator activity \u2713</p> </li> <li> <p>MF2: DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228) \u2713</p> </li> <li>CC2: Occurs in nucleus (GO:0005634) \u2713</li> <li> <p>BP: Part of BMP signaling pathway (GO:0030509) \u2713</p> </li> <li> <p>Co-SMAD: Medea (FB:FBgn0288966)</p> </li> <li>MF: DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228) \u2713</li> <li>CC: Occurs in nucleus (GO:0005634) \u2713</li> <li> <p>BP: Part of BMP signaling pathway (GO:0030509) \u2713</p> </li> <li> <p>Inhibitory SMAD: Daughters against dpp (FB:FBgn0020493)</p> </li> <li>MF: BMP receptor binding (GO:0070700) \u2713</li> <li>BP: Part of negative regulation of BMP signaling pathway (GO:0030514) \u2713</li> <li>Causal relation: Directly negatively regulates (RO:0002630) Mad's co-SMAD binding activity \u2713</li> </ol>"},{"location":"reviews/60ad85f700000189-BMP_signaling_pathway_via_dpp_tkv_put__D_mel_/#evaluation-against-go-cam-best-practices","title":"Evaluation against GO-CAM Best Practices:","text":"<ol> <li>Signaling Pathway Representation:</li> <li>The model correctly follows the guidelines for protein ligand-activated signaling receptors.</li> <li>The ligand (dpp) has receptor ligand activity and occurs in extracellular space.</li> <li>The signaling is properly propagated from ligand \u2192 type II receptor \u2192 type I receptor \u2192 SMAD proteins.</li> <li> <p>The correct causal relation \"directly positively regulates\" (RO:0002629) is used between components.</p> </li> <li> <p>Receptor-Ligand Interactions:</p> </li> <li>The model correctly shows dpp ligand directly positively regulating the put receptor.</li> <li>The receptor put then directly positively regulates the co-receptor tkv.</li> <li> <p>This follows the standard BMP pathway where type II receptors activate type I receptors.</p> </li> <li> <p>Cellular Locations:</p> </li> <li> <p>Appropriate cellular locations are annotated for each component:</p> <ul> <li>Ligand (dpp): extracellular space \u2713</li> <li>Receptors (put, tkv): plasma membrane \u2713</li> <li>Cytoplasmic SMAD (Mad with co-SMAD binding): cytosol \u2713</li> <li>Nuclear SMAD activities (Mad and Med transcription activities): nucleus \u2713</li> </ul> </li> <li> <p>Negative Regulation:</p> </li> <li>The model includes Dad as an inhibitory SMAD correctly using \"directly negatively regulates\" (RO:0002630).</li> <li> <p>Dad is correctly annotated as being part of negative regulation of BMP signaling pathway.</p> </li> <li> <p>Molecular Function Annotations:</p> </li> <li> <p>All proteins have appropriate molecular functions:</p> <ul> <li>dpp: receptor ligand activity</li> <li>put/tkv: BMP receptor activity</li> <li>Mad: co-SMAD binding and DNA-binding transcription activator activity</li> <li>Med: DNA-binding transcription activator activity</li> <li>Dad: BMP receptor binding</li> </ul> </li> <li> <p>Evidence Codes:</p> </li> <li>All assertions in the model are supported by appropriate evidence codes and PMIDs.</li> <li>The model uses a mix of ECO:0000314 (direct assay), ECO:0000315 (mutant phenotype), ECO:0000353 (physical interaction), and ECO:0000304 (author statement) evidence codes, which is appropriate for different types of assertions.</li> </ol>"},{"location":"reviews/60ad85f700000189-BMP_signaling_pathway_via_dpp_tkv_put__D_mel_/#recommendations-for-improvement","title":"Recommendations for Improvement:","text":"<ol> <li> <p>Input Relations: While the causal relations are defined, the model does not explicitly show \"has input\" relations for some activities. For example, it would be helpful to clarify what Mad's DNA-binding transcription activator activity has as input (likely specific DNA sequences).</p> </li> <li> <p>Medea's Interactions: The model shows Mad directly positively regulating Medea's transcription factor activity, but it might be more complete to also represent any physical interaction between Mad and Medea since they likely form a complex to regulate transcription.</p> </li> <li> <p>Pathway Completeness: Consider adding the downstream genes that are regulated by the Mad/Medea transcription factor complex to make the pathway more complete.</p> </li> <li> <p>Specificity of Annotation: For the DNA-binding transcription activator activities, it might be useful to note which specific genes are regulated if known.</p> </li> </ol>"},{"location":"reviews/60ad85f700000189-BMP_signaling_pathway_via_dpp_tkv_put__D_mel_/#conclusion","title":"Conclusion:","text":"<p>This GO-CAM model (60ad85f700000189) correctly represents the BMP signaling pathway in Drosophila melanogaster, following the GO-CAM best practices for signaling receptor pathways. The model accurately depicts the flow of activity from the extracellular ligand through plasma membrane receptors to intracellular signaling components, with appropriate molecular functions, cellular locations, and causal relations.</p> <p>The model is biologically accurate, showing: 1. The sequential activation of type II and type I BMP receptors 2. The activation of SMAD transcription factors 3. The negative regulation by inhibitory SMADs</p> <p>All components have appropriate evidence codes and literature references. The model is parsimonious while still effectively capturing the key elements of BMP signaling in Drosophila. There are a few minor areas where the model could be expanded for greater completeness, but overall it is a well-constructed representation of the pathway.</p>"},{"location":"reviews/60ad85f700000259-activin_receptor_signaling_pathway_via_Actbeta_babo_put__D_mel_/","title":"60ad85f700000259 activin receptor signaling pathway via Actbeta babo put  D mel","text":"<p>Based on my research and review of the GO-CAM model gomodel:60ad85f700000259, titled \"activin receptor signaling pathway via Actbeta-babo/put (D.mel)\", I will now provide a comprehensive review of this model.</p>"},{"location":"reviews/60ad85f700000259-activin_receptor_signaling_pathway_via_Actbeta_babo_put__D_mel_/#review-of-go-cam-model-gomodel60ad85f700000259","title":"Review of GO-CAM Model: gomodel:60ad85f700000259","text":""},{"location":"reviews/60ad85f700000259-activin_receptor_signaling_pathway_via_Actbeta_babo_put__D_mel_/#overview","title":"Overview","text":"<p>This GO-CAM model represents the activin receptor signaling pathway in Drosophila melanogaster, specifically focusing on the pathway where Activin-beta (Actbeta) signals through the Baboon (Babo) type I receptor and Punt (Put) type II receptor. The model captures the signaling cascade from the ligand (Actbeta) to downstream transcriptional activators.</p>"},{"location":"reviews/60ad85f700000259-activin_receptor_signaling_pathway_via_Actbeta_babo_put__D_mel_/#model-structure-and-components","title":"Model Structure and Components","text":"<p>The model includes the following key components:</p> <ol> <li> <p>Actbeta (FBgn0024913) - The ligand that initiates the signaling pathway, with cytokine activity (GO:0005125) occurring in the extracellular space (GO:0005615).</p> </li> <li> <p>Punt (FBgn0003169) - A type II receptor with activin receptor activity (GO:0017002).</p> </li> <li> <p>Baboon (FBgn0011300) - A type I receptor with activin receptor activity (GO:0017002) occurring in the plasma membrane (GO:0005886).</p> </li> <li> <p>Smox (FBgn0025800) - The Drosophila homolog of Smad2, with co-SMAD binding activity (GO:0070410) and DNA-binding transcription factor activity (GO:0000981) occurring in the nucleus (GO:0005634).</p> </li> <li> <p>Medea (FBgn0288966) - The R-Smad transcription activator with DNA-binding transcription activator activity (GO:0001228) occurring in the nucleus (GO:0005634).</p> </li> </ol> <p>The model shows causal connections between these components that depict the flow of the activin signaling pathway, with the \"directly positively regulates\" (RO:0002629) relationship connecting the activities in a cascade.</p>"},{"location":"reviews/60ad85f700000259-activin_receptor_signaling_pathway_via_Actbeta_babo_put__D_mel_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Pathway Completeness: The model captures the essential components of the Drosophila activin signaling pathway from ligand to transcriptional activator.</p> </li> <li> <p>Proper Evidence Codes: Each activity and relationship has appropriate evidence codes (ECO terms) and references to scientific literature.</p> </li> <li> <p>Correct Subcellular Localization: The components have appropriate cellular compartment annotations (extracellular space for ligand, plasma membrane for receptors, nucleus for transcription factors).</p> </li> <li> <p>Causal Relationships: The model properly uses the \"directly positively regulates\" predicate to connect the components of the pathway in the correct order.</p> </li> <li> <p>Biological Accuracy: The pathway represented is consistent with the scientific literature on activin signaling in Drosophila.</p> </li> </ol>"},{"location":"reviews/60ad85f700000259-activin_receptor_signaling_pathway_via_Actbeta_babo_put__D_mel_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Complex Representation: The model could be improved by explicitly representing the receptor complex formation between Baboon and Punt. Based on the \"How to annotate complexes in GO-CAM\" document, when the activity is shared by two proteins (as in heterodimeric receptors), both proteins should be shown.</p> </li> <li> <p>Smad Activation Details: The phosphorylation of Smox by the activated receptor complex is implied but not explicitly captured. Additional detail about this activation step would strengthen the model.</p> </li> <li> <p>Smad Nuclear Translocation: While the model shows Smox in the nucleus, the process of nuclear translocation after phosphorylation is not explicitly captured.</p> </li> <li> <p>Target Gene Regulation: The model shows Medea as a downstream effector but does not include specific target genes that are regulated by the Smox-Medea complex.</p> </li> <li> <p>Cellular Context: The model doesn't specify the cell type or developmental context in which this signaling occurs, though this information might be outside the scope of this particular model.</p> </li> </ol>"},{"location":"reviews/60ad85f700000259-activin_receptor_signaling_pathway_via_Actbeta_babo_put__D_mel_/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model accurately represents the activin signaling pathway as described in the literature for Drosophila. Key findings from the literature supporting this model include:</p> <ol> <li> <p>The paper by Brummel et al. (1999) established that Baboon signals through dSmad2 (Smox) and controls cell proliferation during Drosophila larval development.</p> </li> <li> <p>Upadhyay et al. (2017) described how the activin pathway in Drosophila uses the type I receptor Baboon and either of the type II receptors Punt or Wishful thinking.</p> </li> <li> <p>The phosphorylated R-Smad (Smox) forms a complex with the co-Smad (Medea) before translocating to the nucleus to regulate transcriptional responses.</p> </li> </ol>"},{"location":"reviews/60ad85f700000259-activin_receptor_signaling_pathway_via_Actbeta_babo_put__D_mel_/#suggestions-for-enhancement","title":"Suggestions for Enhancement","text":"<ol> <li> <p>Add Receptor Complex Formation: Explicitly represent the Baboon-Punt receptor complex formation upon Actbeta binding.</p> </li> <li> <p>Include Phosphorylation Step: Add the phosphorylation of Smox by the activated receptor complex.</p> </li> <li> <p>Add Nuclear Translocation: Include the translocation of phosphorylated Smox-Medea complex from cytoplasm to nucleus.</p> </li> <li> <p>Add Specific Target Genes: If known, include specific target genes regulated by the Smox-Medea complex.</p> </li> <li> <p>Include Cross-Pathway Interactions: If applicable, add interactions with other signaling pathways that have been shown to modulate activin signaling in Drosophila.</p> </li> </ol>"},{"location":"reviews/60ad85f700000259-activin_receptor_signaling_pathway_via_Actbeta_babo_put__D_mel_/#summary","title":"Summary","text":"<p>Overall, this GO-CAM model (gomodel:60ad85f700000259) provides a good representation of the activin receptor signaling pathway in Drosophila melanogaster. The model captures the key components of the pathway from ligand to transcriptional activator and properly represents the causal relationships between them. With some enhancements to represent complex formation and additional mechanistic details, the model could provide an even more comprehensive representation of this signaling pathway.</p>"},{"location":"reviews/60ad85f700000309-Notch_signaling_pathway_via_N_Dl__D_mel_/","title":"60ad85f700000309 Notch signaling pathway via N Dl  D mel","text":"<p>Based on all the information I've gathered, I'll now review the GO-CAM model 60ad85f700000309.</p>"},{"location":"reviews/60ad85f700000309-Notch_signaling_pathway_via_N_Dl__D_mel_/#review-of-go-cam-model-gomodel60ad85f700000309-notch-signaling-pathway-via-n-dl-in-d-melanogaster","title":"Review of GO-CAM Model: gomodel:60ad85f700000309 (Notch signaling pathway via N-Dl in D. melanogaster)","text":""},{"location":"reviews/60ad85f700000309-Notch_signaling_pathway_via_N_Dl__D_mel_/#model-summary","title":"Model Summary","text":"<p>This model (available at https://bioregistry.io/go.model:60ad85f700000309) depicts the Notch signaling pathway in Drosophila melanogaster, focusing on the interaction between Notch receptor (N) and its ligand Delta (Dl), and the subsequent signaling cascade. The model was last edited in 2023 and has a \"production\" status.</p>"},{"location":"reviews/60ad85f700000309-Notch_signaling_pathway_via_N_Dl__D_mel_/#model-components","title":"Model Components","text":"<p>The model consists of five key activities:</p> <ol> <li>Delta (FB:FBgn0000463) - Acts as a receptor ligand (GO:0048018) at the membrane (GO:0016020)</li> <li>Notch (FB:FBgn0004647) - Functions as a transmembrane signaling receptor (GO:0004888) in the plasma membrane (GO:0005886)</li> <li>Kuzbanian/Kuz (FB:FBgn0259984) - Performs metalloendopeptidase activity (GO:0004222)</li> <li>Presenilin/Psn (FB:FBgn0284421) - Exhibits endopeptidase activity (GO:0004175) at the cell surface (GO:0009986)</li> <li>Notch again (FB:FBgn0004647) - Functions as a transcription coactivator (GO:0003713) in the nucleus (GO:0005634)</li> </ol>"},{"location":"reviews/60ad85f700000309-Notch_signaling_pathway_via_N_Dl__D_mel_/#causal-flow","title":"Causal Flow","text":"<p>The model accurately depicts the canonical Notch signaling pathway: 1. Delta (ligand) directly positively regulates (RO:0002629) Notch (receptor) 2. Notch (receptor) directly positively regulates (RO:0002629) Kuzbanian 3. Kuzbanian directly positively regulates (RO:0002629) Presenilin 4. Presenilin directly positively regulates (RO:0002629) Notch (nuclear transcription coactivator)</p>"},{"location":"reviews/60ad85f700000309-Notch_signaling_pathway_via_N_Dl__D_mel_/#evidence-and-references","title":"Evidence and References","text":"<p>The model uses appropriate evidence codes with all activities supported by direct experimental evidence (ECO:0000314) from published literature. Key references include: - PMID:15611340 (referenced multiple times for Delta-Notch interaction) - PMID:9244301 (for Kuzbanian's role) - PMID:11390662 (for transcription coactivator activity) - PMID:17545467 (for pathway involvement)</p>"},{"location":"reviews/60ad85f700000309-Notch_signaling_pathway_via_N_Dl__D_mel_/#quality-assessment","title":"Quality Assessment","text":""},{"location":"reviews/60ad85f700000309-Notch_signaling_pathway_via_N_Dl__D_mel_/#strengths","title":"Strengths:","text":"<ol> <li>Well-supported by evidence: Each activity and causal relationship is backed by peer-reviewed publications.</li> <li>Correct cellular context: The model correctly places proteins in their appropriate cellular locations (membrane, cell surface, nucleus).</li> <li>Complete signaling cascade: The model includes all key steps of Notch signaling from ligand binding to nuclear translocation.</li> <li>Proper causal relations: Uses RO:0002629 (directly positively regulates) consistently and appropriately.</li> </ol>"},{"location":"reviews/60ad85f700000309-Notch_signaling_pathway_via_N_Dl__D_mel_/#suggestions-for-improvement","title":"Suggestions for improvement:","text":"<ol> <li> <p>Specify proteolytic cleavage sites: The model could be more explicit about the different proteolytic processing events. According to the literature, Kuzbanian (an ADAM metalloprotease) performs S2 cleavage of Notch, while Presenilin (part of the \u03b3-secretase complex) performs S3 cleavage. These distinct roles could be better specified.</p> </li> <li> <p>Include additional molecular components: The model could include:</p> </li> <li>The full \u03b3-secretase complex (of which Presenilin is a part)</li> <li>Downstream transcriptional targets of activated Notch (like E(spl) genes)</li> <li> <p>Su(H) (Suppressor of Hairless), which forms a complex with the Notch intracellular domain</p> </li> <li> <p>Additional contextual information: The GO:0005575 (cellular component) term used for Kuzbanian is a root term indicating \"cellular component\". This could be made more specific based on literature showing Kuzbanian's localization.</p> </li> <li> <p>Expand biological context: The model could indicate that this represents lateral inhibition, a key process during neurogenesis in Drosophila.</p> </li> </ol>"},{"location":"reviews/60ad85f700000309-Notch_signaling_pathway_via_N_Dl__D_mel_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a high-quality GO-CAM model that accurately represents the core Notch signaling pathway in Drosophila melanogaster. The model follows best practices for signaling receptor annotation as outlined in the \"Signaling receptor activity annotation guidelines\". It correctly captures the sequential proteolytic processing of Notch by Kuzbanian and Presenilin, leading to the release of the Notch intracellular domain and its function as a transcription coactivator in the nucleus.</p> <p>The model is biologically accurate, well-supported by evidence, and demonstrates a clear causal flow using appropriate relations. With minor enhancements to cellular localization information and additional downstream components, this model could serve as an excellent reference for the Notch signaling pathway.</p>"},{"location":"reviews/60ad85f700000612-TRIM47_activity_on_ILF3/","title":"60ad85f700000612 TRIM47 activity on ILF3","text":"<p>Based on my review of all the provided information, I'll now provide a comprehensive assessment of the GO-CAM model 60ad85f700000612 titled \"TRIM47-activity-on-ILF3\".</p>"},{"location":"reviews/60ad85f700000612-TRIM47_activity_on_ILF3/#review-of-go-cam-model-gomodel60ad85f700000612","title":"Review of GO-CAM Model: gomodel:60ad85f700000612","text":""},{"location":"reviews/60ad85f700000612-TRIM47_activity_on_ILF3/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (gomodel:60ad85f700000612) titled \"TRIM47-activity-on-ILF3\" depicts a molecular pathway involving four proteins:</p> <ol> <li>HAVCR2/Tim-3 (UniProtKB:Q8TDQ0) - Hepatitis A virus cellular receptor 2 (also known as T-cell immunoglobulin and mucin domain-containing protein 3)</li> <li>TRIM47 (UniProtKB:Q96LD4) - E3 ubiquitin-protein ligase TRIM47</li> <li>ILF3/NF90 (UniProtKB:Q12906) - Interleukin enhancer-binding factor 3 (also known as Nuclear factor associated with dsRNA)</li> <li>EIF2AK2/PKR (UniProtKB:P19525) - Interferon-induced, double-stranded RNA-activated protein kinase</li> </ol> <p>The model presents a causal chain where: - HAVCR2/Tim-3 binds to protein (GO:0005515) and directly positively regulates (RO:0002629) the ubiquitin protein ligase activity (GO:0061630) of TRIM47 - TRIM47 then directly negatively regulates (RO:0002630) the virus receptor activity (GO:0001618) of ILF3/NF90 - EIF2AK2/PKR has kinase activity (GO:0016301) in the cytoplasm (GO:0005737) and directly positively regulates (RO:0002629) the virus receptor activity of ILF3/NF90</p>"},{"location":"reviews/60ad85f700000612-TRIM47_activity_on_ILF3/#model-quality-assessment","title":"Model Quality Assessment","text":""},{"location":"reviews/60ad85f700000612-TRIM47_activity_on_ILF3/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the molecular mechanism described in the literature (primarily PMID:34110282), where Tim-3 promotes the ubiquitination and degradation of NF90 (ILF3) by recruiting the E3 ubiquitin ligase TRIM47. This interaction inhibits antiviral innate immunity by targeting a key viral sensor, NF90.</p> <p>The evidence used is appropriate, with all assertions backed by experimental evidence (ECO:0000314) from PMID:34110282 for the HAVCR2-TRIM47-ILF3 pathway, and PMID:21123651 for the EIF2AK2-ILF3 pathway.</p>"},{"location":"reviews/60ad85f700000612-TRIM47_activity_on_ILF3/#go-cam-best-practices","title":"GO-CAM Best Practices","text":""},{"location":"reviews/60ad85f700000612-TRIM47_activity_on_ILF3/#entity-representation","title":"Entity Representation:","text":"<ul> <li>The entities are correctly represented with appropriate UniProtKB identifiers.</li> <li>Each activity is properly enabled by the correct gene product.</li> </ul>"},{"location":"reviews/60ad85f700000612-TRIM47_activity_on_ILF3/#molecular-function-annotation","title":"Molecular Function Annotation:","text":"<ul> <li>Appropriate molecular functions are used for each protein:</li> <li>HAVCR2/Tim-3: protein binding (GO:0005515)</li> <li>TRIM47: ubiquitin protein ligase activity (GO:0061630)</li> <li>ILF3/NF90: virus receptor activity (GO:0001618)</li> <li>EIF2AK2/PKR: kinase activity (GO:0016301)</li> </ul>"},{"location":"reviews/60ad85f700000612-TRIM47_activity_on_ILF3/#causal-relations","title":"Causal Relations:","text":"<ul> <li>The causal relationships use the correct relation ontology (RO) terms:</li> <li>RO:0002629 (directly positively regulates) for HAVCR2\u2192TRIM47 and EIF2AK2\u2192ILF3</li> <li>RO:0002630 (directly negatively regulates) for TRIM47\u2192ILF3</li> </ul>"},{"location":"reviews/60ad85f700000612-TRIM47_activity_on_ILF3/#cellular-context","title":"Cellular Context:","text":"<ul> <li>EIF2AK2/PKR is correctly annotated as occurring in the cytoplasm (GO:0005737).</li> <li>The model could be improved by also specifying the cellular locations for the other proteins, especially since the literature discusses cytoplasmic localization of ILF3 during viral infection.</li> </ul>"},{"location":"reviews/60ad85f700000612-TRIM47_activity_on_ILF3/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li>Missing Cellular Context: </li> <li>Location information for HAVCR2, TRIM47, and ILF3 should be added to provide complete cellular context.</li> <li> <p>According to the literature, ILF3 accumulates in the cytoplasm during viral infection, which is relevant to the model.</p> </li> <li> <p>Incomplete Molecular Mechanism Details:</p> </li> <li>The model could be enhanced by including the specific ubiquitination site (Lys-297) on ILF3 mentioned in the literature.</li> <li> <p>The phosphorylation of ILF3 at Thr-188 and Thr-315 by PKR is an important regulatory mechanism that could be explicitly represented.</p> </li> <li> <p>Complex Representation:</p> </li> <li> <p>According to the GO-CAM complex annotation guidelines, the model correctly shows each protein with its specific activity rather than using complex IDs, since the activities of individual components are known.</p> </li> <li> <p>Conflicting Regulation:</p> </li> <li> <p>The model shows both positive regulation (by EIF2AK2/PKR) and negative regulation (by TRIM47) of ILF3 virus receptor activity. While this reflects the literature, it might be helpful to clarify that these represent competing regulatory mechanisms that operate under different conditions (viral infection vs. immune evasion).</p> </li> <li> <p>Evidence Code Usage:</p> </li> <li>All assertions use ECO:0000314 (direct assay evidence used in manual assertion) which is appropriate given the experimental nature of the evidence.</li> </ol>"},{"location":"reviews/60ad85f700000612-TRIM47_activity_on_ILF3/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model provides a good representation of the pathway described in the literature, particularly capturing the role of Tim-3 in promoting TRIM47-mediated ubiquitination and degradation of ILF3/NF90, which inhibits antiviral immunity. The model also correctly represents the opposing regulatory effect of PKR on ILF3.</p>"},{"location":"reviews/60ad85f700000612-TRIM47_activity_on_ILF3/#recommended-improvements","title":"Recommended Improvements:","text":"<ol> <li>Add cellular location information for all proteins.</li> <li>Consider adding specific details about the ubiquitination site (Lys-297) on ILF3.</li> <li>Include the phosphorylation of ILF3 by PKR as part of the regulatory mechanism.</li> <li>Provide additional context about how these opposing regulatory mechanisms (ubiquitination vs. phosphorylation of ILF3) are balanced during viral infection.</li> </ol> <p>Overall, the model is accurate and consistent with the literature, but these additions would enhance its completeness and utility for understanding this important immunoregulatory pathway.</p>"},{"location":"reviews/60ad85f700001873-epidermal_growth_factor_receptor_signaling_pathway_via_spi_Egfr__D_mel_/","title":"60ad85f700001873 epidermal growth factor receptor signaling pathway via spi Egfr  D mel","text":"<p>Based on my review of the GO-CAM model and the relevant guidelines, here is my evaluation:</p>"},{"location":"reviews/60ad85f700001873-epidermal_growth_factor_receptor_signaling_pathway_via_spi_Egfr__D_mel_/#review-of-go-cam-model-gomodel60ad85f700001873","title":"Review of GO-CAM Model: gomodel:60ad85f700001873","text":""},{"location":"reviews/60ad85f700001873-epidermal_growth_factor_receptor_signaling_pathway_via_spi_Egfr__D_mel_/#model-overview","title":"Model Overview","text":"<p>This model represents the epidermal growth factor receptor (EGFR) signaling pathway in Drosophila melanogaster (fruit fly). The model follows the classic EGFR signaling cascade from ligand binding through the Ras/MAPK pathway to transcriptional regulation.</p>"},{"location":"reviews/60ad85f700001873-epidermal_growth_factor_receptor_signaling_pathway_via_spi_Egfr__D_mel_/#strengths","title":"Strengths","text":"<ol> <li> <p>Pathway Completeness: The model captures the full signaling cascade from ligand (Spi) to transcriptional regulation, including both activating (Pnt) and repressing (Aop, Cic, Gro) transcription factors.</p> </li> <li> <p>Cellular Localization: Appropriate cellular compartments are specified for each protein activity (e.g., extracellular space for ligand, plasma membrane for receptor, cytoplasm for adaptors, nucleus for transcription factors).</p> </li> <li> <p>Evidence Base: Each activity and causal relation is supported by appropriate evidence codes and literature citations, primarily using direct assay evidence (ECO:0000314).</p> </li> <li> <p>Causal Relations: The model correctly uses \"directly positively regulates\" (RO:0002629) for activation relationships and \"directly negatively regulates\" (RO:0002630) for inhibitory relationships.</p> </li> </ol>"},{"location":"reviews/60ad85f700001873-epidermal_growth_factor_receptor_signaling_pathway_via_spi_Egfr__D_mel_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Receptor-Ligand Relation: According to the signaling receptor guidelines, the relation between the Spi ligand activity and EGFR receptor activity should be captured with \"directly positively regulates\" (RO:0002629), which is properly implemented in this model.</p> </li> <li> <p>Missing Input Relations: While causal relationships between activities are well-captured, some \"has input\" relations might be missing according to the signaling receptor guidelines. For example, the receptor (Egfr) should have adaptor proteins (Drk, Shc, Csw) as inputs, but these aren't explicitly modeled with \"has input\" relations.</p> </li> <li> <p>Complex Representation: No protein complexes are represented in the model. If any of the signaling events involve stable complexes (e.g., adaptor protein complexes), these could be explicitly modeled following the complex annotation guidelines.</p> </li> <li> <p>Additional Context: While the model is comprehensive, it could potentially benefit from contextual information about when and where this signaling pathway operates in Drosophila development.</p> </li> </ol>"},{"location":"reviews/60ad85f700001873-epidermal_growth_factor_receptor_signaling_pathway_via_spi_Egfr__D_mel_/#technical-issues","title":"Technical Issues","text":"<ol> <li> <p>Automated Changes: The model has undergone several automated predicate replacements (noted in the comments), but these appear to be appropriate updates to standardize the relations used.</p> </li> <li> <p>Predicate Consistency: The model consistently uses RO:0002629 (directly positively regulates) and RO:0002630 (directly negatively regulates) throughout, which aligns with current GO-CAM standards.</p> </li> </ol>"},{"location":"reviews/60ad85f700001873-epidermal_growth_factor_receptor_signaling_pathway_via_spi_Egfr__D_mel_/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model accurately represents the canonical EGFR signaling pathway in Drosophila based on published literature. The pathway flow from: - Spi ligand \u2192 EGFR \u2192 Adaptors (Drk, Shc, Csw) \u2192 Sos (GEF) \u2192 Ras \u2192 Raf \u2192 Dsor1 \u2192 Rolled (MAPK) \u2192 Transcription factors</p> <p>is consistent with the known biology of this pathway.</p>"},{"location":"reviews/60ad85f700001873-epidermal_growth_factor_receptor_signaling_pathway_via_spi_Egfr__D_mel_/#overall-assessment","title":"Overall Assessment","text":"<p>This is a well-constructed GO-CAM model that accurately represents the EGFR signaling pathway in Drosophila melanogaster. It follows GO-CAM best practices for signaling pathway representation and is supported by appropriate evidence. The model is biologically accurate and provides a clear representation of the causal relationships in the pathway.</p> <p>The model may benefit from minor enhancements regarding explicit \"has input\" relations and possibly more contextual information, but these are not critical issues affecting the model's overall quality or accuracy.</p> <p>I recommend approving this model as it stands, with consideration for the minor enhancements suggested above in future revisions.</p>"},{"location":"reviews/60ad85f700002694-_de_novo__AMP_biosynthetic_process__Mouse_/","title":"60ad85f700002694  de novo  AMP biosynthetic process  Mouse","text":"<p>Based on my review of the model and the relevant literature, I'll now provide a comprehensive assessment of GO-CAM model 60ad85f700002694, titled \"'de novo' AMP biosynthetic process (Mouse)\".</p>"},{"location":"reviews/60ad85f700002694-_de_novo__AMP_biosynthetic_process__Mouse_/#go-cam-model-review-gomodel60ad85f700002694","title":"GO-CAM Model Review: gomodel:60ad85f700002694","text":""},{"location":"reviews/60ad85f700002694-_de_novo__AMP_biosynthetic_process__Mouse_/#summary","title":"Summary","text":"<p>This GO-CAM model represents the mouse 'de novo' AMP biosynthetic pathway, which consists of a series of sequential enzymatic reactions leading to the synthesis of AMP. The model appears to be derived from a human pathway (gomodel:R-HSA-73817) and adapted for mouse genes.</p>"},{"location":"reviews/60ad85f700002694-_de_novo__AMP_biosynthetic_process__Mouse_/#strengths","title":"Strengths","text":"<ol> <li> <p>Complete pathway representation: The model effectively captures the entire 'de novo' AMP biosynthetic process, with all key enzymatic steps properly represented.</p> </li> <li> <p>Well-supported annotations: Most activity associations are backed by appropriate evidence codes and literature references.</p> </li> <li> <p>Correct use of causal relationships: The model appropriately uses the RO:0002413 (\"provides input for\") relationship to connect sequential activities in the pathway.</p> </li> <li> <p>Proper cellular location annotation: For several activities (e.g., GART's activities), the cellular location is specified as cytosol (GO:0005829), which is accurate.</p> </li> <li> <p>Detailed molecular functions: Each enzyme's specific molecular function is accurately captured.</p> </li> </ol>"},{"location":"reviews/60ad85f700002694-_de_novo__AMP_biosynthetic_process__Mouse_/#issues-and-recommendations","title":"Issues and Recommendations","text":""},{"location":"reviews/60ad85f700002694-_de_novo__AMP_biosynthetic_process__Mouse_/#1-missing-organisms-for-evidence","title":"1. Missing Organisms for Evidence","text":"<p>Several evidence annotations use human UniProt IDs in the \"with\" field (e.g., UniProtKB:P22102) while the model represents mouse proteins. Though orthology evidence is appropriately marked with ECO:0000266, the model would benefit from consistently using mouse-specific evidence where available.</p> <p>Recommendation: When using human protein evidence, ensure the orthology is well-established and consider adding mouse-specific references where possible.</p>"},{"location":"reviews/60ad85f700002694-_de_novo__AMP_biosynthetic_process__Mouse_/#2-missing-cellular-locations","title":"2. Missing Cellular Locations","text":"<p>While some activities have specified cellular locations (GO:0005829 - cytosol), others lack this annotation. For consistency, all activities should have their cellular locations specified.</p> <p>Recommendation: Add cellular location annotations to all activities in the model.</p>"},{"location":"reviews/60ad85f700002694-_de_novo__AMP_biosynthetic_process__Mouse_/#3-isolated-terminal-activity","title":"3. Isolated Terminal Activity","text":"<p>The final activity in the pathway (gomodel:60ad85f700002694/60ad85f700002729, adenylosuccinate lyase activity) appears as a terminal node without any outgoing causal connections. This creates an incomplete representation of the pathway's outcome.</p> <p>Recommendation: Connect this final activity to the appropriate biological process or consider adding the final product formation.</p>"},{"location":"reviews/60ad85f700002694-_de_novo__AMP_biosynthetic_process__Mouse_/#4-potential-protein-complex-representation","title":"4. Potential Protein Complex Representation","text":"<p>Based on the GO-CAM best practices for representing complexes, the model correctly represents individual enzymes with their specific activities. However, it's worth noting that some of these enzymes (like GART) are multifunctional and contain multiple domains with different catalytic activities. The model correctly represents this by showing different activities enabled by the same gene product.</p> <p>Recommendation: The model follows best practices for representing individual protein functions. No changes needed.</p>"},{"location":"reviews/60ad85f700002694-_de_novo__AMP_biosynthetic_process__Mouse_/#5-evidence-usage-consistency","title":"5. Evidence Usage Consistency","text":"<p>There are some inconsistencies in evidence code usage. For instance, some activities use ECO:0000314 (direct assay) while others use ECO:0000266 (sequence orthology) or ECO:0000315 (mutant phenotype).</p> <p>Recommendation: Ensure evidence codes are applied consistently and appropriately based on the available experimental data.</p>"},{"location":"reviews/60ad85f700002694-_de_novo__AMP_biosynthetic_process__Mouse_/#pathway-accuracy-assessment","title":"Pathway Accuracy Assessment","text":"<p>The model accurately represents the 'de novo' AMP biosynthetic pathway as described in the literature. Key enzymes involved are:</p> <ol> <li>PPAT (Phosphoribosyl pyrophosphate amidotransferase) - Initiates the pathway</li> <li>GART (Trifunctional enzyme) - Catalyzes three steps in the pathway</li> <li>PFAS (Phosphoribosylformylglycinamidine synthase)</li> <li>PAICS (Bifunctional enzyme)</li> <li>ADSL (Adenylosuccinate lyase)</li> <li>ATIC (Bifunctional enzyme)</li> <li>ADSS2 (Adenylosuccinate synthase)</li> </ol> <p>The causal flow between activities follows the established reaction sequence in the pathway, with each enzyme's product serving as the substrate for the next enzyme in the pathway.</p>"},{"location":"reviews/60ad85f700002694-_de_novo__AMP_biosynthetic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model 60ad85f700002694 is a high-quality representation of the mouse 'de novo' AMP biosynthetic pathway. It accurately captures the enzymatic steps, molecular functions, and causal relationships involved in this process. With minor improvements to cellular location annotations and ensuring complete connectivity for terminal activities, this model would serve as an excellent reference resource for researchers studying purine biosynthesis in mice.</p> <p>The model is consistent with the literature regarding the 'de novo' purine biosynthetic pathway and follows GO-CAM best practices for representing enzymatic pathways and protein activities.</p>"},{"location":"reviews/60ad85f700002947-_de_novo__IMP_biosynthetic_process__Mouse_/","title":"60ad85f700002947  de novo  IMP biosynthetic process  Mouse","text":"<p>After reviewing the GO-CAM model and related information, I'm now ready to provide a comprehensive review.</p>"},{"location":"reviews/60ad85f700002947-_de_novo__IMP_biosynthetic_process__Mouse_/#review-of-go-cam-model-60ad85f700002947","title":"Review of GO-CAM Model: 60ad85f700002947","text":""},{"location":"reviews/60ad85f700002947-_de_novo__IMP_biosynthetic_process__Mouse_/#overview","title":"Overview","text":"<p>This model titled \"'de novo' IMP biosynthetic process (Mouse)\" represents the de novo purine biosynthesis pathway in mouse (NCBITaxon:10090). The model focuses specifically on the pathway leading to the synthesis of inosine monophosphate (IMP), which is a key intermediate in purine nucleotide biosynthesis.</p>"},{"location":"reviews/60ad85f700002947-_de_novo__IMP_biosynthetic_process__Mouse_/#model-structure-and-content","title":"Model Structure and Content","text":"<p>The model consists of 8 activities connected in a linear pathway, each representing a step in the de novo IMP biosynthetic process (GO:0006189). All activities are appropriately connected using the causal relationship predicate \"provides input for\" (RO:0002413), which correctly indicates the sequential steps in this metabolic pathway.</p> <p>The activities in the model include: 1. Amidophosphoribosyltransferase activity (GO:0004044) - enabled by Ppat (MGI:MGI:2387203) 2. Phosphoribosylamine-glycine ligase activity (GO:0004637) - enabled by Gart (MGI:MGI:95654) 3. Phosphoribosylglycinamide formyltransferase activity (GO:0004644) - enabled by Gart (MGI:MGI:95654) 4. Phosphoribosylformylglycinamidine synthase activity (GO:0004642) - enabled by Pfas (MGI:MGI:2684864) 5. Phosphoribosylformylglycinamidine cyclo-ligase activity (GO:0004641) - enabled by Gart (MGI:MGI:95654) 6. Phosphoribosylaminoimidazolecarboxamide synthase activity (GO:0004639) - enabled by Paics (MGI:MGI:1914304) 7. (S)-2-(5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamido) succinate lyase activity (GO:0070626) - enabled by Adsl (MGI:MGI:103202) 8. Phosphoribosylaminoimidazolecarboxamide formyltransferase activity (GO:0004643) and IMP cyclohydrolase activity (GO:0003937) - both enabled by Atic (MGI:MGI:1351352)</p>"},{"location":"reviews/60ad85f700002947-_de_novo__IMP_biosynthetic_process__Mouse_/#evidence-and-annotations","title":"Evidence and Annotations","text":"<p>The model includes appropriate evidence codes for each activity: - ECO:0000314 (direct assay evidence used in manual assertion) - ECO:0000315 (mutant phenotype evidence used in manual assertion) - ECO:0000266 (sequence orthology evidence used in manual assertion)</p> <p>All annotations are supported by PMIDs, which is good practice. The model references both mouse-specific studies and human ortholog evidence where appropriate.</p>"},{"location":"reviews/60ad85f700002947-_de_novo__IMP_biosynthetic_process__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Biological Accuracy: The model accurately represents the de novo purine biosynthesis pathway, with each step correctly ordered and assigned to the appropriate gene products.</p> </li> <li> <p>Comprehensive Representation: All major steps in the pathway from PRPP to IMP are represented.</p> </li> <li> <p>Appropriate Use of GO-CAM Conventions: The model uses the correct causal relationships between activities and properly annotates each activity with its cellular location when known (e.g., GO:0005829/cytosol for some activities).</p> </li> <li> <p>Evidence: Each activity is supported by appropriate evidence codes and literature references.</p> </li> <li> <p>Orthology Evidence: Where direct mouse evidence might be limited, sequence orthology evidence is appropriately used and cited.</p> </li> <li> <p>Multi-functional Proteins: The model correctly handles proteins with multiple functions, such as Gart (MGI:MGI:95654), which performs three distinct enzymatic activities in this pathway.</p> </li> <li> <p>Bifunctional Enzyme Annotation: The final enzyme Atic is correctly modeled with its two distinct catalytic activities (AICAR formyltransferase and IMP cyclohydrolase), which is biochemically accurate.</p> </li> </ol>"},{"location":"reviews/60ad85f700002947-_de_novo__IMP_biosynthetic_process__Mouse_/#minor-issues-and-suggestions-for-improvement","title":"Minor Issues and Suggestions for Improvement","text":"<ol> <li> <p>Visual Layout: While not visible in the JSON representation, it would be helpful if the visual layout of the model in a graphical interface clearly showed the linear flow of the pathway.</p> </li> <li> <p>Additional Contextual Information: The model could potentially benefit from additional information about regulation of this pathway or connections to other metabolic processes.</p> </li> <li> <p>Subcellular Localization: Only some activities have explicit subcellular locations specified. It would be helpful to annotate all activities with their subcellular locations if this information is available.</p> </li> </ol>"},{"location":"reviews/60ad85f700002947-_de_novo__IMP_biosynthetic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>This is a high-quality GO-CAM model that accurately represents the de novo IMP biosynthetic pathway in mouse. The model follows GO-CAM best practices and provides a clear representation of the sequential enzymatic activities in this pathway. The evidence supporting each activity is appropriate, with a mix of direct experimental evidence and orthology-based annotations.</p> <p>The model successfully captures the biological complexity of this pathway, including the multi-functional enzymes like Gart and the bifunctional Atic protein. The cited literature supports the annotations and the causal relationships between activities are biologically accurate.</p> <p>Overall, this model meets the quality standards for GO-CAM and provides valuable information about purine biosynthesis in mouse. It serves as a good example of how to model a metabolic pathway using the GO-CAM framework.</p>"},{"location":"reviews/60ad85f700003015-_de_novo__GMP_biosynthetic_process__Mouse_/","title":"60ad85f700003015  de novo  GMP biosynthetic process  Mouse","text":"<p>Now I'll review the model in detail based on the information I have gathered. Let me organize my review:</p>"},{"location":"reviews/60ad85f700003015-_de_novo__GMP_biosynthetic_process__Mouse_/#review-of-go-cam-model-gomodel60ad85f700003015","title":"Review of GO-CAM Model: gomodel:60ad85f700003015","text":"<p>Title: 'de novo' GMP biosynthetic process (Mouse) Taxon: NCBITaxon:10090 (Mouse) Status: Production Comments: Sourced from gomodel: R-HSA-73817</p>"},{"location":"reviews/60ad85f700003015-_de_novo__GMP_biosynthetic_process__Mouse_/#overview","title":"Overview","text":"<p>This GO-CAM model represents the 'de novo' GMP biosynthetic process in mouse. It depicts the molecular activities of several enzymes involved in the purine biosynthesis pathway, specifically the steps leading to GMP formation. The model includes multiple gene products and their molecular functions, all participating in the GO:0006177 (GMP biosynthetic process).</p>"},{"location":"reviews/60ad85f700003015-_de_novo__GMP_biosynthetic_process__Mouse_/#model-structure-and-content","title":"Model Structure and Content","text":"<p>The model describes a linear pathway of enzymatic activities connected by causal relationships (primarily RO:0002413 \"provides input for\") that form the 'de novo' GMP biosynthetic process. Each enzyme is represented with: - Gene product (enabled by) - Molecular function - Process participation (part of) - Location information (in some cases) - Causal relationships to downstream activities</p>"},{"location":"reviews/60ad85f700003015-_de_novo__GMP_biosynthetic_process__Mouse_/#review-of-biological-content","title":"Review of Biological Content","text":"<ol> <li>Pathway Accuracy: </li> <li>The model correctly represents the de novo purine biosynthesis pathway leading to GMP production</li> <li>The sequence of enzymatic reactions appears to follow the established biochemical pathway</li> <li> <p>The causal connections (RO:0002413 \"provides input for\") accurately represent substrate-product relationships</p> </li> <li> <p>Gene Products and Activities:</p> </li> <li>All gene products are correctly annotated with appropriate molecular functions</li> <li> <p>The model includes key enzymes such as:</p> <ul> <li>PPAT (MGI:MGI:2387203) - amidophosphoribosyltransferase activity</li> <li>GART (MGI:MGI:95654) - multifunctional enzyme with three activities (phosphoribosylamine-glycine ligase, phosphoribosylglycinamide formyltransferase, phosphoribosylformylglycinamidine cyclo-ligase)</li> <li>PFAS (MGI:MGI:2684864) - phosphoribosylformylglycinamidine synthase</li> <li>PAICS (MGI:MGI:1914304) - bifunctional enzyme (phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase)</li> <li>ADSL (MGI:MGI:103202) - adenylosuccinate lyase</li> <li>ATIC (MGI:MGI:1351352) - bifunctional enzyme (phosphoribosylaminoimidazolecarboxamide formyltransferase and IMP cyclohydrolase)</li> <li>IMPDH1/2 (MGI:MGI:96567/MGI:MGI:109367) - IMP dehydrogenase</li> <li>GMPS (MGI:MGI:2448526) - GMP synthase</li> </ul> </li> <li> <p>Evidence Support:</p> </li> <li>Each annotation is supported by appropriate evidence codes and references</li> <li>The model uses a combination of experimental evidence codes (ECO:0000314, ECO:0000315) and sequence orthology evidence (ECO:0000266)</li> <li>Multiple PMIDs are cited to support the annotations</li> </ol>"},{"location":"reviews/60ad85f700003015-_de_novo__GMP_biosynthetic_process__Mouse_/#compliance-with-go-cam-modeling-standards","title":"Compliance with GO-CAM Modeling Standards","text":"<ol> <li>Molecular Function Annotations:</li> <li>Each protein is annotated with appropriate molecular functions that reflect their enzymatic activities</li> <li> <p>For bifunctional/multifunctional proteins (like GART, ATIC, PAICS), all functions are properly represented</p> </li> <li> <p>Causal Relationships:</p> </li> <li>The model uses appropriate causal relationships (RO:0002413 \"provides input for\") to show how the product of one reaction serves as input for the next</li> <li> <p>The flow of activities follows the biochemical pathway in the correct order</p> </li> <li> <p>Cellular Component Information:</p> </li> <li>Some activities are annotated with cellular location (GO:0005829 cytosol) which is appropriate for this pathway</li> <li> <p>Not all activities have location annotations, which could be improved</p> </li> <li> <p>Handling of Multi-Function Proteins:</p> </li> <li>The model appropriately represents multi-function proteins like GART and ATIC by creating separate activity nodes for each function and connecting them causally</li> </ol>"},{"location":"reviews/60ad85f700003015-_de_novo__GMP_biosynthetic_process__Mouse_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li>Cellular Component Annotations:</li> <li>Consider adding cellular component annotations for all activities for consistency</li> <li> <p>Currently, some activities (like GART's functions) have location information while others don't</p> </li> <li> <p>Process Representation:</p> </li> <li> <p>While each activity is correctly annotated as part of GO:0006177 (GMP biosynthetic process), it might be valuable to also include the more specific sub-processes where applicable</p> </li> <li> <p>Visual Organization:</p> </li> <li>The model contains a linear chain of enzymatic reactions; ensuring the visual layout in Noctua clearly shows this progression would enhance comprehensibility (not assessable from JSON format)</li> </ol>"},{"location":"reviews/60ad85f700003015-_de_novo__GMP_biosynthetic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model (gomodel:60ad85f700003015) is scientifically accurate and well-constructed. It effectively represents the 'de novo' GMP biosynthetic process in mouse with appropriate molecular functions, gene products, and causal relationships. The model is well-supported by evidence and follows GO-CAM modeling standards.</p> <p>The model demonstrates good curation practices, particularly in the representation of multi-function proteins and the use of causal relationships to connect enzymatic activities. Minor improvements could be made to ensure consistent cellular component annotations across all activities.</p> <p>Overall, this model meets the standards for a production-quality GO-CAM and provides a valuable resource for understanding the GMP biosynthetic pathway in mouse.</p>"},{"location":"reviews/60ad85f700003288-_de_novo__UMP_biosynthetic_process__Mouse_/","title":"60ad85f700003288  de novo  UMP biosynthetic process  Mouse","text":"<p>Let me now provide my review of GO-CAM model: gomodel:60ad85f700003288 - \"'de novo' UMP biosynthetic process (Mouse)\".</p>"},{"location":"reviews/60ad85f700003288-_de_novo__UMP_biosynthetic_process__Mouse_/#go-cam-model-review-de-novo-ump-biosynthetic-process-mouse","title":"GO-CAM Model Review: \"'de novo' UMP biosynthetic process (Mouse)\"","text":""},{"location":"reviews/60ad85f700003288-_de_novo__UMP_biosynthetic_process__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (gomodel:60ad85f700003288) represents the 'de novo' UMP biosynthetic process in mouse. The model describes the pathway for de novo pyrimidine synthesis, specifically the synthesis of UMP. This pathway involves several enzymatic activities carried out by three mouse proteins:</p> <ol> <li>CAD protein (MGI:MGI:1916969) - a multifunctional protein with three activities:</li> <li>Carbamoyl-phosphate synthase (glutamine-hydrolyzing) activity (GO:0004088)</li> <li>Aspartate carbamoyltransferase activity (GO:0004070)</li> <li> <p>Dihydroorotase activity (GO:0004151)</p> </li> <li> <p>Dihydroorotate dehydrogenase (DHODH) (MGI:MGI:1928378) - with dihydroorotate dehydrogenase activity (GO:0004152)</p> </li> <li> <p>Uridine 5'-monophosphate synthase (UMPS) (MGI:MGI:1298388) - a bifunctional enzyme with:</p> </li> <li>Orotate phosphoribosyltransferase activity (GO:0004588)</li> <li>Orotidine-5'-phosphate decarboxylase activity (GO:0004590)</li> </ol>"},{"location":"reviews/60ad85f700003288-_de_novo__UMP_biosynthetic_process__Mouse_/#model-accuracy-assessment","title":"Model Accuracy Assessment","text":""},{"location":"reviews/60ad85f700003288-_de_novo__UMP_biosynthetic_process__Mouse_/#biological-content","title":"Biological Content","text":"<p>The model correctly represents the de novo UMP biosynthetic pathway as described in the literature. The enzymes and their activities are accurately annotated based on the evidence from UniProt entries and cited literature. The CAD protein in mammals is indeed a multifunctional enzyme that contains the first three activities of the pathway, which is correctly represented.</p> <p>The causal flow of the pathway is properly represented with the \"provides input for\" (RO:0002413) relationships showing the sequential enzymatic reactions, and the \"part of\" (BFO:0000050) relationship properly placing these activities within the 'de novo' UMP biosynthetic process.</p>"},{"location":"reviews/60ad85f700003288-_de_novo__UMP_biosynthetic_process__Mouse_/#evidence-support","title":"Evidence Support","text":"<p>The model uses a combination of evidence types including: - Direct assays (ECO:0000314) - Mutant phenotypes (ECO:0000315) - Sequence orthology (ECO:0000266)</p> <p>All these evidence types are appropriate for the assertions made in the model. The references, including PMID papers like 5125237 (which describes the copurification of carbamoyl phosphate synthetase and aspartate transcarbamylase), provide strong support for the model's assertions.</p>"},{"location":"reviews/60ad85f700003288-_de_novo__UMP_biosynthetic_process__Mouse_/#model-structure","title":"Model Structure","text":"<p>The causal flow of activities is logical and accurately represents the biochemical pathway: 1. Carbamoyl-phosphate synthase activity \u2192 Aspartate carbamoyltransferase activity \u2192 Dihydroorotase activity \u2192 Dihydroorotate dehydrogenase activity \u2192 Orotate phosphoribosyltransferase activity \u2192 Orotidine-5'-phosphate decarboxylase activity</p> <p>This flow correctly represents the de novo pyrimidine synthesis pathway where each enzymatic activity provides substrate for the next step.</p>"},{"location":"reviews/60ad85f700003288-_de_novo__UMP_biosynthetic_process__Mouse_/#compliance-with-go-cam-guidelines","title":"Compliance with GO-CAM Guidelines","text":"<p>The model follows GO-CAM best practices for representing enzymatic pathways: 1. Each molecular function is properly enabled by a specific gene product 2. The causal relationships between functions use appropriate predicates (RO:0002413 for \"provides input for\") 3. All activities are properly associated with the parent biological process (GO:0044205 - 'de novo' UMP biosynthetic process)</p>"},{"location":"reviews/60ad85f700003288-_de_novo__UMP_biosynthetic_process__Mouse_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is accurate and well-structured, there are a few potential improvements:</p> <ol> <li> <p>Subcellular Localization: The model doesn't explicitly include information about subcellular localization of these activities. According to UniProt, CAD is found in both cytoplasm and nucleus, DHODH is located in the mitochondrial inner membrane, and UMPS is found in the cytoplasm and nucleus. Adding this information would enhance the model's completeness.</p> </li> <li> <p>Regulatory Information: The model could be enhanced by including regulatory information. For instance, CAD is regulated by phosphorylation, particularly by MAP kinase and protein kinase A, which could be relevant to include if supported by mouse-specific evidence.</p> </li> <li> <p>Complex Formation: While the CAD protein is a multifunctional enzyme, it's known to form homohexamers. This complex formation aspect could be represented in the model if evidence exists for how it affects the pathway.</p> </li> </ol>"},{"location":"reviews/60ad85f700003288-_de_novo__UMP_biosynthetic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model is an accurate and well-structured representation of the 'de novo' UMP biosynthetic process in mouse. The biological content, evidence support, and structural organization are all of high quality and adhere to GO-CAM guidelines. The suggested improvements would be enhancements rather than corrections to what is already a sound model.</p> <p>The model effectively captures the essential elements of this metabolic pathway and provides a clear representation of how these enzymes work sequentially to produce UMP through de novo synthesis.</p>"},{"location":"reviews/60d5209a00000233-tumor_necrosis_factor_mediated_signaling_pathway_via_grnd_egr__D_mel_/","title":"60d5209a00000233 tumor necrosis factor mediated signaling pathway via grnd egr  D mel","text":"<p>Now that I have reviewed the relevant guidelines, let me examine the details of the GO-CAM model. This model represents the tumor necrosis factor-mediated signaling pathway via grnd-egr in Drosophila melanogaster (fruit fly). Let me analyze the components and structure of this model for consistency with GO-CAM best practices.</p>"},{"location":"reviews/60d5209a00000233-tumor_necrosis_factor_mediated_signaling_pathway_via_grnd_egr__D_mel_/#review-of-go-cam-model-60d5209a00000233","title":"Review of GO-CAM Model 60d5209a00000233","text":""},{"location":"reviews/60d5209a00000233-tumor_necrosis_factor_mediated_signaling_pathway_via_grnd_egr__D_mel_/#model-overview","title":"Model Overview","text":"<p>This model (gomodel:60d5209a00000233) represents the tumor necrosis factor-mediated signaling pathway in Drosophila melanogaster, specifically focusing on signaling via the Grnd receptor and Egr ligand. It illustrates a complete signaling cascade from ligand binding through JNK (Jun N-terminal kinase) pathway activation.</p>"},{"location":"reviews/60d5209a00000233-tumor_necrosis_factor_mediated_signaling_pathway_via_grnd_egr__D_mel_/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":"<p>The model captures the TNF signaling pathway in Drosophila with the following key components: - Egr (Eiger) as the ligand with receptor ligand activity - Grnd (Grindelwald) as the TNF receptor - Traf6 as an adaptor protein - Tab2 as a signaling adaptor - A MAP kinase cascade including Msn, Tak1, Hep, and Bsk (JNK)</p> <p>This represents a biologically accurate depiction of the Drosophila TNF signaling pathway according to current literature.</p>"},{"location":"reviews/60d5209a00000233-tumor_necrosis_factor_mediated_signaling_pathway_via_grnd_egr__D_mel_/#go-cam-standards-compliance","title":"GO-CAM Standards Compliance","text":""},{"location":"reviews/60d5209a00000233-tumor_necrosis_factor_mediated_signaling_pathway_via_grnd_egr__D_mel_/#1-ligand-receptor-interaction","title":"1. Ligand-Receptor Interaction","text":"<ul> <li>Ligand (egr/Eiger): Correctly annotated with receptor ligand activity (GO:0048018), occurring in extracellular space (GO:0005615), and part of TNF signaling pathway (GO:0033209)</li> <li>Receptor (grnd/Grindelwald): Properly annotated with TNF receptor activity (GO:0005031), occurring in plasma membrane (GO:0005886), and part of TNF signaling pathway (GO:0033209)</li> <li>Causal relation: The ligand activity correctly \"directly positively regulates\" (RO:0002629) the receptor activity, following signaling guidelines</li> </ul>"},{"location":"reviews/60d5209a00000233-tumor_necrosis_factor_mediated_signaling_pathway_via_grnd_egr__D_mel_/#2-downstream-signaling","title":"2. Downstream Signaling","text":"<ul> <li>The model correctly uses direct regulation through the signaling cascade</li> <li>Each protein activity is correctly part of the TNF-mediated signaling pathway (GO:0033209)</li> <li>The causal relationships use \"directly positively regulates\" (RO:0002629) throughout the cascade</li> <li>The cellular locations are properly annotated (plasma membrane, cytoplasm, cytosol) as appropriate</li> </ul>"},{"location":"reviews/60d5209a00000233-tumor_necrosis_factor_mediated_signaling_pathway_via_grnd_egr__D_mel_/#3-adaptor-proteins","title":"3. Adaptor Proteins","text":"<ul> <li>Traf6 (FB:FBgn0265464) is correctly annotated with TNF receptor binding activity (GO:0032813)</li> <li>Tab2 (FB:FBgn0086358) is correctly annotated with signaling adaptor activity (GO:0035591)</li> <li>Both adaptors properly regulate downstream activities</li> </ul>"},{"location":"reviews/60d5209a00000233-tumor_necrosis_factor_mediated_signaling_pathway_via_grnd_egr__D_mel_/#4-mapk-cascade","title":"4. MAPK Cascade","text":"<ul> <li>The model correctly captures the full MAPK cascade with:</li> <li>Msn (misshapen) with JNK kinase kinase kinase activity</li> <li>Tak1 with JNK kinase kinase kinase activity</li> <li>Hep (hemipterous) with JNK kinase kinase activity</li> <li>Bsk (basket) with JNK kinase activity</li> <li>The hierarchy of regulation is correctly represented with appropriate causal relationships</li> </ul>"},{"location":"reviews/60d5209a00000233-tumor_necrosis_factor_mediated_signaling_pathway_via_grnd_egr__D_mel_/#evidence-usage","title":"Evidence Usage","text":"<ul> <li>All activities and associations have appropriate evidence codes</li> <li>References (PMIDs) are included for each assertion</li> <li>The model uses a variety of evidence types including:</li> <li>Direct assay evidence (ECO:0000314)</li> <li>Mutant phenotype evidence (ECO:0000315)</li> <li>Genetic interaction evidence (ECO:0000316)</li> <li>Author statements (ECO:0000304)</li> </ul>"},{"location":"reviews/60d5209a00000233-tumor_necrosis_factor_mediated_signaling_pathway_via_grnd_egr__D_mel_/#specific-suggestions-for-improvement","title":"Specific Suggestions for Improvement","text":"<ol> <li> <p>Cellular Component for Tab2: Tab2's activity doesn't have a specified cellular component (occurs_in relation). Based on the model, it should be annotated as occurring in the cytoplasm (GO:0005737), similar to related components.</p> </li> <li> <p>Redundant JNK kinase kinase kinase activities: Both Msn and Tak1 are annotated with JNK kinase kinase kinase activities (though Msn has GO:0042656 and Tak1 has GO:0004706). While this is technically possible, it would be helpful to clarify their relationship to each other (do they work in complex, in parallel, or in different contexts?).</p> </li> <li> <p>Activity Flow Clarity: While the causal connections are correct, the model could benefit from clarifying if the MAPK pathway components (Msn, Tak1, Hep, Bsk) act in parallel or in series. The current model suggests they act in series, which seems biologically accurate.</p> </li> <li> <p>Completeness of the Model: The model ends with Bsk (JNK) activity but doesn't show downstream transcription factors (like AP-1/Jun) that would typically be activated. This is not necessarily incorrect, but adding this component would make the model more complete.</p> </li> </ol>"},{"location":"reviews/60d5209a00000233-tumor_necrosis_factor_mediated_signaling_pathway_via_grnd_egr__D_mel_/#overall-assessment","title":"Overall Assessment","text":"<p>This is a well-constructed GO-CAM model that accurately represents the TNF signaling pathway in Drosophila melanogaster. It follows the GO-CAM best practices for signaling pathways, with appropriate molecular functions, cellular components, biological processes, and causal relationships.</p> <p>The model correctly shows: 1. A protein ligand (Egr) activating its receptor (Grnd) 2. Signal transduction through adaptor proteins (Traf6, Tab2) 3. A complete MAPK cascade (Msn/Tak1 \u2192 Hep \u2192 Bsk)</p> <p>With minor suggested improvements, this model provides a clear and accurate representation of this important signaling pathway and complies with GO-CAM annotation guidelines.</p>"},{"location":"reviews/60d5209a00000521-torso_signaling_pathway__D_mel_/","title":"60d5209a00000521 torso signaling pathway  D mel","text":"<p>Now that I have a better understanding of the GO-CAM guidelines, I'll review the torso signaling pathway model (gomodel:60d5209a00000521). </p>"},{"location":"reviews/60d5209a00000521-torso_signaling_pathway__D_mel_/#review-of-go-cam-model-torso-signaling-pathway-dmel","title":"Review of GO-CAM Model: Torso signaling pathway (D.mel)","text":"<p>Model ID: gomodel:60d5209a00000521 Title: Torso signaling pathway (D.mel) Taxon: NCBITaxon:7227 (Drosophila melanogaster) Status: Production</p>"},{"location":"reviews/60d5209a00000521-torso_signaling_pathway__D_mel_/#overview-of-the-model","title":"Overview of the Model","text":"<p>This GO-CAM model represents the torso signaling pathway in Drosophila melanogaster. The torso signaling pathway is critical in embryonic development, particularly for terminal patterning. The model includes multiple activities from ligand-receptor interactions through downstream signaling events, ultimately affecting transcriptional regulation.</p>"},{"location":"reviews/60d5209a00000521-torso_signaling_pathway__D_mel_/#model-strengths","title":"Model Strengths","text":"<ol> <li> <p>Comprehensive pathway representation: The model includes the key components of the torso signaling pathway from ligands (trunk, torsolike proteins) to the receptor (torso) to downstream effectors and transcription factors.</p> </li> <li> <p>Proper use of causal relationships: The model accurately uses causal relationships (RO:0002629 - directly positively regulates, RO:0002630 - directly negatively regulates, and RO:0002304 - causally upstream of, positive effect) to connect activities in the signaling cascade.</p> </li> <li> <p>Evidence supported by literature: The activities and relationships are supported by appropriate evidence codes and literature references (PMIDs).</p> </li> <li> <p>Cellular compartmentalization: The model correctly annotates the cellular locations for different activities (e.g., extracellular space, plasma membrane, cytoplasm, nucleus).</p> </li> <li> <p>Complete RTK signaling cascade: The model includes the canonical receptor tyrosine kinase signaling cascade (Ras-Raf-MEK-ERK pathway).</p> </li> </ol>"},{"location":"reviews/60d5209a00000521-torso_signaling_pathway__D_mel_/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li> <p>Missing molecular function annotations: Several activities (FB:FBgn0003867, FB:FBgn0261016, FB:FBgn0004650, FB:FBgn0005390) are annotated with the generic \"molecular_function\" (GO:0003674) with evidence code ECO:0000307 (no evidence data found used in manual assertion). These should be updated with more specific molecular functions when evidence becomes available.</p> </li> <li> <p>Receptor ligand relationships: According to the \"Signaling receptor activity annotation guidelines,\" the relationship between ligands and receptors should be properly modeled. The model correctly uses RO:0002629 (directly positively regulates) for the trk (FB:FBgn0003751) relationship to the torso receptor (FB:FBgn0003733). However, for the other ligands (tsl, clos, fs1M3, fs1N), the model uses RO:0002304 (causally upstream of, positive effect), which indicates indirect regulation. If these are direct ligands, consider using RO:0002629 instead.</p> </li> <li> <p>Receptor-effector modeling: The torso receptor (FB:FBgn0003733) correctly uses \"directly positively regulates\" (RO:0002629) to connect to its immediate downstream effectors (Shc and csw).</p> </li> <li> <p>Context annotations: Most activities have appropriate \"occurs_in\" annotations to specify cellular context. This is in line with GO-CAM best practices.</p> </li> <li> <p>MAPK pathway representation: The model correctly represents the MAPK pathway cascade with appropriate causal relationships (Raf \u2192 Dsor1 \u2192 rl).</p> </li> <li> <p>Transcriptional regulation: The downstream effects on transcription factors (groucho and cic) are properly modeled, with the MAPK activity (rl) negatively regulating these transcriptional repressors, which aligns with the biological understanding of the pathway.</p> </li> <li> <p>Clarification of certain relationships: The relationship between drk and Sos activities could be further clarified with additional evidence if available.</p> </li> </ol>"},{"location":"reviews/60d5209a00000521-torso_signaling_pathway__D_mel_/#suggested-improvements","title":"Suggested Improvements","text":"<ol> <li> <p>Update generic molecular functions: When evidence becomes available, update the generic GO:0003674 molecular function terms for tsl, clos, fs1M3, and fs1N proteins with more specific functions.</p> </li> <li> <p>Review ligand-receptor relationships: Ensure that all ligand-receptor relationships use the appropriate causal relationship (direct vs. indirect regulation).</p> </li> <li> <p>Consider adding additional annotations: If known, consider adding additional input/output annotations to better characterize the biochemical aspects of each activity.</p> </li> <li> <p>Verification of causal relationships: Double-check that all causal relationships accurately reflect the mechanistic understanding of the pathway from the literature.</p> </li> </ol>"},{"location":"reviews/60d5209a00000521-torso_signaling_pathway__D_mel_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model of the torso signaling pathway in Drosophila melanogaster is well-constructed and follows most GO-CAM best practices. It provides a comprehensive representation of the signaling pathway from ligand-receptor interactions to downstream effectors and transcriptional regulation. The few issues identified are mostly related to the specificity of molecular function annotations for some components and potentially the precise nature of some causal relationships.</p> <p>The model effectively captures the biological knowledge of this important developmental signaling pathway in fruit flies and will be a valuable resource for the research community.</p>"},{"location":"reviews/60d5209a00001406-_de_novo__XMP_biosynthetic_process__Mouse_/","title":"60d5209a00001406  de novo  XMP biosynthetic process  Mouse","text":"<p>Based on the information I've gathered, I'll now provide a comprehensive review of the GO-CAM model gomodel:60d5209a00001406.</p>"},{"location":"reviews/60d5209a00001406-_de_novo__XMP_biosynthetic_process__Mouse_/#review-of-go-cam-model-60d5209a00001406","title":"Review of GO-CAM Model: 60d5209a00001406","text":""},{"location":"reviews/60d5209a00001406-_de_novo__XMP_biosynthetic_process__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (gomodel:60d5209a00001406) represents the \"'de novo' XMP biosynthetic process\" in mouse (Mus musculus). The model was adapted from an existing human Reactome pathway (gomodel:R-HSA-73817) and describes the sequential enzymatic steps involved in the de novo biosynthesis of xanthosine monophosphate (XMP).</p>"},{"location":"reviews/60d5209a00001406-_de_novo__XMP_biosynthetic_process__Mouse_/#content-evaluation","title":"Content Evaluation","text":""},{"location":"reviews/60d5209a00001406-_de_novo__XMP_biosynthetic_process__Mouse_/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model accurately represents the de novo XMP biosynthetic pathway, capturing each enzymatic step with appropriate gene products, molecular functions, and causal relationships. The evidence for these annotations is well-supported by literature references, including:</p> <ol> <li>PMID:6480832 - Supporting evidence for ADSL activity</li> <li>PMID:27590927 - A comprehensive paper on CRISPR-Cas9 induced mutations in de novo purine synthesis pathway</li> <li>PMID:2183217 - Describes cloning of human multifunctional de novo purine biosynthetic genes</li> <li>PMID:26144885 - Additional evidence for purine synthesis pathways</li> </ol> <p>All enzymes in the pathway are correctly connected via \"provides input for\" (RO:0002413) relationships, accurately representing the sequential nature of the biochemical reactions.</p>"},{"location":"reviews/60d5209a00001406-_de_novo__XMP_biosynthetic_process__Mouse_/#activity-flow","title":"Activity Flow","text":"<p>The model demonstrates proper flow of molecular activities, with each gene product performing a specific enzymatic function that feeds into the next step of the pathway. The causal relationships form a coherent linear pathway:</p> <ol> <li>PPAT (Phosphoribosyl pyrophosphate amidotransferase) \u2192 GART (Phosphoribosylamine--glycine ligase activity)</li> <li>GART \u2192 PFAS (Phosphoribosylformylglycinamidine synthase activity)</li> <li>PFAS \u2192 GART (Phosphoribosylglycinamide formyltransferase activity)</li> <li>GART \u2192 PAICS (Phosphoribosylaminoimidazole carboxylase activity)</li> <li>PAICS \u2192 PAICS (Phosphoribosylaminoimidazolesuccinocarboxamide synthase activity)</li> <li>PAICS \u2192 ADSL (Adenylosuccinate lyase activity)</li> <li>ADSL \u2192 ATIC (Phosphoribosylaminoimidazolecarboxamide formyltransferase activity)</li> <li>ATIC \u2192 ATIC (IMP cyclohydrolase activity)</li> <li>ATIC \u2192 IMPDH (IMP dehydrogenase activity)</li> </ol> <p>This accurately represents the known biochemical steps in the XMP biosynthetic pathway.</p>"},{"location":"reviews/60d5209a00001406-_de_novo__XMP_biosynthetic_process__Mouse_/#cellular-context","title":"Cellular Context","text":"<p>The model includes cellular location information for some activities. GART's phosphoribosylamine--glycine ligase and phosphoribosylglycinamide formyltransferase activities are correctly annotated as occurring in the cytosol (GO:0005829), which is consistent with current knowledge about this pathway.</p>"},{"location":"reviews/60d5209a00001406-_de_novo__XMP_biosynthetic_process__Mouse_/#go-cam-best-practices-compliance","title":"GO-CAM Best Practices Compliance","text":"<p>The model follows GO-CAM best practices:</p> <ol> <li>Activities and Entities: Each molecular function is properly enabled by a specific gene product.</li> <li>Evidence: Annotations are supported by appropriate evidence codes and literature references.</li> <li>Causal Relationships: The \"provides input for\" (RO:0002413) predicate is used correctly to connect sequential steps in the pathway.</li> <li>Part_of Relationships: Each activity is properly annotated as part_of the \"de novo XMP biosynthetic process\" (GO:0097294).</li> </ol> <p>The model does not use complexes, but that's appropriate in this case as each enzymatic activity is represented by a specific gene product, following the first rule from the \"How to annotate complexes in GO-CAM\" document, where \"the subunit that carries the molecular activity is known.\"</p>"},{"location":"reviews/60d5209a00001406-_de_novo__XMP_biosynthetic_process__Mouse_/#minor-issues-and-suggestions","title":"Minor Issues and Suggestions","text":"<ol> <li> <p>Missing reactions: The model doesn't seem to explicitly capture the first reaction in the pathway (conversion of PRPP to PRA by PPAT). This step is referenced in the model (PPAT \u2192 GART) but the PPAT activity itself isn't fully detailed.</p> </li> <li> <p>Consistency of evidence: While most annotations have robust evidence support, ensuring consistent depth of evidence across all steps would strengthen the model.</p> </li> <li> <p>Subcellular localization: Only some activities (those of GART) have specific cellular component annotations. Adding this information for other enzymes where known would enhance the model's completeness.</p> </li> </ol>"},{"location":"reviews/60d5209a00001406-_de_novo__XMP_biosynthetic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:60d5209a00001406 is a high-quality representation of the \"'de novo' XMP biosynthetic process\" in mouse. It accurately captures the sequential enzymatic steps with proper molecular functions, causal relationships, and supporting evidence.</p> <p>The model follows GO-CAM best practices and provides a clear, parsable representation of the pathway. Each activity is appropriately connected to form a coherent biological process, making this model a valuable resource for understanding purine biosynthesis.</p> <p>The minor suggestions noted above would further enhance an already well-constructed model, but they don't detract from its overall quality and utility.</p>"},{"location":"reviews/60e7989d00000165-dTMP_biosynthetic_process1A__Mouse_/","title":"60e7989d00000165 dTMP biosynthetic process1A  Mouse","text":"<p>Based on all the information I've gathered, I'll now provide a comprehensive review of GO-CAM model \"60e7989d00000165\" titled \"dTMP biosynthetic process1A (Mouse)\".</p>"},{"location":"reviews/60e7989d00000165-dTMP_biosynthetic_process1A__Mouse_/#review-of-go-cam-model-dtmp-biosynthetic-process1a-mouse","title":"Review of GO-CAM Model: dTMP biosynthetic process1A (Mouse)","text":""},{"location":"reviews/60e7989d00000165-dTMP_biosynthetic_process1A__Mouse_/#model-overview","title":"Model Overview","text":"<p>This model (gomodel:60e7989d00000165) represents the de novo thymidylate biosynthesis pathway in mouse cells, particularly focusing on the nuclear de novo thymidylate synthesis pathway. The model describes how dUMP is converted to dTMP through a series of enzymatic activities in the nucleus.</p>"},{"location":"reviews/60e7989d00000165-dTMP_biosynthetic_process1A__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the current understanding of nuclear dTMP biosynthesis based on published literature. The research in PMID:19513116 confirms that de novo thymidylate synthesis occurs in the nucleus and involves the key enzymes included in this model:</p> <ol> <li>Dihydrofolate reductase (DHFR)</li> <li>Thymidylate synthase (TYMS)</li> <li>Serine hydroxymethyltransferase (SHMT1 and SHMT2)</li> <li>Nucleoside diphosphate kinases (NME1, NME2, NME3)</li> <li>dUTP diphosphatase (DUT)</li> </ol> <p>The nuclear localization of these enzymes is well-supported by the literature, and the compartmentalization to the nucleus allows for folate-dependent dTTP biosynthesis directly at the replication fork during DNA synthesis.</p>"},{"location":"reviews/60e7989d00000165-dTMP_biosynthetic_process1A__Mouse_/#causal-flow-analysis","title":"Causal Flow Analysis","text":"<p>The model correctly represents the flow of enzymatic reactions:</p> <ol> <li>Ribonucleoside-diphosphate reductase complex (GO:0005971) performs ribonucleoside-diphosphate reductase activity to convert UDP to dUDP</li> <li>Multiple nucleoside diphosphate kinases (NME1, NME2, NME3) convert dUDP to dUTP</li> <li>dUTP diphosphatase (DUT) converts dUTP to dUMP</li> <li>Thymidylate synthase (TYMS) converts dUMP to dTMP, using methyleneTHF as a one-carbon donor</li> <li>Serine hydroxymethyltransferases (SHMT1 and SHMT2\u03b1) generate methyleneTHF for thymidylate biosynthesis</li> <li>DHFR (Dihydrofolate reductase) regenerates THF for subsequent cycles</li> </ol> <p>All enzymes are correctly represented as occurring in the nucleus (GO:0005634), which is consistent with the paper that demonstrates that purified intact nuclei can convert dUMP to dTMP in the presence of NADPH and serine.</p>"},{"location":"reviews/60e7989d00000165-dTMP_biosynthetic_process1A__Mouse_/#technical-go-cam-model-review","title":"Technical GO-CAM Model Review","text":""},{"location":"reviews/60e7989d00000165-dTMP_biosynthetic_process1A__Mouse_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Proper use of causal predicates: The model consistently uses RO:0002413 (provides input for) to connect activities, which is appropriate for this metabolic pathway.</p> </li> <li> <p>Detailed molecular functions: Each enzyme has the correct molecular function and is properly enabled by the appropriate gene products.</p> </li> <li> <p>Subcellular localization: The model correctly indicates that these activities occur in the nucleus (GO:0005634), which is a key finding from the referenced papers.</p> </li> <li> <p>Evidence quality: The model uses appropriate evidence codes with relevant PMIDs to support associations.</p> </li> <li> <p>Use of complexes: The ribonucleoside-diphosphate reductase complex (GO:0005971) is correctly represented as enabling the ribonucleoside-diphosphate reductase activity.</p> </li> </ol>"},{"location":"reviews/60e7989d00000165-dTMP_biosynthetic_process1A__Mouse_/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Complex representation: While the model correctly includes the ribonucleoside-diphosphate reductase complex (GO:0005971), it doesn't specify the member proteins of this complex. According to GO-CAM best practices for complexes, when the precise subunit carrying the activity is not known, using the complex ID is appropriate. However, documenting the complex members would improve completeness.</p> </li> <li> <p>Biological process association: While some activities have 'part_of' relationships to \"GO:0006231 dTMP biosynthetic process\", not all activities have this relationship explicitly stated. Adding this association to all relevant activities would improve consistency.</p> </li> <li> <p>Input-output documentation: Some activities clearly document inputs and outputs with molecule associations, while others don't have these explicitly stated. Adding complete input/output molecules for all activities would improve clarity.</p> </li> <li> <p>Missing redundancy representation: The model demonstrates functional redundancy between SHMT1 and SHMT2\u03b1 as described in the literature, but doesn't explicitly represent this relationship.</p> </li> </ol>"},{"location":"reviews/60e7989d00000165-dTMP_biosynthetic_process1A__Mouse_/#literature-support","title":"Literature Support","text":"<p>The model is well-supported by:</p> <ol> <li>PMID:19513116 - Demonstrates nuclear dTMP biosynthesis and the role of both SHMT1 and SHMT2 (particularly SHMT2\u03b1) in this process.</li> <li>PMID:9488696 - Used for evidence about nucleoside diphosphate kinase activities.</li> <li>PMID:360074 - Provides evidence about dihydrofolate reductase activity.</li> <li>PMID:22057276 - Provides evidence about thymidylate synthase activity.</li> </ol> <p>The model correctly represents the findings from these publications, particularly the important discovery that dTMP biosynthesis occurs in the nucleus and that SHMT2 contributes to this process via its cytoplasmic/nuclear isoform (SHMT2\u03b1).</p>"},{"location":"reviews/60e7989d00000165-dTMP_biosynthetic_process1A__Mouse_/#overall-assessment","title":"Overall Assessment","text":"<p>This GO-CAM model is scientifically accurate and technically well-constructed. It effectively represents the current understanding of nuclear de novo thymidylate biosynthesis in mouse cells, with appropriate evidence from the literature.</p> <p>The model is parsimonious and well-organized, making it easy to follow the pathway from UDP through to dTMP. It correctly captures the localization of these activities to the nucleus, which is a key biological finding highlighted in the cited literature.</p>"},{"location":"reviews/60e7989d00000165-dTMP_biosynthetic_process1A__Mouse_/#recommendations-for-improvement","title":"Recommendations for improvement:","text":"<ol> <li>Consider adding member proteins to the ribonucleoside-diphosphate reductase complex</li> <li>Add 'part_of' biological process associations to all activities that contribute to dTMP biosynthesis</li> <li>Complete input/output molecules for all activities for improved clarity</li> </ol> <p>Overall, this is a high-quality GO-CAM model that accurately represents the biology of nuclear dTMP biosynthesis.</p>"},{"location":"reviews/60e7989d00000281-UDP_biosynthetic_process__Mouse_/","title":"60e7989d00000281 UDP biosynthetic process  Mouse","text":"<p>Based on the information gathered about the GO-CAM model, let me provide a comprehensive review:</p>"},{"location":"reviews/60e7989d00000281-UDP_biosynthetic_process__Mouse_/#review-of-go-cam-model-gomodel60e7989d00000281","title":"Review of GO-CAM Model: gomodel:60e7989d00000281","text":""},{"location":"reviews/60e7989d00000281-UDP_biosynthetic_process__Mouse_/#general-information","title":"General Information","text":"<ul> <li>Title: UDP biosynthetic process (Mouse)</li> <li>Taxon: NCBITaxon:10090 (Mouse)</li> <li>Status: Production</li> <li>ID: gomodel:60e7989d00000281</li> <li>Curator: ORCID:0000-0001-7476-6306</li> </ul>"},{"location":"reviews/60e7989d00000281-UDP_biosynthetic_process__Mouse_/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents the UDP biosynthetic process in mouse, focusing on the de novo pyrimidine synthesis pathway. The model shows the sequential enzymatic activities that lead to the production of UDP (uridine diphosphate), which is an essential nucleotide for various cellular processes.</p>"},{"location":"reviews/60e7989d00000281-UDP_biosynthetic_process__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the established pathway for de novo pyrimidine biosynthesis:</p> <ol> <li>The pathway begins with CAD protein (MGI:MGI:1916969), a multi-domain protein that catalyzes the first three steps of pyrimidine synthesis:</li> <li>Carbamoyl phosphate synthetase activity (GO:0004088)</li> <li>Aspartate carbamoyltransferase activity (GO:0004070)</li> <li> <p>Dihydroorotase activity (GO:0004151)</p> </li> <li> <p>This is followed by dihydroorotate dehydrogenase (DHODH, MGI:MGI:1928378) with dihydroorotate dehydrogenase activity (GO:0004152)</p> </li> <li> <p>Then UMP synthase (UMPS, MGI:MGI:1298388), which has both:</p> </li> <li>Orotate phosphoribosyltransferase activity (GO:0004588)</li> <li> <p>Orotidine-5'-phosphate decarboxylase activity (GO:0004590)</p> </li> <li> <p>Finally, UMP kinase (Cmpk1, MGI:MGI:1913838) with UMP kinase activity (GO:0033862)</p> </li> </ol> <p>Each enzyme is connected by appropriate causal relationships (RO:0002413 \"provides input for\"), properly showing the sequential nature of the pathway.</p>"},{"location":"reviews/60e7989d00000281-UDP_biosynthetic_process__Mouse_/#evidence-quality","title":"Evidence Quality","text":"<p>The model is well-supported with evidence from multiple peer-reviewed publications: - PMID:6249586 - A study on dihydroorotate dehydrogenase in Ehrlich ascites tumor cells - PMID:20413687 - Additional evidence for DHODH activity - PMID:965379 - Referenced for multiple activities in the pathway - PMID:2419341 - On orotidine-5'-monophosphate decarboxylase - PMID:3308878 - Supporting evidence for UMPS activity - PMID:33771897 - Recent study (2021) on CAD protein activity - PMID:5125237 - Early study on carbamoyl phosphate synthetase - PMID:11912132 - Evidence for UMP kinase activity</p> <p>The evidence codes used are appropriate: - ECO:0000315 (mutant phenotype evidence) - ECO:0000314 (direct assay evidence) - ECO:0000266 (sequence orthology evidence)</p>"},{"location":"reviews/60e7989d00000281-UDP_biosynthetic_process__Mouse_/#go-cam-structure-and-compliance","title":"GO-CAM Structure and Compliance","text":"<p>The model follows GO-CAM best practices:</p> <ol> <li> <p>Activities and processes: Each gene product is properly associated with its molecular function and the overall biological process (GO:0006225 - UDP biosynthetic process).</p> </li> <li> <p>Causal relationships: The model uses appropriate causal relations (RO:0002413 \"provides input for\") to connect the activities in the correct sequence:</p> </li> <li> <p>CAD (carbamoyl phosphate synthase) \u2192 CAD (aspartate carbamoyltransferase) \u2192 CAD (dihydroorotase) \u2192 DHODH \u2192 UMPS (orotate phosphoribosyltransferase) \u2192 UMPS (orotidine-5'-phosphate decarboxylase) \u2192 Cmpk1</p> </li> <li> <p>Evidence: Each activity and causal relationship is supported by appropriate evidence and literature references.</p> </li> <li> <p>Organizational clarity: The model is organized in a way that clearly represents the sequential steps of the UDP biosynthetic pathway.</p> </li> </ol>"},{"location":"reviews/60e7989d00000281-UDP_biosynthetic_process__Mouse_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is generally well-constructed, a few minor improvements could enhance its clarity and completeness:</p> <ol> <li> <p>Consider adding substrate/product information: While the causal connections show the flow of activities, explicitly noting the substrate/product for each reaction could enhance understanding (although this is implicit in the GO terms).</p> </li> <li> <p>Expand pathway context: The model could potentially be expanded to show how this pathway connects to broader nucleotide metabolism (e.g., connections to CTP synthesis from UTP).</p> </li> <li> <p>Add cellular component information: Adding cellular location information for each activity would provide additional context (e.g., CAD is known to shuttle between cytoplasm and nucleus).</p> </li> <li> <p>Link to regulatory elements: Information about regulation of this pathway (e.g., feedback inhibition by UTP) could enhance the model's utility.</p> </li> </ol>"},{"location":"reviews/60e7989d00000281-UDP_biosynthetic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:60e7989d00000281 is a high-quality representation of the UDP biosynthetic process in mouse. It accurately depicts the enzymatic activities and their sequential relationships, is well-supported by evidence, and follows GO-CAM best practices. The model provides a valuable representation of this fundamental metabolic pathway and serves as a good reference for understanding pyrimidine biosynthesis.</p>"},{"location":"reviews/60e7989d00001485-Tetrahydrofolate_interconversion_1a__Mouse_/","title":"60e7989d00001485 Tetrahydrofolate interconversion 1a  Mouse","text":"<p>Now that I have a good understanding of the model and its components, let me review it according to GO-CAM best practices.</p>"},{"location":"reviews/60e7989d00001485-Tetrahydrofolate_interconversion_1a__Mouse_/#go-cam-model-review-tetrahydrofolate-interconversion-1a-mouse","title":"GO-CAM Model Review: Tetrahydrofolate interconversion 1a (Mouse)","text":""},{"location":"reviews/60e7989d00001485-Tetrahydrofolate_interconversion_1a__Mouse_/#model-overview","title":"Model Overview","text":"<p>Model ID: gomodel:60e7989d00001485 Title: Tetrahydrofolate interconversion 1a (Mouse) Taxon: Mouse (NCBITaxon:10090) Status: Production Comment: Sourced from gomodel:R-HSA-196757</p> <p>This model represents the tetrahydrofolate interconversion pathway in mouse, specifically showing the coordination between dihydrofolate reductase (DHFR), serine hydroxymethyltransferase (SHMT) isoforms, and thymidylate synthase (TYMS) enzymes in the nucleus.</p>"},{"location":"reviews/60e7989d00001485-Tetrahydrofolate_interconversion_1a__Mouse_/#model-components","title":"Model Components","text":"<p>The model contains 4 activities:</p> <ol> <li>Glycine hydroxymethyltransferase activity (GO:0004372) </li> <li>Enabled by: Shmt1 (MGI:MGI:98299)</li> <li>Occurs in: Nucleus (GO:0005634)</li> <li> <p>Part of: Tetrahydrofolate interconversion (GO:0035999)</p> </li> <li> <p>Dihydrofolate reductase activity (GO:0004146)</p> </li> <li>Enabled by: Dhfr (MGI:MGI:94890)</li> <li>Occurs in: Nucleus (GO:0005634)</li> <li> <p>Part of: Tetrahydrofolate interconversion (GO:0035999)</p> </li> <li> <p>Glycine hydroxymethyltransferase activity (GO:0004372)</p> </li> <li>Enabled by: Shmt2 (MGI:MGI:1277989)</li> <li>Occurs in: Nucleus (GO:0005634)</li> <li> <p>Part of: Tetrahydrofolate interconversion (GO:0035999)</p> </li> <li> <p>Thymidylate synthase activity (GO:0004799)</p> </li> <li>Enabled by: Tyms (MGI:MGI:98878)</li> <li>Occurs in: Nucleus (GO:0005634)</li> <li>Part of: Tetrahydrofolate interconversion (GO:0035999)</li> </ol>"},{"location":"reviews/60e7989d00001485-Tetrahydrofolate_interconversion_1a__Mouse_/#causal-relationships","title":"Causal Relationships","text":"<p>The model contains the following causal associations (all using the \"provides input for\" (RO:0002413) relationship):</p> <ol> <li>Shmt1 -&gt; Tyms</li> <li>Dhfr -&gt; Shmt1</li> <li>Dhfr -&gt; Shmt2</li> <li>Shmt2 -&gt; Tyms</li> <li>Tyms -&gt; Dhfr</li> </ol> <p>This forms a cyclic pathway where: - SHMT1 and SHMT2 both provide methyleneTHF for TYMS - TYMS produces dihydrofolate, which is a substrate for DHFR - DHFR regenerates tetrahydrofolate, which is used by SHMT1 and SHMT2</p>"},{"location":"reviews/60e7989d00001485-Tetrahydrofolate_interconversion_1a__Mouse_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model is supported by several publications: - PMID:19513116 - Key study showing nuclear localization of these enzymes and their roles in de novo thymidylate biosynthesis - PMID:22057276 - Additional evidence for the pathway - PMID:360074 - Early study on DHFR</p> <p>The primary paper (PMID:19513116) provides strong evidence that both SHMT1 and SHMT2\u03b1 (a cytoplasmic/nuclear isoform of SHMT2) localize to the nucleus during S-phase and contribute to nuclear thymidylate synthesis. The paper demonstrates that purified nuclei can convert dUMP to dTMP in the presence of serine and NADPH, and that this activity depends on SHMT.</p>"},{"location":"reviews/60e7989d00001485-Tetrahydrofolate_interconversion_1a__Mouse_/#go-cam-quality-assessment","title":"GO-CAM Quality Assessment","text":""},{"location":"reviews/60e7989d00001485-Tetrahydrofolate_interconversion_1a__Mouse_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Biological accuracy: The model accurately represents the tetrahydrofolate interconversion cycle as described in the literature, particularly PMID:19513116.</p> </li> <li> <p>Correct molecular functions: The model uses appropriate GO terms for molecular functions, correctly associating:</p> </li> <li>Dihydrofolate reductase activity (GO:0004146) with Dhfr</li> <li>Glycine hydroxymethyltransferase activity (GO:0004372) with Shmt1 and Shmt2</li> <li> <p>Thymidylate synthase activity (GO:0004799) with Tyms</p> </li> <li> <p>Cellular component: All activities are correctly annotated to occur in the nucleus (GO:0005634), which aligns with the nuclear localization of these enzymes during S-phase as demonstrated in PMID:19513116.</p> </li> <li> <p>Causal relationships: The model correctly uses \"provides input for\" (RO:0002413) to represent the substrate-product relationships between the enzymes in this metabolic pathway.</p> </li> <li> <p>Evidence quality: Each causal relationship and functional annotation is supported by appropriate experimental evidence with proper ECO codes and literature references.</p> </li> </ol>"},{"location":"reviews/60e7989d00001485-Tetrahydrofolate_interconversion_1a__Mouse_/#issues-and-suggestions","title":"Issues and Suggestions:","text":"<ol> <li> <p>Cell Cycle Context: While PMID:19513116 shows that these enzymes localize to the nucleus specifically during S-phase and G2/M phases of the cell cycle, the model does not explicitly represent this cell cycle-dependent nature of the pathway. Consider adding part_of relationships to S phase (GO:0051320) for all activities.</p> </li> <li> <p>SHMT2 Isoform Representation: The model does not explicitly distinguish between the mitochondrial SHMT2 and the cytoplasmic/nuclear SHMT2\u03b1 isoform. According to PMID:19513116, it is specifically the SHMT2\u03b1 isoform that localizes to the nucleus. The model could be improved by specifying that the nuclear glycine hydroxymethyltransferase activity is enabled by the SHMT2\u03b1 isoform.</p> </li> <li> <p>Additional context: The model could benefit from including the biological significance of nuclear localization of these enzymes, such as their role in preventing uracil misincorporation into DNA during replication, as mentioned in PMID:19513116.</p> </li> <li> <p>Expansion opportunity: The model could potentially be expanded to include the relationship with the mitochondrial one-carbon metabolism pathway, which generates formate for cytoplasmic one-carbon metabolism, as mentioned in the introduction of PMID:19513116.</p> </li> </ol>"},{"location":"reviews/60e7989d00001485-Tetrahydrofolate_interconversion_1a__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the tetrahydrofolate interconversion pathway in the nucleus of mouse cells. The model is supported by strong experimental evidence from the literature, particularly PMID:19513116, which demonstrates the nuclear localization of these enzymes and their roles in de novo thymidylate biosynthesis.</p> <p>The model correctly captures the cyclic nature of the pathway, where methyleneTHF produced by SHMT1 and SHMT2 is used by TYMS to produce dihydrofolate, which is then reduced by DHFR to regenerate tetrahydrofolate for use by SHMT enzymes. The causal relationships are appropriately represented using the \"provides input for\" relation.</p> <p>With minor enhancements to represent the cell cycle context and SHMT2 isoform specificity, this model would be even more comprehensive in representing the current state of knowledge about nuclear tetrahydrofolate interconversion.</p>"},{"location":"reviews/60ff660000000882-GMP_salvage_2a__from_adenosine__Mouse_/","title":"60ff660000000882 GMP salvage 2a  from adenosine  Mouse","text":"<p>Based on my review, I'll now provide an analysis of the GO-CAM model 60ff660000000882 for GMP salvage from adenosine in Mouse.</p>"},{"location":"reviews/60ff660000000882-GMP_salvage_2a__from_adenosine__Mouse_/#review-of-go-cam-model-gmp-salvage-from-adenosine-mouse","title":"Review of GO-CAM Model: GMP Salvage from Adenosine (Mouse)","text":"<p>Model ID: gomodel:60ff660000000882 Title: GMP salvage 2a, from adenosine (Mouse) Taxon: Mouse (NCBITaxon:10090) Status: Production Comments: Sourced from R-HSA-73817 and R-HSA-74217</p>"},{"location":"reviews/60ff660000000882-GMP_salvage_2a__from_adenosine__Mouse_/#overview","title":"Overview","text":"<p>This model represents the GMP (guanosine monophosphate) salvage pathway in mouse, specifically showing how adenosine can be converted to GMP through a series of enzymatic reactions. The model includes 6 molecular activities connected through causal associations with <code>RO:0002413</code> (provides input for) relationships.</p>"},{"location":"reviews/60ff660000000882-GMP_salvage_2a__from_adenosine__Mouse_/#components-and-activity-flow","title":"Components and Activity Flow","text":"<p>The model depicts the following sequence of activities:</p> <ol> <li>Adenosine deaminase activity (GO:0004000) by Ada</li> <li> <p>Provides input for purine-nucleoside phosphorylase activity</p> </li> <li> <p>Purine-nucleoside phosphorylase activity (GO:0004731) by Pnp</p> </li> <li>Part of GMP salvage process (GO:0032263)</li> <li> <p>Provides input for hypoxanthine phosphoribosyltransferase activity</p> </li> <li> <p>Hypoxanthine phosphoribosyltransferase activity (GO:0004422) by Hprt1</p> </li> <li>Part of GMP salvage process (GO:0032263)</li> <li>Provides input for two parallel IMP dehydrogenase activities</li> </ol> <p>4a. IMP dehydrogenase activity (GO:0003938) by Impdh1    - Part of GMP salvage process (GO:0032263)    - Provides input for GMP synthase activity</p> <p>4b. IMP dehydrogenase activity (GO:0003938) by Impdh2     - Part of GMP salvage process (GO:0032263)    - Provides input for GMP synthase activity</p> <ol> <li>GMP synthase (glutamine-hydrolyzing) activity (GO:0003922) by Gmps</li> </ol>"},{"location":"reviews/60ff660000000882-GMP_salvage_2a__from_adenosine__Mouse_/#evidence-and-references","title":"Evidence and References","text":"<p>The model uses appropriate evidence codes: - ECO:0000314 (direct assay evidence used in manual assertion) - ECO:0000315 (mutant phenotype evidence used in manual assertion) - ECO:0000304 (author statement supported by traceable reference)</p> <p>Key references include: - PMID:240826 - For GMP synthase activity - PMID:718989 - For hypoxanthine phosphoribosyltransferase activity - PMID:12944494 - For IMP dehydrogenase activity - PMID:31838626 - For IMP dehydrogenase activity - PMID:819300 - For purine-nucleoside phosphorylase activity</p>"},{"location":"reviews/60ff660000000882-GMP_salvage_2a__from_adenosine__Mouse_/#qc-assessment","title":"QC Assessment","text":""},{"location":"reviews/60ff660000000882-GMP_salvage_2a__from_adenosine__Mouse_/#strengths","title":"Strengths","text":"<ol> <li>Appropriate representation of enzymatic pathway: The model correctly represents the GMP salvage pathway from adenosine with appropriate enzymes.</li> <li>Good evidence support: Each activity is supported by evidence from the literature.</li> <li>Logical flow of activities: The causal connections accurately represent the metabolic flow from adenosine to GMP.</li> <li>Accurate gene products: The mouse gene products used are appropriate for the activities represented.</li> <li>Parallel activities properly modeled: The model correctly shows that both IMPDH1 and IMPDH2 can perform the IMP dehydrogenase activity as parallel routes.</li> </ol>"},{"location":"reviews/60ff660000000882-GMP_salvage_2a__from_adenosine__Mouse_/#minor-issues","title":"Minor Issues","text":"<ol> <li> <p>Missing biological process annotation: While the HPRT1, IMPDH1, and IMPDH2 activities are appropriately annotated as part of the GMP salvage process (GO:0032263), the ADA and GMPS activities are not annotated to a biological process. For consistency, all activities should be annotated to their respective biological processes.</p> </li> <li> <p>Evidence completeness: I noticed that the causal association between purine-nucleoside phosphorylase activity and adenosine deaminase activity lacks explicit evidence citations.</p> </li> </ol>"},{"location":"reviews/60ff660000000882-GMP_salvage_2a__from_adenosine__Mouse_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Add biological process annotations: Add GO:0032263 (GMP salvage) annotations to the adenosine deaminase activity and GMP synthase activities for completeness.</p> </li> <li> <p>Add evidence to missing causal association: Add appropriate evidence for the causal association between the adenosine deaminase and purine-nucleoside phosphorylase activities.</p> </li> <li> <p>Consider adding metabolites: While not required in GO-CAM models, adding the key metabolites as nodes in the pathway (adenosine, inosine, hypoxanthine, IMP, XMP, GMP) could make the model more informative for users unfamiliar with the pathway.</p> </li> </ol>"},{"location":"reviews/60ff660000000882-GMP_salvage_2a__from_adenosine__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the GMP salvage pathway from adenosine in mouse. The model follows GO-CAM best practices, uses appropriate molecular functions and gene products, and is supported by relevant evidence. The model is parsimonious and clearly represents the flow of activities in this metabolic pathway. The minor issues noted do not significantly impact the biological accuracy or usefulness of the model.</p>"},{"location":"reviews/60ff660000000897-GMP_salvage_2b__from_adenosine__Mouse_/","title":"60ff660000000897 GMP salvage 2b  from adenosine  Mouse","text":"<p>Based on all the information collected, I'll now conduct a comprehensive review of the GO-CAM model gomodel:60ff660000000897.</p>"},{"location":"reviews/60ff660000000897-GMP_salvage_2b__from_adenosine__Mouse_/#review-of-go-cam-model-gmp-salvage-2b-from-adenosine-mouse","title":"Review of GO-CAM Model: GMP salvage 2b, from adenosine (Mouse)","text":"<p>Model ID: gomodel:60ff660000000897</p>"},{"location":"reviews/60ff660000000897-GMP_salvage_2b__from_adenosine__Mouse_/#summary-of-the-model","title":"Summary of the Model","text":"<p>This GO-CAM represents the GMP (guanosine monophosphate) salvage pathway in mouse, starting from adenosine. The pathway describes how adenosine is converted through several enzymatic steps to eventually form GMP.</p>"},{"location":"reviews/60ff660000000897-GMP_salvage_2b__from_adenosine__Mouse_/#biological-context","title":"Biological Context","text":"<p>The GMP salvage pathway is part of purine metabolism that allows cells to recycle purine nucleosides rather than synthesizing them de novo, which is more energetically costly. In this specific model, adenosine is converted through a series of enzymatic reactions to form GMP.</p>"},{"location":"reviews/60ff660000000897-GMP_salvage_2b__from_adenosine__Mouse_/#model-structure-and-flow-analysis","title":"Model Structure and Flow Analysis","text":"<p>The model represents the following enzymatic cascade:</p> <ol> <li>Starting Point: Adenosine is phosphorylated by adenosine kinase (Adk, MGI:MGI:87930)</li> <li>Intermediate Conversions:</li> <li>AMP is deaminated to IMP by three different AMP deaminase enzymes (Ampd1, Ampd2, Ampd3)</li> <li>IMP is oxidized to XMP by IMP dehydrogenase enzymes (Impdh1, Impdh2)</li> <li>End Point: XMP is converted to GMP by GMP synthase (Gmps)</li> </ol> <p>All reactions are connected with appropriate causal relationships using RO:0002413 (\"provides input for\"), showing the directional flow of the pathway with good biochemical accuracy.</p>"},{"location":"reviews/60ff660000000897-GMP_salvage_2b__from_adenosine__Mouse_/#detailed-component-analysis","title":"Detailed Component Analysis","text":""},{"location":"reviews/60ff660000000897-GMP_salvage_2b__from_adenosine__Mouse_/#molecular-functions-and-associated-gene-products","title":"Molecular Functions and Associated Gene Products:","text":"Activity Gene Product Function Evidence 60ff660000000906 Adk (MGI:MGI:87930) Adenosine kinase activity (GO:0004001) ECO:0000314 (direct assay) 60ff660000000904 Ampd1 (MGI:MGI:88015) AMP deaminase activity (GO:0003876) ECO:0000315 (mutant phenotype) 60ff660000000907 Ampd2 (MGI:MGI:88016) AMP deaminase activity (GO:0003876) ECO:0000315 (mutant phenotype) 60ff660000000910 Ampd3 (MGI:MGI:1096344) AMP deaminase activity (GO:0003876) ECO:0000315 (mutant phenotype) 60ff660000000914 Impdh2 (MGI:MGI:109367) IMP dehydrogenase activity (GO:0003938) ECO:0000314 (direct assay) 60ff660000000902 Impdh1 (MGI:MGI:96567) IMP dehydrogenase activity (GO:0003938) ECO:0000314 (direct assay) 60ff660000000899 Gmps (MGI:MGI:2448526) GMP synthase activity (GO:0003922) ECO:0000314 (direct assay)"},{"location":"reviews/60ff660000000897-GMP_salvage_2b__from_adenosine__Mouse_/#biological-process-context","title":"Biological Process Context:","text":"<p>All activities (except for Adk) are annotated as part of the GMP salvage biological process (GO:0032263), which is appropriate for this pathway.</p>"},{"location":"reviews/60ff660000000897-GMP_salvage_2b__from_adenosine__Mouse_/#causal-relationships","title":"Causal Relationships:","text":"<p>The causal flow is accurate, starting with Adk providing input for the three parallel AMP deaminase activities, which provide input for the two IMP dehydrogenase activities, which finally provide input for the GMP synthase activity.</p>"},{"location":"reviews/60ff660000000897-GMP_salvage_2b__from_adenosine__Mouse_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model uses a good combination of evidence types: - ECO:0000314 (direct assay evidence) for most enzymatic reactions - ECO:0000315 (mutant phenotype evidence) for the AMP deaminase activities - ECO:0000304 (author statement) for some of the process annotations - ECO:0000266 (sequence orthology) for some process annotations</p> <p>All evidence is supported by appropriate literature references, including PMID:12944494, which appears to be a key publication for this pathway.</p>"},{"location":"reviews/60ff660000000897-GMP_salvage_2b__from_adenosine__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Biochemical Accuracy: The model correctly represents the enzymatic steps in the GMP salvage pathway.</li> <li>Completeness: Includes all major enzymatic activities required for converting adenosine to GMP.</li> <li>Isoform Representation: Appropriately captures the biological redundancy with multiple AMP deaminase isoforms (Ampd1, Ampd2, Ampd3) and IMP dehydrogenase isoforms (Impdh1, Impdh2).</li> <li>Evidence Quality: Uses appropriate evidence types with relevant primary literature citations.</li> <li>Causal Flow: Clear directional flow showing the input-output relationships between activities.</li> </ol>"},{"location":"reviews/60ff660000000897-GMP_salvage_2b__from_adenosine__Mouse_/#potential-improvements","title":"Potential Improvements","text":"<ol> <li> <p>Biological Process Annotation: The adenosine kinase activity (Adk) lacks a biological process annotation. It should also be annotated to the GMP salvage process (GO:0032263) for consistency with the other activities.</p> </li> <li> <p>Evidence Consistency: Some activities use multiple evidence types while others use only one. A more uniform approach to evidence provision could strengthen the model.</p> </li> <li> <p>Contextualization: The model comments indicate it was \"Sourced from: R-HSA-73817 and R-HSA-74217\", which are likely Reactome pathway identifiers. It might be helpful to provide the titles of these source pathways in the comments for better context.</p> </li> </ol>"},{"location":"reviews/60ff660000000897-GMP_salvage_2b__from_adenosine__Mouse_/#conclusion","title":"Conclusion","text":"<p>This is a high-quality GO-CAM model that accurately represents the GMP salvage pathway in mouse. It has a clear biological flow with appropriate gene products performing relevant molecular functions, connected by causal relationships that reflect the pathway's directionality. The evidence provided is sound and based on experimental data.</p> <p>The model is parsimonious and focused, making it easy to understand while still capturing the key aspects of the biological process. The inclusion of multiple isoforms for some enzymatic steps (AMP deaminase and IMP dehydrogenase) accurately reflects the biological reality of functional redundancy in this pathway.</p> <p>Overall, this model meets the standards for GO-CAM best practices with only minor opportunities for improvement.</p>"},{"location":"reviews/60ff660000000917-GMP_salvage_3__from_adenine__Mouse_/","title":"60ff660000000917 GMP salvage 3  from adenine  Mouse","text":"<p>Based on the information gathered, I can now provide a comprehensive review of the GO-CAM model \"gomodel:60ff660000000917\" titled \"GMP salvage 3, from adenine (Mouse)\".</p>"},{"location":"reviews/60ff660000000917-GMP_salvage_3__from_adenine__Mouse_/#review-of-go-cam-model-gmp-salvage-3-from-adenine-mouse","title":"Review of GO-CAM Model: GMP salvage 3, from adenine (Mouse)","text":""},{"location":"reviews/60ff660000000917-GMP_salvage_3__from_adenine__Mouse_/#model-overview","title":"Model Overview","text":"<ul> <li>Model ID: gomodel:60ff660000000917</li> <li>Title: GMP salvage 3, from adenine (Mouse)</li> <li>Taxon: Mouse (NCBITaxon:10090)</li> <li>Status: Production</li> <li>Comments: Sourced from: R-HSA-73817 and R-HSA-74217</li> </ul>"},{"location":"reviews/60ff660000000917-GMP_salvage_3__from_adenine__Mouse_/#model-structure-and-pathway-representation","title":"Model Structure and Pathway Representation","text":"<p>This GO-CAM model represents the GMP salvage pathway in mouse, which is a metabolic pathway that recycles guanine nucleotides rather than synthesizing them de novo. The pathway depicted starts from adenine and shows the enzymatic conversion steps leading to GMP.</p>"},{"location":"reviews/60ff660000000917-GMP_salvage_3__from_adenine__Mouse_/#key-activities-in-the-model","title":"Key Activities in the Model:","text":"<ol> <li>Adenine Phosphoribosyltransferase Activity (GO:0003999)</li> <li>Performed by: MGI:MGI:88061 (Aprt)</li> <li> <p>Converts adenine to AMP</p> </li> <li> <p>AMP Deaminase Activity (GO:0003876)</p> </li> <li>Performed by three enzymes:<ul> <li>MGI:MGI:88015 (Ampd1)</li> <li>MGI:MGI:88016 (Ampd2)</li> <li>MGI:MGI:1096344 (Ampd3)</li> </ul> </li> <li> <p>Converts AMP to IMP</p> </li> <li> <p>IMP Dehydrogenase Activity (GO:0003938)</p> </li> <li>Performed by two enzymes:<ul> <li>MGI:MGI:96567 (Impdh1)</li> <li>MGI:MGI:109367 (Impdh2)</li> </ul> </li> <li> <p>Converts IMP to XMP</p> </li> <li> <p>GMP Synthase Activity (GO:0003922)</p> </li> <li>Performed by: MGI:MGI:2448526 (Gmps)</li> <li>Converts XMP to GMP</li> </ol>"},{"location":"reviews/60ff660000000917-GMP_salvage_3__from_adenine__Mouse_/#pathway-flow","title":"Pathway Flow:","text":"<p>The model uses the predicate \"RO:0002413\" (provides input for) to connect these activities, showing a clear linear progression through the pathway:</p> <p>Adenine \u2192 AMP \u2192 IMP \u2192 XMP \u2192 GMP</p>"},{"location":"reviews/60ff660000000917-GMP_salvage_3__from_adenine__Mouse_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model is well-supported with evidence annotations: - Most activities have experimental evidence (ECO:0000314 \"direct assay evidence\" or ECO:0000315 \"mutant phenotype evidence\") - References to primary literature are included (PMID:31838626, PMID:24940686, PMID:12944494, etc.) - The model aligns with our current understanding of the GMP salvage pathway as described in the literature</p>"},{"location":"reviews/60ff660000000917-GMP_salvage_3__from_adenine__Mouse_/#model-quality-assessment","title":"Model Quality Assessment","text":""},{"location":"reviews/60ff660000000917-GMP_salvage_3__from_adenine__Mouse_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Clear Pathway Representation: The model properly represents the GMP salvage pathway from adenine to GMP with the correct enzymatic activities and gene products.</p> </li> <li> <p>Appropriate Use of Predicates: The model uses \"provides input for\" (RO:0002413) consistently to show metabolic flow, which is appropriate for this type of pathway.</p> </li> <li> <p>Comprehensive Evidence: Each activity is supported by experimental evidence and literature references.</p> </li> <li> <p>Biological Accuracy: The pathway depicted correctly represents the known steps in GMP salvage metabolism.</p> </li> <li> <p>Multiple Isozymes: The model appropriately includes multiple isozymes for some steps (AMP deaminase, IMP dehydrogenase), reflecting the biological redundancy.</p> </li> <li> <p>Part-of Relations: Activities are correctly indicated as being part of the GMP salvage process (GO:0032263).</p> </li> </ol>"},{"location":"reviews/60ff660000000917-GMP_salvage_3__from_adenine__Mouse_/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Missing Evidence for Some Associations: Some causal associations lack evidence annotations, such as the connection from Aprt (MGI:MGI:88061) to Ampd3 (MGI:MGI:1096344).</p> </li> <li> <p>Biological Process Association: Some activities in the model don't have explicit part-of relations to the GMP salvage process, though they are implicitly part of it through the pathway connections.</p> </li> </ol>"},{"location":"reviews/60ff660000000917-GMP_salvage_3__from_adenine__Mouse_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model generally complies with GO-CAM best practices:</p> <ol> <li> <p>Activity Representation: Each enzymatic step is properly represented by a molecular activity enabled by a specific gene product.</p> </li> <li> <p>Causal Connections: Activities are appropriately connected with causal relationships.</p> </li> <li> <p>Evidence Documentation: Evidence and provenance information is generally well-documented.</p> </li> <li> <p>Contextual Information: The model provides proper taxon context (mouse).</p> </li> </ol>"},{"location":"reviews/60ff660000000917-GMP_salvage_3__from_adenine__Mouse_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Add Evidence for All Associations: Ensure all causal connections have proper evidence annotations.</p> </li> <li> <p>Consider Adding Metabolites: Although not required in GO-CAM, explicitly noting the metabolites involved at each step (AMP, IMP, XMP, GMP) could enhance the model's clarity.</p> </li> <li> <p>Add More Process Context: Explicitly indicate the part-of relation to GO:0032263 (GMP salvage) for all activities in the pathway.</p> </li> </ol>"},{"location":"reviews/60ff660000000917-GMP_salvage_3__from_adenine__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"GMP salvage 3, from adenine (Mouse)\" is a well-constructed representation of the GMP salvage pathway in mouse. It correctly depicts the enzymatic activities involved in converting adenine to GMP through a series of steps, with appropriate gene products, evidence, and causal connections. With minor improvements to evidence documentation and process context, the model would fully meet all GO-CAM best practices.</p>"},{"location":"reviews/60ff660000001341-AMP_salvage_2b__from_adenosine__Mouse_/","title":"60ff660000001341 AMP salvage 2b  from adenosine  Mouse","text":"<p>Based on my review of the GO-CAM model gomodel:60ff660000001341 \"AMP salvage 2b, from adenosine (Mouse)\" and the information obtained from the UniProt entries and literature, I can now provide a comprehensive review:</p>"},{"location":"reviews/60ff660000001341-AMP_salvage_2b__from_adenosine__Mouse_/#go-cam-review-gomodel60ff660000001341","title":"GO-CAM Review: gomodel:60ff660000001341","text":""},{"location":"reviews/60ff660000001341-AMP_salvage_2b__from_adenosine__Mouse_/#summary-of-the-model","title":"Summary of the Model","text":"<p>This model represents the AMP salvage pathway in mouse, specifically focusing on the conversion pathway from adenosine to AMP. The model includes five proteins connected in a cascade of molecular functions that illustrate the metabolic pathway:</p> <ol> <li>Adenosine deaminase (Ada) - converts adenosine to inosine</li> <li>Purine nucleoside phosphorylase (Pnp) - converts inosine to hypoxanthine</li> <li>Hypoxanthine phosphoribosyltransferase (Hprt1) - converts hypoxanthine to IMP</li> <li>Adenylosuccinate synthase (Adss1) - converts IMP to adenylosuccinate</li> <li>Adenylosuccinate lyase (Adsl) - converts adenylosuccinate to AMP</li> </ol> <p>Each step is connected by the \"provides input for\" (RO:0002413) relation, forming a clear metabolic pathway.</p>"},{"location":"reviews/60ff660000001341-AMP_salvage_2b__from_adenosine__Mouse_/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model accurately represents the purine salvage pathway in mouse, specifically the AMP salvage pathway starting from adenosine. The proteins included and their molecular functions are correctly assigned based on their known enzymatic activities:</p> <ul> <li>Ada (MGI:MGI:87916) with adenosine deaminase activity (GO:0004000)</li> <li>Pnp (MGI:MGI:97365) with purine-nucleoside phosphorylase activity (GO:0004731)</li> <li>Hprt1 (MGI:MGI:96217) with hypoxanthine phosphoribosyltransferase activity (GO:0004422)</li> <li>Adss1 (MGI:MGI:87947) with adenylosuccinate synthase activity (GO:0004019)</li> <li>Adsl (MGI:MGI:103202) with adenylosuccinate lyase activity (GO:0004018)</li> </ul> <p>The literature cited (PMID:8064675, PMID:6771472, PMID:1939273, PMID:11560929, PMID:5891253, PMID:25681585) supports the roles of these enzymes in the pathway. The recent literature review (PMID:25681585) specifically discusses this pathway in the context of heart function and ischemia, indicating its biological importance.</p>"},{"location":"reviews/60ff660000001341-AMP_salvage_2b__from_adenosine__Mouse_/#model-structure-evaluation","title":"Model Structure Evaluation","text":"<p>The model follows GO-CAM best practices for representing metabolic pathways:</p> <ol> <li> <p>Proper use of causal relations: The model correctly uses RO:0002413 (\"provides input for\") to connect the enzymatic activities in sequence.</p> </li> <li> <p>Consistent part_of relationships: Three of the five activities (Pnp, Hprt1, and Adss1) are correctly annotated as being part of the AMP salvage process (GO:0044209). However, Ada and Adsl are not annotated with this biological process.</p> </li> <li> <p>Evidence codes: Each activity and causal connection includes appropriate evidence codes (ECO:0000314 - direct assay evidence used in manual assertion) with references to supporting literature.</p> </li> </ol>"},{"location":"reviews/60ff660000001341-AMP_salvage_2b__from_adenosine__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>The model clearly depicts the sequential steps in the AMP salvage pathway.</li> <li>Each molecular function is correctly assigned to the appropriate gene product.</li> <li>The causal relationships between activities are appropriately represented.</li> <li>The model includes strong experimental evidence from multiple publications.</li> </ol>"},{"location":"reviews/60ff660000001341-AMP_salvage_2b__from_adenosine__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Consistent process annotation: Ada and Adsl activities should be annotated as part of the AMP salvage process (GO:0044209) for consistency, as they are integral to this pathway.</p> </li> <li> <p>Completeness of annotation: While the current model focuses on the conversion of adenosine to AMP, it would be beneficial to include information about regulation of these enzymes, particularly given the importance of this pathway in ischemic conditions (as shown in PMID:25681585).</p> </li> <li> <p>Complex annotation considerations: The model doesn't involve protein complexes, but if any of these enzymes function as part of a complex, the model should follow the GO-CAM best practices for complexes as documented in the \"How to annotate complexes in GO-CAM\" guide.</p> </li> </ol>"},{"location":"reviews/60ff660000001341-AMP_salvage_2b__from_adenosine__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:60ff660000001341 (https://bioregistry.io/go.model:60ff660000001341) provides an accurate and well-supported representation of the AMP salvage pathway in mouse. It effectively illustrates the conversion of adenosine to AMP through a series of enzymatic reactions, with each step properly annotated with molecular functions and evidence.</p> <p>The model is scientifically sound and follows most GO-CAM best practices. With minor improvements to process annotations, this model serves as a valuable resource for understanding purine nucleotide metabolism in mouse.</p>"},{"location":"reviews/61283a3000000217-cobalamin_metabolic_process_1__adenosylation_of_cobalamin__Mouse_/","title":"61283a3000000217 cobalamin metabolic process 1  adenosylation of cobalamin  Mouse","text":"<p>Now I have a better understanding of the model and relevant guidelines. Let me review the GO-CAM model gomodel:61283a3000000217 titled \"cobalamin metabolic process 1, adenosylation of cobalamin (Mouse)\".</p>"},{"location":"reviews/61283a3000000217-cobalamin_metabolic_process_1__adenosylation_of_cobalamin__Mouse_/#go-cam-model-review-gomodel61283a3000000217","title":"GO-CAM Model Review: gomodel:61283a3000000217","text":""},{"location":"reviews/61283a3000000217-cobalamin_metabolic_process_1__adenosylation_of_cobalamin__Mouse_/#model-overview","title":"Model Overview","text":"<p>This model represents the cobalamin (Vitamin B12) metabolic process in mouse, specifically focusing on the adenosylation pathway of cobalamin. The model includes 6 activities connected in a causal sequence that depicts the processing and conversion of cobalamin into its active forms.</p>"},{"location":"reviews/61283a3000000217-cobalamin_metabolic_process_1__adenosylation_of_cobalamin__Mouse_/#activities-in-the-model","title":"Activities in the Model","text":"<ol> <li>MMACHC (MGI:MGI:1914346) has two activities:</li> <li>Oxidoreductase activity (GO:0016491) occurring in cytosol (GO:0005829)</li> <li> <p>Cyanocobalamin reductase activity (GO:0033787)    Both activities are part of cobalamin metabolic process (GO:0009235)</p> </li> <li> <p>MMADHC (MGI:MGI:1923786)</p> </li> <li>Molecular carrier activity (GO:0140104) </li> <li> <p>Part of cobalamin metabolic process (GO:0009235)</p> </li> <li> <p>MMAB (MGI:MGI:1924947)</p> </li> <li>Corrinoid adenosyltransferase activity (GO:0008817) occurring in mitochondrial matrix (GO:0005759)</li> <li> <p>Part of cobalamin metabolic process (GO:0009235)</p> </li> <li> <p>MMAA (MGI:MGI:1923805)</p> </li> <li>Molecular carrier activity (GO:0140104) occurring in mitochondrial matrix (GO:0005759)</li> <li>Has cobamamide (CHEBI:18408) as input</li> <li> <p>Part of cobalamin metabolic process (GO:0009235)</p> </li> <li> <p>MMUT (MGI:MGI:97239)</p> </li> <li>Methylmalonyl-CoA mutase activity (GO:0004494) occurring in mitochondrial matrix (GO:0005759)</li> <li>Part of succinyl-CoA biosynthetic process (GO:1901290)</li> </ol>"},{"location":"reviews/61283a3000000217-cobalamin_metabolic_process_1__adenosylation_of_cobalamin__Mouse_/#causal-connections","title":"Causal Connections","text":"<ul> <li>MMACHC (oxidoreductase) \u2192 MMADHC (provides input for)</li> <li>MMACHC (cyanocobalamin reductase) \u2192 MMADHC (provides input for)</li> <li>MMADHC \u2192 MMAB (causally upstream of, positive effect)</li> <li>MMAB \u2192 MMAA (provides input for)</li> <li>MMAA \u2192 MMUT (positively regulates activity with output target molecule)</li> </ul>"},{"location":"reviews/61283a3000000217-cobalamin_metabolic_process_1__adenosylation_of_cobalamin__Mouse_/#review-assessment","title":"Review Assessment","text":""},{"location":"reviews/61283a3000000217-cobalamin_metabolic_process_1__adenosylation_of_cobalamin__Mouse_/#strengths","title":"Strengths","text":"<ol> <li> <p>Appropriate Use of Molecular Functions: The molecular functions assigned to each protein align with their established biochemical roles in cobalamin metabolism.</p> </li> <li> <p>Accurate Cellular Localization: The model correctly represents the subcellular localization of these activities, with MMACHC in the cytosol and the later steps (MMAA, MMAB, MMUT) in the mitochondrial matrix.</p> </li> <li> <p>Logical Causal Flow: The causal connections follow the biological sequence of cobalamin processing from the initial processing by MMACHC to the final utilization by MMUT.</p> </li> <li> <p>Correct Use of Molecular Carrier Activity: The model appropriately uses \"molecular carrier activity\" (GO:0140104) for MMADHC and MMAA, which transport cobalamin derivatives between processing steps, consistent with the \"Molecular carrier activity\" guidelines.</p> </li> <li> <p>Proper Evidence Attribution: Evidence codes and references are provided for most annotations, often citing relevant literature and using appropriate evidence codes.</p> </li> </ol>"},{"location":"reviews/61283a3000000217-cobalamin_metabolic_process_1__adenosylation_of_cobalamin__Mouse_/#issues-and-suggestions-for-improvement","title":"Issues and Suggestions for Improvement","text":"<ol> <li>Missing Input Molecules: While MMAA has cobamamide (adenosylcobalamin) specified as input, other molecules in the pathway are missing their inputs/outputs. For instance:</li> <li>MMACHC should have cyanocobalamin as input</li> <li>The output of MMACHC should be specified (cob(II)alamin)</li> <li> <p>MMADHC should explicitly show what form of cobalamin it's carrying</p> </li> <li> <p>Incomplete Causal Relationship Evidence: The causal connections between activities lack evidence codes in some cases. Each causal relationship should have supporting evidence, particularly:</p> </li> <li>The connection between MMACHC \u2192 MMADHC</li> <li> <p>The connection between MMAB \u2192 MMAA</p> </li> <li> <p>Pathway Completeness: The model focuses on the adenosylation pathway but doesn't fully represent the branch to methylcobalamin synthesis, which is another important outcome of cobalamin metabolism.</p> </li> <li> <p>Inconsistent Biological Process Annotation: While most proteins are correctly annotated as part of \"cobalamin metabolic process\" (GO:0009235), MMUT is annotated to \"succinyl-CoA biosynthetic process\" (GO:1901290). While technically accurate, it might be more consistent to also include it as part of the cobalamin metabolic process.</p> </li> <li> <p>Missing Molecular Details: The specific chemical modifications happening at each step could be more explicitly represented, particularly:</p> </li> <li>The decyanation function of MMACHC</li> <li>The adenosyl transfer by MMAB</li> <li>The specific role of MMAA in adenosylcobalamin delivery to MMUT</li> </ol>"},{"location":"reviews/61283a3000000217-cobalamin_metabolic_process_1__adenosylation_of_cobalamin__Mouse_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Add Missing Inputs/Outputs: Complete the model by specifying all relevant input and output molecules for each activity.</p> </li> <li> <p>Add Evidence for Causal Relationships: Provide literature evidence for all causal connections in the model.</p> </li> <li> <p>Consider Expanding to Include Methylcobalamin Pathway: For completeness, the model could be expanded to include the parallel pathway leading to methylcobalamin synthesis via MTR, which would give a more complete picture of cobalamin metabolism.</p> </li> <li> <p>Standardize Biological Process Annotations: Consider annotating MMUT to both succinyl-CoA biosynthesis and cobalamin metabolic process to maintain consistency.</p> </li> <li> <p>Review Activity Annotations: Ensure that each protein's activity is described with the most specific GO term available. For instance, MMACHC's oxidoreductase activity could potentially use a more specific child term.</p> </li> </ol>"},{"location":"reviews/61283a3000000217-cobalamin_metabolic_process_1__adenosylation_of_cobalamin__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:61283a3000000217 provides a good representation of the cobalamin adenosylation pathway in mouse, with appropriate molecular functions, cellular locations, and causal connections. The model follows GO-CAM best practices for representing molecular carrier activities and complex biochemical pathways. With the suggested improvements to complete molecular details and evidence, it would provide an even more comprehensive and well-supported representation of this important metabolic pathway.</p>"},{"location":"reviews/613aae0000000011-SP_ANN_SEC14L1/","title":"613aae0000000011 SP ANN SEC14L1","text":"<p>Now I'll review the GO-CAM model with ID gomodel:613aae0000000011.</p>"},{"location":"reviews/613aae0000000011-SP_ANN_SEC14L1/#summary-of-the-model","title":"Summary of the Model","text":"<p>This GO-CAM model (titled \"SP-ANN-SEC14L1\") represents molecular interactions between three proteins:</p> <ol> <li>MAVS (UniProtKB:Q7Z434) - Mitochondrial antiviral-signaling protein</li> <li>RIG-I (UniProtKB:O95786) - Antiviral innate immune response receptor RIG-I</li> <li>SEC14L1 (UniProtKB:Q92503) - SEC14-like protein 1</li> </ol> <p>The model depicts a key part of the RIG-I-mediated antiviral signaling pathway, showing how these proteins interact to regulate innate immune responses against viral infections.</p>"},{"location":"reviews/613aae0000000011-SP_ANN_SEC14L1/#analysis-of-the-model","title":"Analysis of the Model","text":""},{"location":"reviews/613aae0000000011-SP_ANN_SEC14L1/#activities-and-interactions","title":"Activities and Interactions","text":"<p>The model contains four main activities:</p> <ol> <li>RIG-I pattern recognition receptor activity (GO:0038187) - Occurs in the cytoplasm (GO:0005737)</li> <li>RIG-I binding (GO:0039552) by MAVS - Occurs in the mitochondrial membrane (GO:0031966)</li> <li>Molecular adaptor activity (GO:0060090) by MAVS - Occurs in the mitochondrial membrane (GO:0031966)</li> <li>Protein sequestering activity (GO:0140311) by SEC14L1 - Occurs in the cytoplasm (GO:0005737)</li> </ol>"},{"location":"reviews/613aae0000000011-SP_ANN_SEC14L1/#causal-relationships","title":"Causal Relationships","text":"<ol> <li>RIG-I's pattern recognition receptor activity directly positively regulates (RO:0002629) MAVS's RIG-I binding activity</li> <li>MAVS's RIG-I binding activity directly positively regulates (RO:0002629) MAVS's molecular adaptor activity</li> <li>SEC14L1's protein sequestering activity directly negatively regulates (RO:0002630) MAVS's RIG-I binding activity</li> </ol>"},{"location":"reviews/613aae0000000011-SP_ANN_SEC14L1/#evaluation-of-the-model","title":"Evaluation of the Model","text":""},{"location":"reviews/613aae0000000011-SP_ANN_SEC14L1/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>Based on the literature review:</p> <ol> <li> <p>RIG-I and MAVS Interaction: The model correctly represents that RIG-I's pattern recognition receptor activity leads to its binding with MAVS. As confirmed in the PMID:16127453 paper, RIG-I contains CARD domains that interact with the CARD-like domain of MAVS to initiate signaling.</p> </li> <li> <p>MAVS Adaptor Function: The model appropriately shows MAVS functioning as a molecular adaptor that gets activated after RIG-I binding, which is consistent with known biology. MAVS serves as a critical adaptor in RIG-I-mediated antiviral signaling.</p> </li> <li> <p>SEC14L1 as a Negative Regulator: The negative regulation of MAVS by SEC14L1 is supported by the UniProt entry for SEC14L1, which states it \"may play a role in innate immunity by inhibiting the antiviral RIG-I signaling pathway\" and \"prevents the interaction of RIG-I with MAVS/IPS1.\"</p> </li> <li> <p>Subcellular Localization: The model correctly locates MAVS at the mitochondrial membrane and RIG-I and SEC14L1 in the cytoplasm.</p> </li> </ol>"},{"location":"reviews/613aae0000000011-SP_ANN_SEC14L1/#go-cam-best-practices-compliance","title":"GO-CAM Best Practices Compliance","text":"<ol> <li> <p>Causal Relationships: The model properly uses the appropriate relationship predicates (RO:0002629 for positive regulation and RO:0002630 for negative regulation).</p> </li> <li> <p>Molecular Functions: Each protein is annotated with appropriate molecular functions from GO.</p> </li> <li> <p>Cellular Components: Each activity is properly annotated with the cellular component where it occurs.</p> </li> <li> <p>Evidence and References: Each annotation has appropriate evidence codes (ECO:0000314 - direct assay evidence used in manual assertion) and PubMed references.</p> </li> <li> <p>Complex Representation: The model does not involve protein complexes, so the guidelines for representing complexes are not applicable here.</p> </li> </ol>"},{"location":"reviews/613aae0000000011-SP_ANN_SEC14L1/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Additional Downstream Events: The model could be extended to include downstream events in the signaling pathway, such as the activation of IRF3/IRF7 and NF-\u03baB, leading to type I interferon production.</p> </li> <li> <p>Mechanistic Details: Additional details about how SEC14L1 sequesters MAVS could enhance the model's informativeness.</p> </li> <li> <p>Temporal Dynamics: If known, information about the temporal aspects of these interactions could be added.</p> </li> </ol>"},{"location":"reviews/613aae0000000011-SP_ANN_SEC14L1/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model (gomodel:613aae0000000011) accurately represents a key aspect of the RIG-I-mediated antiviral signaling pathway, showing how RIG-I recognizes viral RNA, activates MAVS through direct binding, and how SEC14L1 negatively regulates this interaction. The model follows GO-CAM best practices and is well-supported by the available literature.</p> <p>The model is parsimonious and focuses on the core interactions without unnecessary complexity, making it easy to understand. It provides a clear representation of a specific regulatory mechanism in antiviral immune responses.</p> <p>From a quality control perspective, this model appears to be scientifically accurate and technically sound, with appropriate GO terms, relationship predicates, and evidence codes.</p>"},{"location":"reviews/613aae0000000500-cobalamin_metabolic_process_3__methylation_of_cobalamin__Mouse_/","title":"613aae0000000500 cobalamin metabolic process 3  methylation of cobalamin  Mouse","text":"<p>Now I'll review the model based on the information gathered:</p>"},{"location":"reviews/613aae0000000500-cobalamin_metabolic_process_3__methylation_of_cobalamin__Mouse_/#go-cam-model-review-gomodel613aae0000000500","title":"GO-CAM Model Review: gomodel:613aae0000000500","text":""},{"location":"reviews/613aae0000000500-cobalamin_metabolic_process_3__methylation_of_cobalamin__Mouse_/#model-overview","title":"Model Overview","text":"<p>Title: cobalamin metabolic process 3, methylation of cobalamin (Mouse) Taxon: NCBITaxon:10090 (Mouse) Status: Production Comments: Sourced From: R-HSA-196741 and R-HSA-3204318</p>"},{"location":"reviews/613aae0000000500-cobalamin_metabolic_process_3__methylation_of_cobalamin__Mouse_/#model-structure-and-biological-content","title":"Model Structure and Biological Content","text":"<p>This model represents the cobalamin (vitamin B12) metabolic process in mouse, specifically focusing on the methylation of cobalamin. The model contains 5 activities connected in a pathway that describes the key steps in cobalamin processing:</p> <ol> <li>Mmachc (MGI:MGI:1914346) - Performs oxidoreductase activity (GO:0016491) in the cytosol (GO:0005829).</li> <li>Mmadhc (MGI:MGI:1923786) - Functions as a molecular carrier (GO:0140104) in the cytosol.</li> <li>Mtrr (MGI:MGI:1891037) - Has [methionine synthase] reductase (NADPH) activity (GO:0030586), processing cob(II)alamin to methylcobalamin.</li> <li>Mtr (MGI:MGI:894292) - Possesses methionine synthase activity (GO:0008705).</li> </ol> <p>The model correctly represents the flow of the cobalamin metabolic pathway: - Mmachc (oxidoreductase) \u2192 Mmadhc (molecular carrier) \u2192 Mtr/Mtrr</p>"},{"location":"reviews/613aae0000000500-cobalamin_metabolic_process_3__methylation_of_cobalamin__Mouse_/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model uses appropriate evidence codes: - ECO:0000266 (sequence orthology evidence used in manual assertion) for many associations - ECO:0000315 (mutant phenotype evidence used in manual assertion) for Mtrr and Mtr activities</p> <p>Evidence is supported by relevant publications, with most assertions citing peer-reviewed literature.</p>"},{"location":"reviews/613aae0000000500-cobalamin_metabolic_process_3__methylation_of_cobalamin__Mouse_/#molecular-interactions-and-causal-relationships","title":"Molecular Interactions and Causal Relationships","text":"<p>The causal relationships in the model are correctly represented using <code>RO:0002413</code> (provides input for) to connect activities in logical sequence: 1. Mmachc provides input for Mmadhc 2. Mmadhc provides input for both Mtr and another Mtr activity 3. Mtrr processes cob(II)alamin to methylcobalamin and provides input for Mtr</p>"},{"location":"reviews/613aae0000000500-cobalamin_metabolic_process_3__methylation_of_cobalamin__Mouse_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>The model follows best practices for representing molecular carrier activity: - Mmadhc is correctly annotated as enabling molecular carrier activity (GO:0140104) - The model properly represents the transported molecules using has_input and has_output relationships - Mtrr correctly shows cob(II)alamin (CHEBI:16304) as input and methylcobalamin (CHEBI:28115) as output</p>"},{"location":"reviews/613aae0000000500-cobalamin_metabolic_process_3__methylation_of_cobalamin__Mouse_/#strengths","title":"Strengths","text":"<ol> <li>The model clearly represents the sequence of activities in the cobalamin metabolism pathway.</li> <li>Appropriate molecular functions are assigned to each protein.</li> <li>Chemical entities (cobalamin forms) are properly represented.</li> <li>Cellular locations are specified (cytosol).</li> <li>Evidence is well-documented with relevant publications.</li> </ol>"},{"location":"reviews/613aae0000000500-cobalamin_metabolic_process_3__methylation_of_cobalamin__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Activity Duplication: There appear to be two activities for Mtr (MGI:MGI:894292) in the model (gomodel:613aae0000000500/613aae0000000554 and gomodel:613aae0000000500/6168d1e000000325). One has more complete annotation than the other.</p> </li> <li> <p>Evidence Gaps: Some of the causal associations lack evidence annotations.</p> </li> <li> <p>Incomplete Annotations: The duplicated Mtr activity (6168d1e000000325) lacks evidence for molecular function, occurs_in and part_of annotations.</p> </li> </ol>"},{"location":"reviews/613aae0000000500-cobalamin_metabolic_process_3__methylation_of_cobalamin__Mouse_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Consolidate Duplicate Activities: Combine the two Mtr activities into a single, well-annotated activity to improve model clarity.</p> </li> <li> <p>Add Missing Evidence: Provide evidence for all causal associations.</p> </li> <li> <p>Complete Annotations: Ensure all activities have complete evidence for their molecular function, cellular location, and biological process associations.</p> </li> <li> <p>Add Description: Consider adding a textual description to explain the model and its biological relevance.</p> </li> </ol>"},{"location":"reviews/613aae0000000500-cobalamin_metabolic_process_3__methylation_of_cobalamin__Mouse_/#conclusion","title":"Conclusion","text":"<p>Overall, gomodel:613aae0000000500 is a well-constructed representation of the cobalamin metabolic process in mouse. It correctly depicts the roles of Mmachc, Mmadhc, Mtrr, and Mtr in cobalamin processing, with appropriate molecular functions, cellular locations, and causal relationships. The model is supported by relevant literature and follows GO-CAM best practices for representing molecular carrier activity and metabolic pathways.</p> <p>With the suggested improvements, particularly consolidating the duplicate Mtr activities and adding missing evidence, the model will be even more valuable for understanding cobalamin metabolism.</p>"},{"location":"reviews/613aae0000000579-SP_ANN_TPPP/","title":"613aae0000000579 SP ANN TPPP","text":"<p>Based on all the information I've gathered, I'll now review the GO-CAM model 613aae0000000579.</p>"},{"location":"reviews/613aae0000000579-SP_ANN_TPPP/#review-of-go-cam-model-613aae0000000579","title":"Review of GO-CAM Model 613aae0000000579","text":""},{"location":"reviews/613aae0000000579-SP_ANN_TPPP/#overview","title":"Overview","text":"<p>The GO-CAM model gomodel:613aae0000000579 titled \"SP-ANN-TPPP\" represents molecular interactions between S100 proteins (S100B, S100A6, and S100A2) and the Tubulin Polymerization Promoting Protein (TPPP). The model focuses on how these S100 proteins negatively regulate TPPP's dimerization and subsequent activities.</p>"},{"location":"reviews/613aae0000000579-SP_ANN_TPPP/#model-content","title":"Model Content","text":"<p>The model includes five activities: 1. Protein binding (GO:0005515) by S100B 2. Protein binding (GO:0005515) by S100A6 3. Protein binding (GO:0005515) by S100A2 4. Protein dimerization activity (GO:0046983) by TPPP 5. Microtubule nucleator activity (GO:0140490) by TPPP</p> <p>The causal relationships demonstrate that the protein binding activities of all three S100 proteins directly negatively regulate (RO:0002630) the protein dimerization activity of TPPP, which in turn directly positively regulates (RO:0002629) the microtubule nucleator activity of TPPP.</p>"},{"location":"reviews/613aae0000000579-SP_ANN_TPPP/#model-assessment","title":"Model Assessment","text":""},{"location":"reviews/613aae0000000579-SP_ANN_TPPP/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model is well-supported by the literature. The paper by Doi et al. (PMID: 33831707) specifically describes how S100 proteins (including S100B, S100A6, and S100A2) regulate TPPP by inhibiting its dimerization in a calcium-dependent manner. </p> <p>The functional importance of TPPP dimerization for its microtubule nucleation activity is well-documented in Fu et al. (PMID: 31522887), which describes TPPP as a Golgi outpost protein that nucleates microtubules and is critical for myelination. The Olah et al. paper (PMID: 22484033) specifically demonstrates that TPPP forms dimers that have enhanced tubulin polymerization promoting activity.</p>"},{"location":"reviews/613aae0000000579-SP_ANN_TPPP/#go-cam-best-practices","title":"GO-CAM Best Practices","text":"<p>The model follows GO-CAM best practices in several ways: 1. The activities are appropriately connected with correct causal relationships 2. Each protein activity is properly enabled by the correct gene product 3. Evidence is properly cited with PMIDs 4. The model represents a clear biological pathway with logical flow</p>"},{"location":"reviews/613aae0000000579-SP_ANN_TPPP/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Calcium Dependence: The interaction between S100 proteins and TPPP is calcium-dependent, as described in the literature. This calcium dependency is not explicitly represented in the model. Consider adding calcium binding activities for the S100 proteins, which would be upstream of their protein binding activities.</p> </li> <li> <p>Cellular Location: TPPP's microtubule nucleator activity is noted to occur in the Golgi apparatus (GO:0005794), which is appropriate. However, the S100 proteins' binding activities don't have cellular locations specified. According to the literature, these interactions appear to occur in the cytoplasm, which could be added to provide more context.</p> </li> <li> <p>Mechanistic Detail: The model could benefit from additional mechanistic details that explain how S100 proteins inhibit TPPP dimerization. For example, the literature suggests they bind to the C-terminus of TPPP.</p> </li> <li> <p>Additional Functions: TPPP has other functions mentioned in the literature, including tubulin binding, GTPase activity, and promoting microtubule bundling. These could be considered for inclusion in a more comprehensive model.</p> </li> </ol>"},{"location":"reviews/613aae0000000579-SP_ANN_TPPP/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model accurately represents a key regulatory mechanism for TPPP activity based on the literature. The model captures how S100 proteins inhibit TPPP dimerization, which in turn affects its microtubule nucleator activity. This pathway is important for understanding microtubule dynamics and could have implications for myelination processes and potentially neurodegenerative diseases.</p> <p>The model would benefit from additional details regarding calcium dependency, cellular locations for all activities, and potentially additional functions of TPPP to provide a more comprehensive representation of this biological pathway.</p>"},{"location":"reviews/613aae0000000813-Liver_apoptosis_regulation_by_CASP6__Human_/","title":"613aae0000000813 Liver apoptosis regulation by CASP6  Human","text":"<p>Now, I'll provide a comprehensive review of the GO-CAM model 613aae0000000813:</p>"},{"location":"reviews/613aae0000000813-Liver_apoptosis_regulation_by_CASP6__Human_/#review-of-go-cam-model-613aae0000000813","title":"Review of GO-CAM Model 613aae0000000813","text":""},{"location":"reviews/613aae0000000813-Liver_apoptosis_regulation_by_CASP6__Human_/#model-information","title":"Model Information","text":"<ul> <li>ID: gomodel:613aae0000000813</li> <li>Title: Liver apoptosis regulation by CASP6 (Human)</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: Production</li> <li>Comments: Automated change 2024-10-10: GO:0097153 replaced by GO:0004197</li> </ul>"},{"location":"reviews/613aae0000000813-Liver_apoptosis_regulation_by_CASP6__Human_/#overview-of-the-model","title":"Overview of the Model","text":"<p>This GO-CAM model represents the regulatory mechanism by which CASP6 (Caspase-6) controls liver damage in nonalcoholic steatohepatitis (NASH) in humans. The model depicts how AMPK (AMP-activated protein kinase) negatively regulates CASP6 activity, which, when activated, promotes apoptosis through BID cleavage.</p>"},{"location":"reviews/613aae0000000813-Liver_apoptosis_regulation_by_CASP6__Human_/#model-components-and-activities","title":"Model Components and Activities","text":"<p>The model contains four main activities:</p> <ol> <li>BID (UniProtKB:P55957-4)</li> <li>Molecular Function: GO:0043028 (cysteine-type endopeptidase regulator activity involved in apoptotic process)</li> <li>Biological Process: GO:0090200 (positive regulation of release of cytochrome c from mitochondria)</li> <li> <p>Evidence: ECO:0000304 (author statement supported by traceable reference), PMID:15661737</p> </li> <li> <p>PRKAA1/AMPK (UniProtKB:Q13131-2)</p> </li> <li>Molecular Function: GO:0004674 (protein serine/threonine kinase activity)</li> <li>Biological Process: GO:1903944 (negative regulation of hepatocyte apoptotic process)</li> <li>Evidence: ECO:0000314 (direct assay evidence used in manual assertion), PMID:32029622</li> <li> <p>Causally negatively regulates (RO:0002630) CASP6 activity</p> </li> <li> <p>PRKAA2/AMPK (UniProtKB:P54646)</p> </li> <li>Molecular Function: GO:0004674 (protein serine/threonine kinase activity)</li> <li>Biological Process: GO:1903944 (negative regulation of hepatocyte apoptotic process)</li> <li>Evidence: ECO:0000314 (direct assay evidence used in manual assertion), PMID:32029622</li> <li> <p>Causally negatively regulates (RO:0002630) CASP6 activity</p> </li> <li> <p>CASP6 (UniProtKB:P55212)</p> </li> <li>Molecular Function: GO:0004197 (cysteine-type endopeptidase activity)</li> <li>Biological Process: GO:0097284 (hepatocyte apoptotic process)</li> <li>Evidence: ECO:0000314 (direct assay evidence used in manual assertion), PMID:32029622</li> <li>Causally positively regulates (RO:0002629) BID activity</li> </ol>"},{"location":"reviews/613aae0000000813-Liver_apoptosis_regulation_by_CASP6__Human_/#causal-relations-in-the-model","title":"Causal Relations in the Model","text":"<p>The model depicts the following causal relationships: 1. Both PRKAA1 and PRKAA2 (AMPK subunits) directly negatively regulate CASP6 activity 2. CASP6 directly positively regulates BID activity 3. BID is involved in the positive regulation of cytochrome c release from mitochondria, leading to apoptosis</p>"},{"location":"reviews/613aae0000000813-Liver_apoptosis_regulation_by_CASP6__Human_/#literature-support","title":"Literature Support","text":"<p>The model is primarily supported by PMID:32029622, which describes: - AMPK phosphorylates caspase-6 at Ser-257, inhibiting its activation - When AMPK activity is reduced (as in steatosis-induced conditions), caspase-6 is activated - Active caspase-6 cleaves BID to induce cytochrome c release, generating a feedforward loop leading to hepatocyte death - The AMPK-caspase-6 axis regulates liver damage in NASH</p> <p>This is consistent with the model structure showing AMPK negatively regulating CASP6, and CASP6 positively regulating BID.</p>"},{"location":"reviews/613aae0000000813-Liver_apoptosis_regulation_by_CASP6__Human_/#quality-assessment","title":"Quality Assessment","text":""},{"location":"reviews/613aae0000000813-Liver_apoptosis_regulation_by_CASP6__Human_/#strengths","title":"Strengths:","text":"<ol> <li>Evidence Quality: The model uses appropriate evidence codes and literature references to support its assertions.</li> <li>Biological Accuracy: The causal relationships are consistent with the cited literature, particularly PMID:32029622.</li> <li>GO Term Usage: The GO terms used are appropriate for the activities and processes described.</li> <li>Relevance: The model captures an important regulatory mechanism in liver disease.</li> </ol>"},{"location":"reviews/613aae0000000813-Liver_apoptosis_regulation_by_CASP6__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement:","text":"<ol> <li> <p>Incomplete Feedforward Loop: The model doesn't fully represent the feedforward loop described in the literature. According to PMID:32029622, active caspase-6 cleaves BID, leading to cytochrome c release, which further activates upstream caspases. This loop could be more explicitly modeled.</p> </li> <li> <p>Missing Context Information: The model could benefit from including additional context about the steatosis-induced conditions that lead to reduced AMPK activity, which is a key initiating factor mentioned in the literature.</p> </li> <li> <p>Phosphorylation Mechanism: The specific mechanism by which AMPK inhibits CASP6 (phosphorylation at Ser-257) is not explicitly represented in the model. This could be added to provide more mechanistic detail.</p> </li> <li> <p>Additional Participants: The literature describes that once CASP6 is activated, it cleaves BID at both Asp59 and Asp75, generating specific cleaved products. These specific cleavage sites and products could be included for completeness.</p> </li> <li> <p>Missing Connections: The model doesn't explicitly show the connection between BID cleavage, cytochrome c release, and the activation of other caspases that sustain the apoptotic cascade.</p> </li> </ol>"},{"location":"reviews/613aae0000000813-Liver_apoptosis_regulation_by_CASP6__Human_/#technical-correctness","title":"Technical Correctness:","text":"<ol> <li> <p>The GO term update from GO:0097153 to GO:0004197 for caspase activity is appropriate and appears to be an automated update.</p> </li> <li> <p>The causal relationships use the correct relationship types:</p> </li> <li>RO:0002630 (directly negatively regulates) for AMPK's effect on CASP6</li> <li> <p>RO:0002629 (directly positively regulates) for CASP6's effect on BID</p> </li> <li> <p>The model correctly represents that both PRKAA1 and PRKAA2 can negatively regulate CASP6, which is consistent with the literature describing either AMPK subunit can phosphorylate procaspase-6 at Ser-257.</p> </li> </ol>"},{"location":"reviews/613aae0000000813-Liver_apoptosis_regulation_by_CASP6__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the AMPK-caspase-6-BID regulatory axis in liver apoptosis based on the supporting literature. It uses appropriate GO terms, relationship types, and evidence codes. The model correctly captures the key activities and regulatory relationships, although it could be enhanced by including more detail about the feedforward loop and specific molecular mechanisms described in the literature. With these minor additions, the model would more comprehensively represent the biological system as described in the literature.</p>"},{"location":"reviews/613aae0000000885-SP_ANN_PTPRM/","title":"613aae0000000885 SP ANN PTPRM","text":"<p>Now, let me analyze this GO-CAM model and provide my review:</p>"},{"location":"reviews/613aae0000000885-SP_ANN_PTPRM/#review-of-go-cam-model-gomodel613aae0000000885-sp-ann-ptprm","title":"Review of GO-CAM Model: gomodel:613aae0000000885 (SP-ANN-PTPRM)","text":""},{"location":"reviews/613aae0000000885-SP_ANN_PTPRM/#overview","title":"Overview","text":"<p>This GO-CAM model gomodel:613aae0000000885 titled \"SP-ANN-PTPRM\" represents a signaling pathway in humans (NCBITaxon:9606) that includes interactions between several proteins: receptor-type tyrosine-protein phosphatase mu (PTPRM), p120-catenin (CTNND1), palmitoyltransferase ZDHHC7, and the glucose transporter GLUT4 (SLC2A4).</p>"},{"location":"reviews/613aae0000000885-SP_ANN_PTPRM/#model-components-and-structure","title":"Model Components and Structure","text":"<p>The model consists of 5 activities with causal relationships between them:</p> <ol> <li>CTNND1 (p120-catenin) performs:</li> <li>Cadherin binding (GO:0045296) at the cell surface (GO:0009986)</li> <li> <p>This activity provides input for the protein sequestering activity of CTNND1</p> </li> <li> <p>CTNND1 also performs:</p> </li> <li>Protein sequestering activity (GO:0140311) in the cytoplasm (GO:0005737)</li> <li> <p>This activity directly negatively regulates the glucose transporter activity of SLC2A4</p> </li> <li> <p>ZDHHC7 performs:</p> </li> <li>Palmitoyltransferase activity (GO:0016409)</li> <li> <p>This activity directly positively regulates the glucose transporter activity of SLC2A4</p> </li> <li> <p>PTPRM performs:</p> </li> <li>Phosphatase activity (GO:0016791) at the cell-cell junction (GO:0005911)</li> <li> <p>This activity directly negatively regulates the protein sequestering activity of CTNND1</p> </li> <li> <p>SLC2A4 (GLUT4) performs:</p> </li> <li>D-glucose transmembrane transporter activity (GO:0055056) at the plasma membrane (GO:0005886)</li> </ol>"},{"location":"reviews/613aae0000000885-SP_ANN_PTPRM/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model is supported by multiple primary research articles:</p> <ul> <li>The cadherin binding activity of CTNND1 is supported by PMID:15240885</li> <li>The cellular location of CTNND1 at the cell surface is supported by PMID:17047063</li> <li>The protein sequestering activity of CTNND1 is supported by PMID:21998202</li> <li>The phosphatase activity of PTPRM and its regulation of CTNND1 is supported by PMID:10753936</li> <li>The palmitoyltransferase activity of ZDHHC7 regulating GLUT4 is supported by PMID:28057756</li> <li>The glucose transporter activity of SLC2A4 and its cellular location is supported by PMID:25004245 and PMID:31112275</li> </ul> <p>All annotations appear to be supported by experimental evidence code ECO:0000314 (direct assay evidence used in manual assertion).</p>"},{"location":"reviews/613aae0000000885-SP_ANN_PTPRM/#consistency-with-go-cam-guidelines","title":"Consistency with GO-CAM Guidelines","text":"<p>After examining the model and relevant literature, I've identified the following points regarding consistency with GO-CAM guidelines:</p> <ol> <li> <p>Appropriate use of causal relationships: The model correctly uses the predicate RO:0002411 (provides input for), RO:0002630 (directly negatively regulates), and RO:0002629 (directly positively regulates) to connect activities.</p> </li> <li> <p>Complex annotation: This model doesn't include any protein complexes, so the complex annotation guidelines don't apply directly here. Each protein is represented individually with its own molecular function.</p> </li> <li> <p>Location annotation: Each activity is appropriately annotated with a cellular component term.</p> </li> <li> <p>Evidence support: Each assertion is backed by experimental evidence from published literature.</p> </li> </ol>"},{"location":"reviews/613aae0000000885-SP_ANN_PTPRM/#biological-consistency","title":"Biological Consistency","text":"<p>Looking at the biological content of the model and the supporting literature:</p> <ol> <li> <p>PTPRM-CTNND1 relationship: The paper by Kim et al. (PMID:21998202) provides evidence that PTPRM dephosphorylates p120-catenin (CTNND1), reducing its cytoplasmic localization. This is correctly represented in the model.</p> </li> <li> <p>CTNND1-SLC2A4 relationship: The same paper demonstrates that cytoplasmic p120-catenin prevents SLC2A4/GLUT4 membrane trafficking. This is correctly represented through the negative regulatory relationship.</p> </li> <li> <p>ZDHHC7-SLC2A4 relationship: The paper by Du et al. (PMID:28057756) shows that ZDHHC7 palmitoylates GLUT4 and regulates its membrane translocation. This positive regulatory relationship is correctly captured.</p> </li> </ol>"},{"location":"reviews/613aae0000000885-SP_ANN_PTPRM/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Activity flow completeness: The model could potentially benefit from including the membrane translocation activity of GLUT4, which appears to be a key regulatory step in this pathway based on the literature.</p> </li> <li> <p>Temporal aspects: The model doesn't explicitly capture the temporal sequence of events involving CTNND1 translocation from membrane to cytoplasm.</p> </li> <li> <p>Representation of phosphorylation state: While the model shows PTPRM dephosphorylating CTNND1, it doesn't explicitly represent the phosphorylated state of CTNND1.</p> </li> </ol>"},{"location":"reviews/613aae0000000885-SP_ANN_PTPRM/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model effectively represents a regulatory pathway involving PTPRM, CTNND1, ZDHHC7, and GLUT4/SLC2A4. The model is consistent with GO-CAM best practices and accurately captures the biological relationships described in the literature. The causal relationships between activities are well-supported by experimental evidence.</p> <p>The model effectively illustrates how PTPRM promotes GLUT4 membrane trafficking by dephosphorylating p120-catenin, which otherwise would sequester GLUT4 and prevent its translocation to the plasma membrane. In parallel, ZDHHC7 positively regulates GLUT4 membrane trafficking through palmitoylation.</p> <p>This model provides a clear and parsimonious representation of this signaling pathway and would be understandable to researchers familiar with this biological system.</p>"},{"location":"reviews/613aae0000001005-SP_ANN_RECQL5/","title":"613aae0000001005 SP ANN RECQL5","text":"<p>Now that I have gathered the necessary information, I'll review the GO-CAM model.</p>"},{"location":"reviews/613aae0000001005-SP_ANN_RECQL5/#go-cam-model-review-for-gomodel613aae0000001005","title":"GO-CAM Model Review for gomodel:613aae0000001005","text":""},{"location":"reviews/613aae0000001005-SP_ANN_RECQL5/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (ID: gomodel:613aae0000001005) is titled \"SP-ANN-RECQL5\" and describes activities related to the human RECQL5 helicase and its interactions with RAD51 and MUS81 proteins in the context of DNA replication and repair processes.</p>"},{"location":"reviews/613aae0000001005-SP_ANN_RECQL5/#structure-analysis","title":"Structure Analysis","text":"<p>The model consists of four main activities:</p> <ol> <li>RECQL5 Helicase Activity:</li> <li>Enabled by: RECQL5 protein (UniProtKB:O94762)</li> <li>Molecular function: Helicase activity (GO:0004386)</li> <li>Occurs in: Replication fork (GO:0005657)</li> <li>Part of biological process: Mitotic DNA-templated DNA replication (GO:1990506)</li> <li>Has input: ATP (CHEBI:15422) and water (CHEBI:15377)</li> <li>Has output: ADP (CHEBI:16761) and phosphate (CHEBI:26020)</li> <li> <p>This activity causally regulates two downstream activities:</p> <ul> <li>Positively regulates (RO:0002629) MUS81 endonuclease activity</li> <li>Negatively regulates (RO:0002630) RAD51 DNA binding</li> </ul> </li> <li> <p>RAD51 DNA Binding Activity:</p> </li> <li>Enabled by: RAD51 protein (UniProtKB:Q06609)</li> <li>Molecular function: Single-stranded DNA binding (GO:0003697)</li> <li> <p>Occurs in: Presynaptic intermediate filament cytoskeleton (GO:0099182)</p> </li> <li> <p>CDK1 Kinase Activity:</p> </li> <li>Enabled by: CDK1 protein (UniProtKB:P06493)</li> <li>Molecular function: Kinase activity (GO:0016301)</li> <li> <p>Positively regulates (RO:0002629) RECQL5 helicase activity</p> </li> <li> <p>MUS81 Endonuclease Activity:</p> </li> <li>Enabled by: MUS81 protein (UniProtKB:Q96NY9)</li> <li>Molecular function: Endonuclease activity (GO:0004519)</li> <li>Occurs in: Replication fork (GO:0005657)</li> </ol>"},{"location":"reviews/613aae0000001005-SP_ANN_RECQL5/#accuracy-assessment","title":"Accuracy Assessment","text":"<ol> <li>Scientific Accuracy:</li> <li>The interactions between RECQL5, RAD51, and MUS81 are well-supported by the scientific literature.</li> <li>The causal relationship where RECQL5 negatively regulates RAD51 activity is consistent with the literature that shows RECQL5 disrupts RAD51 presynaptic filaments (Hu et al., 2007, PMID:18003859).</li> <li>The model correctly shows CDK1 positively regulating RECQL5, which is consistent with the literature showing CDK1 can phosphorylate RECQL5 at Ser-727 to enhance its activity at stalled replication forks (Di Marco et al., 2017, PMID:28575661).</li> <li> <p>The model properly shows RECQL5 positively regulating MUS81 endonuclease activity, which aligns with research showing their cooperation in processing stalled replication forks.</p> </li> <li> <p>Concerns/Issues:</p> </li> <li> <p>The annotation of RAD51 localized to \"presynaptic intermediate filament cytoskeleton\" (GO:0099182) appears incorrect. Based on the literature, RAD51 forms nucleoprotein filaments on DNA at sites of DNA damage, particularly at stalled replication forks. A more appropriate location would be \"replication fork\" (GO:0005657) or \"site of DNA damage\" (GO:0035861).</p> </li> <li> <p>The model lacks information about how CDK1-mediated phosphorylation of RECQL5 enhances its function, specifically at Ser-727, which is mentioned in PMID:28575661.</p> </li> </ol>"},{"location":"reviews/613aae0000001005-SP_ANN_RECQL5/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li>Update RAD51 Localization:</li> <li> <p>Change the \"occurs_in\" annotation for RAD51 from \"presynaptic intermediate filament cytoskeleton\" (GO:0099182) to a more appropriate term like \"replication fork\" (GO:0005657) or \"site of DNA damage\" (GO:0035861).</p> </li> <li> <p>Add Phosphorylation Details:</p> </li> <li> <p>Consider adding information about RECQL5 phosphorylation at Ser-727 by CDK1, which enhances its ability to disrupt RAD51 filaments as described in PMID:28575661.</p> </li> <li> <p>Add Additional Context:</p> </li> <li> <p>It would be beneficial to add more context about the biological process, such as specifying the role of this pathway in preventing inappropriate homologous recombination and maintaining genome stability.</p> </li> <li> <p>Expand Model with Additional Activities:</p> </li> <li>The model could be expanded to include more details about how RECQL5 and MUS81 cooperate in processing stalled replication forks at common fragile sites.</li> </ol>"},{"location":"reviews/613aae0000001005-SP_ANN_RECQL5/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model effectively captures the core relationships between RECQL5, RAD51, CDK1, and MUS81 in the context of DNA replication and repair. The causal relationships are appropriate and supported by published research. With the suggested improvements, particularly regarding RAD51 localization and additional phosphorylation details, the model would provide an even more accurate representation of these molecular interactions.</p>"},{"location":"reviews/617b481400000389-KAT5_regulation_of_the_cytoskeleton_by_acetylation_of_proteins__Human_/","title":"617b481400000389 KAT5 regulation of the cytoskeleton by acetylation of proteins  Human","text":"<p>Now I'm ready to review this GO-CAM model.</p> <p>Based on my analysis of the GO-CAM model gomodel:617b481400000389 titled \"KAT5 regulation of the cytoskeleton by acetylation of proteins (Human)\" and the associated scientific literature, I can provide the following comprehensive review:</p>"},{"location":"reviews/617b481400000389-KAT5_regulation_of_the_cytoskeleton_by_acetylation_of_proteins__Human_/#overall-assessment","title":"Overall Assessment","text":"<p>This GO-CAM model represents a molecular pathway involving KAT5 (TIP60), AURKB (Aurora B), SIRT1, and NDC80 (HEC1) in regulating chromosome segregation during mitosis through protein acetylation and phosphorylation. The model is based on two key publications (PMID:26829474 and PMID:30409912) and effectively captures important molecular interactions involved in ensuring accurate kinetochore-microtubule attachment and sister chromatid segregation.</p>"},{"location":"reviews/617b481400000389-KAT5_regulation_of_the_cytoskeleton_by_acetylation_of_proteins__Human_/#model-structure-and-connectivity","title":"Model Structure and Connectivity","text":"<p>The model contains 6 molecular activities connected through causal associations: 1. CDK1 (P06493) protein serine/threonine kinase activity \u2192 KAT5 (Q92993) peptide-lysine-N-acetyltransferase activity 2. KAT5 (Q92993) peptide-lysine-N-acetyltransferase activity \u2192 AURKB (Q96GD4) protein serine/threonine kinase activity 3. AURKB (Q96GD4) protein serine/threonine kinase activity \u2192 NDC80 (O14777) kinetochore adaptor activity 4. SIRT1 (Q96EB6-2) NAD-dependent protein deacetylase activity \u2192 NDC80 (O14777) kinetochore adaptor activity 5. SIRT1 (Q96EB6-2) NAD-dependent protein deacetylase activity \u2192 AURKB (Q96GD4) protein serine/threonine kinase activity 6. KAT5 (Q92993) peptide-lysine-N-acetyltransferase activity \u2192 AURKB (Q96GD4) protein serine/threonine kinase activity</p> <p>All activities are part of the biological process \"positive regulation of mitotic sister chromatid segregation\" (GO:0062033) or \"attachment of mitotic spindle microtubules to kinetochore\" (GO:0051315), which is appropriate given the functions described in the literature.</p>"},{"location":"reviews/617b481400000389-KAT5_regulation_of_the_cytoskeleton_by_acetylation_of_proteins__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Well-supported by evidence: All molecular functions and causal relationships are supported by experimental evidence from peer-reviewed publications.</p> </li> <li> <p>Appropriate directionality: The causal relationships use proper RO terms to indicate the positive regulation (RO:0002629, \"directly positively regulates\") and negative regulation (RO:0002630, \"directly negatively regulates\").</p> </li> <li> <p>Comprehensive representation: The model effectively captures the dynamic balance between acetylation (by KAT5) and deacetylation (by SIRT1) which is central to the mitotic regulatory mechanism described in the papers.</p> </li> <li> <p>Biologically accurate: The model correctly represents the multi-step signaling cascade from CDK1 phosphorylation of KAT5, to KAT5 acetylation of AURKB, to AURKB regulation of NDC80 function at the kinetochore.</p> </li> </ol>"},{"location":"reviews/617b481400000389-KAT5_regulation_of_the_cytoskeleton_by_acetylation_of_proteins__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing specific phosphorylation sites: The model doesn't specify that CDK1 phosphorylates KAT5 at Ser90, which is an important regulatory mechanism highlighted in the PMID:26829474 paper. Including this specific phosphorylation site would enhance the precision of the model.</p> </li> <li> <p>Missing specific acetylation sites: The model doesn't specify that KAT5 acetylates AURKB at Lys215 or that KAT5 acetylates NDC80/HEC1 at Lys53 and Lys59. These specific sites are crucial for the regulatory mechanism.</p> </li> <li> <p>Incomplete representation of SIRT1 relationships: While the model correctly shows that SIRT1 negatively regulates NDC80, it could be more specific about SIRT1's deacetylation of NDC80 at Lys53 and Lys59, as described in PMID:30409912.</p> </li> <li> <p>Missing temporal dynamics: The model doesn't capture the temporal dynamics of the acetylation/deacetylation cycle during different phases of mitosis, which is an important aspect discussed in both papers.</p> </li> <li> <p>Possible missing interactions: The model doesn't include direct interaction between KAT5 and NDC80, though PMID:30409912 shows that KAT5 directly acetylates NDC80. This represents a potential gap in the model.</p> </li> </ol>"},{"location":"reviews/617b481400000389-KAT5_regulation_of_the_cytoskeleton_by_acetylation_of_proteins__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add the specific phosphorylation site (Ser90) for CDK1's action on KAT5.</p> </li> <li> <p>Add the specific acetylation sites for KAT5's action on AURKB (Lys215) and NDC80 (Lys53/Lys59).</p> </li> <li> <p>Add a direct causal relationship from KAT5 to NDC80 to represent KAT5's direct acetylation of NDC80.</p> </li> <li> <p>Consider adding annotations or notes to indicate the temporal dynamics of these modifications during mitotic progression.</p> </li> <li> <p>Consider adding more details about how these modifications affect protein-protein interactions or complex formation (e.g., how Lys215 acetylation of AURKB prevents PP2A-mediated dephosphorylation of Thr232).</p> </li> </ol>"},{"location":"reviews/617b481400000389-KAT5_regulation_of_the_cytoskeleton_by_acetylation_of_proteins__Human_/#consistency-with-go-cam-guidelines","title":"Consistency with GO-CAM Guidelines","text":"<p>The model generally follows GO-CAM best practices in terms of: - Appropriate use of molecular function terms - Proper connectivity between activities - Correct use of causal relationship predicates - Association of activities with relevant biological processes</p> <p>The model effectively uses the appropriate evidence codes (ECO:0000314 for direct assay evidence) and provides proper citation of the research literature.</p>"},{"location":"reviews/617b481400000389-KAT5_regulation_of_the_cytoskeleton_by_acetylation_of_proteins__Human_/#biological-context-and-significance","title":"Biological Context and Significance","text":"<p>This model represents an important regulatory mechanism for ensuring accurate chromosome segregation during mitosis. The work illustrates how post-translational modifications (acetylation, phosphorylation, and deacetylation) are coordinated to regulate kinetochore-microtubule attachments, which is crucial for maintaining genomic stability. Errors in this process can lead to aneuploidy, a hallmark of cancer cells.</p>"},{"location":"reviews/617b481400000389-KAT5_regulation_of_the_cytoskeleton_by_acetylation_of_proteins__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:617b481400000389 effectively captures key molecular interactions involved in regulating chromosome segregation through KAT5-mediated acetylation. While there are some areas where more detail could be added, the model successfully represents the core regulatory mechanisms described in the literature and provides a valuable resource for understanding this important biological process.</p>"},{"location":"reviews/617b481400000460-KAT5_involvement_in_DNA_repair_via_homologous_recombination__Human_/","title":"617b481400000460 KAT5 involvement in DNA repair via homologous recombination  Human","text":"<p>Now, let me review the GO-CAM model in detail. Based on the information I've gathered, I'll analyze the model \"KAT5 involvement in DNA repair via homologous recombination (Human)\" (gomodel:617b481400000460).</p>"},{"location":"reviews/617b481400000460-KAT5_involvement_in_DNA_repair_via_homologous_recombination__Human_/#go-cam-model-review-kat5-involvement-in-dna-repair-via-homologous-recombination-human","title":"GO-CAM Model Review: KAT5 involvement in DNA repair via homologous recombination (Human)","text":""},{"location":"reviews/617b481400000460-KAT5_involvement_in_DNA_repair_via_homologous_recombination__Human_/#overview","title":"Overview:","text":"<p>This GO-CAM model represents the role of KAT5 (TIP60) in DNA double-strand break repair, specifically how it influences the choice between DNA repair pathways (homologous recombination vs. non-homologous end joining) through its interactions with histone modifications and 53BP1.</p>"},{"location":"reviews/617b481400000460-KAT5_involvement_in_DNA_repair_via_homologous_recombination__Human_/#scientific-content-assessment","title":"Scientific Content Assessment:","text":"<p>The model captures several key molecular activities and their causal relationships:</p> <ol> <li> <p>RNF168 (UniProtKB:Q8IYW5) performs histone H2AK15 ubiquitin ligase activity (GO:0140858) at sites of double-strand breaks (GO:0035861), which provides input for TP53BP1 ubiquitin-modified histone reader activity and DNA-binding transcription factor activity.</p> </li> <li> <p>KAT5 (UniProtKB:Q92993) performs histone H2A acetyltransferase activity (GO:0043998) at sites of double-strand breaks, which maintains a regulatory relationship with TP53BP1 methylated histone binding activity.</p> </li> <li> <p>MBTD1 (UniProtKB:Q05BQ5) performs methylated histone binding (GO:0035064) and directly negatively regulates TP53BP1 binding to methylated histones.</p> </li> <li> <p>EPC1 (UniProtKB:Q9H2F5) performs chromatin-protein adaptor activity (GO:0140463) and directly positively regulates MBTD1 activities.</p> </li> <li> <p>TP53BP1 (UniProtKB:Q12888) performs both methylated histone binding (GO:0035064) and ubiquitin-modified histone reader activity (GO:0061649).</p> </li> <li> <p>Additional regulatory proteins: PIAS4 and SENP3 regulate KAT5 through sumoylation processes.</p> </li> </ol>"},{"location":"reviews/617b481400000460-KAT5_involvement_in_DNA_repair_via_homologous_recombination__Human_/#pathway-logic","title":"Pathway Logic:","text":"<p>The model correctly depicts the competition between homologous recombination (HR) and non-homologous end joining (NHEJ) pathways at double-strand breaks:</p> <ul> <li>The TIP60 complex (KAT5) promotes HR by:</li> <li>Acetylating H2AK15, which prevents ubiquitination of this site by RNF168</li> <li> <p>Using MBTD1 to compete with 53BP1 for binding to H4K20me2</p> </li> <li> <p>53BP1 promotes NHEJ by:</p> </li> <li>Binding to H4K20me2 via its Tudor domain</li> <li>Binding to H2AK15ub via its UDR motif</li> </ul>"},{"location":"reviews/617b481400000460-KAT5_involvement_in_DNA_repair_via_homologous_recombination__Human_/#model-strengths","title":"Model Strengths:","text":"<ol> <li> <p>The model accurately captures the bivalent chromatin recognition system of 53BP1 (binding to both H4K20me2 and H2AK15ub).</p> </li> <li> <p>It correctly represents the antagonistic relationship between KAT5 and 53BP1, where KAT5 promotes HR by interfering with 53BP1 binding.</p> </li> <li> <p>The regulatory relationships use appropriate causal predicates (RO:0002413 \"provides input for\", RO:0002629 \"directly positively regulates\", and RO:0002630 \"directly negatively regulates\").</p> </li> <li> <p>The model incorporates MBTD1 as a key component of the TIP60 complex that competes with 53BP1 for H4K20me2 binding.</p> </li> <li> <p>The inclusion of EPC1 as an adaptor protein for MBTD1 is supported by the literature.</p> </li> <li> <p>The model shows how PIAS4 and SENP3 regulate KAT5 activity, reflecting the dynamic regulation of repair pathway choice.</p> </li> </ol>"},{"location":"reviews/617b481400000460-KAT5_involvement_in_DNA_repair_via_homologous_recombination__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement:","text":"<ol> <li> <p>Representation of the NuA4/TIP60 Complex: While the model shows KAT5 and some components, the full TIP60 complex isn't explicitly represented. According to best practices for complex annotation, using GO:0035267 (NuA4 histone acetyltransferase complex) might be appropriate in some places rather than individual proteins if the specific activity-carrying subunits aren't clearly identified.</p> </li> <li> <p>Cell Cycle Regulation: The model could be expanded to include cell cycle-dependent regulation of repair pathway choice. During S/G2 phases, HR is favored, while NHEJ predominates in G1.</p> </li> <li> <p>Bi-directional Process: It would be valuable to explicitly show that H2AK15 is a site of competition between ubiquitination (by RNF168) and acetylation (by KAT5), which directly impacts 53BP1 recruitment.</p> </li> <li> <p>Acetylation Target Specification: The histone H2A acetyltransferase activity (GO:0043998) could be more specifically annotated as H2AK15 acetyltransferase activity if that term is available, to better reflect the site-specific nature of this mechanism.</p> </li> <li> <p>Biological Process Annotation: The model correctly shows the part_of relationships to double-strand break repair processes (GO:0000724 and GO:0006303), but could potentially benefit from explicitly showing the antagonistic relationship between these processes.</p> </li> </ol>"},{"location":"reviews/617b481400000460-KAT5_involvement_in_DNA_repair_via_homologous_recombination__Human_/#technicalquality-issues","title":"Technical/Quality Issues:","text":"<ol> <li> <p>All activities and relationships in the model are properly supported with evidence codes and PMID references.</p> </li> <li> <p>The subcellular localization is consistently annotated as \"site of double-strand break\" (GO:0035861).</p> </li> <li> <p>I noticed the use of RO:0012010 in one causal association, which is not among the standard predicates listed in your guidelines (which include RO:0002413, RO:0002629, RO:0002630, RO:0002304, and RO:0002305). This should be checked for consistency.</p> </li> </ol>"},{"location":"reviews/617b481400000460-KAT5_involvement_in_DNA_repair_via_homologous_recombination__Human_/#conclusion","title":"Conclusion:","text":"<p>The GO-CAM model \"KAT5 involvement in DNA repair via homologous recombination (Human)\" is scientifically accurate and effectively represents the current understanding of how KAT5/TIP60 influences DNA repair pathway choice. It properly captures the competition between KAT5 and 53BP1 for binding to modified histones at double-strand breaks, and how this affects the choice between HR and NHEJ repair mechanisms.</p> <p>The model follows most GO-CAM best practices for representing molecular activities, causal relationships, and cellular context. With a few minor refinements, particularly in the representation of protein complexes and the competitive relationship between repair pathways, this model could provide an even more comprehensive representation of this important biological process.</p>"},{"location":"reviews/617b481400000521-KAT5_involvement_in_nucleotide_excision_repair__Human_/","title":"617b481400000521 KAT5 involvement in nucleotide excision repair  Human","text":"<p>Now I can review the GO-CAM model:</p> <p>Based on the information provided, I'll review the GO-CAM model gomodel:617b481400000521 titled \"KAT5 involvement in nucleotide excision repair (Human)\".</p>"},{"location":"reviews/617b481400000521-KAT5_involvement_in_nucleotide_excision_repair__Human_/#review-of-go-cam-model-gomodel617b481400000521","title":"Review of GO-CAM Model gomodel:617b481400000521","text":""},{"location":"reviews/617b481400000521-KAT5_involvement_in_nucleotide_excision_repair__Human_/#basic-model-information","title":"Basic Model Information","text":"<ul> <li>Model ID: gomodel:617b481400000521</li> <li>Title: KAT5 involvement in nucleotide excision repair (Human)</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: Production</li> </ul>"},{"location":"reviews/617b481400000521-KAT5_involvement_in_nucleotide_excision_repair__Human_/#overview-of-the-model","title":"Overview of the Model","text":"<p>This model describes the role of KAT5 (also known as TIP60) in nucleotide excision repair (NER) through its interaction with ERCC4/XPF and SIRT1. The model focuses on how KAT5 acetylates XPF, which facilitates XPF-ERCC1 complex assembly and activation for DNA repair.</p>"},{"location":"reviews/617b481400000521-KAT5_involvement_in_nucleotide_excision_repair__Human_/#activities-and-causal-associations","title":"Activities and Causal Associations","text":"<p>The model includes four molecular activities:</p> <ol> <li>SIRT1 NAD-dependent protein lysine deacetylase activity:</li> <li>Enabled by: UniProtKB:Q96EB6 (SIRT1)</li> <li>Function: GO:0034979 (NAD-dependent protein lysine deacetylase activity)</li> <li> <p>Causal association: Negatively regulates XPF protein binding</p> </li> <li> <p>KAT5 peptide-lysine-N-acetyltransferase activity:</p> </li> <li>Enabled by: UniProtKB:Q92993 (KAT5/TIP60)</li> <li>Function: GO:0061733 (peptide-lysine-N-acetyltransferase activity)</li> <li> <p>Causal association: Positively regulates XPF protein binding</p> </li> <li> <p>XPF protein binding activity:</p> </li> <li>Enabled by: UniProtKB:Q92889-2 (ERCC4/XPF isoform 2)</li> <li>Function: GO:0005515 (protein binding)</li> <li>Part of: GO:0006289 (nucleotide-excision repair)</li> <li> <p>Causal association: Positively regulates XPF endonuclease activity</p> </li> <li> <p>XPF single-stranded DNA endonuclease activity:</p> </li> <li>Enabled by: UniProtKB:Q92889-2 (ERCC4/XPF isoform 2)</li> <li>Function: GO:0000014 (single-stranded DNA endodeoxyribonuclease activity)</li> <li>Part of: GO:0006289 (nucleotide-excision repair)</li> </ol>"},{"location":"reviews/617b481400000521-KAT5_involvement_in_nucleotide_excision_repair__Human_/#evidence","title":"Evidence","text":"<p>All activities and causal associations are supported by evidence from: - Evidence: ECO:0000314 (direct assay evidence used in manual assertion) - Reference: PMID:32034146 - Provenance: ORCID:0000-0001-7299-6685 (dated 2021-11-04)</p>"},{"location":"reviews/617b481400000521-KAT5_involvement_in_nucleotide_excision_repair__Human_/#scientific-accuracy-assessment","title":"Scientific Accuracy Assessment","text":"<p>The model accurately represents the findings from Wang et al. (2020) [PMID:32034146], which demonstrated that:</p> <ol> <li>TIP60 (KAT5) acetylates XPF at Lys-911, which disrupts the Glu907-Lys911 salt bridge.</li> <li>This acetylation exposes a second binding site for ERCC1, promoting XPF-ERCC1 complex formation.</li> <li>SIRT1 can deacetylate XPF, counteracting the effect of KAT5.</li> <li>These regulatory events are important for nucleotide excision repair (NER) and interstrand crosslink (ICL) repair functions.</li> </ol> <p>The biological relationships described in the paper are properly captured in the model through the causal associations.</p>"},{"location":"reviews/617b481400000521-KAT5_involvement_in_nucleotide_excision_repair__Human_/#go-cam-best-practices-compliance","title":"GO-CAM Best Practices Compliance","text":"<ol> <li>Entity Representation: </li> <li>The model uses appropriate UniProtKB identifiers for proteins.</li> <li> <p>Isoform 2 of XPF (Q92889-2) is correctly specified.</p> </li> <li> <p>Activity Representation:</p> </li> <li>Molecular functions are correctly assigned to each protein.</li> <li> <p>The use of \"protein binding\" [GO:0005515] for XPF is appropriate in this context as it specifically refers to the binding between XPF and ERCC1.</p> </li> <li> <p>Causal Relationships:</p> </li> <li> <p>The causal relationships use appropriate relation ontology terms:</p> <ul> <li>RO:0002629 (directly positively regulates) for KAT5 \u2192 XPF binding</li> <li>RO:0002630 (directly negatively regulates) for SIRT1 \u2192 XPF binding</li> <li>RO:0002629 (directly positively regulates) for XPF binding \u2192 XPF endonuclease activity</li> </ul> </li> <li> <p>Biological Process Integration:</p> </li> <li> <p>Both XPF activities are correctly integrated with the \"nucleotide-excision repair\" process [GO:0006289].</p> </li> <li> <p>Complex Representation:</p> </li> <li>The model follows GO-CAM guidelines for complex representation (according to \"How to annotate complexes in GO-CAM\").</li> <li>Rather than using a complex ID for the XPF-ERCC1 complex, the model correctly represents the specific subunit (XPF) that undergoes acetylation.</li> <li> <p>Since the action happens at the level of the interaction between two proteins (rather than an intrinsic complex activity), this approach is appropriate.</p> </li> <li> <p>Evidence and Attribution:</p> </li> <li>All activities and causal associations include the appropriate evidence codes and reference information.</li> <li>The provenance with ORCID is properly attributed.</li> </ol>"},{"location":"reviews/617b481400000521-KAT5_involvement_in_nucleotide_excision_repair__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li>Terminology Clarification:</li> <li> <p>The model uses GO:0005515 (protein binding) for XPF, but it might be more specific to use a term that captures the interaction with ERCC1 specifically.</p> </li> <li> <p>Additional Biological Context:</p> </li> <li>The model could potentially include the specific acetylation site (Lys-911) of XPF as an annotation to provide more detailed molecular information.</li> <li> <p>The connection to DNA damage response or UV-induced damage could be explicitly added to provide fuller biological context.</p> </li> <li> <p>Model Completeness:</p> </li> <li>The model focuses on the core regulatory mechanisms described in the paper but doesn't capture the downstream effects on DNA repair or the cellular outcomes. These additional elements could enhance the model's comprehensiveness.</li> </ol>"},{"location":"reviews/617b481400000521-KAT5_involvement_in_nucleotide_excision_repair__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:617b481400000521 accurately represents the molecular mechanisms of KAT5's involvement in nucleotide excision repair through XPF acetylation as described in the primary literature. It follows GO-CAM best practices for representing molecular activities, causal associations, and biological processes. The model is well-structured, biologically accurate, and provides a clear representation of how KAT5 and SIRT1 regulate XPF-ERCC1 complex formation during DNA repair.</p> <p>The model is parsimonious and focuses on the essential elements needed to represent the biological pathway, making it easy for a human to understand the regulatory circuit controlling XPF-ERCC1 complex assembly and function in nucleotide excision repair.</p>"},{"location":"reviews/617b481400000559-KAT5_regulation_of_lipid_droplet_disassembly__Human_/","title":"617b481400000559 KAT5 regulation of lipid droplet disassembly  Human","text":"<p>Based on my review of the GO-CAM model (gomodel:617b481400000559) titled \"KAT5 regulation of lipid droplet disassembly (Human)\" and the relevant information I've gathered, here's my detailed assessment:</p>"},{"location":"reviews/617b481400000559-KAT5_regulation_of_lipid_droplet_disassembly__Human_/#model-structure-review","title":"Model Structure Review","text":"<p>This model represents a cellular pathway where KAT5 (histone acetyltransferase) regulates lipid droplet disassembly in response to glucose starvation in human cells. The model includes the following key activities and relationships:</p> <ol> <li> <p>PRKAA1 (Q13131, AMPK alpha-1) and PRKAA2 (P54646, AMPK alpha-2) both perform protein serine/threonine kinase activity (GO:0004674), as part of cellular response to glucose starvation (GO:0042149), and both positively regulate KAT5 transcription activity and phosphorylate CHKA.</p> </li> <li> <p>KAT5 (Q92993) performs peptide-lysine-N-acetyltransferase activity (GO:0061733), as part of cellular response to glucose starvation (GO:0042149), and negatively regulates CHKA homodimerization while positively regulating CHKA protein binding.</p> </li> <li> <p>CHKA (P35790-1, isoform 1) has:</p> </li> <li>Protein homodimerization activity (GO:0042803) in the cytosol, part of phosphatidylcholine biosynthetic process</li> <li>Protein binding activity (GO:0005515) in lipid droplets, in response to glucose starvation</li> <li>Choline kinase activity (GO:0004103) in the cytosol</li> <li>Ethanolamine kinase activity (GO:0004305) in the cytosol</li> <li>Protein tyrosine kinase activity (GO:0004713) in lipid droplets, part of lipid droplet disassembly</li> </ol>"},{"location":"reviews/617b481400000559-KAT5_regulation_of_lipid_droplet_disassembly__Human_/#scientific-content-assessment","title":"Scientific Content Assessment","text":"<p>The model accurately captures the findings reported in the primary article (PMID:34077757), specifically:</p> <ol> <li> <p>Mechanism of regulation: The model correctly shows that AMPK (PRKAA1 and PRKAA2) phosphorylates CHKA at Ser-279 upon glucose deprivation, which promotes its localization to lipid droplets.</p> </li> <li> <p>KAT5-mediated acetylation: KAT5 subsequently acetylates CHKA at Lys-247, promoting dissociation of the CHKA homodimer into monomers.</p> </li> <li> <p>Functional shift: The model accurately depicts that acetylated monomeric CHKA is converted into a protein tyrosine kinase that phosphorylates lipid droplet structural proteins (though I note the model doesn't explicitly show the downstream targets PLIN2 and PLIN3).</p> </li> <li> <p>Biological outcome: The model appropriately shows the culmination of this pathway as lipid droplet disassembly (GO:1905691).</p> </li> </ol>"},{"location":"reviews/617b481400000559-KAT5_regulation_of_lipid_droplet_disassembly__Human_/#annotation-quality-review","title":"Annotation Quality Review","text":"<ol> <li> <p>Correct use of GO terms: The molecular functions, biological processes, and cellular components are appropriately assigned.</p> </li> <li> <p>Proper use of causal associations: </p> </li> <li>RO:0002629 (directly positively regulates) and RO:0002630 (directly negatively regulates) are used correctly to show direct regulation.</li> <li> <p>RO:0002304 (causally upstream of, positive effect) is correctly used for the indirect positive regulation.</p> </li> <li> <p>Evidence annotations: All activities are appropriately supported with ECO:0000314 (direct assay evidence used in manual assertion) and refer to the primary paper PMID:34077757.</p> </li> <li> <p>Localization information: The model correctly includes cellular localization information for CHKA, showing its presence in both cytosol and lipid droplets.</p> </li> </ol>"},{"location":"reviews/617b481400000559-KAT5_regulation_of_lipid_droplet_disassembly__Human_/#go-cam-best-practices-compliance","title":"GO-CAM Best Practices Compliance","text":"<p>The model follows GO-CAM best practices for:</p> <ol> <li> <p>Activity flow: The activities are connected in a way that is consistent with the biological pathway.</p> </li> <li> <p>Complex representation: The model correctly handles the CHKA homodimer, following the guidelines in \"How to annotate complexes in GO-CAM\" by properly showing the homodimerization activity.</p> </li> <li> <p>Protein modification effects: The model appropriately captures how post-translational modifications (phosphorylation followed by acetylation) affect protein function.</p> </li> </ol>"},{"location":"reviews/617b481400000559-KAT5_regulation_of_lipid_droplet_disassembly__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<p>While the model is scientifically accurate and well-constructed, I'd suggest a few minor improvements:</p> <ol> <li> <p>Complete the pathway: Consider adding the specific lipid droplet proteins (PLIN2 and PLIN3) that are phosphorylated by monomeric CHKA's tyrosine kinase activity. This would complete the mechanistic picture of how lipid droplet disassembly occurs.</p> </li> <li> <p>Clearer activity visualization: The model might benefit from a clearer visual representation of the transition from CHKA homodimer to monomer following acetylation.</p> </li> <li> <p>Additional contextual information: Consider adding information about adenylate charge sensing (a key function of AMPK) as part of the glucose starvation response.</p> </li> </ol>"},{"location":"reviews/617b481400000559-KAT5_regulation_of_lipid_droplet_disassembly__Human_/#overall-assessment","title":"Overall Assessment","text":"<p>This GO-CAM model (gomodel:617b481400000559) is a high-quality representation of the KAT5-mediated regulation of lipid droplet disassembly pathway. It accurately captures the scientific content from the literature, follows GO-CAM best practices, and provides a clear depiction of the activity flow in the pathway. The model is parsimonious and presents the information in a way that would be understandable to a human curator.</p> <p>The model effectively represents a novel and important regulatory mechanism where a metabolic enzyme (CHKA) is converted to a protein kinase through post-translational modifications, leading to lipid droplet disassembly during glucose starvation.</p>"},{"location":"reviews/617b481400000672-KAT5_chromatin_localization__Human_/","title":"617b481400000672 KAT5 chromatin localization  Human","text":"<p>Now that I've gathered all the necessary information, I'll review the GO-CAM model:</p>"},{"location":"reviews/617b481400000672-KAT5_chromatin_localization__Human_/#review-of-go-cam-model-gomodel617b481400000672","title":"Review of GO-CAM Model: gomodel:617b481400000672","text":""},{"location":"reviews/617b481400000672-KAT5_chromatin_localization__Human_/#model-overview","title":"Model Overview","text":"<p>Title: KAT5 chromatin localization (Human) Taxon: Human (NCBITaxon:9606) Status: Production</p>"},{"location":"reviews/617b481400000672-KAT5_chromatin_localization__Human_/#summary","title":"Summary","text":"<p>This model describes the chromatin localization of KAT5 (also known as Tip60) and its activities in the context of positive regulation of transcription and DNA damage response. The model shows how KAT5 is regulated through phosphorylation by CDK9 and VRK1, and how KAT5's subsequent activities affect transcription and DNA damage response.</p>"},{"location":"reviews/617b481400000672-KAT5_chromatin_localization__Human_/#model-strengths","title":"Model Strengths","text":"<ol> <li>Accurate representation of KAT5 molecular activities:</li> <li>The model correctly represents KAT5's chromatin binding activity (GO:0003682)</li> <li> <p>The histone acetyltransferase activity (GO:0004402) and H4K16 acetyltransferase activity (GO:0046972) are properly represented</p> </li> <li> <p>Proper subcellular localization:</p> </li> <li> <p>The model correctly places KAT5 activities in chromatin (GO:0000785)</p> </li> <li> <p>Biological context:</p> </li> <li> <p>The model appropriately connects KAT5's activities to positive regulation of transcription by RNA polymerase II (GO:0045944) and DNA damage response (GO:0006974)</p> </li> <li> <p>Causal relationships:</p> </li> <li> <p>The model shows the correct regulatory relationships where:</p> <ul> <li>CDK9's protein serine/threonine kinase activity leads to KAT5 chromatin binding</li> <li>VRK1's protein serine/threonine kinase activity leads to KAT5 chromatin binding</li> <li>KAT5's chromatin binding leads to histone acetyltransferase activity</li> </ul> </li> <li> <p>Evidence basis:</p> </li> <li>The model uses appropriate evidence codes (ECO:0000314 - direct assay evidence used in manual assertion)</li> <li>References to primary literature (PMID:29335245 and PMID:33076429) are provided</li> </ol>"},{"location":"reviews/617b481400000672-KAT5_chromatin_localization__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>Specificity of phosphorylation sites:</li> <li> <p>The model does not specify which specific serine residues are phosphorylated. Based on the literature (PMID:29335245), CDK9 phosphorylates KAT5 at serine 90 (S90), which is critical for its association with chromatin. This detail could be added to the model.</p> </li> <li> <p>Temporal sequence of activities:</p> </li> <li> <p>While the causal relationships are correctly represented, the temporal sequence is not entirely clear. The literature indicates that S90 phosphorylation is required for subsequent S86 phosphorylation by GSK3, which together enhance KAT5's HAT activity. This sequential relationship could be made more explicit.</p> </li> <li> <p>Missing GSK3 regulation:</p> </li> <li> <p>According to PMID:29335245, GSK3 phosphorylates S86 of KAT5 using S90 phosphorylation as a priming site. This important regulatory component is missing from the model.</p> </li> <li> <p>Model completeness:</p> </li> <li> <p>The model focuses primarily on the regulation of KAT5 localization but could be expanded to include:</p> <ul> <li>H2AX acetylation by KAT5, which is important for NBS1 recruitment to DNA damage sites</li> <li>ATM acetylation by KAT5, which is required for ATM activation in DNA damage response</li> </ul> </li> <li> <p>Complex representation:</p> </li> <li>According to the GO-CAM guidelines for complexes, if KAT5 is part of the NuA4 histone acetyltransferase complex during these activities, this could be represented. The model currently treats KAT5 as an individual protein rather than as part of its known complex.</li> </ol>"},{"location":"reviews/617b481400000672-KAT5_chromatin_localization__Human_/#recommendations","title":"Recommendations","text":"<ol> <li>Add specific phosphorylation sites:</li> <li>Specify that CDK9 phosphorylates KAT5 at S90</li> <li> <p>Specify that VRK1 phosphorylates KAT5 (though the exact site may not be specified in the literature)</p> </li> <li> <p>Include GSK3 regulation:</p> </li> <li> <p>Add GSK3's role in phosphorylating KAT5 at S86, which depends on prior S90 phosphorylation</p> </li> <li> <p>Expand downstream events:</p> </li> <li>Include KAT5's role in acetylating H2AX at K5</li> <li> <p>Include KAT5's role in acetylating ATM at K3016</p> </li> <li> <p>Clarify complex participation:</p> </li> <li> <p>If appropriate, indicate KAT5's participation in the NuA4 histone acetyltransferase complex when performing its acetyltransferase activities</p> </li> <li> <p>Add additional disease relevance:</p> </li> <li>Consider adding information about KAT5's role in cancer resistance to DNA-damaging agents, which is mentioned in the literature</li> </ol>"},{"location":"reviews/617b481400000672-KAT5_chromatin_localization__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the key activities of KAT5 in chromatin and its regulation by kinases. The model effectively captures how KAT5's activities contribute to transcriptional regulation and DNA damage response. With the suggested improvements, particularly regarding the specificity of phosphorylation sites and the inclusion of GSK3 regulation, the model would provide an even more complete representation of the biological mechanisms involved in KAT5 function.</p>"},{"location":"reviews/617b481400000793-KAT5_autoacetylation_and_deacetylation_by_HDAC3_and_SIRT1__Human_/","title":"617b481400000793 KAT5 autoacetylation and deacetylation by HDAC3 and SIRT1  Human","text":"<p>Now that I've gathered the necessary information, I'll review the GO-CAM model gomodel:617b481400000793 titled \"KAT5 autoacetylation and deacetylation by HDAC3 and SIRT1 (Human)\".</p>"},{"location":"reviews/617b481400000793-KAT5_autoacetylation_and_deacetylation_by_HDAC3_and_SIRT1__Human_/#go-cam-review-kat5-autoacetylation-and-deacetylation-by-hdac3-and-sirt1-human","title":"GO-CAM Review: KAT5 autoacetylation and deacetylation by HDAC3 and SIRT1 (Human)","text":""},{"location":"reviews/617b481400000793-KAT5_autoacetylation_and_deacetylation_by_HDAC3_and_SIRT1__Human_/#model-summary","title":"Model Summary","text":"<p>This model (gomodel:617b481400000793) depicts the process of KAT5 (also known as TIP60) autoacetylation and its subsequent deacetylation by HDAC3 and SIRT1 in human cells. The model is centered around DNA repair-dependent chromatin remodeling (GO:0140861).</p>"},{"location":"reviews/617b481400000793-KAT5_autoacetylation_and_deacetylation_by_HDAC3_and_SIRT1__Human_/#model-components","title":"Model Components","text":"<ol> <li>KAT5 (UniProtKB:Q92993) with two activities:</li> <li>Peptide-lysine-N-acetyltransferase activity (GO:0061733)</li> <li> <p>Histone acetyltransferase activity (GO:0004402)</p> </li> <li> <p>HDAC3 (UniProtKB:O15379) with:</p> </li> <li> <p>Protein lysine deacetylase activity (GO:0033558)</p> </li> <li> <p>SIRT1 (UniProtKB:Q96EB6) with:</p> </li> <li>NAD-dependent protein lysine deacetylase activity (GO:0034979)</li> </ol>"},{"location":"reviews/617b481400000793-KAT5_autoacetylation_and_deacetylation_by_HDAC3_and_SIRT1__Human_/#causal-relationships","title":"Causal Relationships","text":"<ul> <li>KAT5's peptide-lysine-N-acetyltransferase activity directly positively regulates (RO:0002629) its own histone acetyltransferase activity.</li> <li>HDAC3's protein lysine deacetylase activity directly negatively regulates (RO:0002630) KAT5's peptide-lysine-N-acetyltransferase activity.</li> <li>SIRT1's NAD-dependent protein lysine deacetylase activity directly negatively regulates (RO:0002630) KAT5's peptide-lysine-N-acetyltransferase activity.</li> </ul>"},{"location":"reviews/617b481400000793-KAT5_autoacetylation_and_deacetylation_by_HDAC3_and_SIRT1__Human_/#subcellular-location","title":"Subcellular Location","text":"<ul> <li>Both KAT5 activities occur in the nucleus (GO:0005634).</li> </ul>"},{"location":"reviews/617b481400000793-KAT5_autoacetylation_and_deacetylation_by_HDAC3_and_SIRT1__Human_/#evidence","title":"Evidence","text":"<p>The model is supported by evidence from two publications: - PMID:25301942 - Demonstrating the role of HDAC3 in deacetylating KAT5/TIP60 - PMID:20100829 - Examining how SIRT1 regulates KAT5/TIP60 autoacetylation</p>"},{"location":"reviews/617b481400000793-KAT5_autoacetylation_and_deacetylation_by_HDAC3_and_SIRT1__Human_/#review-assessment","title":"Review Assessment","text":""},{"location":"reviews/617b481400000793-KAT5_autoacetylation_and_deacetylation_by_HDAC3_and_SIRT1__Human_/#biological-content-accuracy","title":"Biological Content Accuracy","text":"<p>The model correctly represents the relationship between KAT5 autoacetylation and its deacetylation by both HDAC3 and SIRT1, as supported by the literature. The mechanisms depicted are consistent with what is known about these proteins:</p> <ol> <li> <p>KAT5 autoacetylation: KAT5 (TIP60) is known to acetylate itself at multiple lysine residues (including K104, K120, K148, K150, K187, and K189), which enhances its histone acetyltransferase activity. This is correctly depicted in the model.</p> </li> <li> <p>Deacetylation by HDAC3: According to PMID:25301942, HDAC3 deacetylates KAT5 (TIP60), which reduces its acetyltransferase activity. This negative regulation is appropriately represented.</p> </li> <li> <p>Deacetylation by SIRT1: The literature (PMID:20100829) confirms that SIRT1 regulates KAT5 (TIP60) by deacetylating it, which affects its activity. This is correctly represented in the model.</p> </li> <li> <p>Biological context: The model places these activities in the context of DNA repair-dependent chromatin remodeling, which is consistent with the known functions of these proteins.</p> </li> </ol>"},{"location":"reviews/617b481400000793-KAT5_autoacetylation_and_deacetylation_by_HDAC3_and_SIRT1__Human_/#model-structure-and-causal-flow","title":"Model Structure and Causal Flow","text":"<p>The causal flow in the model is logical and well-structured: - KAT5 first acetylates itself, which enhances its own activity - Both HDAC3 and SIRT1 can deacetylate KAT5, negatively regulating its activity</p> <p>The use of causal relationships (\"directly positively regulates\" and \"directly negatively regulates\") is appropriate for representing these molecular interactions.</p>"},{"location":"reviews/617b481400000793-KAT5_autoacetylation_and_deacetylation_by_HDAC3_and_SIRT1__Human_/#go-cam-best-practice-compliance","title":"GO-CAM Best Practice Compliance","text":"<p>The model complies with GO-CAM best practices:</p> <ol> <li> <p>Proper use of molecular function terms: The model uses appropriate molecular function terms for each protein.</p> </li> <li> <p>Appropriate causal relationships: The causal relationships (RO:0002629 and RO:0002630) correctly represent the positive and negative regulatory relationships.</p> </li> <li> <p>Annotation of cellular context: The model includes the subcellular location (nucleus) for KAT5 activities, which provides important context.</p> </li> <li> <p>Evidence support: Each assertion is supported by published evidence with appropriate ECO codes.</p> </li> <li> <p>Complex annotation: The model correctly represents individual proteins rather than complexes, as the activities are known to be carried out by specific proteins, following the complex annotation guidelines.</p> </li> </ol>"},{"location":"reviews/617b481400000793-KAT5_autoacetylation_and_deacetylation_by_HDAC3_and_SIRT1__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<p>While the model is well-constructed, I have a few minor suggestions for improvement:</p> <ol> <li> <p>Add cellular location for deacetylase activities: Consider adding the subcellular location for HDAC3 and SIRT1 activities for completeness, as these also occur in the nucleus.</p> </li> <li> <p>Additional context information: The model could be enriched by adding information about the specific lysine residues on KAT5 that are acetylated/deacetylated, as these are mentioned in the literature (K104, K120, K148, K150, K187, and K189).</p> </li> <li> <p>Link to downstream processes: Consider extending the model to show how KAT5's acetyltransferase activity affects DNA repair or chromatin remodeling specifically, to better illustrate the biological significance.</p> </li> </ol>"},{"location":"reviews/617b481400000793-KAT5_autoacetylation_and_deacetylation_by_HDAC3_and_SIRT1__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"KAT5 autoacetylation and deacetylation by HDAC3 and SIRT1 (Human)\" is biologically accurate, well-structured, and follows GO-CAM best practices. It effectively represents the regulatory relationships between these proteins based on published evidence. The model provides a clear representation of how KAT5 activity is regulated through acetylation and deacetylation in the context of DNA repair-dependent chromatin remodeling.</p>"},{"location":"reviews/617b481400000995-Epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/","title":"617b481400000995 Epidermal growth factor receptor signaling pathway 1  Mouse","text":"<p>Now I'll review the model in detail based on the information gathered:</p>"},{"location":"reviews/617b481400000995-Epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#review-of-go-cam-model-gomodel617b481400000995","title":"Review of GO-CAM Model gomodel:617b481400000995","text":""},{"location":"reviews/617b481400000995-Epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#model-overview","title":"Model Overview","text":"<p>Title: Epidermal growth factor receptor signaling pathway 1 (Mouse) Taxon: Mouse (NCBITaxon:10090) Status: Production  </p> <p>This model represents the epidermal growth factor receptor (EGFR) signaling pathway in mouse. It depicts the interactions between: 1. Egf (MGI:MGI:95290) as the ligand 2. Egfr (MGI:MGI:95294) as the receptor 3. Two metalloproteinases involved in ligand maturation:    - Mep1a (MGI:MGI:96963)    - Adam10 (MGI:MGI:109548)</p>"},{"location":"reviews/617b481400000995-Epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#evaluation-of-model-structure","title":"Evaluation of Model Structure","text":""},{"location":"reviews/617b481400000995-Epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#strengths","title":"Strengths:","text":"<ol> <li>Appropriate Representation of Core Components:</li> <li>The model correctly depicts Egf as enabling receptor ligand activity</li> <li>Egfr is correctly represented with epidermal growth factor receptor activity</li> <li> <p>The causal relationship showing Egf directly positively regulating Egfr is correct</p> </li> <li> <p>Well-evidenced Assertions:</p> </li> <li>Every activity and relationship is supported by published evidence (PMIDs)</li> <li> <p>Multiple evidence codes are used appropriately (ECO:0000314, ECO:0000315, ECO:0000266)</p> </li> <li> <p>Cellular Context:</p> </li> <li> <p>Appropriate cellular locations are provided for all components:</p> <ul> <li>Egf occurs in extracellular space (GO:0005615)</li> <li>Egfr occurs in plasma membrane (GO:0005886)</li> <li>Metalloproteinases occur in plasma membrane (GO:0005886)</li> </ul> </li> <li> <p>Process Context:</p> </li> <li>Activities are correctly placed in the context of their biological processes:<ul> <li>Egf and Egfr are part of EGFR signaling pathway (GO:0007173)</li> <li>Metalloproteinases are part of EGF receptor ligand maturation (GO:0038004)</li> </ul> </li> </ol>"},{"location":"reviews/617b481400000995-Epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#issues-identified","title":"Issues Identified:","text":"<ol> <li>Metalloproteinase Causal Relationships:</li> <li> <p>Both Mep1a and Adam10 are shown to causally affect Egf activity using RO:0002304 (causally upstream of, positive effect) relationship, rather than the more specific RO:0002629 (directly positively regulates) that would better indicate their direct effect on Egf</p> </li> <li> <p>Missing Input Relationships:</p> </li> <li> <p>According to the signaling receptor guidelines, the relation between a receptor and its target is captured with 'has input' relation, but this relationship is missing for the Egfr activity (it should have an input representing its downstream target)</p> </li> <li> <p>Information Flow Incompleteness:</p> </li> <li> <p>The model stops at receptor activation and does not include any downstream signaling events that would typically follow EGFR activation (such as activation of kinase cascades)</p> </li> <li> <p>No Complex Representation:</p> </li> <li>While not necessarily an issue (as EGFR can signal as a monomer), it's worth noting that EGFR often dimerizes upon ligand binding, which isn't represented in this model</li> </ol>"},{"location":"reviews/617b481400000995-Epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#scientific-content-assessment","title":"Scientific Content Assessment","text":"<p>The biological content of the model is consistent with the EGFR signaling literature. The referenced papers (PMID:7752576, PMID:6248866, PMID:22923609, etc.) provide evidence for:</p> <ol> <li>The role of Egf as a ligand for Egfr</li> <li>The involvement of metalloproteinases in Egf maturation</li> <li>The EGFR pathway's role in kidney development (as seen in PMID:7752576)</li> </ol> <p>The model accurately captures these fundamental aspects of EGFR signaling, particularly the ligand-receptor interaction and the maturation of the Egf ligand by metalloproteinases.</p>"},{"location":"reviews/617b481400000995-Epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li>Update Causal Relationships:</li> <li> <p>Replace RO:0002304 (causally upstream of, positive effect) with RO:0002629 (directly positively regulates) for the relationships between metalloproteinases and Egf activity to more precisely indicate their direct regulatory effect</p> </li> <li> <p>Add Downstream Signaling:</p> </li> <li> <p>Consider extending the model to include at least one downstream signaling component activated by EGFR (e.g., Grb2, Sos, or Ras) to better represent the signaling cascade</p> </li> <li> <p>Add 'has input' Relations:</p> </li> <li> <p>Add appropriate 'has input' relations for the Egfr activity to represent its downstream targets, following the signaling receptor guidelines</p> </li> <li> <p>Consider Receptor Dimerization:</p> </li> <li>If supported by evidence, consider representing EGFR dimerization upon ligand binding, which is a key aspect of its activation mechanism</li> </ol>"},{"location":"reviews/617b481400000995-Epidermal_growth_factor_receptor_signaling_pathway_1__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:617b481400000995 provides a solid foundation for representing the EGFR signaling pathway in mouse, with appropriate activities, cellular locations, and biological process contexts. The model follows many GO-CAM best practices and is well-supported by evidence.</p> <p>The suggested improvements would enhance the model's completeness and precision in representing the EGFR signaling pathway, particularly by using more specific causal relationships and extending the pathway downstream of receptor activation.</p>"},{"location":"reviews/617b481400003575-SP_RNF169/","title":"617b481400003575 SP RNF169","text":"<p>Based on all this information, I'll now review the GO-CAM model with ID gomodel:617b481400003575.</p>"},{"location":"reviews/617b481400003575-SP_RNF169/#review-of-go-cam-model-gomodel617b481400003575-sp-rnf169","title":"Review of GO-CAM Model gomodel:617b481400003575 (SP-RNF169)","text":""},{"location":"reviews/617b481400003575-SP_RNF169/#model-overview","title":"Model Overview","text":"<p>This model titled \"SP-RNF169\" depicts a signaling pathway in human cells (NCBITaxon:9606) involving the regulation of DNA damage response through DYRK1A-mediated phosphorylation of RNF169, which in turn negatively regulates TP53BP1 recruitment to DNA double-strand break sites.</p> <p>The model includes four main protein activities:</p> <ol> <li>DYRK1A (UniProtKB:Q13627) - Protein serine kinase activity (GO:0106310)</li> <li>RNF169 (UniProtKB:Q8NCN4) - Ubiquitin-modified histone reader activity (GO:0061649)</li> <li>TP53BP1 (UniProtKB:Q12888) - Ubiquitin-modified histone reader activity (GO:0061649)</li> <li>UIMC1/RAP80 (UniProtKB:Q96RL1) - Ubiquitin-modified histone reader activity (GO:0061649)</li> </ol>"},{"location":"reviews/617b481400003575-SP_RNF169/#biological-accuracy-of-the-model","title":"Biological Accuracy of the Model","text":"<p>The model accurately captures the scientific evidence from the literature:</p> <ol> <li>DYRK1A phosphorylates RNF169 at multiple sites (Ser368 and Ser403)</li> <li>This phosphorylation enhances RNF169's ability to limit TP53BP1 deposition at DNA double-strand break (DSB) sites</li> <li>RNF169 negatively regulates both TP53BP1 and RAP80-BRCA1 recruitment to DSBs</li> <li>This regulatory mechanism influences DNA repair pathway choice between NHEJ (non-homologous end joining) and HR (homologous recombination)</li> </ol> <p>The evidence presented in PMID:30773093 directly supports this model, showing that DYRK1A regulates RNF169 through phosphorylation, which in turn affects recruitment of 53BP1 to sites of DNA damage.</p>"},{"location":"reviews/617b481400003575-SP_RNF169/#model-structure-assessment","title":"Model Structure Assessment","text":""},{"location":"reviews/617b481400003575-SP_RNF169/#strengths","title":"Strengths:","text":"<ol> <li>Well-supported by evidence: The model accurately reflects the experimental evidence cited in the referenced papers</li> <li>Appropriate causal relationships: Uses the correct causal relationships (RO:0002629 \"directly positively regulates\" and RO:0002630 \"directly negatively regulates\")</li> <li>Proper evidence citation: Each activity and causal relationship is properly supported by evidence with PMID citations</li> <li>Biological process context: The activities are placed in the appropriate biological process context (TP53BP1 and UIMC1/RAP80 in DSB repair processes)</li> </ol>"},{"location":"reviews/617b481400003575-SP_RNF169/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li>Representation of detailed molecular mechanisms: While the model shows the regulation relationships, it could be expanded to include:</li> <li>The specific phosphorylation sites on RNF169 (Ser368 and Ser403) as described in the paper</li> <li> <p>The molecular details of how phosphorylated RNF169 competes with TP53BP1 at DSB sites</p> </li> <li> <p>Biological process annotations: </p> </li> <li>Both RNF169 and TP53BP1 are involved in DSB repair processes, but only TP53BP1 has this annotation. RNF169 should also have a process annotation.</li> <li> <p>DYRK1A is shown as phosphorylating RNF169 but doesn't have any biological process annotation related to DNA damage response.</p> </li> <li> <p>Complex representation: </p> </li> <li> <p>According to the GO-CAM guidelines for complexes, since the model involves proteins that form complexes or interact at DSBs, it would be informative to represent any known complex formations.</p> </li> <li> <p>Cellular component annotations:</p> </li> <li>The model would benefit from adding the cellular component information, especially that RNF169, TP53BP1, and UIMC1/RAP80 localize to sites of double-strand breaks (GO:0035861)</li> </ol>"},{"location":"reviews/617b481400003575-SP_RNF169/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li>Add cellular component annotations:</li> <li> <p>Add \"site of double-strand break\" (GO:0035861) as cellular component for RNF169, TP53BP1, and UIMC1 activities</p> </li> <li> <p>Expand biological process annotations:</p> </li> <li>Add \"double-strand break repair via homologous recombination\" (GO:0000724) for RNF169</li> <li> <p>Add \"DNA damage response\" process for DYRK1A to provide context</p> </li> <li> <p>Complete representation of regulation:</p> </li> <li> <p>Consider adding a step showing how RNF169 promotes homologous recombination repair as a consequence of limiting TP53BP1 recruitment</p> </li> <li> <p>Additional molecular functions:</p> </li> <li>If appropriate based on the literature, add DYRK1A's activity on other substrates in the DNA damage response pathway</li> </ol>"},{"location":"reviews/617b481400003575-SP_RNF169/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:617b481400003575) provides a clear representation of how DYRK1A regulates DNA repair pathway choice through phosphorylation of RNF169, which in turn regulates TP53BP1 and UIMC1/RAP80 recruitment to DNA damage sites. The model is well-supported by the literature evidence and uses appropriate causal relationships.</p> <p>The model faithfully represents the published findings of the cited papers, particularly PMID:30773093, which established the regulatory role of DYRK1A on RNF169 and the subsequent effect on 53BP1 recruitment. The regulation shown is biologically accurate and has significant implications for understanding DNA repair pathway choice.</p> <p>With the suggested improvements, this model would more comprehensively represent the molecular mechanisms involved in this regulatory pathway and provide a more complete view of the biological context in which these interactions occur.</p>"},{"location":"reviews/6197061700000593-ERBB2_EGFR_signaling_pathway_1__Mouse_/","title":"6197061700000593 ERBB2 EGFR signaling pathway 1  Mouse","text":"<p>Let me now evaluate the GO-CAM model with ID gomodel:6197061700000593 based on the information gathered.</p>"},{"location":"reviews/6197061700000593-ERBB2_EGFR_signaling_pathway_1__Mouse_/#model-review-for-erbb2-egfr-signaling-pathway-1-mouse-gomodel6197061700000593","title":"Model Review for ERBB2-EGFR signaling pathway 1 (Mouse), gomodel:6197061700000593","text":""},{"location":"reviews/6197061700000593-ERBB2_EGFR_signaling_pathway_1__Mouse_/#overview-of-the-model","title":"Overview of the Model","text":"<p>The model represents the ERBB2-EGFR signaling pathway in mouse (taxon: NCBITaxon:10090). This pathway involves four key molecular activities:</p> <ol> <li>ADAM17 (A Disintegrin and Metalloprotease 17) - Performing metalloendopeptidase activity</li> <li>HB-EGF (Heparin-binding EGF-like growth factor) - Acting as a receptor ligand</li> <li>EGFR (Epidermal Growth Factor Receptor) - Functioning as an EGF receptor</li> <li>ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2) - Exhibiting protein tyrosine kinase activity</li> </ol>"},{"location":"reviews/6197061700000593-ERBB2_EGFR_signaling_pathway_1__Mouse_/#pathway-structure-and-causal-relationships","title":"Pathway Structure and Causal Relationships","text":"<p>The pathway is structured in the following causal sequence: - ADAM17 metalloendopeptidase activity positively regulates (RO:0002304) HB-EGF receptor ligand activity - HB-EGF receptor ligand activity directly positively regulates (RO:0002629) EGFR epidermal growth factor receptor activity - EGFR epidermal growth factor receptor activity directly positively regulates (RO:0002629) ERBB2 protein tyrosine kinase activity</p>"},{"location":"reviews/6197061700000593-ERBB2_EGFR_signaling_pathway_1__Mouse_/#model-review-and-evaluation","title":"Model Review and Evaluation","text":""},{"location":"reviews/6197061700000593-ERBB2_EGFR_signaling_pathway_1__Mouse_/#completeness-and-accuracy","title":"Completeness and Accuracy","text":"<ol> <li>Activity Annotations:</li> <li> <p>Each of the four activities is properly annotated with appropriate molecular functions:</p> <ul> <li>MGI:MGI:1096335 (Adam17) \u2192 GO:0004222 (metalloendopeptidase activity)</li> <li>MGI:MGI:96070 (Hbegf) \u2192 GO:0048018 (receptor ligand activity)</li> <li>MGI:MGI:95294 (Egfr) \u2192 GO:0005006 (epidermal growth factor receptor activity)</li> <li>MGI:MGI:95410 (Erbb2) \u2192 GO:0004713 (protein tyrosine kinase activity)</li> </ul> </li> <li> <p>Cellular Context:</p> </li> <li> <p>Appropriate cellular locations are specified:</p> <ul> <li>ADAM17 activity occurs in plasma membrane (GO:0005886)</li> <li>HB-EGF activity occurs in extracellular space (GO:0005615)</li> <li>EGFR activity occurs in plasma membrane (GO:0005886)</li> <li>ERBB2 activity occurs in plasma membrane (GO:0005886)</li> </ul> </li> <li> <p>Biological Process:</p> </li> <li>The activities are correctly associated with relevant biological processes:<ul> <li>ADAM17 \u2192 GO:0140448 (signaling receptor ligand precursor processing)</li> <li>HB-EGF, EGFR, ERBB2 \u2192 GO:0038134 (ERBB2-EGFR signaling pathway)</li> </ul> </li> </ol>"},{"location":"reviews/6197061700000593-ERBB2_EGFR_signaling_pathway_1__Mouse_/#evidence-quality","title":"Evidence Quality","text":"<ul> <li>The model uses multiple evidence codes:</li> <li>ECO:0000314 (direct assay evidence used in manual assertion)</li> <li>ECO:0000315 (mutant phenotype evidence used in manual assertion)</li> <li> <p>ECO:0000316 (genetic interaction evidence used in manual assertion)</p> </li> <li> <p>Evidence is supported by specific primary literature citations:</p> </li> <li>PMID:21946538, PMID:16357442, PMID:14993236, PMID:19029950</li> </ul>"},{"location":"reviews/6197061700000593-ERBB2_EGFR_signaling_pathway_1__Mouse_/#causal-flow-and-logical-consistency","title":"Causal Flow and Logical Consistency","text":"<ul> <li>The causal flow of the pathway is logically consistent:</li> <li>ADAM17 cleaves the HB-EGF precursor to release active HB-EGF</li> <li>HB-EGF binds to and activates EGFR</li> <li> <p>Activated EGFR dimerizes with ERBB2 and leads to ERBB2 transactivation through phosphorylation</p> </li> <li> <p>The relationship types used are appropriate:</p> </li> <li>\"Causally upstream of, positive effect\" (RO:0002304) for ADAM17 \u2192 HB-EGF</li> <li>\"Directly positively regulates\" (RO:0002629) for HB-EGF \u2192 EGFR and EGFR \u2192 ERBB2</li> </ul>"},{"location":"reviews/6197061700000593-ERBB2_EGFR_signaling_pathway_1__Mouse_/#alignment-with-biological-knowledge","title":"Alignment with Biological Knowledge","text":"<p>The model accurately represents the known biology of the ERBB2-EGFR signaling pathway:</p> <ol> <li> <p>ADAM17 role: ADAM17 is correctly modeled as processing HB-EGF precursor, which aligns with its known function in shedding membrane-bound growth factors.</p> </li> <li> <p>HB-EGF function: HB-EGF is correctly shown as a ligand that activates EGFR, which matches its known role as an EGFR ligand.</p> </li> <li> <p>EGFR-ERBB2 interaction: The model correctly captures that EGFR activation leads to ERBB2 activation, reflecting their known heterodimerization and transphosphorylation.</p> </li> </ol>"},{"location":"reviews/6197061700000593-ERBB2_EGFR_signaling_pathway_1__Mouse_/#potential-improvements","title":"Potential Improvements","text":"<ol> <li>Additional Components:</li> <li>The model could include downstream effectors of EGFR-ERBB2 signaling, such as PI3K, MAPK signaling, or other key pathways.</li> <li> <p>Regulatory components like phosphatases or negative feedback regulators could be added.</p> </li> <li> <p>Detailed Mechanism:</p> </li> <li>The specific mechanism of EGFR-ERBB2 heterodimerization could be more explicitly modeled.</li> <li> <p>The specific tyrosine residues phosphorylated during activation could be specified.</p> </li> <li> <p>Additional Context:</p> </li> <li>Additional context-specific information (e.g., tissue-specific roles) could enhance the model.</li> </ol>"},{"location":"reviews/6197061700000593-ERBB2_EGFR_signaling_pathway_1__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:6197061700000593 representing the ERBB2-EGFR signaling pathway in mouse is well-constructed and follows GO-CAM best practices. It accurately captures the key components and causal relationships in this signaling pathway with appropriate evidence. The model is concise, focusing on the core aspects of the pathway, which makes it easy to understand.</p> <p>The model correctly represents the activation sequence from ADAM17-mediated processing of HB-EGF to the activation of EGFR and subsequent activation of ERBB2. All activities are properly contextualized with cellular locations and biological processes, and the evidence provided is appropriate and specific.</p> <p>While the model could potentially be expanded to include downstream effectors or more detailed mechanisms, it successfully captures the essential aspects of the ERBB2-EGFR signaling pathway. As a core model, it provides a solid foundation that could be extended in future iterations.</p>"},{"location":"reviews/6197061700001485-Silencing_of_fetal_hemoglobin__by_ZNF410__Human_/","title":"6197061700001485 Silencing of fetal hemoglobin  by ZNF410  Human","text":"<p>Based on my examination of the GO-CAM model \"Silencing of fetal hemoglobin by ZNF410 (Human)\" with ID gomodel:6197061700001485, I can provide the following review:</p>"},{"location":"reviews/6197061700001485-Silencing_of_fetal_hemoglobin__by_ZNF410__Human_/#summary-of-the-model","title":"Summary of the Model","text":"<p>This GO-CAM model represents the molecular pathway by which ZNF410 represses fetal hemoglobin expression in human erythroid cells. The model includes four key activities:</p> <ol> <li>ZNF410 (UniProtKB:Q86VK4) performing DNA-binding transcription factor activity (GO:0003700)</li> <li>CHD4 (UniProtKB:Q14839) performing transcription corepressor activity (GO:0003714)</li> <li>HBG1 (UniProtKB:P69891) performing oxygen carrier activity (GO:0005344)</li> <li>HBG2 (UniProtKB:P69892) performing oxygen carrier activity (GO:0005344)</li> </ol> <p>The causal flow is: - ZNF410 directly positively regulates CHD4 - CHD4 causally upstream with negative effect on both HBG1 and HBG2</p>"},{"location":"reviews/6197061700001485-Silencing_of_fetal_hemoglobin__by_ZNF410__Human_/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The model accurately represents recent scientific findings about ZNF410's role in fetal hemoglobin silencing, as shown by the PMID:33859416 reference. This 2021 paper by Vinjamur et al. demonstrates that ZNF410 is a transcription factor that represses fetal globin by controlling CHD4, which is part of the NuRD chromatin remodeling complex.</p> <p>The model correctly shows that ZNF410 does not directly repress HBG1/HBG2, but rather acts through CHD4, which then negatively regulates the fetal hemoglobin genes.</p>"},{"location":"reviews/6197061700001485-Silencing_of_fetal_hemoglobin__by_ZNF410__Human_/#cell-type-specificity","title":"Cell Type Specificity","text":"<p>The model appropriately specifies that these interactions occur in: - Erythroid lineage cells (CL:0000764) for ZNF410 and CHD4 activities - Erythrocytes (CL:0000232) for HBG1 and HBG2 activities</p> <p>This is consistent with the biological context of fetal hemoglobin regulation.</p>"},{"location":"reviews/6197061700001485-Silencing_of_fetal_hemoglobin__by_ZNF410__Human_/#quality-of-evidence","title":"Quality of Evidence","text":"<p>All activities and causal relationships are supported by experimental evidence (ECO:0000314 - direct assay evidence used in manual assertion) from primary literature (PMID:33859416, PMID:22096240, PMID:19065339).</p>"},{"location":"reviews/6197061700001485-Silencing_of_fetal_hemoglobin__by_ZNF410__Human_/#go-cam-best-practices-review","title":"GO-CAM Best Practices Review","text":""},{"location":"reviews/6197061700001485-Silencing_of_fetal_hemoglobin__by_ZNF410__Human_/#strengths","title":"Strengths:","text":"<ol> <li>Appropriate causal relations: The model uses the correct causal predicates:</li> <li>\"directly positively regulates\" (RO:0002629) for ZNF410 \u2192 CHD4</li> <li> <p>\"causally upstream of, negative effect\" (RO:0002305) for CHD4 \u2192 HBG1/HBG2</p> </li> <li> <p>Correct activity annotations: Each protein is annotated with a specific molecular function that accurately represents its role.</p> </li> <li> <p>Proper anatomical context: Each activity is properly located in the appropriate cell type.</p> </li> <li> <p>Biological process association: Each activity is linked to the relevant biological process.</p> </li> </ol>"},{"location":"reviews/6197061700001485-Silencing_of_fetal_hemoglobin__by_ZNF410__Human_/#compliance-with-go-cam-guidelines","title":"Compliance with GO-CAM Guidelines:","text":"<p>Based on the document \"How_to_annotate_complexes_in_GO-CAM,\" the model appears to follow the guidelines for representing protein activities. Although CHD4 is part of the NuRD complex, the model appropriately represents CHD4 as the specific subunit carrying the transcription corepressor activity, rather than using the complex ID, which aligns with guideline #1.</p>"},{"location":"reviews/6197061700001485-Silencing_of_fetal_hemoglobin__by_ZNF410__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Additional mechanistic detail: The model could be enhanced by including more details about how CHD4 represses fetal hemoglobin genes. Per the research in PMID:33859416, CHD4 is part of the NuRD chromatin remodeling complex that represses HBG1/HBG2. Including additional components of this complex and their activities would provide a more complete representation.</p> </li> <li> <p>Developmental context: The model could benefit from including information about the developmental timing of this silencing mechanism, as fetal hemoglobin silencing is a developmentally regulated process.</p> </li> <li> <p>Upstream regulators: If known, adding the upstream factors that regulate ZNF410 expression or activity would enhance the model.</p> </li> </ol>"},{"location":"reviews/6197061700001485-Silencing_of_fetal_hemoglobin__by_ZNF410__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"Silencing of fetal hemoglobin by ZNF410 (Human)\" accurately represents the current understanding of how ZNF410 regulates fetal hemoglobin expression through CHD4. The model is consistent with GO-CAM best practices, using appropriate functional annotations, causal relations, and cellular contexts. </p> <p>The model is parsimonious and focuses on the core regulatory mechanism, which makes it easy to understand. The model could be expanded to include more mechanistic details about the NuRD complex and developmental context, but as it stands, it provides a clear and accurate representation of this biological pathway.</p>"},{"location":"reviews/6197061700001622-Epidermal_growth_factor_receptor_signaling_pathway_2__Mouse_/","title":"6197061700001622 Epidermal growth factor receptor signaling pathway 2  Mouse","text":"<p>Based on the information gathered, I can now review the GO-CAM model gomodel:6197061700001622 titled \"Epidermal growth factor receptor signaling pathway 2 (Mouse)\". Here's my review:</p>"},{"location":"reviews/6197061700001622-Epidermal_growth_factor_receptor_signaling_pathway_2__Mouse_/#review-of-go-cam-model-gomodel6197061700001622","title":"Review of GO-CAM Model: gomodel:6197061700001622","text":""},{"location":"reviews/6197061700001622-Epidermal_growth_factor_receptor_signaling_pathway_2__Mouse_/#model-overview","title":"Model Overview","text":"<p>This model represents the epidermal growth factor receptor (EGFR) signaling pathway in mouse. It includes four molecular activities connected through causal associations:</p> <ol> <li>ADAM17 (MGI:MGI:1096335) - metallodipeptidase activity (GO:0070573)</li> <li>Mep1a (MGI:MGI:96963) - metallodipeptidase activity (GO:0070573)</li> <li>TGF\u03b1 (MGI:MGI:98724) - receptor ligand activity (GO:0048018)</li> <li>EGFR (MGI:MGI:95294) - transmembrane receptor protein tyrosine kinase activity (GO:0004714)</li> </ol>"},{"location":"reviews/6197061700001622-Epidermal_growth_factor_receptor_signaling_pathway_2__Mouse_/#model-strengths","title":"Model Strengths","text":"<ol> <li> <p>Appropriate GO terms: The molecular functions used are appropriate for the proteins involved. EGFR has transmembrane receptor protein tyrosine kinase activity, TGF\u03b1 has receptor ligand activity, and the metalloproteases (ADAM17 and Mep1a) have metallodipeptidase activity.</p> </li> <li> <p>Correct cellular locations: Activities are correctly located, with the ligand (TGF\u03b1) in the extracellular space (GO:0005615) and the receptor (EGFR) and proteases (ADAM17, Mep1a) in the plasma membrane (GO:0005886).</p> </li> <li> <p>Appropriate biological processes: Each activity is assigned to relevant biological processes - EGFR and TGF\u03b1 are part of the EGFR signaling pathway (GO:0007173), while the metalloproteases are part of signaling receptor ligand precursor processing (GO:0140448).</p> </li> <li> <p>Causal relationships: The model correctly shows the causal relationships between the activities:</p> </li> <li>ADAM17 and Mep1a positively regulate (RO:0002304) TGF\u03b1 activity</li> <li> <p>TGF\u03b1 directly positively regulates (RO:0002629) EGFR activity</p> </li> <li> <p>Evidence: Each activity and causal relationship is supported by appropriate evidence from the scientific literature.</p> </li> </ol>"},{"location":"reviews/6197061700001622-Epidermal_growth_factor_receptor_signaling_pathway_2__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>TGF\u03b1 causal relationship with EGFR: While the model uses RO:0002629 (directly positively regulates) between TGF\u03b1 and EGFR, the signaling receptor guidelines indicate this relationship should be \"directly positively regulates.\" This appears to be correct, so no change is needed.</p> </li> <li> <p>Information flow clarity: The model correctly shows that ADAM17 and Mep1a process TGF\u03b1, which then activates EGFR. However, it's not explicitly shown what happens downstream of EGFR activation.</p> </li> <li> <p>ADAM17 role clarification: Based on the PMID:14993236 paper, ADAM17 is a key sheddase for TGF\u03b1. The model accurately represents this but could be extended to show the downstream effects of EGFR activation.</p> </li> <li> <p>Precursor processing: The model shows that both ADAM17 and Mep1a contribute to signaling receptor ligand precursor processing (GO:0140448), which is accurately represented in the model. However, the details of how these metalloproteases process TGF\u03b1 from its precursor form could be clarified.</p> </li> </ol>"},{"location":"reviews/6197061700001622-Epidermal_growth_factor_receptor_signaling_pathway_2__Mouse_/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<p>The model follows the GO-CAM guidelines for representing signaling receptor pathways, specifically:</p> <ol> <li>The ligand (TGF\u03b1) enables receptor ligand activity and is located in the extracellular space</li> <li>The receptor (EGFR) enables transmembrane receptor protein tyrosine kinase activity and is located in the plasma membrane</li> <li>The causal relationship between the ligand activity and receptor activity is \"directly positively regulates\"</li> <li>The activities are appropriately placed in their biological processes</li> </ol>"},{"location":"reviews/6197061700001622-Epidermal_growth_factor_receptor_signaling_pathway_2__Mouse_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents key aspects of the EGFR signaling pathway:</p> <ol> <li>TGF\u03b1 is a ligand that activates EGFR</li> <li>ADAM17 is a major sheddase for TGF\u03b1 as confirmed by PMID:14993236</li> <li>Mep1a also contributes to TGF\u03b1 processing</li> <li>These components function in the plasma membrane and extracellular space as expected</li> </ol>"},{"location":"reviews/6197061700001622-Epidermal_growth_factor_receptor_signaling_pathway_2__Mouse_/#recommendations","title":"Recommendations","text":"<ol> <li> <p>Add downstream components: Consider extending the model to include the downstream effectors of EGFR activation, such as the RAS-MAPK pathway or PI3K pathway.</p> </li> <li> <p>Include feedback regulation: EGFR signaling often involves feedback loops; these could be added to make the model more comprehensive.</p> </li> <li> <p>Document model creation: Include comments about the reasoning behind model construction or any specific considerations, especially regarding the choice to represent both ADAM17 and Mep1a as processors of TGF\u03b1.</p> </li> <li> <p>Add additional relations: Consider adding more molecular activities or associations to represent the full complexity of EGFR signaling.</p> </li> </ol>"},{"location":"reviews/6197061700001622-Epidermal_growth_factor_receptor_signaling_pathway_2__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:6197061700001622 accurately represents key aspects of the EGFR signaling pathway in mouse, focusing on TGF\u03b1 processing by metalloproteases (ADAM17 and Mep1a) and subsequent EGFR activation. The model adheres to GO-CAM best practices and is supported by appropriate evidence. While complete, it could be extended to include downstream signaling components to provide a more comprehensive representation of EGFR signaling.</p>"},{"location":"reviews/6197061700001643-Epidermal_growth_factor_receptor_signaling_pathway_3__Mouse__/","title":"6197061700001643 Epidermal growth factor receptor signaling pathway 3  Mouse","text":"<p>Based on my review of the GO-CAM model (gomodel:6197061700001643) titled \"Epidermal growth factor receptor signaling pathway 3 (Mouse)\" and the supporting literature and documentation, I can now provide a comprehensive assessment of the model.</p>"},{"location":"reviews/6197061700001643-Epidermal_growth_factor_receptor_signaling_pathway_3__Mouse__/#model-summary","title":"Model Summary","text":"<p>This GO-CAM model represents the epidermal growth factor receptor (EGFR) signaling pathway in mice, specifically focusing on the role of Amphiregulin (Areg) as a ligand that activates EGFR, and the involvement of ADAM17 in processing the Areg precursor.</p> <p>The model contains three main activities: 1. Amphiregulin (Areg) acting as a receptor ligand 2. EGFR functioning as a transmembrane receptor tyrosine kinase 3. ADAM17 (Adam10) functioning as a metallopeptidase</p>"},{"location":"reviews/6197061700001643-Epidermal_growth_factor_receptor_signaling_pathway_3__Mouse__/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Proper molecular function annotations: The model correctly assigns receptor ligand activity (GO:0048018) to Areg, transmembrane receptor protein tyrosine kinase activity (GO:0004714) to EGFR, and metallopeptidase activity (GO:0008237) to ADAM17.</p> </li> <li> <p>Cellular component annotations: The model correctly places Areg in the extracellular space (GO:0005615) and EGFR at the plasma membrane (GO:0005886), which is consistent with their biological locations.</p> </li> <li> <p>Biological process annotations: All activities are appropriately annotated as part of the epidermal growth factor receptor signaling pathway (GO:0007173).</p> </li> <li> <p>Evidence support: The model includes multiple literature references supporting the role of Areg in EGFR activation, with solid experimental evidence codes (ECO:0000316 - genetic interaction evidence used in manual assertion).</p> </li> <li> <p>Causal relationships: The model correctly depicts Areg positively regulating EGFR activity using the \"directly positively regulates\" (RO:0002629) relationship, which is appropriate according to the GO-CAM guidelines for signaling receptor activity.</p> </li> <li> <p>ADAM17 connection: The model accurately represents ADAM17's role in processing Areg, using the \"positively regulates\" (RO:0002304) relationship, which is supported by the literature I reviewed.</p> </li> </ol>"},{"location":"reviews/6197061700001643-Epidermal_growth_factor_receptor_signaling_pathway_3__Mouse__/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li>Incomplete representation of ADAM17's role: While the model correctly shows ADAM17 regulating Areg, the specific process of ectodomain shedding is not fully represented. ADAM17 (called ADA10_MOUSE in UniProt) cleaves membrane-bound Areg to release the soluble form, which then activates EGFR. The model could be improved by:</li> <li>Adding the specific function \"signaling receptor ligand precursor processing\" (GO:0140448) for ADAM17</li> <li> <p>Clarifying that ADAM17 acts on membrane-bound Areg to release its soluble form</p> </li> <li> <p>Missing cell component for ADAM17: The model should specify that ADAM17 is located at the plasma membrane (GO:0005886), as this is where it performs its proteolytic cleavage of Areg.</p> </li> <li> <p>Evidence details: While the papers cited provide strong evidence for the model, the evidence annotations could be more specific about the experimental methods used in each paper that support each specific relationship.</p> </li> <li> <p>Possible additional connections: Based on the papers I reviewed, the model could be expanded to show:</p> </li> <li>The role of macrophage-derived Areg in tissue repair contexts</li> <li>The connection between EGFR activation and downstream signaling pathways like ERK/MAPK</li> </ol>"},{"location":"reviews/6197061700001643-Epidermal_growth_factor_receptor_signaling_pathway_3__Mouse__/#literature-alignment","title":"Literature Alignment","text":"<p>The model accurately represents the key findings from the literature:</p> <ol> <li> <p>PMID:23333074 shows that Areg directly activates EGFR and enhances regulatory T cell function.</p> </li> <li> <p>PMID:30770250 confirms that Areg is a critical EGFR ligand that contributes to tissue repair, particularly through macrophage-derived Areg.</p> </li> <li> <p>PMID:14993236 provides strong evidence that ADAM17 is the main sheddase for Areg, TGF\u03b1, HB-EGF, and epiregulin, while ADAM10 is the main sheddase for EGF and betacellulin.</p> </li> </ol>"},{"location":"reviews/6197061700001643-Epidermal_growth_factor_receptor_signaling_pathway_3__Mouse__/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the Areg-EGFR signaling axis with appropriate molecular functions, cellular locations, and causal relationships. The model is supported by strong scientific evidence and aligns with GO-CAM annotation best practices. The few suggestions for improvement mentioned above would enhance the model's completeness and precision, but they don't detract significantly from its current utility and accuracy.</p> <p>The model correctly depicts that ADAM17 (metallopeptidase) positively regulates Areg (receptor ligand), which in turn directly positively regulates EGFR (receptor tyrosine kinase), forming a coherent biological pathway that matches current understanding of this signaling system in mouse.</p>"},{"location":"reviews/6197061700002226-ERBB2_ERBB4_signaling_pathway_2__Mouse__/","title":"6197061700002226 ERBB2 ERBB4 signaling pathway 2  Mouse","text":"<p>Now, let me analyze the model gomodel:6197061700002226 using all the information I've gathered:</p>"},{"location":"reviews/6197061700002226-ERBB2_ERBB4_signaling_pathway_2__Mouse__/#review-of-go-cam-model-erbb2-erbb4-signaling-pathway-2-mouse","title":"Review of GO-CAM Model: ERBB2-ERBB4 signaling pathway 2 (Mouse)","text":""},{"location":"reviews/6197061700002226-ERBB2_ERBB4_signaling_pathway_2__Mouse__/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model represents the ERBB2-ERBB4 signaling pathway in mouse. It illustrates a signaling cascade that begins with the ligand epiregulin (Ereg) activating the ERBB4 receptor, which then triggers downstream signaling through ERBB2.</p>"},{"location":"reviews/6197061700002226-ERBB2_ERBB4_signaling_pathway_2__Mouse__/#model-components","title":"Model Components","text":"<p>The model contains four key activities:</p> <ol> <li>Epiregulin (Ereg) activity: </li> <li>Enabled by MGI:MGI:107508 (Ereg)</li> <li>Molecular function: GO:0048018 (receptor ligand activity)</li> <li>Occurs in: GO:0005615 (extracellular space)</li> <li>Part of: GO:0038135 (ERBB2-ERBB4 signaling pathway)</li> <li> <p>Causally regulates: ERBB4 (transmembrane receptor protein tyrosine kinase activity)</p> </li> <li> <p>ADAM17 metallopeptidase activity:</p> </li> <li>Enabled by MGI:MGI:1096335 (Adam17)</li> <li>Molecular function: GO:0008237 (metallopeptidase activity)</li> <li>Occurs in: GO:0005886 (plasma membrane)</li> <li>Part of: GO:0140448 (signaling receptor ligand precursor processing)</li> <li> <p>Causally regulates: Ereg (receptor ligand activity)</p> </li> <li> <p>ERBB4 receptor activity:</p> </li> <li>Enabled by MGI:MGI:104771 (Erbb4)</li> <li>Molecular function: GO:0004714 (transmembrane receptor protein tyrosine kinase activity)</li> <li>Occurs in: GO:0005886 (plasma membrane)</li> <li>Part of: GO:0038135 (ERBB2-ERBB4 signaling pathway)</li> <li> <p>Causally regulates: ERBB2 (protein tyrosine kinase activity)</p> </li> <li> <p>ERBB2 kinase activity:</p> </li> <li>Enabled by MGI:MGI:95410 (Erbb2)</li> <li>Molecular function: GO:0004713 (protein tyrosine kinase activity)</li> <li>Occurs in: GO:0005886 (plasma membrane)</li> <li>Part of: GO:0038135 (ERBB2-ERBB4 signaling pathway)</li> </ol>"},{"location":"reviews/6197061700002226-ERBB2_ERBB4_signaling_pathway_2__Mouse__/#evidence-assessment","title":"Evidence Assessment","text":"<p>The model is supported by evidence from several publications, primarily PMID:9556621, which provides most of the annotations through sequence orthology evidence (ECO:0000266). ADAM17's role is supported by mutant phenotype evidence (ECO:0000315) from PMID:14993236.</p>"},{"location":"reviews/6197061700002226-ERBB2_ERBB4_signaling_pathway_2__Mouse__/#compliance-with-go-cam-guidelines","title":"Compliance with GO-CAM Guidelines","text":""},{"location":"reviews/6197061700002226-ERBB2_ERBB4_signaling_pathway_2__Mouse__/#signaling-receptor-activity-annotation","title":"Signaling Receptor Activity Annotation","text":"<p>This model follows the signaling receptor activity annotation guidelines:</p> <ol> <li>For the ligand (Ereg):</li> <li>Correctly annotated with \"receptor ligand activity\" (GO:0048018)</li> <li>Properly occurs in \"extracellular space\" (GO:0005615)</li> <li> <p>Correctly uses \"directly positively regulates\" (RO:0002629) to connect to the receptor activity</p> </li> <li> <p>For the signaling receptor (ERBB4):</p> </li> <li>Correctly annotated with \"transmembrane receptor protein tyrosine kinase activity\" (GO:0004714)</li> <li>Properly occurs in \"plasma membrane\" (GO:0005886)</li> <li> <p>Uses \"directly positively regulates\" (RO:0002629) to connect to downstream signaling</p> </li> <li> <p>For ERBB2:</p> </li> <li>Correctly annotated with \"protein tyrosine kinase activity\" (GO:0004713)</li> <li>Properly occurs in \"plasma membrane\" (GO:0005886)</li> </ol>"},{"location":"reviews/6197061700002226-ERBB2_ERBB4_signaling_pathway_2__Mouse__/#pathway-representation","title":"Pathway Representation","text":"<p>The model represents the ERBB2-ERBB4 signaling pathway with correct causality flow: - ADAM17 positively regulates Ereg (RO:0002304) - Ereg directly positively regulates ERBB4 (RO:0002629) - ERBB4 directly positively regulates ERBB2 (RO:0002629)</p>"},{"location":"reviews/6197061700002226-ERBB2_ERBB4_signaling_pathway_2__Mouse__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>ADAM17 Annotation:</li> <li> <p>The causal relation between ADAM17 and Ereg uses \"causally upstream of, positive effect\" (RO:0002304) rather than \"directly positively regulates\" (RO:0002629). While not incorrect, consistency in relation types would improve clarity.</p> </li> <li> <p>Biological Context:</p> </li> <li>The model could benefit from expanding the pathway by including downstream targets of ERBB2 activation to better represent the complete signaling cascade.</li> <li> <p>Based on the literature, ERBB4 can form heterodimers with ERBB2 upon ligand binding. This heterodimerization aspect is implied but not explicitly represented in the model.</p> </li> <li> <p>Ligand Processing:</p> </li> <li>The model correctly includes ADAM17 as processing epiregulin. According to the literature (PMID:14993236), ADAM17 is the main sheddase for epiregulin. This aspect of the model is well-supported.</li> </ol>"},{"location":"reviews/6197061700002226-ERBB2_ERBB4_signaling_pathway_2__Mouse__/#overall-assessment","title":"Overall Assessment","text":"<p>The model gomodel:6197061700002226 is a biologically accurate representation of the ERBB2-ERBB4 signaling pathway in mouse, following GO-CAM best practices for signaling pathway annotation. The model captures the core components of this pathway with appropriate molecular functions, cellular components, and causal relationships.</p> <p>The signaling flow from ADAM17 processing epiregulin, epiregulin activating ERBB4, and ERBB4 activating ERBB2 is consistent with the literature evidence and follows proper signaling receptor annotation guidelines. The annotations are supported by appropriate evidence codes and references.</p>"},{"location":"reviews/6197061700002226-ERBB2_ERBB4_signaling_pathway_2__Mouse__/#recommendations","title":"Recommendations","text":"<ol> <li>Consider standardizing the causal relation between ADAM17 and Ereg to use \"directly positively regulates\" for consistency.</li> <li>Consider expanding the model to include downstream targets of ERBB2 activation to provide a more complete representation of the signaling cascade.</li> <li>The model could be enhanced by explicitly representing the heterodimerization of ERBB4 with ERBB2 upon ligand binding, which is an important mechanistic detail of this pathway.</li> </ol>"},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/","title":"6197061700002397 Fatty acid transport by CD36 via LYN mediated endocytosis  Human","text":"<p>Now I'll review the GO-CAM model with ID gomodel:6197061700002397 in detail.</p>"},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#review-of-go-cam-model-6197061700002397","title":"Review of GO-CAM Model: 6197061700002397","text":""},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#basic-information","title":"Basic Information","text":"<ul> <li>Title: Fatty acid transport by CD36 via LYN-mediated endocytosis (Human)</li> <li>Taxon: Human (NCBITaxon:9606)</li> <li>Status: production</li> </ul>"},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#overview","title":"Overview","text":"<p>This model describes the molecular mechanism of fatty acid transport by CD36 through a LYN-mediated endocytosis pathway in humans. The model includes four activities involving four different proteins (CD36, LYN, ZDHHC5, and LYPLA1) that work together to facilitate fatty acid transport.</p>"},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#molecular-activities-in-the-model","title":"Molecular Activities in the Model","text":"<p>The model contains four main activities:</p> <ol> <li>LYPLA1/APT1 (UniProtKB:O75608) - palmitoyl-(protein) hydrolase activity (GO:0008474)</li> <li>Occurs in: plasma membrane (GO:0005886)</li> <li>Part of: fatty acid transport (GO:0015908)</li> <li> <p>Evidence: ECO:0000314 (direct assay evidence used in manual assertion) from PMID:32958780</p> </li> <li> <p>CD36 (UniProtKB:P16671) - cargo receptor activity (GO:0038024)</p> </li> <li>Occurs in: plasma membrane (GO:0005886)</li> <li>Part of: fatty acid transport (GO:0015908)</li> <li>Evidence: ECO:0000314 from PMID:32958780</li> <li> <p>Causally associated with: LYN protein tyrosine kinase activity (RO:0002629 - directly positively regulates)</p> </li> <li> <p>LYN (UniProtKB:P07948) - protein tyrosine kinase activity (GO:0004713)</p> </li> <li>Occurs in: plasma membrane (GO:0005886)</li> <li>Part of: fatty acid transport (GO:0015908)</li> <li>Evidence: ECO:0000314 from PMID:32958780</li> <li> <p>Causally associated with: ZDHHC5 palmitoyltransferase activity (RO:0002630 - directly negatively regulates)</p> </li> <li> <p>ZDHHC5 (UniProtKB:Q9C0B5) - palmitoyltransferase activity (GO:0016409)</p> </li> <li>Occurs in: plasma membrane (GO:0005886)</li> <li>Part of: positive regulation of protein localization to plasma membrane (GO:1903078)</li> <li>Evidence: ECO:0000315 (mutant phenotype evidence used in manual assertion) from PMID:31649195</li> <li>Causally associated with: LYPLA1/APT1 palmitoyl-(protein) hydrolase activity (RO:0002418 - provides input for)</li> </ol>"},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#causal-flow","title":"Causal Flow","text":"<p>The causal flow in this model is: 1. CD36 directly positively regulates LYN 2. LYN directly negatively regulates ZDHHC5 3. ZDHHC5 provides input for LYPLA1/APT1</p>"},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#biological-context","title":"Biological Context","text":"<p>This model represents the mechanism of fatty acid uptake by CD36 through dynamic palmitoylation-regulated endocytosis, as described in the cited primary research paper (PMID:32958780). According to this paper:</p> <ol> <li>CD36 acts as a receptor for fatty acids at the plasma membrane</li> <li>When fatty acids bind to CD36, it activates LYN kinase</li> <li>LYN phosphorylates ZDHHC5 at Tyr91, which inactivates ZDHHC5</li> <li>ZDHHC5 inactivation leads to depalmitoylation of CD36 by APT1 (LYPLA1)</li> <li>Depalmitoylated CD36 undergoes endocytosis, bringing fatty acids into the cell</li> </ol>"},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#evidence-quality","title":"Evidence Quality","text":"<p>All molecular activities in the model are supported by experimental evidence from published literature: - Primary reference is PMID:32958780, which directly demonstrates the mechanisms - Additional evidence from PMID:22022213 for CD36 plasma membrane localization - Evidence for ZDHHC5's role in protein localization from PMID:31649195</p> <p>The evidence codes used are appropriate: - ECO:0000314 (direct assay evidence) for most assertions - ECO:0000315 (mutant phenotype evidence) for ZDHHC5's role in plasma membrane localization</p>"},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#review-of-causal-relations","title":"Review of Causal Relations","text":"<p>The causal relationships in this model are well-supported by the primary literature and use appropriate relation ontology terms:</p> <ol> <li>CD36 \u2192 LYN (RO:0002629 \"directly positively regulates\"): Correct relation as CD36 binding to fatty acids directly activates LYN kinase</li> <li>LYN \u2192 ZDHHC5 (RO:0002630 \"directly negatively regulates\"): Appropriate relation as LYN phosphorylation of ZDHHC5 at Tyr91 inhibits its activity</li> <li>ZDHHC5 \u2192 LYPLA1 (RO:0002418 \"provides input for\"): Correct relation as ZDHHC5 inactivation enables LYPLA1 to depalmitoylate CD36</li> </ol>"},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#review-of-uniprot-entries","title":"Review of UniProt Entries","text":"<p>I've examined the UniProt entries for all proteins in the model:</p> <ol> <li>CD36 (P16671): Correctly identified as a fatty acid transporter located in plasma membrane with multiple palmitoylation sites</li> <li>LYN (P07948): Correctly identified as a tyrosine-protein kinase with a role in signal transduction</li> <li>ZDHHC5 (Q9C0B5): Correctly identified as a palmitoyltransferase with Tyr91 as a phosphorylation site</li> <li>LYPLA1 (O75608): Correctly identified as a palmitoyl-(protein) hydrolase with activity on palmitoylated proteins</li> </ol>"},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<p>Regarding complexes (per \"How to annotate complexes in GO-CAM\" document), this model follows best practices by: 1. Representing each protein with its specific molecular function when known 2. Using appropriate causal relationships between activities 3. Correctly annotating cellular components for each protein</p>"},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Well-supported by primary literature with appropriate evidence codes</li> <li>Clearly represents the causal flow of fatty acid uptake mechanism</li> <li>Correctly identifies all molecular activities and their cellular locations</li> <li>Uses appropriate relation ontology terms for causal connections</li> <li>Matches the biological knowledge described in the primary research paper</li> </ol>"},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#improvement-suggestions","title":"Improvement Suggestions","text":"<ol> <li> <p>Minor suggestion: The model could be expanded to include the downstream effects of CD36 endocytosis, such as the delivery of fatty acids to their intracellular destinations.</p> </li> <li> <p>Potential addition: The model could include the role of CAV1 (Caveolin-1), as the primary paper mentions that CD36 is primarily localized in caveolae and requires CAV1 for internalization.</p> </li> </ol>"},{"location":"reviews/6197061700002397-Fatty_acid_transport_by_CD36_via_LYN_mediated_endocytosis__Human_/#overall-assessment","title":"Overall Assessment","text":"<p>This GO-CAM model accurately represents the current mechanistic understanding of CD36-mediated fatty acid uptake through dynamic palmitoylation-regulated endocytosis. The model is well-constructed, uses appropriate annotations, and is supported by strong experimental evidence from the literature. The causal relationships between the molecular activities are correctly represented, and the model provides a clear picture of this biological process.</p> <p>The model is consistent with GO-CAM best practices and accurately represents the roles of the four key proteins (CD36, LYN, ZDHHC5, and LYPLA1) in fatty acid transport. I recommend acceptance of this model as it stands, with the possible minor additions suggested above if deemed appropriate by the curator.</p>"},{"location":"reviews/61b2b68300000000-NLRP6_inflammasome__Human_/","title":"61b2b68300000000 NLRP6 inflammasome  Human","text":"<p>Now that I have a good understanding of the model and the relevant proteins, let me perform a thorough review of this GO-CAM model.</p>"},{"location":"reviews/61b2b68300000000-NLRP6_inflammasome__Human_/#review-of-go-cam-model-nlrp6-inflammasome-human","title":"Review of GO-CAM Model: NLRP6 inflammasome (Human)","text":""},{"location":"reviews/61b2b68300000000-NLRP6_inflammasome__Human_/#model-summary","title":"Model Summary","text":"<p>The model gomodel:61b2b68300000000 represents the NLRP6 inflammasome complex assembly and its downstream effects in humans. The model captures:</p> <ol> <li>NLRP6 (P59044) inflammasome formation and signaling</li> <li>Caspase-1 (CASP1, P29466) activation and activities</li> <li>Gasdermin D (GSDMD, P57764) pore formation</li> <li>Release of mature cytokines IL-1\u03b2 (P01584) and IL-18 (Q14116)</li> </ol>"},{"location":"reviews/61b2b68300000000-NLRP6_inflammasome__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model correctly captures the key aspects of the NLRP6 inflammasome pathway:</p> <ol> <li> <p>NLRP6 as Pattern Recognition Receptor: The model shows NLRP6 functioning as a pattern recognition receptor (GO:0038187) that recognizes microbial components like lipoteichoic acid (GO:0070891) and double-stranded RNA (GO:0003725).</p> </li> <li> <p>Inflammasome Assembly: NLRP6 is shown to form a functional inflammasome complex (GO:0140739) through its signaling adaptor activity (GO:0035591).</p> </li> <li> <p>Caspase-1 Activation: The model shows that NLRP6 promotes the activation of caspase-1 (P29466) which has cysteine-type endopeptidase activity (GO:0004197).</p> </li> <li> <p>Gasdermin D Pore Formation: Activated caspase-1 cleaves GSDMD, which then forms pores (wide pore channel activity, GO:0022829) in the plasma membrane.</p> </li> <li> <p>Cytokine Release: The model correctly shows IL-1\u03b2 and IL-18 release through GSDMD pores.</p> </li> </ol>"},{"location":"reviews/61b2b68300000000-NLRP6_inflammasome__Human_/#quality-control-assessment","title":"Quality Control Assessment","text":""},{"location":"reviews/61b2b68300000000-NLRP6_inflammasome__Human_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Mechanistic Detail: The model captures the complex signaling cascade from pattern recognition to cytokine release.</p> </li> <li> <p>Evidence Base: Each activity is supported by experimental evidence, primarily from published literature (ECO:0000314) with appropriate PMID citations.</p> </li> <li> <p>Cellular Localization: Appropriate subcellular locations are specified for activities (cytosol, plasma membrane, extracellular space).</p> </li> <li> <p>Causal Relationships: The model uses appropriate causal predicates (RO:0002304 for positive causal relationships, RO:0002629 for direct positive regulation).</p> </li> </ol>"},{"location":"reviews/61b2b68300000000-NLRP6_inflammasome__Human_/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Complex Representation: According to \"How to annotate complexes in GO-CAM\", when the molecular activity is carried by a specific subunit, individual proteins should be represented rather than using the complex GO term. The model follows this principle by showing NLRP6's direct activities rather than using complex terms, which is correct.</p> </li> <li> <p>Self-regulation of NLRP6: The model includes what appears to be a regulatory loop where NLRP6 pattern recognition receptor activity (61b2b68300000000/61b2b68300000001) directly positively regulates NLRP6 molecular condensate scaffold activity (61b2b68300000000/61b2b68300000010), which then directly negatively regulates NLRP6 signaling adaptor activity (61b2b68300000000/61b2b68300000115). This regulatory loop represents phase separation-dependent regulation as described in recent literature (PMID:34678144), which is correct but could be annotated with additional contextual information.</p> </li> <li> <p>Multiple Parallel Paths: The model shows multiple parallel paths of NLRP6 activity in response to different stimuli (bacterial lipoteichoic acid and viral dsRNA). While biologically accurate, a brief comment summarizing these parallel pathways would improve the model's clarity.</p> </li> <li> <p>GSDMD Mechanism Details: Based on recent research (PMID:33883744), GSDMD forms pores that electrostatically filter which molecules can pass through. This nuanced mechanism isn't fully captured in the model but would be a valuable addition.</p> </li> </ol>"},{"location":"reviews/61b2b68300000000-NLRP6_inflammasome__Human_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add Contextual Notes: Include notes about the different stimuli that activate NLRP6 (bacteria vs. virus) and how they lead to similar downstream effects through different initial recognition events.</p> </li> <li> <p>Include Phase Separation Mechanism: Add a note explaining that the NLRP6 molecular condensate scaffold activity (GO:0140693) represents phase separation, which is an essential step for inflammasome assembly as described in PMID:34678144.</p> </li> <li> <p>Enhance GSDMD Mechanism: Consider adding additional detail about how GSDMD pores selectively allow passage of mature IL-1\u03b2 and IL-18 through electrostatic filtering (PMID:33883744).</p> </li> <li> <p>Add Connection to Pyroptosis: While the model correctly shows GSDMD's role in cytokine release, it could also note its role in triggering pyroptotic inflammatory response (GO:0070269), which is already included in one activity but could be more prominently connected.</p> </li> </ol>"},{"location":"reviews/61b2b68300000000-NLRP6_inflammasome__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model is a high-quality representation of the NLRP6 inflammasome pathway that accurately captures the current understanding of this biological process. The model follows GO-CAM best practices for representing complexes and causal relationships. The suggested improvements would enhance its comprehensiveness but are not critical deficiencies. Overall, the model provides a valuable resource for understanding NLRP6 inflammasome biology in humans.</p>"},{"location":"reviews/61b2b68300000203-ERBB2_ERBB4_signaling_pathway_3__Mouse__/","title":"61b2b68300000203 ERBB2 ERBB4 signaling pathway 3  Mouse","text":"<p>Based on the information I've gathered, I'll now review the GO-CAM model with ID \"61b2b68300000203\" which represents the \"ERBB2-ERBB4 signaling pathway 3 (Mouse)\".</p>"},{"location":"reviews/61b2b68300000203-ERBB2_ERBB4_signaling_pathway_3__Mouse__/#go-cam-review-erbb2-erbb4-signaling-pathway-3-mouse","title":"GO-CAM Review: ERBB2-ERBB4 signaling pathway 3 (Mouse)","text":""},{"location":"reviews/61b2b68300000203-ERBB2_ERBB4_signaling_pathway_3__Mouse__/#model-overview","title":"Model Overview","text":"<ul> <li>Model ID: gomodel:61b2b68300000203</li> <li>Title: ERBB2-ERBB4 signaling pathway 3 (Mouse)</li> <li>Taxon: NCBITaxon:10090 (Mouse)</li> <li>Status: Production</li> <li>Comments: </li> <li>Automated change 2022-09-22: GO:0044214 replaced by GO:0005886</li> <li>Automated change 2023-03-16: RO:0002213 replaced by RO:0002629</li> <li>Sourced from: gomodel:R-HSA-1227986</li> </ul>"},{"location":"reviews/61b2b68300000203-ERBB2_ERBB4_signaling_pathway_3__Mouse__/#model-structure-summary","title":"Model Structure Summary","text":"<p>This model represents the ERBB2-ERBB4 signaling pathway in mouse, focusing on: 1. Processing of NRG1 (neuregulin 1) by various enzymes (BACE1, ADAM10, ADAM17) 2. NRG1 binding to and activating ERBB4 receptor 3. ERBB4-ERBB2 receptor heterodimerization and signaling</p>"},{"location":"reviews/61b2b68300000203-ERBB2_ERBB4_signaling_pathway_3__Mouse__/#review-of-the-model-content","title":"Review of the Model Content","text":""},{"location":"reviews/61b2b68300000203-ERBB2_ERBB4_signaling_pathway_3__Mouse__/#overall-flow-and-structure","title":"Overall Flow and Structure","text":"<p>The model correctly depicts the signaling cascade where: 1. Proteases (BACE1, ADAM10, ADAM17) process neuregulin-1 (NRG1) 2. Processed NRG1 acts as a ligand for ERBB4 receptor 3. ERBB4 becomes activated and forms a complex with ERBB2 4. ERBB2 exhibits protein tyrosine kinase activity</p> <p>This follows the known biological pathway as evidenced by the literature cited in the model (especially PMID:19632177, which describes NRG1/ErbB4 signaling).</p>"},{"location":"reviews/61b2b68300000203-ERBB2_ERBB4_signaling_pathway_3__Mouse__/#specific-elements-and-accuracy","title":"Specific Elements and Accuracy","text":""},{"location":"reviews/61b2b68300000203-ERBB2_ERBB4_signaling_pathway_3__Mouse__/#molecular-activities","title":"Molecular Activities:","text":"<ol> <li> <p>NRG1 (MGI:MGI:96083) - correctly annotated with \"receptor ligand activity\" (GO:0048018) and \"occurs in\" extracellular space (GO:0005615), following GO-CAM guidelines for signaling ligands.</p> </li> <li> <p>ERBB4 (MGI:MGI:104771) - correctly annotated with \"neuregulin receptor activity\" (GO:0038131) and \"occurs in\" plasma membrane (GO:0005886).</p> </li> <li> <p>ERBB2 (MGI:MGI:95410) - correctly annotated with \"protein tyrosine kinase activity\" (GO:0004713) and \"occurs in\" plasma membrane (GO:0005886).</p> </li> <li> <p>Processing enzymes - BACE1 (MGI:MGI:1346542), ADAM10 (MGI:MGI:109548), and ADAM17 (MGI:MGI:1096335) are correctly annotated with appropriate peptidase activities and \"part of\" signaling receptor ligand precursor processing (GO:0140448).</p> </li> </ol>"},{"location":"reviews/61b2b68300000203-ERBB2_ERBB4_signaling_pathway_3__Mouse__/#causal-relationships","title":"Causal Relationships:","text":"<p>The causal relationships follow the recommended GO-CAM patterns: 1. The processing enzymes (BACE1, ADAM10, ADAM17) correctly \"causally upstream of, positive effect\" (RO:0002304) on NRG1 ligand activity. 2. NRG1 ligand activity correctly \"directly positively regulates\" (RO:0002629) ERBB4 receptor activity. 3. ERBB4 correctly \"directly positively regulates\" (RO:0002629) ERBB2 kinase activity.</p>"},{"location":"reviews/61b2b68300000203-ERBB2_ERBB4_signaling_pathway_3__Mouse__/#evidence-and-references","title":"Evidence and References:","text":"<ul> <li>The model uses appropriate evidence codes (ECO:0000314 - direct assay, ECO:0000315 - mutant phenotype, ECO:0000266 - sequence orthology)</li> <li>Key references include PMID:8702723, PMID:19632177, PMID:17099708, PMID:23637177, PMID:28751722</li> <li>These references appropriately support the annotated relationships</li> </ul>"},{"location":"reviews/61b2b68300000203-ERBB2_ERBB4_signaling_pathway_3__Mouse__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>NRG1 Processing Detail:     While the model correctly shows that BACE1, ADAM10, and ADAM17 process NRG1, the specific cleavage sites (N-terminal vs C-terminal to the EGF-like domain) as described in PMID:23637177 are not distinguished. This level of detail might be valuable to add if the model is expanded.</p> </li> <li> <p>Downstream Signaling:    The model stops at ERBB2 kinase activity and doesn't indicate further downstream effects like MAPK or PI3K-Akt pathways as shown in PMID:19632177. This could be an area for future expansion of the model.</p> </li> <li> <p>Cellular Outcome:    The biological consequences of this signaling (e.g., myelination in the case of BACE1-processed NRG1 as described in PMID:17099708) are not represented in the model.</p> </li> </ol>"},{"location":"reviews/61b2b68300000203-ERBB2_ERBB4_signaling_pathway_3__Mouse__/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<p>This model largely follows GO-CAM best practices: - It uses appropriate molecular function terms - Activities are connected using proper causal relationships - Cellular components are correctly specified - Biological process associations are appropriate - Evidence codes and references are correctly applied</p> <p>Based on the \"How to annotate complexes in GO-CAM\" guidelines, the representation of the ERBB4-ERBB2 signaling is handled appropriately by assigning specific activities to each receptor component rather than using a complex identifier.</p>"},{"location":"reviews/61b2b68300000203-ERBB2_ERBB4_signaling_pathway_3__Mouse__/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model effectively represents the core ERBB2-ERBB4 signaling pathway in mouse, with accurate molecular functions, cellular locations, and causal relationships. It is well-supported by scientific literature and follows GO-CAM curation best practices.</p> <p>Recommendation: The model is suitable for production status with no critical issues to address. Future enhancements could include expanding downstream signaling events and cellular outcomes of this pathway.</p>"},{"location":"reviews/61b2b68300000617-ERBB2_ERBB3_receptor_signaling_pathway_involved_in_myelination_1__Mouse_/","title":"61b2b68300000617 ERBB2 ERBB3 receptor signaling pathway involved in myelination 1  Mouse","text":"<p>Based on the gathered information, I'll now conduct a comprehensive review of the GO-CAM model gomodel:61b2b68300000617 \"ERBB2-ERBB3 receptor signaling pathway involved in myelination 1 (Mouse)\".</p>"},{"location":"reviews/61b2b68300000617-ERBB2_ERBB3_receptor_signaling_pathway_involved_in_myelination_1__Mouse_/#go-cam-model-review-gomodel61b2b68300000617","title":"GO-CAM Model Review: gomodel:61b2b68300000617","text":""},{"location":"reviews/61b2b68300000617-ERBB2_ERBB3_receptor_signaling_pathway_involved_in_myelination_1__Mouse_/#summary-of-the-model","title":"Summary of the Model","text":"<p>This model represents the ERBB2-ERBB3 receptor signaling pathway involved in myelination in mouse. It captures the signaling cascade from neuregulin (Nrg1) binding to ERBB2/ERBB3 receptors, through adaptor proteins (Grb2), Ras signaling, and the MAPK cascade that influences Schwann cell development and myelination.</p>"},{"location":"reviews/61b2b68300000617-ERBB2_ERBB3_receptor_signaling_pathway_involved_in_myelination_1__Mouse_/#biological-correctness-assessment","title":"Biological Correctness Assessment","text":"<p>The model accurately reflects the known biology of neuregulin-ERBB signaling in Schwann cells:</p> <ol> <li> <p>Ligand-Receptor Interaction: The model correctly shows Nrg1 (MGI:MGI:96083) as the ligand with receptor ligand activity (GO:0048018) that occurs in extracellular space (GO:0005615), which follows the signaling receptor activity annotation guidelines.</p> </li> <li> <p>Receptor Complex: The model appropriately represents ERBB2 (MGI:MGI:95410) and ERBB3 (MGI:MGI:95411) receptors, with ERBB3 having neuregulin receptor activity (GO:0038131) and ERBB2 having protein tyrosine kinase activity (GO:0004713). This is consistent with the biology described in the literature where ERBB3 binds neuregulin, but lacks kinase activity, while ERBB2 provides the kinase activity in the heterodimer.</p> </li> <li> <p>Signaling Cascade: The downstream pathway follows the established MAPK cascade pathway:</p> </li> <li> <p>Grb2 (adaptor protein) \u2192 Sos1 (guanyl-nucleotide exchange factor) \u2192 Hras (GTPase) \u2192 Raf1 (MAPKKK) \u2192 Map2k1/2 (MAPKK) \u2192 Mapk1/3 (MAPK).</p> </li> <li> <p>Cellular Locations: The model correctly assigns cellular locations to the different components, with receptors in the plasma membrane (GO:0005886), adaptor proteins at the cell cortex (GO:0005938), and downstream kinases in the cytosol (GO:0005829).</p> </li> <li> <p>Biological Process Context: All components are appropriately placed in their respective biological processes (ERBB2-ERBB3 signaling pathway, MAPK cascade, Ras protein signal transduction).</p> </li> </ol>"},{"location":"reviews/61b2b68300000617-ERBB2_ERBB3_receptor_signaling_pathway_involved_in_myelination_1__Mouse_/#go-cam-modeling-guidelines-compliance","title":"GO-CAM Modeling Guidelines Compliance","text":"<ol> <li> <p>Causal Relationships: The model uses the correct causal relationship \"directly positively regulates\" (RO:0002629) between activities, following the standard for depicting how one activity influences another.</p> </li> <li> <p>Evidence Codes: Each association has appropriate evidence codes with supporting references, primarily using sequence orthology evidence (ECO:0000266), direct assay evidence (ECO:0000314), or mutant phenotype evidence (ECO:0000315).</p> </li> <li> <p>Complex Representation: The model follows the guidelines for representing the ERBB2-ERBB3 complex. Since each receptor has a distinct activity (ERBB3 for ligand binding, ERBB2 for kinase activity), they are appropriately represented as separate entities rather than using a complex GO term.</p> </li> <li> <p>Signaling Receptor Annotation: The model follows the guidelines for protein ligand-activated signaling receptors:</p> </li> <li>The ligand (Nrg1) enables receptor ligand activity</li> <li>The receptors (ERBB2/ERBB3) are in the plasma membrane</li> <li>Correct causal relations are used between ligand and receptor, and between receptor and downstream elements</li> </ol>"},{"location":"reviews/61b2b68300000617-ERBB2_ERBB3_receptor_signaling_pathway_involved_in_myelination_1__Mouse_/#issues-and-recommendations","title":"Issues and Recommendations","text":"<ol> <li> <p>Missing Cellular Location: Some activities lack cellular location annotations (e.g., gomodel:61b2b68300000617/61b2b68300000642). While these can be inferred from the biological process, it would be better to explicitly annotate them.</p> </li> <li> <p>Evidence Citation Format: There's one reference that has a space before the PMID (e.g., \" PMID:33331896\") which should be corrected for consistency.</p> </li> <li> <p>Missing Direct Link to Myelination: While the model represents the ERBB2-ERBB3 signaling pathway involved in myelination, there's no direct connection shown to the myelination process itself (GO:0042552). Adding a downstream activity that connects this signaling pathway to the actual myelination biological process would make the model more complete.</p> </li> <li> <p>Feedback Regulation: The model doesn't capture any feedback regulation mechanisms, which are known to exist in MAPK signaling pathways. Adding these would enhance the model's completeness.</p> </li> </ol>"},{"location":"reviews/61b2b68300000617-ERBB2_ERBB3_receptor_signaling_pathway_involved_in_myelination_1__Mouse_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:61b2b68300000617) is a well-constructed representation of the ERBB2-ERBB3 receptor signaling pathway involved in myelination in mouse. It accurately captures the molecular activities, their locations, and the causal relationships between them. The model is based on appropriate evidence from the literature and follows GO-CAM best practices. With a few minor improvements, particularly adding the connection to the myelination process itself, this model would be even more valuable for understanding the molecular mechanisms underlying myelination in the peripheral nervous system.</p> <p>The model effectively conveys the essential aspects of neuregulin-ERBB signaling and provides a good foundation for understanding how this pathway influences Schwann cell development and myelination in mice.</p>"},{"location":"reviews/61e0e55600000239-Epidermal_growth_factor_receptor_signaling_pathway_10__Mouse__/","title":"61e0e55600000239 Epidermal growth factor receptor signaling pathway 10  Mouse","text":"<p>Based on my analysis, I'll now provide a comprehensive review of the GO-CAM model with ID 61e0e55600000239.</p>"},{"location":"reviews/61e0e55600000239-Epidermal_growth_factor_receptor_signaling_pathway_10__Mouse__/#go-cam-review-epidermal-growth-factor-receptor-signaling-pathway-10-mouse","title":"GO-CAM Review: Epidermal growth factor receptor signaling pathway 10 (Mouse)","text":""},{"location":"reviews/61e0e55600000239-Epidermal_growth_factor_receptor_signaling_pathway_10__Mouse__/#model-overview","title":"Model Overview","text":"<p>The GO-CAM model gomodel:61e0e55600000239 titled \"Epidermal growth factor receptor signaling pathway 10 (Mouse)\" represents the epidermal growth factor receptor (EGFR) signaling pathway in mouse. The model depicts a signaling cascade from the initial ligand-receptor interaction to downstream effectors.</p>"},{"location":"reviews/61e0e55600000239-Epidermal_growth_factor_receptor_signaling_pathway_10__Mouse__/#pathway-components-and-connectivity","title":"Pathway Components and Connectivity","text":"<p>The model shows the following sequence of molecular events:</p> <ol> <li>TGF\u03b1 (Tgfa) enables receptor ligand activity (GO:0048018) in the extracellular space (GO:0005615)</li> <li>TGF\u03b1 directly positively regulates (RO:0002629) EGFR activity</li> <li> <p>This is properly supported by evidence from PMID:7678348 and PMID:8299590</p> </li> <li> <p>EGFR (Egfr) enables epidermal growth factor receptor activity (GO:0005006) at the plasma membrane (GO:0005886)</p> </li> <li>EGFR directly positively regulates (RO:0002629) Grb2 adaptor activity </li> <li> <p>This interaction is supported by experimental evidence in PMID:7678348</p> </li> <li> <p>Grb2 (Grb2) enables transmembrane receptor protein tyrosine kinase adaptor activity (GO:0005068) at the cell cortex (GO:0005938)</p> </li> <li>Grb2 provides input for (RO:0002413) EGFR protein tyrosine kinase activity</li> <li> <p>This relationship is supported by genetic interaction evidence in PMID:17881575</p> </li> <li> <p>EGFR (Egfr) enables protein tyrosine kinase activity (GO:0004713) at the cell cortex (GO:0005938)</p> </li> <li>EGFR directly positively regulates (RO:0002629) Gab1 adaptor activity</li> <li> <p>This is consistent with established models of EGFR signaling</p> </li> <li> <p>Gab1 (Gab1) enables signaling adaptor activity (GO:0035591) at the cell cortex (GO:0005938)</p> </li> <li>Gab1 directly positively regulates (RO:0002629) SHP2/PTPN11 activity</li> <li> <p>This fits with literature showing Gab1 as a key adaptor downstream of EGFR</p> </li> <li> <p>SHP2 (Ptpn11) enables non-membrane spanning protein tyrosine phosphatase activity (GO:0004726) in the cytosol (GO:0005829)</p> </li> <li>This appears to be the terminal activity in the represented cascade</li> <li>The activity is supported by literature evidence PMID:15273746 and PMID:8955893</li> </ol>"},{"location":"reviews/61e0e55600000239-Epidermal_growth_factor_receptor_signaling_pathway_10__Mouse__/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Proper representation of ligand-receptor relationship: The model correctly shows TGF\u03b1 as an extracellular ligand that activates EGFR at the plasma membrane, consistent with GO-CAM best practices for signaling receptor annotation.</p> </li> <li> <p>Appropriate cellular localization: Each molecule is annotated with the correct cellular component, with TGF\u03b1 in extracellular space, EGFR at the plasma membrane, adaptors (Grb2, Gab1) at the cell cortex, and SHP2 in the cytosol.</p> </li> <li> <p>Well-supported with evidence: Most relationships are supported by experimental evidence, with appropriate ECO codes indicating the type of evidence (direct assay, genetic interaction, etc.).</p> </li> <li> <p>Consistent causal relations: The model uses appropriate causal relationship predicates (RO:0002629 for direct positive regulation and RO:0002413 for provides input for) that accurately represent the signaling flow.</p> </li> <li> <p>Molecular function accuracy: Each protein is assigned the correct molecular function, reflecting its role in the pathway.</p> </li> </ol>"},{"location":"reviews/61e0e55600000239-Epidermal_growth_factor_receptor_signaling_pathway_10__Mouse__/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Feedback mechanisms: The model doesn't capture any potential feedback loops that might exist in the EGFR signaling pathway, such as SHP2-mediated regulation of EGFR.</p> </li> <li> <p>Alternative branches: The model presents a linear pathway without showing alternative branches of the EGFR signaling cascade (such as the PI3K pathway or STAT pathway).</p> </li> <li> <p>Downstream biological outcomes: The biological outcomes of EGFR signaling activation (such as cell proliferation, survival, or migration) are not represented.</p> </li> <li> <p>Temporal aspects: The model doesn't capture the dynamic nature of the signaling process, including receptor internalization and recycling that occurs after EGFR activation.</p> </li> </ol>"},{"location":"reviews/61e0e55600000239-Epidermal_growth_factor_receptor_signaling_pathway_10__Mouse__/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":"<p>The model is biologically accurate in representing the core EGFR-Grb2-Gab1-SHP2 signaling axis. This pathway is well-established in the literature:</p> <ol> <li> <p>TGF\u03b1-EGFR interaction: TGF\u03b1 is a well-known ligand for EGFR that induces receptor dimerization and activation.</p> </li> <li> <p>EGFR-Grb2-Gab1 signaling: Upon activation, EGFR autophosphorylates, creating binding sites for Grb2, which then recruits Gab1 to the receptor complex.</p> </li> <li> <p>Gab1-SHP2 interaction: Gab1 serves as a scaffold for multiple signaling molecules, including SHP2, which then contributes to downstream signaling effects.</p> </li> </ol> <p>The UniProt entries for all involved proteins confirm their molecular functions and interactions as represented in the model.</p>"},{"location":"reviews/61e0e55600000239-Epidermal_growth_factor_receptor_signaling_pathway_10__Mouse__/#go-cam-best-practices-adherence","title":"GO-CAM Best Practices Adherence","text":"<p>The model generally follows GO-CAM best practices:</p> <ol> <li> <p>Signaling receptor activity annotation: The ligand (TGF\u03b1) is correctly annotated with receptor ligand activity (GO:0048018) and situated in the extracellular space, while EGFR has appropriate receptor activity and is at the plasma membrane.</p> </li> <li> <p>Molecular adaptor annotation: Grb2 and Gab1 are correctly annotated as adaptors with appropriate molecular functions and causal relationships.</p> </li> <li> <p>Causal relationships: Appropriate relationship predicates are used throughout the model.</p> </li> <li> <p>Evidence codes: Proper evidence codes are used with PMIDs to support assertions.</p> </li> </ol>"},{"location":"reviews/61e0e55600000239-Epidermal_growth_factor_receptor_signaling_pathway_10__Mouse__/#recommendations-for-enhancement","title":"Recommendations for Enhancement","text":"<ol> <li> <p>Add downstream effectors: Consider extending the model to include downstream effectors activated by SHP2, such as the RAS-RAF-MEK-ERK pathway.</p> </li> <li> <p>Include alternative branches: Add parallel pathways activated by EGFR, such as the PI3K-AKT pathway.</p> </li> <li> <p>Represent regulation: Include negative regulators of the pathway, such as protein phosphatases or ubiquitin ligases that downregulate EGFR.</p> </li> <li> <p>Add contextual information: Include cell type-specific contexts where this pathway is particularly important.</p> </li> </ol>"},{"location":"reviews/61e0e55600000239-Epidermal_growth_factor_receptor_signaling_pathway_10__Mouse__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:61e0e55600000239 is a well-constructed representation of the EGFR-Grb2-Gab1-SHP2 signaling axis in mouse. It adheres to GO-CAM best practices and is supported by experimental evidence. While the model could be enhanced by adding more complexity and downstream effectors, it provides a solid foundation for understanding the core EGFR signaling pathway.</p> <p>The model is biologically accurate, properly localized, and uses appropriate molecular functions and causal relationships. With the suggested enhancements, it could become an even more comprehensive representation of EGFR signaling.</p>"},{"location":"reviews/61e0e55600000407-SP_GADD34__PPP1CA/","title":"61e0e55600000407 SP GADD34  PPP1CA","text":"<p>Now that I have reviewed the model and the supporting literature, let's assess the GO-CAM model (gomodel:61e0e55600000407) for accuracy and adherence to best practices.</p>"},{"location":"reviews/61e0e55600000407-SP_GADD34__PPP1CA/#review-of-go-cam-model-61e0e55600000407-sp_gadd34-ppp1ca","title":"Review of GO-CAM Model: 61e0e55600000407 (SP_GADD34-PPP1CA)","text":""},{"location":"reviews/61e0e55600000407-SP_GADD34__PPP1CA/#model-overview","title":"Model Overview","text":"<p>This GO-CAM model (accessible at https://bioregistry.io/go.model:61e0e55600000407) represents the GADD34-PPP1CA pathway, focusing on the dephosphorylation of EIF2S1 (eIF2\u03b1) and its role in translation regulation. </p>"},{"location":"reviews/61e0e55600000407-SP_GADD34__PPP1CA/#structure-and-content-analysis","title":"Structure and Content Analysis","text":""},{"location":"reviews/61e0e55600000407-SP_GADD34__PPP1CA/#key-components-in-the-model","title":"Key components in the model:","text":"<ol> <li>PPP1CA (P62136) - Serine/threonine-protein phosphatase PP1-alpha catalytic subunit performing phosphatase activity (GO:0016791)</li> <li> <p>Located in the endoplasmic reticulum (GO:0005783)</p> </li> <li> <p>PPP1R15A/GADD34 (O75807) - Protein phosphatase 1 regulatory subunit with molecular adaptor activity (GO:0060090)</p> </li> <li>Located in the endoplasmic reticulum (GO:0005783)</li> <li> <p>Directly positively regulates PPP1CA's phosphatase activity</p> </li> <li> <p>PPP1R15B/CReP (Q5SWA1) - Another protein phosphatase 1 regulatory subunit with molecular adaptor activity (GO:0060090)</p> </li> <li> <p>Directly positively regulates PPP1CA's phosphatase activity</p> </li> <li> <p>EIF2S1/eIF2\u03b1 (P05198) - Translation initiation factor with initiation factor activity (GO:0003743)</p> </li> <li>Located in the cytoplasm (GO:0005737)</li> <li> <p>Target of dephosphorylation by PPP1CA</p> </li> <li> <p>Kinases that phosphorylate EIF2S1:</p> </li> <li>EIF2AK2/PKR (P19525) - Protein serine/threonine kinase activity (GO:0004674)</li> <li>EIF2AK3/PERK (Q9NZJ5) - Protein kinase activity (GO:0004672)<ul> <li>Located in the endoplasmic reticulum (GO:0005783)</li> <li>Part of endoplasmic reticulum stress response (GO:0034976)</li> </ul> </li> <li>EIF2AK4/GCN2 (Q9P2K8) - Protein kinase activity (GO:0004672)<ul> <li>Part of response to amino acid starvation (GO:1990928)</li> </ul> </li> </ol>"},{"location":"reviews/61e0e55600000407-SP_GADD34__PPP1CA/#causal-relationships","title":"Causal Relationships:","text":"<ol> <li>Both PPP1R15A/GADD34 and PPP1R15B/CReP directly positively regulate (RO:0002629) PPP1CA phosphatase activity</li> <li>PPP1CA directly positively regulates (RO:0002629) EIF2S1 translation initiation factor activity</li> <li>All three kinases (EIF2AK2, EIF2AK3, EIF2AK4) directly negatively regulate (RO:0002630) EIF2S1 translation initiation factor activity</li> </ol>"},{"location":"reviews/61e0e55600000407-SP_GADD34__PPP1CA/#assessment-of-compliance-with-go-cam-best-practices","title":"Assessment of Compliance with GO-CAM Best Practices","text":""},{"location":"reviews/61e0e55600000407-SP_GADD34__PPP1CA/#strengths","title":"Strengths:","text":"<ol> <li> <p>Proper use of molecular function terms: Each protein is annotated with an appropriate molecular function term (phosphatase activity, adaptor activity, kinase activity, etc.)</p> </li> <li> <p>Appropriate causal relationships: The model correctly uses direct positive/negative regulation relationships to connect the activities of proteins in the pathway</p> </li> <li> <p>Contextual information included: Where relevant, cellular locations are specified (ER localization for PPP1CA, PPP1R15A, and EIF2AK3) and biological processes are included (ER stress response for EIF2AK3)</p> </li> <li> <p>Evidence supported: Most annotations include evidence codes and PMID references</p> </li> </ol>"},{"location":"reviews/61e0e55600000407-SP_GADD34__PPP1CA/#areas-for-improvement","title":"Areas for Improvement:","text":"<ol> <li> <p>Missing biological process context for key components: PPP1CA and PPP1R15A should be annotated with \"response to endoplasmic reticulum stress\" (GO:0034976) to match the context of EIF2AK3, as this is the primary biological process where this mechanism operates.</p> </li> <li> <p>Incomplete annotation of PPP1R15B: There's no cellular component annotation for PPP1R15B, which should also be located in the endoplasmic reticulum.</p> </li> <li> <p>Missing mechanistic details: The model doesn't fully capture the substrate relationship between EIF2S1 and the phosphatase complex. According to literature (PMID:26095357), EIF2S1 directly interacts with the PEST domain of GADD34 independently of PPP1CA.</p> </li> <li> <p>Missing complex representation: The PPP1CA-PPP1R15A/B holoenzyme complex formation isn't explicitly represented. From PMID:26095357, we know that GADD34 functions as a scaffold bringing together PPP1CA and EIF2S1.</p> </li> <li> <p>Incomplete molecular function annotation: While PPP1CA is annotated with the generic phosphatase activity (GO:0016791), the more specific protein serine/threonine phosphatase activity (GO:0004722) would be more accurate for this context.</p> </li> </ol>"},{"location":"reviews/61e0e55600000407-SP_GADD34__PPP1CA/#literature-consistency-assessment","title":"Literature Consistency Assessment","text":"<p>The model is generally consistent with the literature. PPP1CA is known to dephosphorylate phospho-EIF2S1 when bound to the regulatory subunits PPP1R15A (GADD34) or PPP1R15B (CReP). The difference between these two regulators is that PPP1R15A is induced under stress conditions while PPP1R15B is constitutively expressed.</p> <p>Key points from PMID:26095357 that are correctly captured: - GADD34 and CReP recruit PP1 to dephosphorylate EIF2S1 - The dephosphorylation restores translation after stress responses - The system involves kinases that phosphorylate EIF2S1 in response to various stresses</p> <p>Key points from the literature that could be better represented: - GADD34 functions as a scaffold protein with two distinct interaction domains - one for PP1 and one for EIF2S1 - The PEST domain of GADD34 is responsible for substrate (EIF2S1) binding - The scaffolding function is critical for the specificity of the phosphatase complex</p>"},{"location":"reviews/61e0e55600000407-SP_GADD34__PPP1CA/#suggested-improvements","title":"Suggested Improvements","text":"<ol> <li>Add biological process annotations:</li> <li>Include \"response to endoplasmic reticulum stress\" (GO:0034976) for PPP1CA and PPP1R15A</li> <li> <p>Add \"regulation of translational initiation in response to stress\" (GO:0043558) for PPP1CA and PPP1R15A</p> </li> <li> <p>Update molecular function annotations:</p> </li> <li>Replace generic phosphatase activity (GO:0016791) with protein serine/threonine phosphatase activity (GO:0004722) for PPP1CA</li> <li> <p>Consider using a more specific term for PPP1R15A's adaptor function, such as \"protein phosphatase binding\" (GO:0019903)</p> </li> <li> <p>Complete cellular component annotations:</p> </li> <li> <p>Add endoplasmic reticulum (GO:0005783) location for PPP1R15B</p> </li> <li> <p>Enhance mechanistic details:</p> </li> <li>Add a direct \"has input\" relationship from EIF2S1 to PPP1R15A to capture the substrate recruitment function</li> <li> <p>Consider representing the PP1-GADD34 complex as a distinct entity with the combined activities</p> </li> <li> <p>Add more comprehensive evidence:</p> </li> <li>Include PMID:26095357 as a key reference for the scaffold function of GADD34</li> </ol>"},{"location":"reviews/61e0e55600000407-SP_GADD34__PPP1CA/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model \"SP_GADD34-PPP1CA\" (gomodel:61e0e55600000407) provides a good representation of the EIF2S1 dephosphorylation pathway involving PPP1CA and its regulatory subunits. The model correctly captures the main players and their causal relationships. However, it would benefit from some refinements to better represent the specific molecular mechanisms and biological contexts, particularly the scaffolding function of GADD34 and the specific nature of the PPP1CA-PPP1R15A holoenzyme as detailed in the literature.</p> <p>The model is scientifically accurate but could be enhanced to provide a more complete picture of the biological mechanism. With the suggested improvements, it would better align with GO-CAM best practices and more fully capture the nuances of this important stress response pathway.</p>"},{"location":"reviews/6205c24300000880-Regulation_of_cholesterol_biosynthesis_by_SREBP__SREBF1_and_SREBF2__and_retention_by_the_SREBP_SCAP_complex__Human_/","title":"6205c24300000880 Regulation of cholesterol biosynthesis by SREBP  SREBF1 and SREBF2  and retention by the SREBP SCAP complex  Human","text":"<p>Now let me review the GO-CAM model based on the information I've gathered:</p>"},{"location":"reviews/6205c24300000880-Regulation_of_cholesterol_biosynthesis_by_SREBP__SREBF1_and_SREBF2__and_retention_by_the_SREBP_SCAP_complex__Human_/#go-cam-review-gomodel6205c24300000880-regulation-of-cholesterol-biosynthesis-by-srebp-srebf1-and-srebf2-and-retention-by-the-srebp-scap-complex-human","title":"GO-CAM Review: gomodel:6205c24300000880 - Regulation of cholesterol biosynthesis by SREBP (SREBF1 and SREBF2) and retention by the SREBP-SCAP complex (Human)","text":""},{"location":"reviews/6205c24300000880-Regulation_of_cholesterol_biosynthesis_by_SREBP__SREBF1_and_SREBF2__and_retention_by_the_SREBP_SCAP_complex__Human_/#model-overview","title":"Model Overview","text":"<p>This model represents the regulation of cholesterol biosynthesis through the SREBP pathway in humans. The Sterol Regulatory Element-Binding Protein (SREBP) pathway is a critical regulatory mechanism that controls lipid homeostasis, particularly cholesterol biosynthesis. This GO-CAM depicts how SREBPs are retained in the endoplasmic reticulum by INSIG proteins when cholesterol levels are high, and how they are processed and transported to the nucleus under low cholesterol conditions to activate transcription of genes involved in cholesterol biosynthesis.</p>"},{"location":"reviews/6205c24300000880-Regulation_of_cholesterol_biosynthesis_by_SREBP__SREBF1_and_SREBF2__and_retention_by_the_SREBP_SCAP_complex__Human_/#key-components-in-the-model","title":"Key Components in the Model","text":"<ol> <li>SREBP transcription factors (SREBF1 and SREBF2)</li> <li>Represented by UniProtKB:P36956 (SREBF1) and UniProtKB:Q12772 (SREBF2)</li> <li>DNA-binding transcription factor activity (GO:0000981)</li> <li>Localized in the nucleus (GO:0005634)</li> <li> <p>Part of positive regulation of cholesterol biosynthetic process (GO:0045542)</p> </li> <li> <p>INSIG proteins (INSIG1 and INSIG2)</p> </li> <li>Represented by UniProtKB:O15503 (INSIG1) and UniProtKB:Q9Y5U4 (INSIG2)</li> <li>Oxysterol binding activity (GO:0008142)</li> <li>Protein sequestering activity (GO:0140311)</li> <li>Localized in endoplasmic reticulum membrane (GO:0005789)</li> <li> <p>Part of SREBP-SCAP complex retention in endoplasmic reticulum (GO:0036316)</p> </li> <li> <p>Site-1 and Site-2 proteases</p> </li> <li>UniProtKB:Q14703 (MBTPS1, S1P) and UniProtKB:O43462 (MBTPS2, S2P)</li> <li>Serine-type endopeptidase activity (GO:0004252) and metalloendopeptidase activity (GO:0004222)</li> <li>Localized in Golgi membrane (GO:0000139)</li> <li> <p>Part of protein maturation (GO:0051604)</p> </li> <li> <p>Nuclear import proteins</p> </li> <li>UniProtKB:Q14974 (KPNB1, Importin beta-1)</li> <li>Nuclear import signal receptor activity (GO:0061608)</li> <li> <p>Part of NLS-bearing protein import into nucleus (GO:0006607)</p> </li> <li> <p>Regulatory enzymes</p> </li> <li>UniProtKB:P31749 (AKT1) - protein serine/threonine kinase activity</li> <li>UniProtKB:P35558 (PCK1) - protein serine kinase activity using GTP as donor</li> </ol>"},{"location":"reviews/6205c24300000880-Regulation_of_cholesterol_biosynthesis_by_SREBP__SREBF1_and_SREBF2__and_retention_by_the_SREBP_SCAP_complex__Human_/#pathway-flow-and-causal-relationships","title":"Pathway Flow and Causal Relationships","text":"<p>The model correctly represents the following pathway flow:</p> <ol> <li>Under low sterol conditions, SREBP-SCAP complex is released from the ER</li> <li>PCK1 (phosphoenolpyruvate carboxykinase) acts as a regulatory enzyme that phosphorylates INSIG proteins</li> <li>AKT1 positively regulates PCK1 activity, contributing to SREBP-SCAP complex release</li> <li>SREBP-SCAP complex moves to the Golgi where SREBP is sequentially cleaved by:</li> <li>MBTPS1 (Site-1 protease) which performs the first cleavage</li> <li>MBTPS2 (Site-2 protease) which performs the second cleavage</li> <li>Cleaved, active SREBP fragments are transported to the nucleus via Importin beta-1 (KPNB1)</li> <li>In the nucleus, SREBPs act as transcription factors to promote expression of genes involved in cholesterol biosynthesis</li> </ol>"},{"location":"reviews/6205c24300000880-Regulation_of_cholesterol_biosynthesis_by_SREBP__SREBF1_and_SREBF2__and_retention_by_the_SREBP_SCAP_complex__Human_/#assessment-of-the-model","title":"Assessment of the Model","text":""},{"location":"reviews/6205c24300000880-Regulation_of_cholesterol_biosynthesis_by_SREBP__SREBF1_and_SREBF2__and_retention_by_the_SREBP_SCAP_complex__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Comprehensive pathway representation: The model captures the core components of the SREBP regulatory pathway including SREBP retention, processing, nuclear import, and transcriptional activity.</p> </li> <li> <p>Appropriate use of causal relationships: The model uses the appropriate causal relationship predicates (RO:0002304 'causally upstream of, positive effect', RO:0002305 'causally upstream of, negative effect', RO:0002629 'directly positively regulates', RO:0002630 'directly negatively regulates') to represent the flow of information in the pathway.</p> </li> <li> <p>Accurate cellular compartmentalization: Activities are correctly assigned to their respective cellular locations (ER membrane, Golgi membrane, cytoplasm, nucleus).</p> </li> <li> <p>Evidence quality: The model uses appropriate literature evidence, including experimental evidence (ECO:0000314, ECO:0000315) with references to specific PMIDs.</p> </li> </ol>"},{"location":"reviews/6205c24300000880-Regulation_of_cholesterol_biosynthesis_by_SREBP__SREBF1_and_SREBF2__and_retention_by_the_SREBP_SCAP_complex__Human_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Empty evidence fields: Some causal associations have empty evidence fields (e.g., in activities 6205c24300000880/6205c24300000917 and 6205c24300000880/6205c24300000929), which should be populated with appropriate evidence codes and references.</p> </li> <li> <p>Inconsistent with_objects format: In activity 6205c24300000880/6205c24300001240, the with_objects field contains a formatting issue: <code>[\"With\\nUniProtKB:Q14703\"]</code> should be corrected to <code>[\"UniProtKB:Q14703\"]</code>.</p> </li> <li> <p>Redundant causal relationships: There appear to be some duplicate causal relationships between the same activities with the same predicates (e.g., multiple instances of the same activity associations). This could be simplified for a cleaner model.</p> </li> <li> <p>Missing small molecule components: While the model correctly captures protein components of the pathway, it doesn't explicitly represent the small molecules (cholesterol, oxysterols) that regulate the INSIG-SCAP interaction. Although small molecules cannot be annotated directly, a note could be added for clarity.</p> </li> </ol>"},{"location":"reviews/6205c24300000880-Regulation_of_cholesterol_biosynthesis_by_SREBP__SREBF1_and_SREBF2__and_retention_by_the_SREBP_SCAP_complex__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Add evidence to all causal associations: Complete the evidence fields for all causal associations to ensure proper documentation of the supporting literature.</p> </li> <li> <p>Fix the formatting issue in the with_objects field for activity 6205c24300000880/6205c24300001240.</p> </li> <li> <p>Remove redundant causal relationships: Review and consolidate duplicate causal relationships to streamline the model and prevent confusion.</p> </li> <li> <p>Add comments to clarify small molecule regulation: Consider adding a comment to explain the role of cholesterol/oxysterols in regulating the INSIG-SCAP interaction.</p> </li> <li> <p>Consider adding downstream metabolic enzymes: If appropriate, expand the model to include some key downstream enzymes in cholesterol biosynthesis that are regulated by SREBPs (e.g., HMG-CoA reductase).</p> </li> </ol>"},{"location":"reviews/6205c24300000880-Regulation_of_cholesterol_biosynthesis_by_SREBP__SREBF1_and_SREBF2__and_retention_by_the_SREBP_SCAP_complex__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:6205c24300000880) provides a good representation of the SREBP regulatory pathway for cholesterol biosynthesis. The model accurately captures the key molecular activities, their cellular locations, biological contexts, and causal relationships. With a few minor improvements to ensure complete evidence and remove redundancies, this would be an excellent reference model for the SREBP pathway that controls cholesterol homeostasis.</p>"},{"location":"reviews/6205c24300001663-IL2_signaling_pathway__Human_/","title":"6205c24300001663 IL2 signaling pathway  Human","text":"<p>After reviewing all the documentation and information about this GO-CAM model (gomodel:6205c24300001663), I'll now provide a comprehensive review:</p>"},{"location":"reviews/6205c24300001663-IL2_signaling_pathway__Human_/#review-of-go-cam-model-il2-signaling-pathway-human-gomodel6205c24300001663","title":"Review of GO-CAM model: IL2 signaling pathway (Human) gomodel:6205c24300001663","text":""},{"location":"reviews/6205c24300001663-IL2_signaling_pathway__Human_/#overview","title":"Overview","text":"<p>This GO-CAM model represents the IL-2 signaling pathway in humans, a critical pathway in immune system regulation. The model captures the sequence of molecular interactions beginning with IL-2 cytokine activity through receptor binding, co-receptor activation, and subsequent protein kinase signaling cascade leading to transcription factor activation.</p>"},{"location":"reviews/6205c24300001663-IL2_signaling_pathway__Human_/#strengths-of-the-model","title":"Strengths of the model","text":"<ol> <li> <p>Accurate pathway representation: The model correctly captures the IL-2 signaling pathway with IL-2 (cytokine) activating its receptor IL-2RA, which then activates co-receptors IL-2RB and IL-2RG, leading to activation of JAK kinases (JAK1 and JAK3), and ultimately STAT transcription factors (STAT5A and STAT3).</p> </li> <li> <p>Correct molecular function annotations: Each protein is annotated with appropriate molecular functions:</p> </li> <li>IL-2 as cytokine activity (GO:0005125)</li> <li>IL-2RA as interleukin-2 receptor activity (GO:0004911)</li> <li>IL-2RB and IL-2RG as co-receptor activity (GO:0015026)</li> <li>JAK1 and JAK3 as protein tyrosine kinase activity (GO:0004713)</li> <li> <p>STAT5A and STAT3 as DNA-binding transcription factor activity (GO:0003700)</p> </li> <li> <p>Appropriate cellular locations: The model correctly places:</p> </li> <li>IL-2 in extracellular space (GO:0005615)</li> <li>Receptors at the plasma membrane (GO:0005886)</li> <li>JAK proteins at the cytoplasmic side of the plasma membrane (GO:0031234)</li> <li> <p>STAT proteins in the nucleus (GO:0005634)</p> </li> <li> <p>Well-supported by evidence: Each annotation is supported by appropriate evidence codes and literature references (mainly from PMID:7973659, PMID:16293754, and others).</p> </li> <li> <p>Consistent with GO-CAM guidelines: The model follows the signaling receptor activity annotation guidelines, particularly the receptor with co-receptor example that specifically mentions this model.</p> </li> </ol>"},{"location":"reviews/6205c24300001663-IL2_signaling_pathway__Human_/#minor-issues-and-suggestions-for-improvement","title":"Minor issues and suggestions for improvement","text":"<ol> <li>Causal flow completeness: The model shows:</li> <li>IL-2 \u2192 IL-2RA \u2192 IL-2RB \u2192 JAK1 \u2192 STAT3</li> <li>IL-2 \u2192 IL-2RA \u2192 IL-2RB \u2192 IL-2RG \u2192 JAK3 \u2192 STAT5A</li> </ol> <p>However, according to the literature, STAT5A can also be activated by JAK1, which isn't explicitly captured in this model. This is a minor omission that could be added to make the model more complete.</p> <ol> <li> <p>Receptor complex representation: The quaternary structure of the IL-2 receptor complex (as described in PMID:16293754) where IL-2RA, IL-2RB, and IL-2RG form a complex is implicit in the model but not explicitly represented. This could potentially be clarified, though the current representation with causal relationships does capture the functional relationships.</p> </li> <li> <p>Downstream effects: The model could potentially be extended to include downstream effects of STAT activation, such as gene expression changes and cellular responses (proliferation, differentiation, etc.).</p> </li> </ol>"},{"location":"reviews/6205c24300001663-IL2_signaling_pathway__Human_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM best practices","text":"<p>This model adheres to the GO-CAM best practices for signaling receptor pathways by:</p> <ol> <li>Using appropriate molecular functions for ligands, receptors, co-receptors, and downstream effectors</li> <li>Using the correct causal relationships between activities (\"RO:0002629 directly positively regulates\")</li> <li>Correctly representing the spatial context with cellular component annotations</li> <li>Linking all activities to the appropriate biological process (GO:0038110 \"interleukin-2-mediated signaling pathway\")</li> <li>Supporting annotations with appropriate evidence codes and literature references</li> </ol>"},{"location":"reviews/6205c24300001663-IL2_signaling_pathway__Human_/#literature-alignment","title":"Literature alignment","text":"<p>The model is consistent with the current understanding of IL-2 signaling as described in the literature (PMID:7973659, PMID:16293754). The pathway accurately represents:</p> <ol> <li>The role of IL-2 as a cytokine that binds to IL-2RA</li> <li>The involvement of co-receptors IL-2RB and IL-2RG</li> <li>The activation of JAK1 and JAK3 by these receptors</li> <li>The subsequent activation of STAT transcription factors</li> </ol>"},{"location":"reviews/6205c24300001663-IL2_signaling_pathway__Human_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:6205c24300001663) is a well-constructed, evidence-backed representation of the IL-2 signaling pathway in humans that adheres to GO-CAM best practices. It accurately captures the key molecular activities, their spatial contexts, and the causal relationships between them. The minor suggestions noted above could further enhance the model, but they do not detract from its current high quality and usefulness.</p> <p>The model would be valuable for researchers studying IL-2 signaling and immunological processes, as it provides a clear molecular framework of this important immune regulatory pathway.</p>"},{"location":"reviews/62183af000000536-DNA_damage_sensor_activity_of_SIRT6_and_its_regulation_by_SIRT1__Human_/","title":"62183af000000536 DNA damage sensor activity of SIRT6 and its regulation by SIRT1  Human","text":"<p>Based on the information I've gathered, let me now review the GO-CAM model with ID 62183af000000536.</p>"},{"location":"reviews/62183af000000536-DNA_damage_sensor_activity_of_SIRT6_and_its_regulation_by_SIRT1__Human_/#review-of-go-cam-model-gomodel62183af000000536","title":"Review of GO-CAM Model: gomodel:62183af000000536","text":""},{"location":"reviews/62183af000000536-DNA_damage_sensor_activity_of_SIRT6_and_its_regulation_by_SIRT1__Human_/#model-overview","title":"Model Overview","text":"<ul> <li>Title: \"DNA damage sensor activity of SIRT6 and its regulation by SIRT1 (Human)\"</li> <li>Taxon: Human (NCBITaxon:9823)</li> <li>Status: Production</li> <li>Contributors: User with ORCID: 0000-0001-7299-6685 (contributed 2022-03-01)</li> </ul>"},{"location":"reviews/62183af000000536-DNA_damage_sensor_activity_of_SIRT6_and_its_regulation_by_SIRT1__Human_/#key-proteins-in-the-model","title":"Key Proteins in the Model","text":"<ol> <li>SIRT1 (UniProtKB:Q96EB6) - NAD-dependent protein deacetylase sirtuin-1</li> <li>SIRT6 (UniProtKB:Q8N6T7) - NAD-dependent protein deacylase sirtuin-6</li> </ol>"},{"location":"reviews/62183af000000536-DNA_damage_sensor_activity_of_SIRT6_and_its_regulation_by_SIRT1__Human_/#model-activities-and-connections","title":"Model Activities and Connections","text":"<p>The model describes the synergistic relationship between SIRT1 and SIRT6 in DNA damage detection and repair. The flow of activities in the model is:</p> <ol> <li>SIRT1 (UniProtKB:Q96EB6) enables NAD-dependent protein lysine deacetylase activity (GO:0034979)</li> <li>Part of positive regulation of double-strand break repair (GO:2000781)</li> <li> <p>Directly positively regulates (RO:0002629) SIRT6's damaged DNA binding activity</p> </li> <li> <p>SIRT6 (UniProtKB:Q8N6T7) enables damaged DNA binding (GO:0003684)</p> </li> <li>Occurs in site of double-strand break (GO:0035861)</li> <li>Part of positive regulation of double-strand break repair (GO:2000781)</li> <li> <p>Directly positively regulates (RO:0002629) SIRT6's DNA damage sensor activity</p> </li> <li> <p>SIRT6 (UniProtKB:Q8N6T7) enables DNA damage sensor activity (GO:0140612)</p> </li> <li>Occurs in site of double-strand break (GO:0035861)</li> <li>Part of positive regulation of double-strand break repair (GO:2000781)</li> <li> <p>Directly positively regulates (RO:0002629) SIRT6's histone H3K56 deacetylase activity</p> </li> <li> <p>SIRT6 (UniProtKB:Q8N6T7) enables histone H3K56 deacetylase activity, NAD-dependent (GO:0140765)</p> </li> <li>Occurs in site of double-strand break (GO:0035861)</li> <li>Part of positive regulation of double-strand break repair (GO:2000781)</li> </ol>"},{"location":"reviews/62183af000000536-DNA_damage_sensor_activity_of_SIRT6_and_its_regulation_by_SIRT1__Human_/#evidence-used","title":"Evidence Used","text":"<ul> <li>All activities are supported by experimental evidence codes (ECO:0000314 - direct assay evidence used in manual assertion)</li> <li>Primary evidence comes from PMID:32538779, PMID:31995034, and PMID:23911928</li> </ul>"},{"location":"reviews/62183af000000536-DNA_damage_sensor_activity_of_SIRT6_and_its_regulation_by_SIRT1__Human_/#assessment","title":"Assessment","text":""},{"location":"reviews/62183af000000536-DNA_damage_sensor_activity_of_SIRT6_and_its_regulation_by_SIRT1__Human_/#strengths","title":"Strengths:","text":"<ol> <li> <p>Accurate Molecular Functions: The model appropriately depicts the molecular functions of SIRT1 (deacetylase activity) and SIRT6 (damaged DNA binding, DNA damage sensor activity, and histone deacetylase activity).</p> </li> <li> <p>Appropriate Causal Relationships: The causal relationships between activities follow the biological mechanism described in the literature. SIRT1 deacetylates SIRT6 at K33, which promotes SIRT6's ability to recognize DNA breaks (damaged DNA binding). This leads to SIRT6's DNA damage sensor activity and eventually its histone deacetylase activity, all contributing to DNA repair.</p> </li> <li> <p>Cellular Location: The model correctly identifies that SIRT6's activities occur at the site of double-strand break (GO:0035861).</p> </li> <li> <p>Biological Process Context: All activities are appropriately part of the biological process \"positive regulation of double-strand break repair\" (GO:2000781).</p> </li> <li> <p>Strong Evidence Base: The model is supported by multiple published studies with experimental evidence.</p> </li> </ol>"},{"location":"reviews/62183af000000536-DNA_damage_sensor_activity_of_SIRT6_and_its_regulation_by_SIRT1__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement:","text":"<ol> <li> <p>Target of SIRT1 Deacetylation: The model could be more explicit about SIRT1's deacetylation target. According to PMID:32538779, SIRT1 specifically deacetylates SIRT6 at residue K33. This could be included as context for SIRT1's activity or as a has_input relationship.</p> </li> <li> <p>Histone Deacetylation Targets: The model shows SIRT6 deacetylating H3K56, which is accurate, but PMID:32538779 also indicates that SIRT6 deacetylates H3K9. The model could be expanded to include this additional deacetylation activity.</p> </li> <li> <p>SIRT6 Polymerization: The literature suggests that SIRT1-mediated deacetylation promotes SIRT6 polymerization, which is important for its ability to recognize DNA breaks. This aspect of the mechanism is not explicitly captured in the model.</p> </li> <li> <p>Additional Context: The model could benefit from inclusion of other contextual information such as:</p> </li> <li>The role of gammaH2AX in retaining SIRT6 at the DNA damage site</li> <li> <p>The fact that SIRT6's initial recruitment to DNA breaks is independent of H2AX, but retention requires gammaH2AX</p> </li> <li> <p>Acetylation State: The model could explicitly represent the acetylation state of SIRT6, showing how it changes from acetylated to deacetylated following SIRT1 activity.</p> </li> </ol>"},{"location":"reviews/62183af000000536-DNA_damage_sensor_activity_of_SIRT6_and_its_regulation_by_SIRT1__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model effectively captures the key molecular activities and relationships between SIRT1 and SIRT6 in DNA damage detection and repair. The model aligns well with the recent scientific literature and follows GO-CAM best practices. With the suggested improvements, the model could more comprehensively represent the detailed molecular mechanisms described in the supporting literature.</p> <p>The model correctly shows that SIRT1's deacetylation activity positively regulates SIRT6's ability to bind damaged DNA, which in turn promotes its DNA damage sensor activity and histone deacetylase activity. This cascade of events contributes to effective DNA double-strand break repair.</p> <p>I recommend accepting this model with the suggested minor improvements to enhance its completeness and detail.</p>"},{"location":"reviews/622aace900000443-Fructose_catabolic_process__Mouse_/","title":"622aace900000443 Fructose catabolic process  Mouse","text":"<p>Based on my review of the GO-CAM model 622aace900000443 \"Fructose catabolic process (Mouse)\" and the supporting information, I can provide the following assessment:</p>"},{"location":"reviews/622aace900000443-Fructose_catabolic_process__Mouse_/#go-cam-model-review-fructose-catabolic-process-mouse","title":"GO-CAM Model Review: Fructose Catabolic Process (Mouse)","text":"<p>Model ID: gomodel:622aace900000443</p>"},{"location":"reviews/622aace900000443-Fructose_catabolic_process__Mouse_/#summary-of-the-model","title":"Summary of the Model","text":"<p>This GO-CAM model represents the fructose catabolic pathway in mouse (NCBITaxon:10090). The model includes five key molecular activities and their causal relationships that together describe how fructose is metabolized:</p> <ol> <li>Ketohexokinase activity (Khk, MGI:MGI:1096353) - catalyzes the conversion of fructose to fructose-1-phosphate</li> <li>Fructose-1-phosphate aldolase activity (Aldob, MGI:MGI:87995) - splits fructose-1-phosphate into dihydroxyacetone phosphate and glyceraldehyde</li> <li>Aldehyde dehydrogenase activity (two variants - Aldh1a1 and Aldh1a7) - converts glyceraldehyde to glycerate</li> <li>Glycerate kinase activity (Glyctk, MGI:MGI:2444085) - phosphorylates glycerate to 2-phosphoglycerate</li> </ol> <p>All of these activities are part of the biological process \"fructose catabolic process\" (GO:0006001) and are localized in the cytosol (GO:0005829).</p>"},{"location":"reviews/622aace900000443-Fructose_catabolic_process__Mouse_/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":"<p>The model presents a scientifically accurate representation of fructose metabolism that is consistent with the literature:</p> <ol> <li> <p>Correct pathway representation: The model correctly represents the primary pathway of fructose metabolism in the liver, which is initiated by ketohexokinase and involves aldolase B as a critical enzyme. This is supported by the PMID:29533924 paper that details the fructose metabolism pathway.</p> </li> <li> <p>Appropriate gene products: The model uses the mouse-specific gene products (MGI IDs) for each activity, which is appropriate for a mouse model.</p> </li> <li> <p>Evidence quality: The model provides good evidence citations, including both experimental evidence codes (ECO:0000314 - direct assay) and literature references (multiple PMIDs are cited).</p> </li> <li> <p>Subcellular localization: The cytosolic localization of these activities is correctly noted, as fructose metabolism primarily occurs in the cytosol.</p> </li> <li> <p>Causal relationships: The \"provides input for\" (RO:0002413) relationships between activities correctly represent the flow of metabolites through the pathway.</p> </li> </ol>"},{"location":"reviews/622aace900000443-Fructose_catabolic_process__Mouse_/#go-cam-compliance-assessment","title":"GO-CAM Compliance Assessment","text":"<p>The model follows GO-CAM best practices:</p> <ol> <li> <p>Activity-centric modeling: Each node in the model represents a molecular activity rather than a gene or protein.</p> </li> <li> <p>Proper evidence annotations: Each assertion is supported by appropriate evidence codes and references.</p> </li> <li> <p>Appropriate causal links: The causal relationships between activities use the \"provides input for\" (RO:0002413) predicate, which is appropriate for metabolic pathways where the product of one reaction is the substrate for the next.</p> </li> <li> <p>Complete activity descriptions: Each activity includes:</p> </li> <li>The molecular function term</li> <li>The gene product that enables the activity</li> <li>The cellular component where the activity occurs</li> <li> <p>The biological process the activity is part of</p> </li> <li> <p>Connected model: All activities are connected in a way that represents the flow of the pathway.</p> </li> </ol>"},{"location":"reviews/622aace900000443-Fructose_catabolic_process__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<p>While the model is generally very good, I identified a few potential areas for improvement:</p> <ol> <li> <p>Evidence for causal associations: The causal associations between activities have empty evidence fields. Ideally, these causal links should also have evidence codes and references.</p> </li> <li> <p>Additional contextual information: The model could potentially benefit from including information about regulation of this pathway, such as how dietary fructose intake affects the pathway flux or how the pathway is regulated under different metabolic conditions.</p> </li> <li> <p>Connection to downstream metabolism: The model could be extended to show how the products of this pathway feed into other metabolic pathways like glycolysis or lipogenesis.</p> </li> </ol>"},{"location":"reviews/622aace900000443-Fructose_catabolic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model 622aace900000443 \"Fructose catabolic process (Mouse)\" is a high-quality representation of fructose metabolism in mouse that adheres to GO-CAM best practices. The model accurately represents the key enzymatic steps and their relationships in the fructose catabolic pathway, with appropriate evidence and annotations. The model provides valuable information about how fructose is metabolized and could serve as a reference for researchers studying fructose metabolism or related metabolic disorders like hereditary fructose intolerance.</p>"},{"location":"reviews/622aace900000790-Galactose_catabolic_process_via_UDP_galactose/","title":"622aace900000790 Galactose catabolic process via UDP galactose","text":"<p>Based on all the information gathered, I'll now provide my review of the GO-CAM model with ID \"622aace900000790\".</p>"},{"location":"reviews/622aace900000790-Galactose_catabolic_process_via_UDP_galactose/#review-of-go-cam-model-gomodel622aace900000790","title":"Review of GO-CAM Model: gomodel:622aace900000790","text":""},{"location":"reviews/622aace900000790-Galactose_catabolic_process_via_UDP_galactose/#overview","title":"Overview","text":"<p>This GO-CAM model describes the \"Galactose catabolic process via UDP-galactose\" in mouse (NCBITaxon:10090) and is sourced from the Reactome pathway model R-HSA-70370. The model represents the Leloir pathway of galactose metabolism in a logical and well-connected manner.</p>"},{"location":"reviews/622aace900000790-Galactose_catabolic_process_via_UDP_galactose/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li>Comprehensive enzyme coverage: The model includes all the key enzymes involved in the galactose catabolic pathway via UDP-galactose:</li> <li>Galactokinase (GALK1, MGI:MGI:95730)</li> <li>Galactose-1-phosphate uridylyltransferase (GALT, MGI:MGI:95638)</li> <li>UDP-glucose 4-epimerase (GALE, MGI:MGI:1921496)</li> <li>Galactose mutarotase (GALM, MGI:MGI:2442420)</li> <li> <p>Phosphoglucomutase (PGM1/PGM2, MGI:MGI:97565 and MGI:MGI:97564)</p> </li> <li> <p>Well-structured causal relationships: The model appropriately uses the \"provides input for\" (RO:0002413) causal relationship to connect the activities in the pathway, reflecting the flow of metabolites through the Leloir pathway.</p> </li> <li> <p>Proper molecular function annotation: Each gene product is annotated with the correct molecular function term and connected to the appropriate biological process.</p> </li> <li> <p>Input/output associations: The model correctly specifies substrates and products using has_input and has_output associations (e.g., CHEBI:18307 for UDP-D-galactose and CHEBI:18066 for UDP-D-glucose).</p> </li> <li> <p>Evidence-based assertions: The model provides evidence codes and literature references (PMIDs) for most assertions, showing a solid foundation in experimental data.</p> </li> </ol>"},{"location":"reviews/622aace900000790-Galactose_catabolic_process_via_UDP_galactose/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Missing anomer specification for some metabolites: The model starts with GALM converting beta-D-galactose to alpha-D-galactose, but the explicit inputs/outputs for this reaction aren't fully specified in the GALM activity node. Based on the literature (PMID:30451973), GALM catalyzes the interconversion between beta-D-galactose (CHEBI:27667) and alpha-D-galactose (CHEBI:28061), but these specific CHEBI IDs aren't used consistently in the model.</p> </li> <li> <p>Possible missing enzyme: Recent research (PMID:30451973) suggests that GALM is a necessary first enzyme in the Leloir pathway for the epimerization between \u03b2- and \u03b1-D-galactose. While GALM is included in the model, its position in the pathway flow could be clearer.</p> </li> <li> <p>Cyclical causal relationships: There's a circular relationship in the model where:</p> </li> <li>GALT (gomodel:622aace900000790/622aace900000795) provides input for GALE (gomodel:622aace900000790/622aace900000806)</li> <li>GALE provides input for GALT</li> </ol> <p>While this reflects the reversible nature of parts of the pathway, it might be helpful to clarify the primary direction of metabolic flow by using directionality-specific causal predicates in addition to the general \"provides input for\".</p> <ol> <li> <p>Incomplete evidence annotation: While many activities have evidence codes, some causal associations lack evidence annotations. For example, the causal associations from GALT to other enzymes don't have explicit evidence.</p> </li> <li> <p>Some missing molecular details: The model doesn't fully capture certain details, such as the role of zinc ions for GALT activity or NAD+ as a cofactor for GALE, which could enrich the molecular understanding of the pathway.</p> </li> </ol>"},{"location":"reviews/622aace900000790-Galactose_catabolic_process_via_UDP_galactose/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model accurately represents the Leloir pathway of galactose metabolism. The scientific content aligns well with current understanding of this pathway:</p> <ol> <li>GALM converts beta-D-galactose to alpha-D-galactose</li> <li>GALK1 phosphorylates alpha-D-galactose to galactose-1-phosphate</li> <li>GALT exchanges UDP-glucose with galactose-1-phosphate to form UDP-galactose and glucose-1-phosphate</li> <li>GALE converts UDP-galactose to UDP-glucose</li> <li>PGM1/PGM2 converts glucose-1-phosphate to glucose-6-phosphate for entry into glycolysis</li> </ol> <p>The inclusion of all key enzymes and appropriate activity relationships makes this a biologically accurate representation of the pathway.</p>"},{"location":"reviews/622aace900000790-Galactose_catabolic_process_via_UDP_galactose/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<ol> <li> <p>Complex representation: The model does not explicitly represent protein complexes, which is fine since the enzymes in this pathway function as individual proteins rather than obligate complexes.</p> </li> <li> <p>Causal relationships: The model uses \"provides input for\" (RO:0002413) consistently for connections between activities, which is appropriate for a metabolic pathway where the product of one reaction becomes the substrate for the next.</p> </li> <li> <p>Part-of relationships: All molecular functions are correctly associated with the \"galactose catabolic process via UDP-galactose\" (GO:0033499) biological process.</p> </li> <li> <p>Evidence codes: The model uses appropriate evidence codes such as ECO:0000314 (direct assay evidence) and ECO:0000315 (mutant phenotype evidence).</p> </li> </ol>"},{"location":"reviews/622aace900000790-Galactose_catabolic_process_via_UDP_galactose/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add specific CHEBI IDs for all inputs/outputs: Ensure all metabolites have the appropriate CHEBI IDs, particularly for the beta-D-galactose (CHEBI:27667) and alpha-D-galactose (CHEBI:28061) involved in the GALM reaction.</p> </li> <li> <p>Clarify the cyclical relationship: Consider using more specific causal relationship terms that indicate directionality to better represent the primary flow of the pathway while acknowledging reversible steps.</p> </li> <li> <p>Complete evidence annotations: Add evidence codes and references for all causal associations between activities.</p> </li> <li> <p>Include cofactor information: Consider adding cofactor information for enzymes where relevant (e.g., NAD+ for GALE, zinc ions for GALT).</p> </li> <li> <p>Double-check pathway flow: Ensure the directionality of the pathway is clear, particularly with respect to where GALM fits in the overall flow.</p> </li> </ol>"},{"location":"reviews/622aace900000790-Galactose_catabolic_process_via_UDP_galactose/#conclusion","title":"Conclusion","text":"<p>Overall, gomodel:622aace900000790 is a well-constructed GO-CAM model that accurately represents the galactose catabolic process via UDP-galactose. The model includes all key enzymes and their relationships, with appropriate evidence. With a few minor improvements to address the issues mentioned above, this model would serve as an excellent reference for understanding this metabolic pathway.</p> <p>The model is parsimonious and should be easy for humans to understand. It successfully captures the essential components and relationships of the Leloir pathway of galactose metabolism in mouse.</p>"},{"location":"reviews/622aace900000962-Pentose_phosphate_shunt_1__Mouse_/","title":"622aace900000962 Pentose phosphate shunt 1  Mouse","text":"<p>Based on my review of this GO-CAM model (gomodel:622aace900000962), here's my detailed assessment:</p>"},{"location":"reviews/622aace900000962-Pentose_phosphate_shunt_1__Mouse_/#go-cam-review-pentose-phosphate-shunt-1-mouse","title":"GO-CAM Review: Pentose-phosphate shunt 1 (Mouse)","text":""},{"location":"reviews/622aace900000962-Pentose_phosphate_shunt_1__Mouse_/#overview","title":"Overview","text":"<p>The GO-CAM model gomodel:622aace900000962 represents the pentose phosphate pathway (PPP) in mouse, focusing on the activities and interactions of the key enzymes involved in this metabolic pathway. The model was sourced from gomodel:R-HSA-71336 and captures both the oxidative and non-oxidative branches of the pentose phosphate pathway.</p>"},{"location":"reviews/622aace900000962-Pentose_phosphate_shunt_1__Mouse_/#model-structure-and-content-assessment","title":"Model Structure and Content Assessment","text":""},{"location":"reviews/622aace900000962-Pentose_phosphate_shunt_1__Mouse_/#molecular-functions-and-causal-links","title":"Molecular Functions and Causal Links","text":"<p>The model effectively represents the pentose phosphate pathway as a series of connected enzymatic activities:</p> <ol> <li>Oxidative Branch:</li> <li>Glucose-6-phosphate dehydrogenase (G6pdx and G6pd2) catalyzing glucose-6-phosphate dehydrogenase activity (GO:0004345)</li> <li>6-phosphogluconolactonase (Pgls) catalyzing 6-phosphogluconolactonase activity (GO:0017057)</li> <li> <p>6-phosphogluconate dehydrogenase (Pgd) catalyzing phosphogluconate dehydrogenase activity (GO:0004616)</p> </li> <li> <p>Non-oxidative Branch:</p> </li> <li>Ribose-5-phosphate isomerase (Rpia) catalyzing ribose-5-phosphate isomerase activity (GO:0004751)</li> <li>Ribulose-5-phosphate epimerase (Rpe) catalyzing D-ribulose-phosphate 3-epimerase activity (GO:0004750)</li> <li>Transketolase (Tkt) catalyzing transketolase activity (GO:0004802)</li> <li>Transaldolase (Taldo1) catalyzing transaldolase activity (GO:0004801)</li> </ol>"},{"location":"reviews/622aace900000962-Pentose_phosphate_shunt_1__Mouse_/#causal-connections","title":"Causal Connections","text":"<p>The model correctly uses the \"provides input for\" relation (RO:0002413) to connect the activities in a way that accurately represents the flow through the pentose phosphate pathway:</p> <ul> <li>G6pdx/G6pd2 \u2192 Pgls</li> <li>Pgls \u2192 Pgd </li> <li>Pgd \u2192 Rpia and Rpe</li> <li>Rpe \u2192 Tkt and Taldo1</li> <li>Rpia \u2192 Taldo1</li> <li>Taldo1 \u2192 Tkt (second transketolase reaction)</li> </ul>"},{"location":"reviews/622aace900000962-Pentose_phosphate_shunt_1__Mouse_/#cellular-context-and-biological-process","title":"Cellular Context and Biological Process","text":"<p>All activities are appropriately annotated as: - Occurring in the cytosol (GO:0005829) - Being part of either:   - The pentose-phosphate shunt (GO:0006098) or   - The oxidative branch of the pentose-phosphate shunt (GO:0009051)</p>"},{"location":"reviews/622aace900000962-Pentose_phosphate_shunt_1__Mouse_/#evidence-and-references","title":"Evidence and References","text":"<p>Evidence codes and references are properly incorporated: - Experimental evidence codes (ECO:0000314, ECO:0000315) are used appropriately - References to primary literature (including PMID:5360673) provide support for the activities and relationships - The evidence is well-distributed across the model with most activities having multiple evidence sources</p>"},{"location":"reviews/622aace900000962-Pentose_phosphate_shunt_1__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Pathway Completeness: The model comprehensively represents the entire pentose phosphate pathway, including both oxidative and non-oxidative branches.</p> </li> <li> <p>Accuracy of Enzyme Activities: Each enzyme is correctly associated with its specific molecular function and the appropriate gene products.</p> </li> <li> <p>Chemical Outputs: The model includes the appropriate chemical outputs (CHEBI terms) for reactions, such as NADPH (CHEBI:57783) and fructose-6-phosphate (CHEBI:57634).</p> </li> <li> <p>Evidence Quality: The model uses high-quality evidence including direct assays and sequence orthology evidence.</p> </li> <li> <p>Causal Connectivity: The pathway is properly connected with causal relationships that accurately represent the metabolic flow.</p> </li> </ol>"},{"location":"reviews/622aace900000962-Pentose_phosphate_shunt_1__Mouse_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li> <p>Input Molecules: While outputs are specified for some activities, inputs could be more consistently documented across all activities to better represent substrate utilization.</p> </li> <li> <p>Regulation Information: The model could be enhanced by including regulatory information (such as the inhibition of 6-phosphogluconate dehydrogenase by fructose 1,6-diphosphate, or the NADPH negative feedback), which would more accurately represent the pathway's regulation as described in the literature.</p> </li> <li> <p>Pathway Connections: The model could benefit from connections to related pathways, such as glycolysis, which shares intermediates with the pentose phosphate pathway.</p> </li> </ol>"},{"location":"reviews/622aace900000962-Pentose_phosphate_shunt_1__Mouse_/#biological-accuracy-assessment","title":"Biological Accuracy Assessment","text":"<p>The represented enzymatic reactions align well with the established understanding of the pentose phosphate pathway. The PMID:5360673 publication and UniProt entry P52209 confirm the key enzymes and their roles in the pathway.</p> <p>The model correctly represents: - The sequential oxidation and decarboxylation in the oxidative branch - The interconversion of sugars in the non-oxidative branch - The cytosolic localization of all the pathway components - The production of NADPH by the oxidative branch</p>"},{"location":"reviews/622aace900000962-Pentose_phosphate_shunt_1__Mouse_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model is a high-quality representation of the pentose phosphate pathway in mouse. It accurately captures the enzymatic activities, their cellular location, and the causal relationships between them. The model is well-supported by experimental evidence and follows GO-CAM best practices for metabolic pathway representation.</p> <p>The model could be further enhanced by including more details on regulation and connections to related metabolic pathways, but as it stands, it provides a clear and accurate representation of the pentose phosphate shunt that would be useful for researchers studying carbohydrate metabolism.</p>"},{"location":"reviews/6246724f00000283-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_deubiquitnation_of_SESN2_by_RNF167_and_STAMBPL1__Human_/","title":"6246724f00000283 Regulation of the mTORC1 signaling via ubiquitination and deubiquitnation of SESN2 by RNF167 and STAMBPL1  Human","text":"<p>Based on the information I've gathered, I'll now review the GO-CAM model gomodel:6246724f00000283, which focuses on \"Regulation of the mTORC1 signaling via ubiquitination and deubiquitnation of SESN2 by RNF167 and STAMBPL1 (Human)\".</p>"},{"location":"reviews/6246724f00000283-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_deubiquitnation_of_SESN2_by_RNF167_and_STAMBPL1__Human_/#review-of-go-cam-model-gomodel6246724f00000283","title":"Review of GO-CAM Model: gomodel:6246724f00000283","text":""},{"location":"reviews/6246724f00000283-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_deubiquitnation_of_SESN2_by_RNF167_and_STAMBPL1__Human_/#overview","title":"Overview","text":"<p>This model represents the regulatory mechanism of mTORC1 signaling through ubiquitination and deubiquitination of Sestrin2 (SESN2) by the E3 ubiquitin ligase RNF167 and the deubiquitinase STAMBPL1, respectively. The model appropriately captures key activities and causal relationships in the leucine-sensing pathway affecting mTORC1 signaling.</p>"},{"location":"reviews/6246724f00000283-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_deubiquitnation_of_SESN2_by_RNF167_and_STAMBPL1__Human_/#model-components-and-structure","title":"Model Components and Structure","text":"<p>The model includes five main activities:</p> <ol> <li>RNF167 (Q9H6Y7) - ubiquitin-protein transferase activity (GO:0004842)</li> <li>STAMBPL1 (Q96FJ0) - K63-linked deubiquitinase activity (GO:0061578)</li> <li>SESN2 (P58004) - protein sequestering activity (GO:0140311)</li> <li>SESN2 (P58004) - L-leucine binding (GO:0070728)</li> <li>WDR24 (Q96S15) - ubiquitin protein ligase activity (GO:0061630)</li> </ol> <p>The model describes the causal relationships between these activities, showing how RNF167 and STAMBPL1 regulate SESN2's ability to inhibit mTORC1 signaling, and how SESN2 in turn regulates WDR24.</p>"},{"location":"reviews/6246724f00000283-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_deubiquitnation_of_SESN2_by_RNF167_and_STAMBPL1__Human_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Accurate Biological Pathway Representation: The model correctly represents the leucine-sensing mechanism through SESN2 and its regulation of mTORC1 signaling, which aligns with the scientific literature.</p> </li> <li> <p>Appropriate Use of Causal Relationships: The model uses the proper causal relationship predicates (RO:0002629 \"directly positively regulates\" and RO:0002630 \"directly negatively regulates\").</p> </li> <li> <p>Cellular Component Annotations: The model accurately represents the subcellular locations where these activities occur, including the lysosomal membrane and cytoplasm.</p> </li> <li> <p>Evidence and References: Each activity and causal relationship is supported by appropriate evidence codes and literature references, primarily from PMID:35114100, PMID:26586190, and PMID:26449471.</p> </li> </ol>"},{"location":"reviews/6246724f00000283-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_deubiquitnation_of_SESN2_by_RNF167_and_STAMBPL1__Human_/#suggested-improvements-and-issues","title":"Suggested Improvements and Issues","text":"<ol> <li> <p>Incomplete Representation of GATOR2 Complex: The model depicts WDR24 as a component of the pathway, but doesn't fully represent its role as part of the GATOR2 complex. According to the literature (PMID:35831510), the GATOR2 complex includes WDR24, MIOS, SEH1L, SEC13, and WDR59. The model could be improved by better representing this complex structure, either by adding the other components or using the complex ID as suggested in GO-CAM best practices.</p> </li> <li> <p>Missing K6-linked Ubiquitination Function: The model shows WDR24 with ubiquitin protein ligase activity (GO:0061630) participating in protein K6-linked ubiquitination (GO:0085020), but doesn't clearly show the target of this activity. According to PMID:36528027, WDR24 mediates K6-linked ubiquitination of NPRL2, a component of the GATOR1 complex. This relationship could be more explicitly modeled.</p> </li> <li> <p>Potential Incomplete Annotation of SESN2 Activities: While the model correctly shows SESN2's protein sequestering activity and L-leucine binding, it might be worth considering adding SESN2's interaction with the GATOR2 complex more explicitly, as this is a key aspect of how it regulates mTORC1 signaling.</p> </li> </ol>"},{"location":"reviews/6246724f00000283-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_deubiquitnation_of_SESN2_by_RNF167_and_STAMBPL1__Human_/#consistency-with-go-cam-best-practices","title":"Consistency with GO-CAM Best Practices","text":"<p>The model follows the GO-CAM best practices for representing molecular functions and causal relationships. It correctly uses the enabled_by relationship to connect activities to their molecular entities, and it appropriately uses the cellular component annotations to indicate where activities occur.</p> <p>In terms of representing complexes, the model could be improved. According to the \"How to annotate complexes in GO-CAM\" document, when the subunit carrying the activity is known, those specific proteins should be represented. However, for activities where the precise subunit is not known, the GO accession for the complex should be used. Given that WDR24 is part of the GATOR2 complex, this aspect could be more clearly represented.</p>"},{"location":"reviews/6246724f00000283-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_deubiquitnation_of_SESN2_by_RNF167_and_STAMBPL1__Human_/#scientific-accuracy","title":"Scientific Accuracy","text":"<p>The biological content represented in the model is consistent with the literature. The key findings from PMID:35114100 (that RNF167 mediates K63-linked ubiquitination of SESN2, which promotes SESN2's interaction with the GATOR2 complex and inhibits mTORC1 signaling, while STAMBPL1 deubiquitinates SESN2) are accurately represented.</p> <p>The model also correctly captures the role of leucine in this pathway, as described in PMID:26586190 and PMID:26449471, which show that SESN2 acts as a leucine sensor that regulates mTORC1 signaling through the GATOR complex.</p>"},{"location":"reviews/6246724f00000283-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_deubiquitnation_of_SESN2_by_RNF167_and_STAMBPL1__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this GO-CAM model (gomodel:6246724f00000283) effectively represents the regulation of mTORC1 signaling via ubiquitination and deubiquitination of SESN2 by RNF167 and STAMBPL1. The model is scientifically accurate and follows GO-CAM best practices. </p> <p>The main recommendations for improvement would be: 1. More explicitly representing the GATOR2 complex structure 2. Clarifying the target of WDR24's ubiquitin ligase activity 3. Potentially adding more detail about SESN2's interaction with the GATOR2 complex</p> <p>These refinements would enhance the model's clarity and completeness but don't diminish its current scientific validity.</p>"},{"location":"reviews/6246724f00000369-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_degradation_of_CASTOR1_by_RNF167__Human__/","title":"6246724f00000369 Regulation of the mTORC1 signaling via ubiquitination and degradation of CASTOR1 by RNF167  Human","text":"<p>Now that I have gathered the necessary information about the model and related proteins/concepts, let me review the GO-CAM model:</p>"},{"location":"reviews/6246724f00000369-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_degradation_of_CASTOR1_by_RNF167__Human__/#review-of-gomodel6246724f00000369","title":"Review of gomodel:6246724f00000369","text":""},{"location":"reviews/6246724f00000369-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_degradation_of_CASTOR1_by_RNF167__Human__/#summary-of-the-model","title":"Summary of the Model","text":"<p>This GO-CAM model titled \"Regulation of the mTORC1 signaling via ubiquitination and degradation of CASTOR1 by RNF167 (Human)\" describes a signaling pathway in which the E3 ubiquitin ligase RNF167 ubiquitinates and promotes the degradation of CASTOR1, leading to the activation of mTORC1 signaling. The model involves several key proteins:</p> <ol> <li>CASTOR1 (Q8WTX7) - Cytosolic arginine sensor for mTORC1 that normally inhibits mTORC1 signaling</li> <li>RNF167 (Q9H6Y7) - E3 ubiquitin ligase </li> <li>WDR24 (Q96S15) - GATOR2 complex component with ubiquitin ligase activity</li> <li>AKT1 (P31749) - Protein kinase that phosphorylates CASTOR1</li> </ol>"},{"location":"reviews/6246724f00000369-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_degradation_of_CASTOR1_by_RNF167__Human__/#accuracy-and-completeness","title":"Accuracy and Completeness","text":""},{"location":"reviews/6246724f00000369-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_degradation_of_CASTOR1_by_RNF167__Human__/#biological-content","title":"Biological Content","text":"<p>The model accurately represents a key regulatory mechanism of mTORC1 signaling based on the literature evidence. According to PMID:33594058, RNF167 targets CASTOR1 for K29-linked ubiquitination and degradation, which relieves CASTOR1's inhibition of mTORC1. The model correctly indicates that AKT1 phosphorylates CASTOR1, which promotes RNF167 binding and subsequent ubiquitination, leading to activation of mTORC1 signaling.</p> <p>The model appropriately includes: - CASTOR1's dual activities as arginine binding (GO:0034618) and protein sequestering (GO:0140311) - RNF167's ubiquitin-protein transferase activity (GO:0004842) - WDR24's ubiquitin protein ligase activity (GO:0061630) - AKT1's protein serine/threonine kinase activity (GO:0004674)</p>"},{"location":"reviews/6246724f00000369-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_degradation_of_CASTOR1_by_RNF167__Human__/#relationships-and-causal-connections","title":"Relationships and Causal Connections","text":"<p>The causal relationships in the model appear correct: - RNF167 activity (GO:0004842) directly negatively regulates CASTOR1 protein sequestering activity (GO:0140311) - CASTOR1 arginine binding (GO:0034618) directly negatively regulates CASTOR1 protein sequestering activity (GO:0140311) - AKT1 protein kinase activity (GO:0004674) provides input for RNF167's activity - CASTOR1 protein sequestering activity directly negatively regulates WDR24's ubiquitin ligase activity</p>"},{"location":"reviews/6246724f00000369-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_degradation_of_CASTOR1_by_RNF167__Human__/#cellular-locations","title":"Cellular Locations","text":"<p>The model correctly identifies: - CASTOR1 activities in the cytosol (GO:0005829) - WDR24 in the lysosomal membrane (GO:0005765)</p>"},{"location":"reviews/6246724f00000369-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_degradation_of_CASTOR1_by_RNF167__Human__/#biological-processes","title":"Biological Processes","text":"<p>The model appropriately annotates: - RNF167's role in protein K29-linked ubiquitination (GO:0035519) - CASTOR1's role in negative regulation of TORC1 signaling (GO:1904262) and positive regulation of TORC1 signaling (GO:1904263) - WDR24's role in protein K6-linked ubiquitination (GO:0085020)</p>"},{"location":"reviews/6246724f00000369-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_degradation_of_CASTOR1_by_RNF167__Human__/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":""},{"location":"reviews/6246724f00000369-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_degradation_of_CASTOR1_by_RNF167__Human__/#complex-representation","title":"Complex Representation","text":"<p>The model follows the GO-CAM guidelines for representing complexes, particularly regarding E3 ubiquitin ligases. According to the \"How_to_annotate_complexes_in_GO-CAM\" and \"E3_ubiquitin_ligases\" documents:</p> <ul> <li>The model correctly represents RNF167 as an E3 ligase with its ubiquitin-protein transferase activity</li> <li>The appropriate causal relationships are used to show how RNF167 regulates CASTOR1</li> <li>WDR24 is correctly represented with its ubiquitin protein ligase activity</li> </ul>"},{"location":"reviews/6246724f00000369-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_degradation_of_CASTOR1_by_RNF167__Human__/#evidence-support","title":"Evidence Support","text":"<p>Each activity and relationship in the model is properly supported by evidence from the literature: - PMID:33594058 provides evidence for RNF167's ubiquitination of CASTOR1 - PMID:26972053 provides evidence for CASTOR1's role as an arginine sensor - PMID:36528027 supports WDR24's role in the GATOR2 complex - PMID:28199306 provides evidence for the localization of WDR24 to the lysosomal membrane</p>"},{"location":"reviews/6246724f00000369-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_degradation_of_CASTOR1_by_RNF167__Human__/#areas-for-improvement","title":"Areas for Improvement","text":"<p>While the model is overall well-constructed and biologically accurate, there are a few areas that could be improved:</p> <ol> <li> <p>Additional molecular details: The model could more explicitly represent how AKT1 phosphorylates CASTOR1 at Ser-14, which enhances its interaction with RNF167. According to PMID:33594058, this phosphorylation is a critical regulatory step.</p> </li> <li> <p>Input molecule for CASTOR1 arginine binding: While the model correctly shows that CASTOR1 binds arginine (CHEBI:32696), it would be helpful to clarify the regulatory role of arginine in this process - when arginine binds to CASTOR1, it disrupts CASTOR1's interaction with the GATOR2 complex.</p> </li> <li> <p>Complete representation of the GATOR2 complex: The model currently includes WDR24 as a representative of the GATOR2 complex, but according to the literature, the complete GATOR2 complex contains WDR24, MIOS, WDR59, SEC13, and SEH1L. While not necessary to include all components, a note about the complete complex could be informative.</p> </li> <li> <p>Lysine residues in CASTOR1 targeted for ubiquitination: The model could specify the lysine residues in CASTOR1 (K61, K96, and K213) that are targeted by RNF167 for K29-linked polyubiquitination, as mentioned in PMID:33594058.</p> </li> </ol>"},{"location":"reviews/6246724f00000369-Regulation_of_the_mTORC1_signaling_via_ubiquitination_and_degradation_of_CASTOR1_by_RNF167__Human__/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model gomodel:6246724f00000369 provides an accurate representation of the regulation of mTORC1 signaling through RNF167-mediated ubiquitination and degradation of CASTOR1. The model correctly captures the key molecular functions, biological processes, cellular locations, and causal relationships supported by published literature.</p> <p>The model effectively highlights how CASTOR1, a cytosolic arginine sensor, can be regulated not only by arginine binding but also through post-translational modifications (phosphorylation by AKT1 followed by ubiquitination by RNF167), leading to its degradation and subsequent activation of mTORC1 signaling.</p> <p>The causal flow of the pathway is logically represented, with appropriate use of regulatory relationships between protein activities. The model complies with GO-CAM best practices for representing E3 ubiquitin ligase activities and complex components.</p> <p>With a few minor additions to include more specific molecular details, this model could serve as an excellent reference for understanding this regulatory mechanism of the mTORC1 pathway.</p>"},{"location":"reviews/6246724f00000549-Renin_angiotensin_pathway__Human_/","title":"6246724f00000549 Renin angiotensin pathway  Human","text":"<p>Let me continue with my review based on the information I've gathered.</p>"},{"location":"reviews/6246724f00000549-Renin_angiotensin_pathway__Human_/#go-cam-model-review-renin-angiotensin-pathway-human","title":"GO-CAM Model Review: Renin-angiotensin pathway (Human)","text":""},{"location":"reviews/6246724f00000549-Renin_angiotensin_pathway__Human_/#model-id-gomodel6246724f00000549","title":"Model ID: gomodel:6246724f00000549","text":""},{"location":"reviews/6246724f00000549-Renin_angiotensin_pathway__Human_/#overview","title":"Overview","text":"<p>This GO-CAM model represents the renin-angiotensin pathway in humans, which is a key regulatory system for blood pressure and fluid balance. The model captures the core components of the pathway, focusing on the key enzymes and receptors involved in the conversion of angiotensinogen to active angiotensin II and the downstream signaling through the angiotensin type I receptor.</p>"},{"location":"reviews/6246724f00000549-Renin_angiotensin_pathway__Human_/#components-included","title":"Components Included","text":"<p>The model includes four principal activities:</p> <ol> <li>ACE (Angiotensin-converting enzyme) - P12821</li> <li>Molecular function: peptidyl-dipeptidase activity (GO:0008241)</li> <li>Occurs in: extracellular space (GO:0005615)</li> <li> <p>Part of: angiotensin maturation (GO:0002003)</p> </li> <li> <p>Renin - P00797-1</p> </li> <li>Molecular function: aspartic-type endopeptidase activity (GO:0004190)</li> <li>Occurs in: extracellular space (GO:0005615)</li> <li> <p>Part of: angiotensin maturation (GO:0002003)</p> </li> <li> <p>Angiotensinogen - P01019</p> </li> <li>Molecular function: hormone activity (GO:0005179)</li> <li>Occurs in: extracellular space (GO:0005615)</li> <li> <p>Part of: maintenance of blood vessel diameter homeostasis by renin-angiotensin (GO:0002034)</p> </li> <li> <p>Angiotensin II receptor type 1 - P30556</p> </li> <li>Molecular function: angiotensin type I receptor activity (GO:0001596)</li> <li>Occurs in: plasma membrane (GO:0005886)</li> <li>Part of: angiotensin-activated signaling pathway (GO:0038166)</li> </ol>"},{"location":"reviews/6246724f00000549-Renin_angiotensin_pathway__Human_/#causal-relations","title":"Causal Relations","text":"<p>The model captures the following causal relationships: - Renin directly positively regulates ACE (RO:0002629) - ACE directly positively regulates Angiotensinogen (RO:0002304) - Angiotensinogen directly positively regulates Angiotensin II receptor type 1 (RO:0002629)</p>"},{"location":"reviews/6246724f00000549-Renin_angiotensin_pathway__Human_/#evidence","title":"Evidence","text":"<p>The model cites appropriate evidence from peer-reviewed literature: - PMID:32079768, 30639100 - Support for angiotensin II receptor type 1 activity - PMID:1567413 - Support for angiotensin-activated signaling pathway - PMID:1378723 - Support for the cellular location of AGTR1 - PMID:11432860, 1320019 - Support for ACE activity - PMID:11274151 - Support for ACE cellular location - PMID:12045255 - Support for Renin activity - PMID:4300938 - Support for Angiotensinogen location</p>"},{"location":"reviews/6246724f00000549-Renin_angiotensin_pathway__Human_/#assessment","title":"Assessment","text":""},{"location":"reviews/6246724f00000549-Renin_angiotensin_pathway__Human_/#biological-accuracy","title":"Biological Accuracy","text":"<p>The model correctly represents the core features of the renin-angiotensin pathway: - Renin cleaves angiotensinogen to produce angiotensin I - ACE converts angiotensin I to angiotensin II - Angiotensin II activates the angiotensin II type 1 receptor</p> <p>The causal relationships are correctly directional, representing the sequential enzymatic conversions and receptor activation.</p>"},{"location":"reviews/6246724f00000549-Renin_angiotensin_pathway__Human_/#compliance-with-go-cam-best-practices","title":"Compliance with GO-CAM Best Practices","text":"<ol> <li> <p>Molecular Functions: Each protein is appropriately annotated with its molecular function (enzyme activity/receptor activity).</p> </li> <li> <p>Cellular Context: All activities are appropriately contextualized with cellular component terms.</p> </li> <li> <p>Biological Process: Each activity is correctly associated with the biological process it contributes to.</p> </li> <li> <p>Causal Relationships: The model uses the appropriate causal relation predicates:</p> </li> <li>RO:0002629 (directly positively regulates) for enzyme-substrate relationships</li> <li> <p>RO:0002304 (causally upstream of, positive effect) for regulatory relationships</p> </li> <li> <p>Evidence: Each annotation and relationship is supported by appropriate evidence codes and literature citations.</p> </li> </ol>"},{"location":"reviews/6246724f00000549-Renin_angiotensin_pathway__Human_/#potential-improvements","title":"Potential Improvements","text":"<ol> <li> <p>Signaling Receptor Annotation: According to the \"Signaling receptor activity annotation guidelines\", the angiotensin II receptor (AGTR1) should have as input the downstream effector it regulates, not the ligand itself. The current model shows the angiotensinogen as directly regulating AGTR1, which isn't fully compliant with the guidelines that specify the receptor should have as input the effector protein it regulates.</p> </li> <li> <p>Completeness: The model could be expanded to include:</p> </li> <li>ACE2 and its role in converting angiotensin II to angiotensin-(1-7)</li> <li>The AGTR2 receptor and its signaling</li> <li>The downstream effectors of AGTR1 signaling (e.g., G-proteins, MAP kinases)</li> <li> <p>Additional biological processes regulated by the renin-angiotensin system</p> </li> <li> <p>Details of Enzymatic Conversions: The model could more explicitly represent the conversion of angiotensinogen to angiotensin I by renin, and the conversion of angiotensin I to angiotensin II by ACE.</p> </li> </ol>"},{"location":"reviews/6246724f00000549-Renin_angiotensin_pathway__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model for the renin-angiotensin pathway (gomodel:6246724f00000549) is scientifically accurate and largely follows GO-CAM best practices. The model captures the key components and relationships of the pathway, supported by appropriate evidence.</p> <p>The main recommendation for improvement is to properly represent the input of the angiotensin II receptor according to signaling receptor annotation guidelines, and potentially to expand the model to include additional components and processes of the renin-angiotensin system for a more comprehensive representation.</p>"},{"location":"reviews/6246724f00000675-IL7_mediated_signaling_pathway__Human_/","title":"6246724f00000675 IL7 mediated signaling pathway  Human","text":"<p>Now I'll review the IL7-mediated signaling pathway GO-CAM model with ID gomodel:6246724f00000675.</p>"},{"location":"reviews/6246724f00000675-IL7_mediated_signaling_pathway__Human_/#model-overview","title":"Model Overview","text":"<p>This model represents the IL-7 mediated signaling pathway in humans. Let me analyze the key components and their flow:</p> <ol> <li>IL7 (UniProtKB:P13232) - Cytokine activity (GO:0005125) in extracellular space</li> <li>IL7R (UniProtKB:P16871) - IL-7 receptor activity (GO:0004917) in plasma membrane</li> <li>IL2RG (UniProtKB:P31785) - Coreceptor activity (GO:0015026) in plasma membrane</li> <li>JAK1 (UniProtKB:P23458) - Protein tyrosine kinase activity (GO:0004713) in plasma membrane</li> <li>JAK3 (UniProtKB:P52333) - Protein tyrosine kinase activity (GO:0004713) in cytoplasmic side of plasma membrane</li> <li>STAT5A (UniProtKB:P42229) - DNA-binding transcription factor activity (GO:0003700) in nucleus</li> <li>STAT1 (UniProtKB:P42224) - DNA-binding transcription factor activity (GO:0003700) in nucleus</li> </ol> <p>The information flow is as follows: - IL7 \u2192 IL7R (directly positively regulates) - IL7R \u2192 IL2RG (directly positively regulates) - IL7R \u2192 JAK1 (directly positively regulates) - IL2RG \u2192 JAK3 (directly positively regulates) - JAK3 \u2192 STAT5A (directly positively regulates) - JAK1 \u2192 STAT1 (directly positively regulates)</p>"},{"location":"reviews/6246724f00000675-IL7_mediated_signaling_pathway__Human_/#review-analysis","title":"Review Analysis","text":""},{"location":"reviews/6246724f00000675-IL7_mediated_signaling_pathway__Human_/#1-biological-accuracy","title":"1. Biological Accuracy","text":"<p>The model represents the established IL-7 signaling pathway with good accuracy. IL-7 is correctly shown to bind to its receptor IL7R, which forms a complex with the common gamma chain (IL2RG). This receptor complex activates JAK kinases (JAK1 and JAK3), which in turn activate STAT transcription factors (STAT5A and STAT1) that translocate to the nucleus.</p> <p>This is consistent with the literature and the UniProt entries I reviewed. For example, from UniProt P13232 (IL7):</p> <p>\"Mechanistically, exerts its biological effects through a receptor composed of IL7RA subunit and the cytokine receptor common subunit gamma/CSF2RG (PubMed:8128231). Binding to the receptor leads to activation of various kinases including JAK1 or JAK3 depending on the cell type and subsequently propagation of signals through activation of several downstream signaling pathways including the PI3K/Akt/mTOR or the JAK-STAT5.\"</p>"},{"location":"reviews/6246724f00000675-IL7_mediated_signaling_pathway__Human_/#2-go-cam-best-practices","title":"2. GO-CAM Best Practices","text":"<p>The model follows most of the GO-CAM best practices for signaling receptor activity:</p> <ul> <li>Cytokine (IL7) is correctly annotated with:</li> <li>MF: cytokine activity (GO:0005125)</li> <li>CC: extracellular space (GO:0005615)</li> <li> <p>BP: interleukin-7-mediated signaling pathway (GO:0038111)</p> </li> <li> <p>Receptor (IL7R) is correctly annotated with:</p> </li> <li>MF: interleukin-7 receptor activity (GO:0004917)</li> <li>CC: plasma membrane (GO:0005886)</li> <li> <p>BP: interleukin-7-mediated signaling pathway (GO:0038111)</p> </li> <li> <p>Coreceptor (IL2RG) is correctly annotated with:</p> </li> <li>MF: coreceptor activity (GO:0015026)</li> <li>CC: plasma membrane (GO:0005886)</li> <li>BP: interleukin-7-mediated signaling pathway (GO:0038111)</li> </ul> <p>The causal relations use \"directly positively regulates\" (RO:0002629) which is correct according to GO-CAM guidelines.</p>"},{"location":"reviews/6246724f00000675-IL7_mediated_signaling_pathway__Human_/#3-areas-for-improvement","title":"3. Areas for Improvement","text":"<ol> <li> <p>JAK3 localization: JAK3 is annotated as localized to \"cytoplasmic side of plasma membrane\" (GO:0009898) while JAK1 is annotated to \"plasma membrane\" (GO:0005886). For consistency, both should likely be annotated in the same cellular component or with greater precision, as both JAKs associate with the receptor at the cytoplasmic side of the plasma membrane.</p> </li> <li> <p>Missing phosphorylation step: The model does not explicitly represent the phosphorylation of STATs by JAKs, which is a key mechanism in this pathway. According to UniProt entry for STAT5A: \"Tyrosine phosphorylated in response to KITLG/SCF, IL2, IL3, IL7, IL15, CSF2/GMCSF, GH1, PRL, EPO and THPO.\"</p> </li> <li> <p>STAT dimerization: The model doesn't capture the dimerization of STATs following phosphorylation, which is an important step before nuclear translocation.</p> </li> <li> <p>Target genes: The model stops at STAT transcription factors but doesn't include any of their target genes, which would complete the signaling cascade.</p> </li> <li> <p>Evidence: While the model includes evidence codes and PMID references for most assertions, it would benefit from additional references for some steps, particularly for STAT1 activation by JAK1.</p> </li> </ol>"},{"location":"reviews/6246724f00000675-IL7_mediated_signaling_pathway__Human_/#4-connectivity-and-flow","title":"4. Connectivity and Flow","text":"<p>The connections between activities are logical and follow the known sequence of events in IL-7 signaling. However, the connection between the JAKs and STATs could be improved by adding the intermediate phosphorylation step.</p>"},{"location":"reviews/6246724f00000675-IL7_mediated_signaling_pathway__Human_/#5-parsimony","title":"5. Parsimony","text":"<p>The model is appropriately parsimonious, focusing on the core components of the IL-7 signaling pathway without unnecessary details. It presents a clear and straightforward representation of the pathway that would be easy for a human to understand.</p>"},{"location":"reviews/6246724f00000675-IL7_mediated_signaling_pathway__Human_/#conclusion-and-recommendations","title":"Conclusion and Recommendations","text":"<p>The IL7-mediated signaling pathway GO-CAM model (gomodel:6246724f00000675) is a well-constructed model that accurately represents the key steps in IL-7 signaling. It follows most GO-CAM best practices and is biologically accurate based on current knowledge.</p>"},{"location":"reviews/6246724f00000675-IL7_mediated_signaling_pathway__Human_/#recommendations-for-improvement","title":"Recommendations for improvement:","text":"<ol> <li> <p>Consistent localization: Ensure consistent cellular component annotation for JAK1 and JAK3.</p> </li> <li> <p>Include phosphorylation: Consider adding explicit representation of the phosphorylation steps between JAKs and STATs.</p> </li> <li> <p>Add STAT dimerization: Add the dimerization step for STATs after their phosphorylation.</p> </li> <li> <p>Extend to target genes: Consider extending the model to include key target genes of STAT5A and STAT1 in the IL-7 response pathway.</p> </li> <li> <p>Additional evidence: Add more evidence codes and literature references, particularly for the JAK1-STAT1 connection.</p> </li> </ol> <p>Overall, this is a high-quality GO-CAM model that effectively represents the IL-7 signaling pathway. The suggested improvements would further enhance its accuracy and usefulness.</p>"},{"location":"reviews/6246724f00000763-TSLP_mediated_signaling_pathway__Human_/","title":"6246724f00000763 TSLP mediated signaling pathway  Human","text":"<p>Based on my research and the provided documents, I'll now review the GO-CAM model gomodel:6246724f00000763 focusing on its biological accuracy, adherence to GO-CAM guidelines, and completeness.</p>"},{"location":"reviews/6246724f00000763-TSLP_mediated_signaling_pathway__Human_/#review-of-go-cam-model-tslp-mediated-signaling-pathway-human","title":"Review of GO-CAM Model: TSLP-mediated signaling pathway (Human)","text":""},{"location":"reviews/6246724f00000763-TSLP_mediated_signaling_pathway__Human_/#model-id-gomodel6246724f00000763","title":"Model ID: gomodel:6246724f00000763","text":""},{"location":"reviews/6246724f00000763-TSLP_mediated_signaling_pathway__Human_/#overview","title":"Overview","text":"<p>This model represents the Thymic Stromal Lymphopoietin (TSLP) signaling pathway in humans. TSLP is a cytokine that plays important roles in allergic/inflammatory responses and immunity. The model traces the signaling cascade from TSLP binding to its receptor complex through JAK kinase activation to STAT5 phosphorylation and nuclear localization.</p>"},{"location":"reviews/6246724f00000763-TSLP_mediated_signaling_pathway__Human_/#biological-content-review","title":"Biological Content Review","text":""},{"location":"reviews/6246724f00000763-TSLP_mediated_signaling_pathway__Human_/#accuracy-of-protein-functions-and-interactions","title":"Accuracy of Protein Functions and Interactions","text":"<ol> <li>TSLP as a cytokine: </li> <li>The model correctly represents TSLP (UniProtKB:Q969D9) with cytokine activity (GO:0005125) occurring in extracellular space (GO:0005615).</li> <li> <p>This aligns with the literature showing TSLP as a cytokine similar to IL-7 that functions in immune regulation.</p> </li> <li> <p>Receptor Complex Formation:</p> </li> <li>The model correctly captures that TSLP signals through a heterodimeric receptor complex consisting of:<ul> <li>IL-7 receptor alpha (IL7R, UniProtKB:P16871) with cytokine receptor activity (GO:0004896)</li> <li>TSLP receptor (CRLF2, UniProtKB:Q9HC73) with coreceptor activity (GO:0015026)</li> </ul> </li> <li> <p>This is supported by PMID:10881176 and PMID:20974963.</p> </li> <li> <p>JAK1/JAK2 Activation:</p> </li> <li>The model represents JAK1 (UniProtKB:P23458) and JAK2 (UniProtKB:O60674) with protein tyrosine kinase activity (GO:0004713).</li> <li> <p>The causal relationships show that the receptor complex activates JAK1 and JAK2, which is accurate according to PMID:20974963.</p> </li> <li> <p>STAT5 Activation:</p> </li> <li>The model includes STAT5A (UniProtKB:P42229) with DNA-binding transcription factor activity (GO:0003700).</li> <li>JAK1 and JAK2 are shown to directly positively regulate STAT5A activity, which is biologically accurate.</li> </ol>"},{"location":"reviews/6246724f00000763-TSLP_mediated_signaling_pathway__Human_/#evidence-and-references","title":"Evidence and References","text":"<ul> <li>The model uses appropriate evidence codes and references:</li> <li>ECO:0000314 (direct assay evidence used in manual assertion) with PMID:20974963 as the primary reference</li> <li>ECO:0000305 (curator inference used in manual assertion) for cellular localization</li> <li>Additional PMIDs (35321112, 10881176, 11418668) providing supporting evidence</li> </ul>"},{"location":"reviews/6246724f00000763-TSLP_mediated_signaling_pathway__Human_/#go-cam-best-practices-review","title":"GO-CAM Best Practices Review","text":""},{"location":"reviews/6246724f00000763-TSLP_mediated_signaling_pathway__Human_/#adherence-to-signaling-receptor-activity-annotation-guidelines","title":"Adherence to Signaling Receptor Activity Annotation Guidelines","text":"<ol> <li>Ligand Representation:</li> <li>TSLP is correctly annotated with cytokine activity (GO:0005125) which is a child of receptor ligand activity (GO:0048018)</li> <li>TSLP is correctly placed in extracellular space (GO:0005615)</li> <li> <p>TSLP is shown to directly positively regulate (RO:0002629) the receptor activity, following guidelines</p> </li> <li> <p>Receptor Complex Representation:</p> </li> <li>IL7R is correctly annotated with cytokine receptor activity (GO:0004896)</li> <li>CRLF2 is correctly annotated with coreceptor activity (GO:0015026)</li> <li>Both are located in the plasma membrane (GO:0005886)</li> <li> <p>The model correctly shows both receptor components as part of cytokine-mediated signaling pathway (GO:0019221)</p> </li> <li> <p>Signaling Flow and Causal Associations:</p> </li> <li> <p>The causal relationships follow the GO-CAM best practices:</p> <ul> <li>TSLP directly positively regulates IL7R</li> <li>IL7R directly positively regulates both CRLF2 and JAK1</li> <li>CRLF2 directly positively regulates JAK2</li> <li>Both JAK1 and JAK2 directly positively regulate STAT5A</li> </ul> </li> <li> <p>Cellular Context:</p> </li> <li>Correct cellular localizations are specified:<ul> <li>TSLP in extracellular space</li> <li>Receptors in plasma membrane</li> <li>JAKs on cytoplasmic side of plasma membrane</li> <li>STAT5A in nucleus</li> </ul> </li> </ol>"},{"location":"reviews/6246724f00000763-TSLP_mediated_signaling_pathway__Human_/#suggestions-for-improvement","title":"Suggestions for Improvement","text":"<ol> <li>Biological Process Context:</li> <li> <p>While IL7R, CRLF2, and TSLP are annotated with \"part of\" cytokine-mediated signaling pathway (GO:0019221), JAK1, JAK2, and STAT5A are not. These should also be annotated as part of this process for consistency.</p> </li> <li> <p>Additional Biological Details:</p> </li> <li>The model could be expanded to include downstream targets of STAT5A transcription factor activity</li> <li> <p>The model could be enhanced by including regulated genes that are important in the TSLP-mediated immune response</p> </li> <li> <p>Annotations:</p> </li> <li> <p>The JAK1 and JAK2 proteins could also be annotated with \"part of\" signal transduction (GO:0007165) or more specifically JAK-STAT cascade (GO:0007259)</p> </li> <li> <p>Supporting Evidence:</p> </li> <li>Some causal associations lack evidence codes and references, which should be added for completeness</li> </ol>"},{"location":"reviews/6246724f00000763-TSLP_mediated_signaling_pathway__Human_/#conclusion","title":"Conclusion","text":"<p>The GO-CAM model for TSLP-mediated signaling accurately represents the current biological understanding of this pathway and largely follows GO-CAM best practices. The model shows:</p> <ol> <li>The cytokine TSLP binding to its heterodimeric receptor complex (IL7R + CRLF2)</li> <li>Activation of JAK1 and JAK2 kinases</li> <li>Subsequent activation of STAT5A transcription factor</li> </ol> <p>The model is well-supported by evidence from the scientific literature, particularly PMID:20974963, which demonstrates the roles of JAK1 and JAK2 in TSLP-mediated STAT5 phosphorylation.</p> <p>With minor improvements in biological process annotations and additional downstream elements, this model would be an even more comprehensive representation of the TSLP signaling pathway.</p>"},{"location":"reviews/6246724f00001645-hyaluronan_biosynthetic_process__Mouse_/","title":"6246724f00001645 hyaluronan biosynthetic process  Mouse","text":"<p>Based on my review of the GO-CAM model and relevant literature, here's my comprehensive review of the GO-CAM model gomodel:6246724f00001645:</p>"},{"location":"reviews/6246724f00001645-hyaluronan_biosynthetic_process__Mouse_/#go-cam-model-review-hyaluronan-biosynthetic-process-mouse","title":"GO-CAM Model Review: Hyaluronan Biosynthetic Process (Mouse)","text":""},{"location":"reviews/6246724f00001645-hyaluronan_biosynthetic_process__Mouse_/#model-overview","title":"Model Overview","text":"<p>This model represents the hyaluronan (HA) biosynthetic process in mouse (NCBITaxon:10090). It demonstrates a pathway involving several key components:</p> <ol> <li>Three hyaluronan synthase proteins (Has1, Has2, Has3) that perform hyaluronan synthase activity</li> <li>An ABC-type transporter (Abcc5) that exports hyaluronan </li> <li>A hyaluronidase enzyme (Cemip/KIAA1199) that breaks down hyaluronan</li> </ol>"},{"location":"reviews/6246724f00001645-hyaluronan_biosynthetic_process__Mouse_/#strengths-of-the-model","title":"Strengths of the Model","text":"<ol> <li> <p>Evidence-Based Annotations: The model includes multiple references to primary literature, with evidence codes (ECO:0000314 - direct assay, ECO:0000315 - mutant phenotype, ECO:0000266 - sequence orthology) supporting the annotated functions.</p> </li> <li> <p>Consistent Process Flow: The causal relationships between activities are well-structured, with hyaluronan synthesis by Has proteins feeding into the transport process via the Abcc5 transporter, which then connects to hyaluronan degradation by Cemip.</p> </li> <li> <p>Cellular Context: Activities are properly contextualized with cellular locations (GO:0005886 plasma membrane) where relevant.</p> </li> <li> <p>Completeness: The model captures the full lifecycle of hyaluronan, from synthesis to transport to degradation.</p> </li> </ol>"},{"location":"reviews/6246724f00001645-hyaluronan_biosynthetic_process__Mouse_/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li> <p>Inputs for Hyaluronan Synthases: While the model indicates that Abcc5 has hyaluronic acid (CHEBI:16336) as a primary input, it does not specify the substrate inputs for the hyaluronan synthase activities of Has1, Has2, and Has3. According to the literature, these enzymes use UDP-GlcA and UDP-GlcNac as precursor nucleotide sugars to synthesize hyaluronan.</p> </li> <li> <p>Molecular Complexity: The literature (PMID:15345330) suggests that hyaluronan synthesis is complex, with possible synthesis occurring in the cytoplasm followed by export via transporters. The model could clarify whether the synthases are directly exporting hyaluronan or if this is exclusively performed by the transporter.</p> </li> <li> <p>Missing Regulatory Components: The paper (PMID:15345330) mentions potential regulation of hyaluronan synthesis by various mechanisms. These regulatory aspects could be incorporated into the model.</p> </li> <li> <p>Functional Distinctions Between Has Enzymes: The model does not distinguish potential functional differences between Has1, Has2, and Has3, though PMID:28189611 hints at possible distinct roles in different tissues.</p> </li> </ol>"},{"location":"reviews/6246724f00001645-hyaluronan_biosynthetic_process__Mouse_/#biological-accuracy-review","title":"Biological Accuracy Review","text":"<p>The model aligns well with current understanding of hyaluronan metabolism:</p> <ol> <li> <p>Hyaluronan Synthesis: The assignment of GO:0050501 (hyaluronan synthase activity) to Has1, Has2, and Has3 is correct according to the literature.</p> </li> <li> <p>Hyaluronan Transport: Based on PMID:15345330, the representation of Abcc5 (ABC-type transporter) as responsible for hyaluronan export is supported. This paper specifically identifies MRP5 (Abcc5) as \"the most likely hyaluronan transporter of human fibroblasts.\"</p> </li> <li> <p>Hyaluronan Degradation: The inclusion of Cemip (KIAA1199) as having hyaluronidase activity is supported by PMID:28189611, which describes it as \"HYaluronan Binding Protein Involved in hyaluronan [HA] Depolymerization (HYBID, KIAA1199).\"</p> </li> <li> <p>Process Integration: The causal relationship between the activities is logical, showing hyaluronan being produced, transported, and then metabolized.</p> </li> </ol>"},{"location":"reviews/6246724f00001645-hyaluronan_biosynthetic_process__Mouse_/#go-cam-best-practices-compliance","title":"GO-CAM Best Practices Compliance","text":"<p>The model follows GO-CAM best practices in several ways:</p> <ol> <li> <p>Causal relationships: The model uses RO:0002413 (provides input for) to establish causal connections between activities, which is appropriate.</p> </li> <li> <p>Molecular activities: Each gene product is associated with a specific molecular function.</p> </li> <li> <p>Cellular context: Activities are properly situated in cellular locations.</p> </li> <li> <p>Process context: Activities are correctly identified as part of specific biological processes.</p> </li> </ol>"},{"location":"reviews/6246724f00001645-hyaluronan_biosynthetic_process__Mouse_/#recommended-improvements","title":"Recommended Improvements","text":"<ol> <li> <p>Add Substrates for Synthases: Include UDP-GlcA and UDP-GlcNac as primary inputs for the hyaluronan synthase activities.</p> </li> <li> <p>Clarify Synthesis Location: If hyaluronan is synthesized in the cytoplasm before export (as suggested in PMID:15345330), this should be explicitly modeled.</p> </li> <li> <p>Distinguish Has Functions: If there are functional or tissue-specific differences between Has1, Has2, and Has3, these could be annotated to provide more biological detail.</p> </li> <li> <p>Add Regulatory Components: Consider adding known regulators of hyaluronan synthesis if well-documented in the literature.</p> </li> </ol>"},{"location":"reviews/6246724f00001645-hyaluronan_biosynthetic_process__Mouse_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model effectively represents the hyaluronan biosynthetic process in mouse, including synthesis, transport, and degradation. While some minor aspects could be enhanced to provide more complete biological context, the model presents a coherent and evidence-supported pathway.</p> <p>The connections between the activities are logical and follow the known biology of hyaluronan metabolism. The causal relationships between hyaluronan synthases, transporter activity, and hyaluronidase activity are correctly modeled using appropriate relationship predicates.</p>"},{"location":"reviews/6246724f00001700-Hyaluronan_catabolic_process__Mouse_/","title":"6246724f00001700 Hyaluronan catabolic process  Mouse","text":"<p>Now I have enough information to properly review the GO-CAM model. Let me synthesize what I've learned about hyaluronan catabolism pathways and analyze this model's strengths and weaknesses.</p>"},{"location":"reviews/6246724f00001700-Hyaluronan_catabolic_process__Mouse_/#go-cam-review-for-model-gomodel6246724f00001700-hyaluronan-catabolic-process-mouse","title":"GO-CAM Review for Model: gomodel:6246724f00001700 - Hyaluronan catabolic process (Mouse)","text":""},{"location":"reviews/6246724f00001700-Hyaluronan_catabolic_process__Mouse_/#1-overview","title":"1. Overview","text":"<p>This model represents the hyaluronan (HA) catabolic process in mice. The model includes proteins involved in HA receptor-mediated endocytosis, HA degradation enzymes, and transporters that facilitate the process. The model successfully captures the main sequential steps of HA catabolism: 1. Cell surface receptor binding of HA (CD44, LYVE1, STAB2, HMMR) 2. Receptor-mediated endocytosis 3. Degradation by hyaluronidases (HYAL1, HYAL2) 4. Further degradation by lysosomal enzymes (GUSB, HEXA, HEXB) 5. Transport of degradation products</p>"},{"location":"reviews/6246724f00001700-Hyaluronan_catabolic_process__Mouse_/#2-strengths-of-the-model","title":"2. Strengths of the Model","text":""},{"location":"reviews/6246724f00001700-Hyaluronan_catabolic_process__Mouse_/#21-biological-accuracy","title":"2.1 Biological Accuracy","text":"<ul> <li>The model correctly represents the key proteins involved in hyaluronan catabolism as documented in literature</li> <li>The causal flow of activities is largely consistent with current understanding of the pathway</li> <li>Appropriate molecular functions are assigned to genes (e.g., CD44 as a HA receptor with cargo receptor activity)</li> <li>Appropriate cellular locations are specified (membrane rafts for receptors, lysosome for degradative enzymes)</li> <li>The model includes both membrane-associated and lysosomal hyaluronidases (HYAL2 and HYAL1 respectively)</li> </ul>"},{"location":"reviews/6246724f00001700-Hyaluronan_catabolic_process__Mouse_/#22-technical-implementation","title":"2.2 Technical Implementation","text":"<ul> <li>The model follows GO-CAM best practices for representing enzymatic cascades</li> <li>The model appropriately uses RO:0002413 (provides input for) to connect sequential steps</li> <li>The model includes evidence codes and appropriate literature references for assertions</li> <li>For most activities, both part_of and occurs_in annotations are provided</li> </ul>"},{"location":"reviews/6246724f00001700-Hyaluronan_catabolic_process__Mouse_/#3-issues-and-recommendations-for-improvement","title":"3. Issues and Recommendations for Improvement","text":""},{"location":"reviews/6246724f00001700-Hyaluronan_catabolic_process__Mouse_/#31-causal-relationships-and-pathway-flow","title":"3.1 Causal Relationships and Pathway Flow","text":"<ul> <li>Recommendation: The relationship between the sodium:proton antiporter activities (Slc9a1 and Chp1) and HYAL2 (hyaluronidase activity) uses RO:0002629 (directly positively regulates), but the mechanism of this regulation isn't clear from the model. Consider adding a textual note explaining this regulatory relationship.</li> </ul>"},{"location":"reviews/6246724f00001700-Hyaluronan_catabolic_process__Mouse_/#32-evidence-and-references","title":"3.2 Evidence and References","text":"<ul> <li>Evidence assessment: Most activities are well-supported by experimental evidence. The model uses a combination of direct assay evidence (ECO:0000314), mutant phenotype evidence (ECO:0000315), physical interaction evidence (ECO:0000353), and sequence orthology evidence (ECO:0000266).</li> <li>Recommendation: For some causal associations, evidence codes are missing. For example, the connection between HEXB's beta-N-acetylhexosaminidase activity and GUSB's beta-glucuronidase activity lacks evidence codes and references.</li> </ul>"},{"location":"reviews/6246724f00001700-Hyaluronan_catabolic_process__Mouse_/#33-annotation-completeness","title":"3.3 Annotation Completeness","text":"<ul> <li>Recommendation: Several molecular activities in the model (particularly gomodel:6246724f00001700/6246724f00001748 for Slc17a5) don't have explicit part_of annotations connecting them to the hyaluronan catabolic process (GO:0030214). This should be added for consistency.</li> </ul>"},{"location":"reviews/6246724f00001700-Hyaluronan_catabolic_process__Mouse_/#34-structural-clarity","title":"3.4 Structural Clarity","text":"<ul> <li>Recommendation: The model could be improved by grouping similar activities more clearly, perhaps through notes or visualization guidance. For example, all the receptor activities lead to hyaluronidase activity, but they're visually scattered throughout the model.</li> </ul>"},{"location":"reviews/6246724f00001700-Hyaluronan_catabolic_process__Mouse_/#4-compliance-with-go-cam-best-practices","title":"4. Compliance with GO-CAM Best Practices","text":"<p>The model generally adheres to GO-CAM best practices. The use of molecular functions, cellular components, and biological processes follows GO-CAM guidelines. The causal relationships accurately represent the flow of activities in the pathway.</p> <p>For receptor activities, the model appropriately represents them according to the GO-CAM guidelines, properly associating them with their membrane raft location and the receptor-mediated endocytosis process.</p>"},{"location":"reviews/6246724f00001700-Hyaluronan_catabolic_process__Mouse_/#5-conclusion","title":"5. Conclusion","text":"<p>This GO-CAM model (gomodel:6246724f00001700) provides a comprehensive representation of the hyaluronan catabolic process in mice. It correctly depicts the key molecular players and their activities in the pathway, from initial receptor binding at the cell surface through lysosomal degradation. The model is well-supported by primary literature evidence.</p> <p>With minor improvements to evidence annotations and explicit connections between some activities and the overall process, this model would serve as an excellent reference for understanding hyaluronan catabolism. The model successfully integrates multiple enzymes and transporters into a coherent pathway representation.</p>"},{"location":"reviews/6258b8f300000188-Chondroitin_sulfate_biosynthetic_process_1__chondroitin_6_sulfate_proteoglycans__Mouse_/","title":"6258b8f300000188 Chondroitin sulfate biosynthetic process 1  chondroitin 6 sulfate proteoglycans  Mouse","text":"<p>Based on my analysis of the GO-CAM model and related information, I will now provide a structured review:</p>"},{"location":"reviews/6258b8f300000188-Chondroitin_sulfate_biosynthetic_process_1__chondroitin_6_sulfate_proteoglycans__Mouse_/#review-of-go-cam-model-6258b8f300000188","title":"Review of GO-CAM Model: 6258b8f300000188","text":""},{"location":"reviews/6258b8f300000188-Chondroitin_sulfate_biosynthetic_process_1__chondroitin_6_sulfate_proteoglycans__Mouse_/#general-information","title":"General Information","text":"<ul> <li>Model ID: gomodel:6258b8f300000188</li> <li>Title: Chondroitin sulfate biosynthetic process 1, chondroitin 6-sulfate proteoglycans (Mouse)</li> <li>Taxon: Mouse (NCBITaxon:10090)</li> <li>Status: Production</li> <li>Comments: Sourced from gomodel:R-HSA-2022870</li> </ul>"},{"location":"reviews/6258b8f300000188-Chondroitin_sulfate_biosynthetic_process_1__chondroitin_6_sulfate_proteoglycans__Mouse_/#overview","title":"Overview","text":"<p>This GO-CAM model represents the chondroitin sulfate biosynthetic process in mouse, specifically focusing on the synthesis of chondroitin 6-sulfate proteoglycans. The model includes multiple glycosyltransferases and sulfotransferases that function in the Golgi apparatus to synthesize and modify chondroitin sulfate chains.</p>"},{"location":"reviews/6258b8f300000188-Chondroitin_sulfate_biosynthetic_process_1__chondroitin_6_sulfate_proteoglycans__Mouse_/#structure-assessment","title":"Structure Assessment","text":"<p>The model follows a logical flow and represents the chondroitin sulfate biosynthetic process well. The activities are properly connected via causal associations using <code>RO:0002413</code> (\"provides input for\") to show the pathway's directionality, which is appropriate for this type of biosynthetic process.</p>"},{"location":"reviews/6258b8f300000188-Chondroitin_sulfate_biosynthetic_process_1__chondroitin_6_sulfate_proteoglycans__Mouse_/#strengths","title":"Strengths:","text":"<ol> <li>Localization: All activities are appropriately located in the Golgi apparatus (GO:0005794), which is the correct subcellular location for glycosaminoglycan synthesis.</li> <li>Biological process context: All activities are correctly annotated as part of the chondroitin sulfate biosynthetic process (GO:0030206).</li> <li>Evidence: The model uses appropriate evidence codes (ECO:0000316, ECO:0000315, ECO:0000314) with relevant PMIDs to support the annotations.</li> <li>Activity flow: The causal connections between activities represent the correct sequence of enzymatic actions in the biosynthetic pathway.</li> </ol>"},{"location":"reviews/6258b8f300000188-Chondroitin_sulfate_biosynthetic_process_1__chondroitin_6_sulfate_proteoglycans__Mouse_/#detailed-analysis","title":"Detailed Analysis","text":""},{"location":"reviews/6258b8f300000188-Chondroitin_sulfate_biosynthetic_process_1__chondroitin_6_sulfate_proteoglycans__Mouse_/#enzymes-and-activities","title":"Enzymes and Activities","text":"<p>The model captures several key enzymes involved in chondroitin sulfate biosynthesis:</p> <ol> <li>Csgalnact1/2 (MGI:MGI:2442354, MGI:MGI:1926002):</li> <li>Molecular function: Glucuronosyl-N-acetylgalactosaminyl-proteoglycan 4-beta-N-acetylgalactosaminyltransferase activity (GO:0047238)</li> <li> <p>These enzymes catalyze the transfer of N-acetylgalactosamine to initiate chondroitin chain synthesis</p> </li> <li> <p>Chsy1/Chsy3 (MGI:MGI:2681120, MGI:MGI:1926173):</p> </li> <li>Dual molecular functions:<ul> <li>N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity (GO:0050510)</li> <li>Glucuronosyl-N-acetylgalactosaminyl-proteoglycan 4-beta-N-acetylgalactosaminyltransferase activity (GO:0047238)</li> </ul> </li> <li> <p>These enzymes elongate the chondroitin chain by alternately adding glucuronic acid and N-acetylgalactosamine</p> </li> <li> <p>Chpf/Chpf2 (MGI:MGI:106576, MGI:MGI:1917522):</p> </li> <li>Also have dual transferase activities</li> <li> <p>Work with Chsy enzymes to polymerize the chondroitin chains</p> </li> <li> <p>Chst3/Chst7 (MGI:MGI:1858224, MGI:MGI:1891767):</p> </li> <li>Molecular function: Chondroitin 6-sulfotransferase activity (GO:0008459)</li> <li>These enzymes add sulfate groups to the 6-position of N-acetylgalactosamine residues in chondroitin</li> </ol>"},{"location":"reviews/6258b8f300000188-Chondroitin_sulfate_biosynthetic_process_1__chondroitin_6_sulfate_proteoglycans__Mouse_/#consistency-with-literature","title":"Consistency with Literature","text":"<p>The model is consistent with the scientific literature on chondroitin sulfate biosynthesis:</p> <ol> <li> <p>The PMID:22952769 paper (\"Chondroitin Sulfate Synthase-2 Is Necessary for Chain Extension of Chondroitin Sulfate but Not Critical for Skeletal Development\") provides evidence for the roles of Chpf (CSS2) and Chsy1 in chondroitin chain extension.</p> </li> <li> <p>The PMID:9597547 paper confirms the role of Chst3 (chondroitin 6-sulfotransferase) in adding sulfate groups to chondroitin.</p> </li> <li> <p>The enzymes are working in the correct sequential order, with the transferases that initiate and elongate the chain followed by the sulfotransferases that modify the chains.</p> </li> </ol>"},{"location":"reviews/6258b8f300000188-Chondroitin_sulfate_biosynthetic_process_1__chondroitin_6_sulfate_proteoglycans__Mouse_/#recommendations","title":"Recommendations","text":"<p>While the model is generally of high quality, I have a few suggestions for improvement:</p> <ol> <li> <p>Substrate representation: The model could benefit from explicitly representing the chondroitin proteoglycan substrates at different stages of modification. This would make the pathway more complete.</p> </li> <li> <p>Complexes: Based on the literature (PMID:22952769), some of these enzymes form complexes that enhance their activity. The model could represent these enzyme complexes according to the \"How to annotate complexes in GO-CAM\" guidelines.</p> </li> <li> <p>Additional biological context: The model could include annotations regarding the biological roles of chondroitin 6-sulfate in mouse development, particularly in cartilage, as indicated in PMID:22952769.</p> </li> </ol>"},{"location":"reviews/6258b8f300000188-Chondroitin_sulfate_biosynthetic_process_1__chondroitin_6_sulfate_proteoglycans__Mouse_/#conclusion","title":"Conclusion","text":"<p>This GO-CAM model (gomodel:6258b8f300000188) is a well-structured representation of the chondroitin sulfate biosynthetic process in mouse. It accurately represents the enzymatic activities, their subcellular localization, and the causal relationships between them. The evidence provided is appropriate and the connections between activities reflect the biological pathway correctly.</p> <p>The model successfully captures the sequential process of chondroitin sulfate synthesis from chain initiation to sulfation. It adheres to GO-CAM best practices and provides a valuable resource for understanding glycosaminoglycan biosynthesis in mouse.</p>"},{"location":"reviews/6258b8f300000398-Heparan_sulfate_proteoglycan_biosynthetic_process__Mouse_/","title":"6258b8f300000398 Heparan sulfate proteoglycan biosynthetic process  Mouse","text":"<p>Based on the review of available GO-CAM best practices and the model itself, I can provide the following assessment:</p>"},{"location":"reviews/6258b8f300000398-Heparan_sulfate_proteoglycan_biosynthetic_process__Mouse_/#final-assessment","title":"Final Assessment","text":"<p>The GO-CAM model gomodel:6258b8f300000398 is a well-constructed representation of the heparan sulfate proteoglycan biosynthetic process in mouse. It follows GO-CAM best practices in terms of:</p> <ol> <li> <p>Appropriate Molecular Function Terms: Each activity uses specific molecular function terms that accurately reflect the enzymatic activities involved.</p> </li> <li> <p>Correct Process Association: All activities are correctly associated with the GO:0015012 (heparan sulfate proteoglycan biosynthetic process).</p> </li> <li> <p>Correct Localization: Most activities are correctly localized to the Golgi apparatus (GO:0005794).</p> </li> <li> <p>Causal Flow: The model uses RO:0002413 (\"provides input for\") consistently to represent the sequential nature of the biosynthetic pathway.</p> </li> <li> <p>Evidence Support: Activities are well-supported by experimental evidence from multiple publications.</p> </li> </ol>"},{"location":"reviews/6258b8f300000398-Heparan_sulfate_proteoglycan_biosynthetic_process__Mouse_/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<ol> <li> <p>Add Missing Cellular Localizations: Ensure all activities, particularly the NDST N-deacetylase activities, include GO:occurs_in annotations to the Golgi apparatus.</p> </li> <li> <p>Add Evidence for Causal Connections: Consider adding specific evidence for the causal connections between activities.</p> </li> <li> <p>De-duplicate Activities: Review and potentially consolidate redundant activities for the same protein with the same molecular function.</p> </li> <li> <p>Fix Annotation Typo: Correct \"UniPortKB:Q76EJ3\" to \"UniProtKB:Q76EJ3\" in the evidence annotation for activity gomodel:6258b8f300000398/6258b8f300000403.</p> </li> <li> <p>Consider Complex Representation: For enzymes that work together (like EXT1/EXT2), consider whether the current representation is the most accurate, or if they should be represented as a complex according to the complex annotation guidelines.</p> </li> </ol> <p>Overall, this is a high-quality GO-CAM model that successfully captures the complexity of heparan sulfate proteoglycan biosynthesis with strong evidence support. With the minor improvements suggested above, it would be even more valuable for the scientific community.</p>"},{"location":"reviews/626b20c100000025-IL9_mediated_signaling_pathway__Human_/","title":"626b20c100000025 IL9 mediated signaling pathway  Human","text":"<p>Based on all the information I've gathered, I will now conduct a comprehensive review of the GO-CAM model \"gomodel:626b20c100000025\" which represents the IL9-mediated signaling pathway in humans.</p>"},{"location":"reviews/626b20c100000025-IL9_mediated_signaling_pathway__Human_/#review-of-go-cam-model-il9-mediated-signaling-pathway-human","title":"Review of GO-CAM Model: IL9-mediated signaling pathway (Human)","text":"<p>Model ID: gomodel:626b20c100000025</p>"},{"location":"reviews/626b20c100000025-IL9_mediated_signaling_pathway__Human_/#overall-assessment","title":"Overall Assessment","text":"<p>This model describes the IL9-mediated signaling pathway in humans, showing the sequence of molecular events from IL9 binding to its receptor through downstream signaling via JAK kinases and ultimately to STAT transcription factors. The model follows the core structure of cytokine signaling pathways, with appropriate functions assigned to each component and the proper connectivity between components.</p>"},{"location":"reviews/626b20c100000025-IL9_mediated_signaling_pathway__Human_/#components-and-structure","title":"Components and Structure","text":"<p>The model includes the following key components: 1. IL9 cytokine (UniProtKB:P15248) with cytokine activity 2. IL9 receptor (UniProtKB:Q01113) with interleukin-9 receptor activity 3. Common gamma chain (UniProtKB:P31785) as a coreceptor 4. JAK family kinases JAK1 (UniProtKB:P23458) and JAK3 (UniProtKB:P52333) 5. STAT transcription factors STAT1 (UniProtKB:P42224), STAT3 (UniProtKB:P40763), and STAT5A (UniProtKB:P42229)</p> <p>The pathway flow follows the expected sequence for a cytokine signaling pathway: - IL9 activates IL9R - IL9R activates both the coreceptor IL2RG and JAK1 - IL2RG activates JAK3 - JAK1 activates STAT1 and STAT3 - JAK3 activates STAT5A</p>"},{"location":"reviews/626b20c100000025-IL9_mediated_signaling_pathway__Human_/#strengths","title":"Strengths","text":"<ol> <li>The model correctly represents the IL9 signaling pathway components and relationships according to current knowledge.</li> <li>All activities are properly connected in the expected causal sequence.</li> <li>The model uses the recommended \"directly positively regulates\" (RO:0002629) predicate for the causal relationships, which is appropriate for these direct molecular interactions.</li> <li>Cellular locations are correctly annotated for each component (extracellular space for IL9, plasma membrane for receptors, etc.).</li> <li>Each annotation is supported by appropriate evidence and literature references.</li> </ol>"},{"location":"reviews/626b20c100000025-IL9_mediated_signaling_pathway__Human_/#compliance-with-go-cam-guidelines","title":"Compliance with GO-CAM Guidelines","text":"<p>Based on the \"Signaling receptor activity annotation guidelines\":</p> <ol> <li>\u2705 The cytokine (IL9) correctly has cytokine activity (GO:0005125) and is located in extracellular space (GO:0005615).</li> <li>\u2705 The receptor (IL9R) has the appropriate receptor activity (GO:0004919) and is located in the plasma membrane (GO:0005886).</li> <li>\u2705 The coreceptor (IL2RG) correctly has coreceptor activity (GO:0015026) and is located in the plasma membrane.</li> <li>\u2705 The causal relationships use \"directly positively regulates\" (RO:0002629) which is correct for these direct molecular interactions.</li> <li>\u2705 All activities are part of the appropriate biological process (GO:0038113, interleukin-9-mediated signaling pathway).</li> <li>\u2705 The transcription factors (STATs) are correctly annotated with DNA-binding transcription factor activity (GO:0003700).</li> </ol>"},{"location":"reviews/626b20c100000025-IL9_mediated_signaling_pathway__Human_/#potential-improvementsissues-to-address","title":"Potential Improvements/Issues to Address","text":"<ol> <li> <p>Missing nuclear localization for some STATs: While STAT3 and STAT1 are correctly annotated as occurring in the nucleus (GO:0005634), STAT5A lacks this cellular location annotation. Since STAT5A is also a transcription factor that must translocate to the nucleus to perform its function, this annotation should be added.</p> </li> <li> <p>Missing inputs for transcription factors: According to the DNA-binding transcription factor activity guidelines, the transcription factors should have the genes they regulate as inputs through the 'has input' relation. The model doesn't specify what genes are regulated by STAT1, STAT3, and STAT5A.</p> </li> <li> <p>Non-specific annotations for JAK kinases: While JAK1 and JAK3 are correctly annotated with protein tyrosine kinase activity (GO:0004713), the model could benefit from more specific annotations about their targets (though the causal connections are present).</p> </li> <li> <p>Missing evidence for some locations: The STAT5A assignment to the nucleus doesn't have evidence codes attached, though this is a well-established biological fact.</p> </li> <li> <p>Activity of IL9 on IL9R could be clearer: The relationship between IL9 and IL9R follows the guidelines, but making it explicitly clear that IL9 has receptor ligand activity might strengthen the model.</p> </li> </ol>"},{"location":"reviews/626b20c100000025-IL9_mediated_signaling_pathway__Human_/#consistency-with-literature","title":"Consistency with Literature","text":"<p>The model is consistent with the known biology of IL9 signaling. IL9 is known to signal through a receptor complex comprising IL9R and the common gamma chain (IL2RG). This leads to activation of JAK1 and JAK3, which then phosphorylate and activate STAT transcription factors.</p> <p>The evidence cited in the model includes key references for this pathway: - PMID:8193355 for IL9R activation by IL9 - PMID:18829468 for IL2RG coreceptor activity - PMID:8756628 for JAK1 activation - PMID:9535918 for STAT transcription factor activity</p> <p>These references support the proposed molecular functions and interactions.</p>"},{"location":"reviews/626b20c100000025-IL9_mediated_signaling_pathway__Human_/#conclusion","title":"Conclusion","text":"<p>Overall, this is a well-constructed GO-CAM model that accurately represents the IL9-mediated signaling pathway in humans. The model follows the GO-CAM best practices for signaling receptor pathways and is supported by appropriate literature evidence. </p> <p>The suggested improvements would enhance the completeness and specificity of the model but are not critical flaws. The model effectively communicates the biological understanding of how IL9 signals through its receptor to activate transcription factors that regulate gene expression, consistent with current knowledge of cytokine signaling pathways.</p>"},{"location":"reviews/gomodel%3A56170d5200000012-kctd10_in_heart_development_PMID_24430697_/","title":"gomodel:56170d5200000012 kctd10 in heart development PMID 24430697","text":"<p>I'll help you review a GO-CAM model, but I need the specific model ID to look up. The \"{model.id}\" placeholder needs to be replaced with an actual model identifier.</p> <p>Model IDs typically look like UUID strings (e.g., \"8a844cd8-1a2b-4d76-a4d2-875d76a3c67f\") or may use a specific format like \"gomodel:12345\".</p> <p>Could you please provide the complete model ID that you'd like me to review?</p>"},{"location":"reviews/gomodel%3A568b0f9600000284-Antibacterial_innate_immune_response_in_the_intestine_via_MAPK_cascade__C__elegans_/","title":"gomodel:568b0f9600000284 Antibacterial innate immune response in the intestine via MAPK cascade  C  elegans","text":"<p>I need a specific GO-CAM model ID to review. The parameter you provided <code>{model.id}</code> appears to be a placeholder rather than an actual model ID.</p> <p>GO-CAM model IDs typically follow a format like \"gomodel:12345678-1234-1234-1234-123456789012\" or sometimes just the UUID portion \"12345678-1234-1234-1234-123456789012\".</p> <p>Could you please provide a valid GO-CAM model ID that you would like me to review?</p>"},{"location":"reviews/gomodel%3A5745387b00001516-Canonical_glycolysis_1__Mouse_/","title":"gomodel:5745387b00001516 Canonical glycolysis 1  Mouse","text":"<p>I'll help you review a GO-CAM model, but you need to provide the specific model ID that you want me to review. The model ID should be in the format of a UUID (like 58a75592-dc4d-4855-8513-27a0f0b6a597) or a complete GO-CAM model ID.</p> <p>Could you please provide the specific model ID you'd like me to review?</p>"},{"location":"reviews/gomodel%3A57c82fad00000695-F13a1_and_F13b_mouse_blood_clotting/","title":"gomodel:57c82fad00000695 F13a1 and F13b mouse blood clotting","text":"<p>I'll help you review a GO-CAM model, but you need to provide a specific model ID. The model ID should be in a format like <code>gomodel:XXXXXXXX-XXXX-XXXX-XXXX-XXXXXXXXXXXX</code> or a local file path if you're working with a file on your system.</p> <p>Could you please provide the specific model ID or file path that you'd like me to review?</p>"},{"location":"reviews/gomodel%3A5966411600000170-Intestinal_smooth_muscle_cell_differentiation_via_foxo1a__mir145__tgfr1b__ltbp3__zeb1a__D__rerio_/","title":"gomodel:5966411600000170 Intestinal smooth muscle cell differentiation via foxo1a  mir145  tgfr1b  ltbp3  zeb1a  D  rerio","text":"<p>I'd be happy to review the GO-CAM model for you, but I notice that you haven't provided a specific model ID. To review a GO-CAM model, I'll need the model ID which typically follows a format like \"go.model:xxxxxxxx-xxxx-xxxx-xxxx-xxxxxxxxxxxx\" or a local file path.</p> <p>Could you please provide: 1. A specific GO-CAM model ID (if you're referring to a model in the database), or 2. A local file path if the model is stored locally?</p> <p>Once you provide this information, I can perform a comprehensive review including checking GO-CAM best practices, biological content consistency, protein information, and overall model structure.</p>"},{"location":"reviews/gomodel%3A59cc772c00000000-IL1beta_mediated_signaling_pathway__Human_/","title":"gomodel:59cc772c00000000 IL1beta mediated signaling pathway  Human","text":"<p>To review a GO-CAM model, I need a specific model ID. The parameter you provided, <code>{model.id}</code>, appears to be a placeholder rather than an actual GO-CAM model ID.</p> <p>GO-CAM model IDs typically have a format like \"gomodel:xxxxxxxx-xxxx-xxxx-xxxx-xxxxxxxxxxxx\" or just the UUID part.</p> <p>Could you please provide the actual GO-CAM model ID that you would like me to review? Once you provide a valid model ID, I can perform a comprehensive review including checking:</p> <ol> <li>Consistency with GO-CAM best practices</li> <li>Biological content accuracy based on literature</li> <li>Proper protein annotation</li> <li>Logical connectivity of activities in the pathway</li> <li>Overall parsimony and understandability of the model</li> </ol>"},{"location":"reviews/gomodel%3A59dc728000000555-_Wnt_FGF_Notch_signaling_inregulation_of_HSC_specification_via_dlc__dld__fgfr4__wnt16__D__rerio_/","title":"gomodel:59dc728000000555  Wnt FGF Notch signaling inregulation of HSC specification via dlc  dld  fgfr4  wnt16  D  rerio","text":"<p>I need a specific GO-CAM model ID to review. GO-CAM model IDs typically start with \"gomodel:\" followed by a UUID. Could you please provide the exact model ID you'd like me to review?</p>"},{"location":"reviews/gomodel%3A5ae3b0f600000435-Regulation_of_sprouting_angiogenesis_via_dll4__egfl6__itgb1a__D__rerio_/","title":"gomodel:5ae3b0f600000435 Regulation of sprouting angiogenesis via dll4  egfl6  itgb1a  D  rerio","text":"<p>I need a specific GO-CAM model ID to review. Could you please provide the model ID in the format \"gomodel:xxxxxxxx-xxxx-xxxx-xxxx-xxxxxxxxxxxx\" or just the UUID part? This will allow me to look up the model and perform a thorough review.</p>"},{"location":"reviews/gomodel%3A5b528b1100000489-XBP_1_is_a_cell_nonautonomous_regulator_of_stress_resistance_and_longevity/","title":"gomodel:5b528b1100000489 XBP 1 is a cell nonautonomous regulator of stress resistance and longevity","text":"<p>I'll need the specific GO-CAM model ID to review it. Please provide the actual model ID you'd like me to review, such as \"go.model:12345678-abcd-1234-5678-abcdef123456\" or a similar identifier.</p>"},{"location":"reviews/gomodel%3A5b91dbd100002057-Antifungal_innate_immune_response_in_the_hypodermis_via_MAPK_cascade__C__elegans_/","title":"gomodel:5b91dbd100002057 Antifungal innate immune response in the hypodermis via MAPK cascade  C  elegans","text":"<p>I need to review a GO-CAM model, but you haven't provided a specific model ID. To help you properly, I need the GO-CAM model ID that you'd like me to review. This should be in a format like \"gomodel:0000000\" or a similar identifier.</p> <p>Could you please provide the specific GO-CAM model ID that you would like me to review?</p>"},{"location":"reviews/gomodel%3A5b91dbd100002241-Antifungal_innate_immune_response_in_the_hypodermis_via_transforming_growth_factor_beta_receptor_signaling_pathway__C__elegans_/","title":"gomodel:5b91dbd100002241 Antifungal innate immune response in the hypodermis via transforming growth factor beta receptor signaling pathway  C  elegans","text":"<p>I need a specific GO-CAM model ID to review for you. The model ID is usually in the format of \"go.model:someUUID\" or a local file path if you're working with a model that hasn't been published yet.</p> <p>Could you please provide the exact model ID you'd like me to review? For example: - A GO-CAM model ID like \"go.model:5c50e699-0000-4000-a000-3c145d124604\" - Or a local file path if available</p>"},{"location":"reviews/gomodel%3A5ce58dde00001215-Mouse_Aatf_antiapoptosis/","title":"gomodel:5ce58dde00001215 Mouse Aatf antiapoptosis","text":"<p>I need to review a GO-CAM model, but you haven't provided a specific model ID. The <code>lookup_gocam</code> tool requires a model ID in the format of a GO model identifier or UUID.</p> <p>Could you please provide the specific model ID you'd like me to review? This would typically be in a format like \"go.model:12345\" or a UUID.</p>"},{"location":"reviews/gomodel%3A5df932e000000330-Protease_activity_in_epithelial_morphogenesis_via_f2rl1_2__spint1a__st14a__D__rerio_/","title":"gomodel:5df932e000000330 Protease activity in epithelial morphogenesis via f2rl1 2  spint1a  st14a  D  rerio","text":"<p>I'll help you review a GO-CAM model, but I need the specific model ID to proceed. The model ID should be in a format like \"go.model:xxxxxxxx-xxxx-xxxx-xxxx-xxxxxxxxxxxx\" where the x's represent a UUID.</p> <p>Could you please provide the specific model ID you'd like me to review?</p>"},{"location":"summaries/overall/","title":"Executive Summary: Key Problems in GO-CAM Model Reviews","text":"<p>This analysis identifies common issues in GO-CAM models based on multiple reviews. The most frequent problems relate to incomplete molecular function annotations, missing causal relationships, inadequate cellular localization, and incomplete biological process context.</p>"},{"location":"summaries/overall/#common-issues-across-go-cam-models","title":"Common Issues Across GO-CAM Models","text":""},{"location":"summaries/overall/#1-molecular-function-annotations","title":"1. Molecular Function Annotations","text":"<ul> <li>Generic function terms: Many models use GO:0003674 (molecular_function) instead of specific function terms</li> <li>Missing specific enzyme activities: Enzymatic activities often lack specificity (e.g., using \"kinase activity\" instead of \"protein serine/threonine kinase activity\")</li> <li>Incomplete transcription factor activities: Transcription factors lack proper DNA binding or activator/repressor activity annotations</li> </ul>"},{"location":"summaries/overall/#2-causal-relationships","title":"2. Causal Relationships","text":"<ul> <li>Missing or incorrect relationship predicates: Improper use of causality terms between activities</li> <li>Incomplete pathway representation: Gaps in causal chains that should connect related activities</li> <li>Lack of input/output specifications: Many enzymatic activities miss explicit molecule inputs/outputs</li> </ul>"},{"location":"summaries/overall/#3-cellular-components","title":"3. Cellular Components","text":"<ul> <li>Missing localization: Activities lack proper cellular component annotations</li> <li>Inconsistent compartmentalization: Activities that should be in the same compartment have different annotations</li> <li>Transport between compartments: Missing activities representing transport across compartments</li> </ul>"},{"location":"summaries/overall/#4-biological-process-context","title":"4. Biological Process Context","text":"<ul> <li>Limited process associations: Activities not properly connected to biological processes</li> <li>Missing high-level processes: Models focus on molecular details while missing connections to higher-level biological processes</li> <li>Process hierarchies: Failure to represent the hierarchy of processes a molecular activity participates in</li> </ul>"},{"location":"summaries/overall/#detailed-examples","title":"Detailed Examples","text":""},{"location":"summaries/overall/#molecular-function-issues","title":"Molecular Function Issues","text":"<ul> <li>In model 56170d5200000012, has2 (hyaluronan synthase 2) is annotated with generic \"molecular function\" instead of its specific \"hyaluronan synthase activity\" (GO:0050501)</li> <li>In model 59dc728000000555, several gene products use generic \"molecular_function\" (GO:0003674) where specific terms would be appropriate</li> </ul>"},{"location":"summaries/overall/#causal-relationship-problems","title":"Causal Relationship Problems","text":"<ul> <li>In model 5e72450500004019, the relation between protein sequestering activities uses \"RO:0002411\" (causally upstream of) rather than the more specific \"RO:0002630\" (directly negatively regulates)</li> <li>In model 5fb9cc0600000627, there's no direct causal connection between cebpa activity and irf2bp2b's repressor activity</li> </ul>"},{"location":"summaries/overall/#cellular-component-issues","title":"Cellular Component Issues","text":"<ul> <li>In model 5df932e000000330, activities lack specific cellular localization information</li> <li>In model 5fadbcf000002236, the final activity (beta-ureidopropionase activity) is missing cellular component annotation</li> </ul>"},{"location":"summaries/overall/#biological-process-context-issues","title":"Biological Process Context Issues","text":"<ul> <li>In model 5b528b1100000489, the model doesn't clearly connect to the larger biological processes of stress resistance and longevity mentioned in the title</li> <li>In model 5ee8120100002841, the model lacks connections to relevant biological processes such as GO:0048745 (smooth muscle tissue development)</li> </ul>"},{"location":"summaries/overall/#recommendations","title":"Recommendations","text":"<ol> <li>Use the most specific molecular function terms available</li> <li>Ensure complete causal chains with appropriate relationship predicates</li> <li>Include cellular component annotations for all activities</li> <li>Connect activities to relevant biological processes at appropriate levels</li> <li>Add input/output specifications for all enzymatic activities</li> <li>Ensure evidence codes and literature references for all assertions</li> </ol>"},{"location":"summaries/summary-adapters/","title":"Executive Summary: GO-CAM Molecular Adaptor Annotation Review","text":"<p>This review analyzes multiple GO-CAM models to evaluate their adherence to the best practices for annotating molecular adaptors. Several key observations emerge:</p> <ol> <li> <p>Strong Compliance Examples: Many models (e.g., 5f46c3b700001031, 5b91dbd100002057) correctly represent molecular adaptors with appropriate molecular function terms (GO:0060090, GO:0035591) and use the recommended causal relationship \"directly positively regulates\" (RO:0002629).</p> </li> <li> <p>Common Issues:</p> </li> <li>Missing specific input relationships for adaptor proteins</li> <li>Incomplete cellular localization annotations</li> <li> <p>Use of generic molecular function terms instead of more specific adaptor function terms</p> </li> <li> <p>Notable Patterns: Models representing immune signaling pathways (especially TLR/IL-1R and MAPK pathways) generally show better adherence to adaptor annotation guidelines than models representing developmental or metabolic pathways.</p> </li> </ol>"},{"location":"summaries/summary-adapters/#detailed-analysis-of-molecular-adaptor-annotations-in-go-cam-models","title":"Detailed Analysis of Molecular Adaptor Annotations in GO-CAM Models","text":""},{"location":"summaries/summary-adapters/#exemplary-models","title":"Exemplary Models","text":""},{"location":"summaries/summary-adapters/#model-5f46c3b700001031-myd88-dependent-tlr4-signaling-pathway","title":"Model 5f46c3b700001031 (MYD88-dependent TLR4 signaling pathway)","text":"<p>This model demonstrates excellent adherence to adaptor annotation guidelines: - MYD88 is correctly annotated with \"signaling adaptor activity\" (GO:0035591) - TIRAP is properly represented as a molecular adaptor  - The causal relationship \"directly positively regulates\" (RO:0002629) is correctly used - Appropriate cellular localization (cytoplasm) is specified</p>"},{"location":"summaries/summary-adapters/#model-5b91dbd100002057-antifungal-innate-immune-response-in-c-elegans","title":"Model 5b91dbd100002057 (Antifungal innate immune response in C. elegans)","text":"<p>This model correctly represents TIR-1 with \"signaling adaptor activity\" (GO:0035591) and uses the correct causal relationship to connect to downstream components in the MAPK pathway.</p>"},{"location":"summaries/summary-adapters/#models-with-minor-issues","title":"Models with Minor Issues","text":""},{"location":"summaries/summary-adapters/#model-568b0f9600000284-antibacterial-innate-immune-response","title":"Model 568b0f9600000284 (Antibacterial innate immune response)","text":"<p>While this model correctly annotates TIR-1 as having signaling adaptor activity and uses appropriate causal relationships, it could be improved by explicitly specifying the input molecules for TIR-1's adaptor function.</p>"},{"location":"summaries/summary-adapters/#model-5ee8120100000524-sp_n4bp3on-mavs","title":"Model 5ee8120100000524 (SP_N4BP3on MAVS)","text":"<p>This model correctly represents MAVS as a signaling adaptor but uses a generic protein binding activity for N4BP3 rather than a more specific adaptor term, despite N4BP3 functioning to connect NEDD4 to its targets.</p>"},{"location":"summaries/summary-adapters/#models-with-significant-issues","title":"Models with Significant Issues","text":""},{"location":"summaries/summary-adapters/#model-59dc728000000555-wnt-fgf-notch-signaling","title":"Model 59dc728000000555 (Wnt-FGF-Notch signaling)","text":"<p>This model shows several molecular components functioning as adaptors but fails to use specific adaptor molecular function terms. Instead, it uses the generic term \"molecular_function\" (GO:0003674).</p>"},{"location":"summaries/summary-adapters/#model-5ee8120100001898-migrasome-signaling","title":"Model 5ee8120100001898 (Migrasome signaling)","text":"<p>This model represents tetraspanin proteins (tspan4a and tspan7) as having adaptor-like functions but annotates them with the generic \"molecular_function\" term instead of appropriate adaptor activity terms.</p>"},{"location":"summaries/summary-adapters/#specific-recommendations-for-improvement","title":"Specific Recommendations for Improvement","text":"<ol> <li>Use specific molecular adaptor terms:</li> <li>Use \"molecular adaptor activity\" (GO:0060090) or its children</li> <li> <p>For signaling pathway adaptors, use \"signaling adaptor activity\" (GO:0035591)</p> </li> <li> <p>Specify inputs correctly:</p> </li> <li> <p>Models should include \"has input\" relationships to specify which molecules the adaptor connects</p> </li> <li> <p>Use the correct causal relations:</p> </li> <li>\"Directly positively regulates\" (RO:0002629) when the adaptor activates downstream molecules</li> <li> <p>\"Provides input for\" (RO:0002413) when bringing together an enzyme and its substrate</p> </li> <li> <p>Include cellular localization:</p> </li> <li>Always annotate where the adaptor activity occurs, particularly for membrane-associated adaptors</li> </ol> <p>Overall, while many GO-CAM models correctly implement the guidelines for molecular adaptor annotation, there remains room for improvement, particularly in explicitly representing the molecules brought together by the adaptor and using appropriately specific molecular function terms.</p>"},{"location":"summaries/summary-carriers/","title":"Review of GO-CAM Models for Molecular Carriers","text":""},{"location":"summaries/summary-carriers/#executive-summary","title":"Executive Summary","text":"<p>The review of various GO-CAM models representing molecular carriers reveals good adherence to best practices in most cases, with some areas for improvement. Many models correctly implement the guidelines by:</p> <ol> <li>Using appropriate molecular carrier activity terms (GO:0140104)</li> <li>Properly specifying inputs and outputs for carrier activities</li> <li>Correctly connecting activities with appropriate causal relationships</li> <li>Providing proper cellular localization</li> </ol> <p>Common issues that appear across models include: - Missing input/output annotations for some carrier molecules - Inconsistent use of causal relations (using various predicates instead of \"provides input for\") - Inadequate specification of carried molecules - Incomplete biological process context</p>"},{"location":"summaries/summary-carriers/#detailed-examples","title":"Detailed Examples","text":""},{"location":"summaries/summary-carriers/#good-implementation-examples","title":"Good Implementation Examples","text":"<ol> <li>TLR4 Signaling Pathway (gomodel:5f46c3b700001031)</li> <li>Link to model</li> <li>Exemplary use of molecular carrier activity for LBP and CD14 carrying LPS</li> <li> <p>Correctly represents:</p> <ul> <li>LBP and CD14 with molecular carrier activity (GO:0140104)</li> <li>LPS (CHEBI:16412) properly annotated as both input and output</li> <li>Appropriate \"provides input for\" (RO:0002413) causal relations</li> <li>Proper localization in extracellular space</li> </ul> </li> <li> <p>TSLP Mediated Signaling Pathway (gomodel:6246724f00000763)</p> </li> <li>Link to model</li> <li>Correctly annotates TSLP with cytokine activity in extracellular space</li> <li>Well-connected pathway from ligand to receptor to downstream effectors</li> </ol>"},{"location":"summaries/summary-carriers/#areas-for-improvement","title":"Areas for Improvement","text":"<ol> <li>IL1beta Mediated Signaling Pathway (gomodel:59cc772c00000000)</li> <li>Link to model</li> <li>Missing input specifications: The CD14 and LBP molecular carrier activities don't explicitly show what they're carrying</li> <li> <p>Recommendation: Add IL-1\u03b2 as input and output for the carrier activities</p> </li> <li> <p>Cobalamin Metabolic Process (gomodel:61283a3000000217)</p> </li> <li>Link to model</li> <li>Missing cellular components: MMADHC has molecular carrier activity but lacks proper cellular localization</li> <li> <p>Recommendation: Add specific localization information for all carrier activities</p> </li> <li> <p>Hyaluronan Biosynthetic Process (gomodel:6246724f00000443)</p> </li> <li>Link to model</li> <li>Missing input annotations: Abcc5 exports hyaluronic acid but lacks clear annotation of inputs</li> <li>Recommendation: Add explicit has_input relationships for the transported molecules</li> </ol>"},{"location":"summaries/summary-carriers/#recommendations-for-improvement","title":"Recommendations for Improvement","text":"<p>Based on the review, curators should ensure:</p> <ol> <li> <p>Complete input/output specification: Each molecular carrier activity should explicitly identify what molecule is being carried using the has_input and has_output relations.</p> </li> <li> <p>Consistent causal relationships: Use \"provides input for\" (RO:0002413) for connecting carrier activities to downstream activities in metabolic/transport pathways.</p> </li> <li> <p>Precise cellular localization: Always specify where the carrier activity takes place using \"occurs in\" relations to cellular component terms.</p> </li> <li> <p>Biological process context: Connect carrier activities to the appropriate biological processes they participate in using \"part of\" relations.</p> </li> <li> <p>Molecular specificity: When appropriate, use specific CHEBI IDs or other identifiers for the carried molecules to enhance clarity and searchability.</p> </li> </ol> <p>These improvements would further strengthen the value of GO-CAM models representing molecular carrier activities, making them more complete and useful resources for understanding molecular transport mechanisms.</p>"},{"location":"summaries/summary-e3/","title":"Executive Summary: GO-CAM Reviews of E3 Ubiquitin Ligases Models","text":"<p>The collected reviews provide a comprehensive assessment of various GO-CAM models describing E3 ubiquitin ligase pathways. Overall, most models correctly represent the activities and relationships of E3 ligases according to the best practice guide, though several common areas for improvement were identified:</p> <ol> <li> <p>Most models correctly use appropriate molecular functions (e.g., ubiquitin protein ligase activity GO:0061630, ubiquitin ligase-substrate adaptor activity GO:1990756)</p> </li> <li> <p>Common strengths include proper causal relationships, cellular localization, and evidence annotations</p> </li> <li> <p>Common improvement areas include:</p> </li> <li>More specific annotations for types of ubiquitination (e.g., K48-linked vs K63-linked)</li> <li>Explicitly showing substrates using \"has input\" relationships</li> <li>Complete representation of complexes when multiple components are involved</li> <li>Consistent biological process annotations</li> </ol>"},{"location":"summaries/summary-e3/#detailed-examples","title":"Detailed Examples","text":""},{"location":"summaries/summary-e3/#effective-implementation-of-e3-ligase-guidelines","title":"Effective Implementation of E3 Ligase Guidelines","text":"<p>The model gomodel:613aae0000000813 (Liver apoptosis regulation by CASP6) effectively represents how AMPK subunits negatively regulate CASP6 activity through phosphorylation, and how CASP6 activates BID through cleavage. The model correctly shows:</p> <ul> <li>CASP6 with cysteine-type endopeptidase activity (GO:0004197)</li> <li>Appropriate causal relationships with \"directly positively regulates\" (RO:0002629) and \"directly negatively regulates\" (RO:0002630)</li> <li>Clear biological context with hepatocyte apoptotic process (GO:0097284)</li> </ul>"},{"location":"summaries/summary-e3/#areas-needing-improvement","title":"Areas Needing Improvement","text":"<p>The model gomodel:6246724f00000283 (Regulation of mTORC1 signaling via ubiquitination of SESN2) correctly shows RNF167 as an E3 ligase, but would benefit from:</p> <ul> <li>More explicit representation of the GATOR2 complex</li> <li>Clarifying the target of WDR24's ubiquitin ligase activity</li> <li>Better representing K63-linked ubiquitination specificity</li> </ul> <p>The model gomodel:6246724f00000369 (Regulation of mTORC1 via ubiquitination of CASTOR1) could be improved by:</p> <ul> <li>Adding specific lysine residues in CASTOR1 (K61, K96, K213) that are targets for K29-linked polyubiquitination</li> <li>Better representing how AKT1 phosphorylates CASTOR1 at Ser-14</li> </ul>"},{"location":"summaries/summary-e3/#exemplary-models","title":"Exemplary Models","text":"<p>gomodel:5ee8120100000947 (SP-ANN-SEC14L1) effectively shows SEC14L1's protein sequestering activity correctly negatively regulating MAVS-RIG-I binding, demonstrating proper use of the guidelines for representing negative regulation through protein sequestration.</p> <p>gomodel:60ad85f700002694 (TSLP-mediated signaling pathway) correctly implements the signaling receptor annotation guidelines, with proper ligand representation, receptor activities, and downstream effects.</p>"}]}